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Abstract
Oral vaccines have consistently underperformed in the low-income countries where they 
are needed most. This has formed a potent obstacle to several public health initiatives that 
rely on such vaccines, including the polio eradication endgame.
This thesis examines the hypothesis that the composition of the intestinal microbiota – 
including  both  pathogenic  and  commensal  microbes  –  contributes  to  the  impaired 
performance of oral vaccines in low-income countries.  Based on a systematic review and 
meta-analysis,  we observed a decrease in the likelihood of  responding to oral  poliovirus 
vaccine  (OPV)  among  infants  with  concurrent  enterovirus  infections  or  diarrhoea.  We 
subsequently  tested  for  multiple  bacterial,  viral,  and  eukaryotic  enteropathogens  and 
sequenced the 16S rRNA gene (to characterise the total bacterial microbiota) among infants 
living in  a  semi-urban slum in  south India  who had received Rotarix  (an oral  rotavirus 
vaccine) and OPV at 6 and 10 weeks of age. We did not observe significant differences in 
bacterial  microbiota  composition  according  to  seroconversion  status  for  either  vaccine. 
However,  the  presence  of  bacterial  pathogens  was  positively  correlated  with  Rotarix 
response and negatively correlated with OPV response, suggesting that distinct mechanisms 
may impact these vaccines. 
The  same  methods  were  applied  to  samples  from 6–11  month-old  infants  who  had 
received OPV after a 3-day course of azithromycin or placebo. Once again, the association 
between  bacterial  microbiota  composition  and  vaccine  outcome  was  modest,  although 
microbiota  diversity  was  negatively  correlated  with  vaccine  poliovirus  replication.  As 
expected,  viral  pathogens  were  associated  with  a  decrease  in  OPV  immunogenicity. 
Moreover, recently acquired viral infections appeared to inhibit OPV response to a greater 
extent than persistent viruses.
Together, these findings have substantiated the inhibitory effect of viral pathogens on 
OPV  response,  while  implicating  bacterial  pathogens  as  a  potential  risk  factor  for  OPV 
failure in early infancy. Risk factors for rotavirus vaccine failure remain elusive.
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Prologue
In June 1959, the world’s leading experts in attenuated poliovirus vaccines gathered at 
Georgetown University, Washington, D. C., to attend the First International Conference on 
Live Poliovirus Vaccines. Efforts to develop a safe and effective live vaccine to protect against 
polio had not been perturbed by the success of Jonas Salk’s inactivated vaccine, licensed in 
1955,  and  had  recently  broken  out  of  the  laboratory  into  large-scale  field  trials.  In  the 
previous year, various live vaccine candidates had been tested in the USA, Poland, Mexico, 
Singapore, Colombia, and Cuba, among others. 
It  was  at  the  end  of  the  third  day  of  the  conference  that  Stanley  Plotkin  from 
Philadelphia’s  Wistar  Institute  took  the  floor  to  present  findings  from  a  trial  recently 
conducted in the Belgian Congo (now the Democratic Republic of Congo). Between August 
1958 and April 1959, more than 45,000 doses of the lab’s CHAT strain of attenuated type 1 
poliovirus had been administered to children under 5 years of age (Plotkin and Koprowski, 
1959). Among 340 children previously lacking immunity to type 1 poliovirus, 60% developed 
neutralising antibodies after being immunised with the virus. While by no means a failure, 
these findings fell somewhat short of the response rates observed in previous trials of the 
vaccine in Europe and North America. As noted by Plotkin:
“The low serologic response was surprising considering the results obtained with the 
CHAT strain both in small, carefully controlled groups [in the USA; Plotkin et al (1959)] 
and in field studies by Przesmycki et al [in Poland; Przesmycki et al (1959)], using exactly 
the same pool of virus material as was used in Léopoldville. These studies indicated a 
serological efficacy of 90 to 95% for the CHAT strain.”
This was the first indication that the immunogenicity of live polio vaccines might be to 
some degree impaired in low-income, tropical countries. It would not be the last.
In the years following the 1959 conference, the attenuated strains developed by Albert 
Sabin at  the  Children’s  Hospital  Research Foundation (Cincinnati,  USA) edged out  their 
competitors (including the CHAT strain) to become the first licensed live poliovirus vaccines. 
Monovalent vaccines targeting each of the three poliovirus serotypes were licensed in the 
USA in 1961 and 1962, and a trivalent vaccine combining all three serotypes was licensed in 
1963.  These  vaccines  have  since  formed  the  cornerstone  of  efforts  to  halt  poliovirus 
transmission. Their use as part of the Global Polio Eradication Initiative has helped to bring 
about the reduction of polio from a global disease responsible for 350,000 cases of paralysis 
each year (the estimated incidence when the programme was launched in 1988) to a disease 
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on the brink of  extinction.  Just  74 wild poliovirus cases were documented in 2015 – the 
lowest number on record.
But the issue of impaired vaccine immunogenicity in low-income countries has not 
gone away. Vaccine trials in these regions have consistently documented seroconversion rates 
inferior  to  the  near-complete  serological  protection  observed  in  high-income  countries 
(Patriarca et al, 1991). This has been a formidable obstacle to polio eradication efforts, but not 
an insurmountable one. In 2007, 874 wild poliovirus cases occurred in India – 66% of the 
world’s  total  (WHO,  2016a).  However,  the  use  of  oral  poliovirus  vaccine  in  routine 
immunisation  alongside  frequent  rounds  of  mass  immunisation  (national  or  subnational 
campaigns  targeting  all  children  under  5  years  of  age)  was  sufficient  to  interrupt  polio 
transmission, and India was declared free of the disease in 2012. It is likely that efforts on a 
similar scale will be required to halt transmission in the two countries that remain endemic 
for polio – Afghanistan and Pakistan – where the issue of impaired vaccine performance is 
compounded by political unrest, vaccine boycotts, and a recent surge in violence targeting 
vaccination workers.
The phenomenon of impaired vaccine efficacy in low-income countries is not unique to 
polio.  Similar  deficits  have  been  observed  for  licensed  oral  vaccines  targeting  rotavirus 
(Madhi et al, 2010) and cholera (Su-Arehawaratana et al, 1992). One live-attenuated Shigella 
vaccine  candidate  developed by the  Pasteur  Institute  was  reactogenic  and immunogenic 
when administered to North American adults;  however,  during trials  in  Bangladesh,  the 
same  vaccine  elicited  no  adverse  reactions,  was  not  excreted,  and  failed  to  induce  a 
serological response in any recipient (WHO, 2006; Levine et al, 2007).
In spite of several decades of research, we have failed to establish a clear understanding 
of the factors responsible for the impaired efficacy of oral vaccines in low-income countries. 
While  it  is  conceivable  that  polio  may  be  eradicated  before  these  mechanisms  are  fully 
elucidated, this obstacle stands in the way of other oral vaccines, including those currently in 
use and those yet to be developed. Moreover, poliovirus has repeatedly demonstrated its 
potential  to spread to regions previously clear of  infection.  Until  eradication is  achieved, 
there is an imperative to better understand the factors that shape our immune response to 
the virus, and potential ways this immunity might be enhanced.
I have spent the last 4 years studying the mechanisms influencing the immunogenicity 
of  oral  vaccines,  with  an  emphasis  on  the  impact  of  the  commensal  and  pathogenic 
organisms that inhabit the gut in infancy. The results of these endeavours are presented in 
the pages that follow. 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Chapter 1: Introduction
1.1. Background
Enteric pathogens represent a substantial threat to public health. This is a threat that 
takes many forms. Bacterial pathogens such as Vibrio cholerae and enterotoxigenic Escherichia 
coli (ETEC) colonise the mucosal surface of the small intestine before releasing toxins that 
induce  diarrhoea,  vomiting,  and  abdominal  cramps.  Rotavirus  and  several  other  enteric 
viruses invade enterocytes in the intestinal epithelium, inducing functional changes and cell 
damage that give rise to severe diarrhoea, vomiting, cramps, and fever. The ingestion of just 
ten  cysts  of  the  flagellate  protozoan Giardia  lamblia  is  sufficient  to  induce  morphological 
changes and apoptosis of epithelial cells in the small intestine, resulting in diarrhoea that 
may  last  in  excess  of  6  weeks  (Rendtorff,  1954).  Together,  enteropathogens  account  for 
several million cases of diarrhoea each year and approximately 800,000 deaths, the majority 
of which occur among children in low-income countries (Liu et al, 2012). 
Not all symptoms are elicited in the gastrointestinal tract. Following replication in the 
intestinal  mucosa,  polioviruses  and several  other  members  of  the  Enterovirus  genus can 
spread via the bloodstream to the central nervous system, where the destruction of nerve 
cells may give rise to paralysis. Enteroviruses may also cause encephalitis, hand-foot-and-
mouth  disease,  myocarditis,  and  a  range  of  other  sequelae  (Pons-Salort  et  al,  2015).  In 
addition to the direct consequences of infection, repeated exposure to bacterial, viral, and 
eukaryotic  enteropathogens  is  thought  to  contribute  to  the  ‘vicious  cycle’  of  intestinal 
damage, malabsorption, and immune dysfunction at the heart of malnutrition and stunting 
among infants in low-income countries (Lang, 2010). Malnutrition, in turn, may contribute to 
more  than  half  of  deaths  that  occur  among  children  under  5  years  of  age  worldwide 
(Caulfield et al, 2004).
Oral  vaccines are,  in  many respects,  ideal  tools  for  tackling enteric  infections.  These 
vaccines are easy to administer and cause minimal discomfort for the recipient. They have 
the  capacity  to  induce  local  immunity  in  the  intestinal  mucosa  (the  primary  site  of 
enteropathogen  replication),  thereby  protecting  the  vaccinated  individual  from  infection 
following  subsequent  pathogen  exposure  and  –  by  blocking  onward  transmission  – 
enhancing the herd effects of vaccination. And they have the potential to be produced in 
large quantities at low cost – the price per dose of oral poliovirus vaccine (OPV) is currently 
less than US $0.15, while inactivated poliovirus vaccine (IPV) costs approximately $0.85 per 
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dose  in  countries  eligible  for  Gavi  support ,  and  more  than  $1.50  per  dose  elsewhere 1
(UNICEF, 2014).
Yet oral vaccines have an Achilles’ heel. They have consistently been shown to be less 
immunogenic  in  the low-income countries  that  experience the greatest  burden of  enteric 
disease. In this chapter, I will outline what is currently known regarding the scale of this 
phenomenon, focusing predominantly on polio and rotavirus vaccines given their central 
role  in  the  chapters  that  follow.  I  will  then  review  our  understanding  of  the  potential 
mechanisms that might account for the impaired performance of oral vaccines in low-income 
countries. In doing so, I will introduce the central concern of this thesis – the potential role of 
the intestinal microbiota in shaping our immune response to oral vaccines.
1.2. Polio
Despite the potential benefits of oral vaccines, they make up only a small portion of the 
global vaccine market in 2016. By far the most widely utilised is OPV, of which several billion 
doses  are  currently  administered  as  part  of  routine  and  supplementary  immunisation 
programmes each year. Although I have touched briefly on the history of OPV above, in this 
section I will expand on the nature of this vaccine, the pathogenesis of the disease it targets, 
and the available data regarding geographic variation in vaccine performance. 
1.2.1. Pathogenesis and clinical course
Polioviruses  are  members  of  the  genus Enterovirus  in  the  family  Picornaviridae –  a 
group of small (~27-nm diameter), non-enveloped viruses that also includes rhinovirus (the 
infectious  agent  responsible  for  the  common  cold)  and  hepatovirus  A (responsible  for 
hepatitis A). Picornaviruses are made up of single-stranded, positive-sense RNA genomes 
approximately 7,500 nucleotides in length, which are surrounded by protein capsids with 
icosahedral symmetry. Polioviruses are stable at acidic pH (a prerequisite for gastrointestinal 
transit). They remain infectious at 4°C for several weeks and at 30°C for several days, but are 
inactivated by temperatures exceeding 55°C (Sutter et al, 2008). 
Following ingestion, polioviruses attach to and enter cells via CD155 (also referred to as 
the poliovirus receptor) – a receptor that is not shared by other members of the Enterovirus 
genus. Replication occurs in both the nasopharynx and gastrointestinal tract. Although some 
 The Gavi Alliance is a public–private partnership set up in 2000 with the aim of improving access to 1
vaccines in the world’s poorest countries.
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uncertainty remains regarding the primary sites of viral replication, studies in humans and 
non-human  primates  point  to  the  importance  of  mucosa-associated  lymphoid  tissues, 
including the tonsils, intestinal M cells, and Peyer’s patches, as well as the lymph nodes that 
drain  these  tissues  (Sabin  and Ward,  1941;  Bodian,  1955;  Sicinski  et  al,  1990).  Following 
replication at these sites, polioviruses may transfer via the bloodstream to other susceptible 
tissues, including the central nervous system, where replication in nerve fibres may lead to 
acute flaccid paralysis (AFP). Recent intramuscular injection or skeletal muscle injury may 
also predispose individuals to ‘provocation poliomyelitis’, wherein invasion of the nervous 
system occurs via retrograde axonal transport (Gromeier and Wimmer, 1998).
Although  the  consequences  of  poliovirus  infection  can  be  severe,  the  majority  of 
infections  are  either  asymptomatic  (~72%)  or  resolve  after  a  period  of  minor  illness 
characterised by fever, nausea, malaise, vomiting, constipation, sore throat, or a combination 
of these symptoms (~24%) (Gelfand et al, 1957; Sutter et al, 2008). Nonparalytic poliomyelitis 
occurs in 1–4% of cases, wherein a period of fever and malaise is followed by the onset of 
aseptic meningitis characterised by severe headache, vomiting, and stiffness in the neck and 
back (Horstmann [1949], as cited by Sutter et al [2008]). Symptoms last for up to 10 days, and 
are typically followed by a swift and complete recovery (Sutter et al, 2008).
Paralytic poliomyelitis occurs in less than 1% of cases (Melnick and Ledinko, 1953). It is 
this form of the disease that is associated with iconic images of the ‘iron lung’ – the coffin-
like  structure  developed in the late  1920s  to  provide artificial  respiration for  individuals 
whose paralysis has compromised their breathing. The clinical course of paralytic disease is a 
cruel one. After a period of minor illness, symptoms typically resolve for several days. This is 
followed by the sudden onset of fever accompanied by flaccid paralysis, usually beginning 
7–28 days after infection (Sartwell, 1952). The extent of paralysis depends on the region and 
severity of nerve damage. Involvement of the spinal column (spinal poliomyelitis) accounts 
for approximately 79% of paralytic cases , and is characterised by paralysis of one or more 2
limbs. Spinal poliomyelitis is generally asymmetric,  more severe proximally than distally, 
and accompanied by the loss (partial or complete) of deep tendon reflexes. In 2% of paralytic 
cases, nerve damage occurs in the bulbar region of the brain stem (bulbar poliomyelitis), 
affecting  muscles  involved in  swallowing,  speech,  and respiration,  among others.  In  the 
remaining 19% of cases, both the spinal column and brain stem are affected (bulbospinal 
poliomyelitis). The maximum extent of paralysis is typically reached within a few days of the 
onset of symptoms. Although the damaged nerve cells cannot be replaced, other muscles 
 Based on documented cases of poliomyelitis in the USA between 1969 and 1979 (CDC, 2009). 2
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may compensate to bring about a partial or complete recovery within 6 months. However, 
paralytic poliomyelitis is fatal in 2–5% of children and 15–30% of adults, and this fatality rate 
increases to 25–75% among individuals with bulbar involvement (CDC, 2009).
Notably, while clinical outcomes vary, infected individuals may contribute to poliovirus 
transmission regardless of whether or not they are symptomatic. Faecal shedding of viruses 
begins within several days of exposure, and reaches peak levels after 7 days (Onorato et al, 
1991).  In  a  study of  110 children infected with wild polioviruses  in  Louisiana,  shedding 
lasted for 1–114 days, with a mean duration of 24 days (Gelfand et al, 1957). As noted above, 
polioviruses also replicate in the nasopharynx, and may be detected in pharyngeal secretions 
for 1–2 weeks (Onorato et al, 1991). Nasopharyngeal shedding is suspected to be the major 
route of poliovirus transmission in areas with good sanitation and hygiene (Salk and Salk, 
1977).  While  it  may  also  contribute  to  circulation  elsewhere,  faecal–oral  transmission  is 
thought to predominate in regions where wild poliovirus persists today.
Figure 1.1 provides a summary of the potential outcomes of poliovirus infection. Further 
details regarding the structure, pathology, and natural history of this virus can be found in 
several  detailed  reviews,  among them Robertson  (1993),  Racaniello  and  Ren  (1996),  and 
Sutter et al (2008).
1.2.2. The polio endgame
When the Global  Polio Eradication Initiative (GPEI)  was formed in 1988,  polio was 3
endemic in 125 countries. Thanks to the roll-out of OPV and IPV, the virus had largely been 
brought  under  control  in  industrialised countries  –  the  UK had not  seen a  domestically 
acquired case of polio since 1984, while the USA had been clear of wild poliovirus cases since 
 The GPEI is a public–private partnership led by the WHO, Rotary International, the US Centers for 3
Disease  Control  and  Prevention,  and  UNICEF.  It  was  launched  following  the  41st  World  Health 
Assembly, held in Geneva in May 1988.
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Figure 1.1. Outcomes of poliovirus infection.
1979. However, polio was thriving elsewhere: it has been estimated that during the 1970s and 
1980s, between 200,000 and 400,000 cases of poliomyelitis occurred each year in India alone 
(John and Vashishtha, 2013).
For its first two decades, the GPEI relied predominantly on the use of trivalent OPV 
(tOPV) to combat poliovirus circulation. Each dose of this vaccine contains 106 median tissue 
culture infective doses (TCID50)  of attenuated type 1 virus, 105 TCID50 of type 2 virus, and 4
105.5 TCID50 of type 3 virus – a ‘balanced’ formulation that was developed in the early 1960s 
to overcome the interference observed among vaccine strains when they are co-administered 
(with type 2 viruses often replicating at the expense of types 1 and/or 3) (Robertson et al, 
1962; Morimoto, 2001). The vaccine strains in use today have not changed from those first 
developed by Albert Sabin at the Children’s Hospital Research Foundation, Cincinnati, in the 
late  1950s.  For  each  serotype,  the  attenuated  strain  was  developed  by  passaging  wild 
polioviruses through kidney, testicular, and/or skin cells obtained from non-human primates 
(preceded  for  serotype  3  by  intracerebral  passage  in  rhesus  macaques),  leading  to  the 
accumulation of genetic changes that removed the neurovirulent potential of the virus while 
still  allowing it to infect the gastrointestinal tract (Sutter et al,  2008). The WHO has been 
responsible for the custody and distribution of Sabin seed strains since 1973 (Cockburn, 1988).
As  a  live-attenuated  vaccine,  OPV  induces  an  immune  response  analogous  to  that 
produced by wild viruses (Ghendon and Sanakoyeva, 1961). The vaccine polioviruses elicit 
both systemic humoral  immunity,  which prevents  the transit  of  poliovirus to  the central 
nervous system and thus protects against paralysis,  and mucosal immunity,  which limits 
poliovirus replication at the nasopharyngeal and intestinal mucosal surfaces (Onorato et al, 
1991). In addition to its low cost and ease of administration, the ability of OPV to induce a 
mucosal immune response is a crucial advantage over IPV – while the latter is capable of 
inducing  a  strong  systemic  immune  response  that  protects  vaccinated  individuals  from 
paralysis, it induces only limited mucosal immunity, and is therefore less effective than OPV 
at preventing poliovirus replication and shedding following subsequent virus exposure .5
Although initial optimism that polio would not see the new millennium turned out to be 
misplaced, the GPEI has made huge steps towards achieving its goal, reducing the annual 
incidence of wild poliovirus cases by more than 99% since its launch. The last case of wild 
 The quantity of virus required to produce a cytopathic effect in 50% of cells in tissue culture.4
 It is worth noting that while IPV fails to induce a strong mucosal immune response on its own, it has 5
recently become clear that the vaccine may boost mucosal immunity among individuals previously 
immunised with OPV (Jafari et al, 2014; John et al, 2014).
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type 2 poliovirus occurred in northern India in 1999, while paralysis attributable to wild type 
3 poliovirus has not been documented since November 2012 (the last case occurring in Yobe, 
Nigeria).  As  of  early  2016,  Afghanistan  and  Pakistan  are  the  last  remaining  refuges  of 
endemic poliovirus transmission.
The continued use of OPV is pivotal to the polio endgame. Currently, 145 countries use 
the vaccine in routine immunisation programmes (WHO, 2016c), with three doses typically 
administered at  monthly intervals starting at  6 weeks of age.  Routine immunisation also 
includes  a  birth  dose  of  OPV  in  high-risk  settings.  To  supplement  these  efforts,  mass 
immunisation campaigns (also termed supplementary immunisation activities [SIAs]) have 
increasingly been used in populations with persistent poliovirus circulation or a heightened 
risk of re-introduction. SIAs are performed at either national or subnational level (targeting 
one or several districts) with the aim of immunising all children under 5 years of age in a 
window  of  several  days.  To  enhance  coverage,  vaccines  are  administered  both  at  fixed 
vaccination posts and in house-to-house visits. Since 2005, SIAs have frequently employed 
monovalent OPV (mOPV) and bivalent OPV (bOPV) targeting poliovirus types 1 and 3 in 
order to improve the protective efficacy against these serotypes (by reducing interference 
between the vaccine strains) (Sutter et al, 2010; Cochi and Linkins, 2012). These changes have 
proven critical to halting the spread of polio in regions where the virus is most resilient, such 
as India (John and Vashishtha, 2013) and Nigeria (Mangal et al, 2014).
In 2014, an estimated 2.3 billion doses of OPV were administered across more than 300 
SIAs in 45 countries (Hagan et al, 2015). If these efforts are sustained, wild type 1 poliovirus 
may soon be consigned to the same fate as types 2 and 3. However, the polio endgame does 
not conclude with the eradication of wild polioviruses. On rare occasions, vaccine-associated 
paralytic poliomyelitis (VAPP) may occur among OPV recipients or their close contacts (Platt 
et al, 2014). There are an estimated 1–2 cases of VAPP per million primary immunisations 
with OPV (Nathanson and Kew, 2010).  Moreover,  like  wild polioviruses,  vaccine viruses 
have the potential to spread from person to person. While circulation is generally short-lived, 
sustained  transmission  chains  may  occur  in  underimmunised  populations.  In  rare 
circumstances,  the  Sabin  strains  may  lose  their  attenuating  mutations,  regaining 
transmissibility and the ability to cause paralysis (Burns et al, 2014). Such viruses are termed 
circulating vaccine-derived polioviruses (cVDPVs), and may have a similar clinical attack 
rate and severity to wild-type viruses (Jenkins et al, 2010). Between 2000 and 2013, outbreaks 
of cVDPV occurred in 18 different countries, causing more than 720 cases of poliomyelitis 
(Burns et al, 2014).
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Given the risk of  VAPP and cVDPVs,  the use of  OPV must  be phased out  from all 
immunisation activities if the eradication of polio is to be achieved (GPEI, 2013). Accordingly, 
we are presently in the midst of the sequential and globally synchronised withdrawal of the 
three  strains  of  OPV.  This  began  with  the  withdrawal  of  serotype  2  in  April  2016  –  a 
transition requiring the replacement of tOPV with bOPV in all routine and supplementary 
immunisation programmes – and will culminate (as currently scheduled) in the cessation of 
bOPV in 2019. To fill the gap in poliovirus immunity, the WHO Strategic Advisory Group of 
Experts (SAGE) on immunisation recommended that all countries introduce at least one dose 
of  IPV  into  routine  immunisation  programmes  by  the  end  of  2015  (SAGE,  2013a).  This 
deadline was met by all but 45 countries, with remaining countries formally committed to 
the introduction of IPV by the end of 2017 (WHO, 2016b). 
Thus, the timely eradication of poliovirus could see the end of OPV use by the close of 
the decade. Until then, the widescale use of mOPV and bOPV in routine immunisation and 
SIAs remains intrinsic to the polio endgame.
1.2.3. Variation in oral poliovirus vaccine performance
As noted above, the impaired performance of OPV in low-income countries was first 
brought to light during the early field trials of this vaccine. The immunogenicity and efficacy 
of OPV has since been examined in numerous studies conducted across the globe. How have 
these  studies  measured  OPV  performance?  And  what  have  they  taught  us  about  the 
discrepancies in vaccine outcomes between high- and low-income countries?
i. Systemic immunity: kinetics, duration, and the microneutralisation assay
Following exposure to live polioviruses, there are several facets to the ensuing immune 
response, with both systemic and mucosal components. Systemic humoral immunity is by 
far the most commonly tested outcome in clinical trials of poliovirus vaccines, and is the 
primary focus in the chapters that follow. It is characterised initially by the production of 
poliovirus-specific IgM antibodies, which appear in serum within 1–3 days of viral exposure 
and persist  for up to 3 months (Ogra and Karzon, 1971;  Ogra et  al,  1980).  Serum IgA is 
detected  in  some  individuals,  and  may  persist  at  low  levels  (Ogra  and  Karzon,  1971; 
Herremans et al, 1999). However, IgG antibodies are the mainstay of the systemic immune 
response. These begin to appear in the 7 days following poliovirus exposure, and increase in 
titre over the next 4–5 weeks to become the predominant class of persistent antibody.
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Systemic immunity following wild poliovirus infection may be long-lived, potentially 
lifelong – a study conducted among members of an isolated community in northern Alaska 
found  that  serum  antibodies  may  persist  for  more  than  40  years  without  subsequent 
re-infection (Paul et al, 1951). Serum antibodies have also been shown to persist for several 
years after OPV administration (Rousseau et al, 1973; Nishio et al, 1984; Tafuri et al, 2008). 
However, titres wane over time (Krugman et al, 1977), and subsequent re-immunisation may 
lead to the reappearance of IgM in serum and a boost in IgG titre (Ogra et al, 1980).
Clinical trials of OPV generally do not distinguish between different classes of serum 
antibody. Instead, neutralising antibodies (predominantly of class IgG) are measured using a 
standardised microneutralisation assay in which known quantities of polioviruses of a given 
serotype are incubated with serum samples at two-fold serial dilutions and subsequently 
tested for their capacity to cause a cytopathic effect in tissue culture – the most dilute sample 
in which viruses are neutralised is then recorded as the antibody titre (WHO, 1997). Notably, 
passive antibody administration has been shown to protect against poliomyelitis in humans 
and non-human primates, and the detection of antibodies at a titre of 1 in 8 or greater is 
considered a good correlate of protection (Hammon et al, 1954; Bodian and Nathanson, 1960). 
Seroconversion following the administration of OPV is generally defined as a four-fold 
rise in neutralising antibody titre between pre- and post-vaccination samples or the detection 
of neutralising antibodies in individuals who were previously seronegative. In infants, the 
presence of passively acquired maternal antibodies, transferred to the foetus via the placenta, 
must also be taken into account. These antibodies decay with a half-life of approximately 28 
days (Gelfand et al, 1960; Robertson, 1993). Accordingly, during immunogenicity studies in 
infants, pre-vaccination antibodies are assumed to decay at this rate and seroconversion is 
defined  as  a  four-fold  rise  in  titre  over  the  expected  level  of  maternal  antibodies  upon 
collection of the post-vaccination sample. 
Notably, seroconversion is strongly correlated with the intestinal replication – or ‘take’ – 
of  homotypic  vaccine  polioviruses,  as  inferred  by  the  presence  of  these  viruses  in  post-
vaccination faecal samples (John, 1975; Onorato et al, 1991). In a recent trial of monovalent 
type 3 OPV (mOPV3) – a trial that I will return to in Chapter 6 of this thesis – seroconversion 
was observed in 85% of infants who shed type 3 poliovirus 7 days after vaccination and 10% 
of  non-shedders.  In  light  of  this  correlation,  the  replication  of  vaccine  poliovirus  has 
frequently been considered as an endpoint in clinical trials of OPV.
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ii. Oral poliovirus vaccine immunogenicity
During the first  trial  of  ‘balanced’  tOPV,  a  single  dose of  vaccine was offered to  all 
residents of Prince Albert (a city in Saskatchewan, Canada) within an 8-day period starting 
on  the  27th  February  1961  (Robertson  et  al,  1962).  In  a  subset  of  approximately  600 
individuals,  two-thirds  of  whom were  infants  or  pre-adolescent  children,  antibody titres 
were  measured  in  serum  samples  collected  pre-  and  post-vaccination.  The  majority  of 
vaccinees already harboured antibodies to one or more serotypes owing to the widespread 
use  of  IPV  since  1955.  However,  among  individuals  without  homotypic  antibody  pre-
vaccination, 92% developed detectable antibodies to type 1 poliovirus (albeit at trace levels in 
26%), while 100% developed antibodies to serotypes 2 and 3. 
Subsequent  trials  in  high-income  countries  have  confirmed  that  tOPV  is  capable  of 
inducing a robust systemic immune response, particularly after multiple doses (Table 1.1). 
Seroconversion rates have been considerably more variable, however, among studies in low-
income  countries.  In  a  comprehensive  review  of  OPV  trials  conducted  in  developing 
countries, Patriarca et al (1991) documented average seroconversion rates after three doses of 
tOPV of 73% for type 1 poliovirus (range, 36−99%), 90% for type 2 (range, 71−100%), and 
70% for type 3 (range, 40−100%). The impaired performance of tOPV was not universal – one 
study in Sri Lanka, for example, recorded seroconversion rates in excess of 97% for all three 
serotypes after a course of three doses commencing at 3 months of age (EPI, 1989). On the 
other hand, in studies conducted in India (Choudhury et al, 1973; Pangi et al, 1977), Iran 
(Mokhtary et al, 1986), Kenya (Metselaar et al, 1977), Ghana (Bottiger et al, 1981), and Brazil 
(de Brito Bastos et al, 1974), seroconversion rates did not exceed 80% for any serotype. 
Table 1.1. Seroprevalence after multiple doses of trivalent oral poliovirus vaccine among infants 
in the USA.
Age at 
vaccination 
(months)
Seroprevalence after two 
doses (%)
Seroprevalence after three 
doses (%)
PV1 PV2 PV3 PV1 PV2 PV3 Ref.
2, 4, 6 93 100 91 97 100 96 Hardy et al (1970)
89 100 93 99 100 99 Cohen-Abbo et al (1995)
2, 4, 12 92 99 90 96 100 96 Hardy et al (1970)
100 100 100 100 100 100 Faden et al (1990)
2, 4, 18 92 100 96 97 100 100 McBean et al (1988)
95 100 90 96 100 98 Modlin et al (1997)
Adapted from a table published by Gindler et al (1995). Abbreviations: PV1, type 1 poliovirus; PV2, 
type 2 poliovirus; PV3, type 3 poliovirus.
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Findings have been similar for mOPV and bOPV (though comparisons of the latter are 
undermined by the scarcity of relevant data from high-income countries). In a systematic 
review by Caceres and Sutter (2001), median homotypic seroconversion rates per dose of 
mOPV among studies in temperate countries – including the USA, Denmark, Hungary, and 
the Netherlands – were 95% for type 1 poliovirus (range, 90–100%), 98% for type 2 (range, 
83–100%), and 94% for type 3 (range, 70–100%). Meanwhile, among studies in non-temperate 
countries – including Brazil, India, Mexico, Singapore, and Uganda – median seroconversion 
rates were 81% for serotype 1 (range, 53–89%), 89% for type 2 (range, 77–93%), and 72% for 
type 3 (range, 52–80%).
Figure 1.2 provides a comparison of  seroconversion rates observed across successive 
doses of tOPV in Vellore, India (John, 1976), and Maryland, USA (McBean et al, 1988). These 
should be interpreted with caution given the notable differences in study design, but provide 
an illustration of the scale of the deficits observed in OPV immunogenicity between low- and 
high-income countries. 
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Figure 1.2. Impaired immunogenicity of trivalent oral poliovirus vaccine in India versus the USA. 
Seroconversion rates for India are obtained from a report by John (1976), which combines results 
from several trials performed in Vellore between 1969 and 1976 (John and Jayabal, 1972; John, 1976; 
John et al, 1976). Up to five doses of tOPV were administered to infants aged between 6 weeks and 6 
years  at  intervals  of  4–8  weeks  in  these  studies.  For  at  least  the  first  two  doses  of  OPV, 
seroconversion  rates  are  derived  from  homotypic  seronegative  infants,  so  maternal  antibodies 
cannot account for the deficits in immunogenicity compared with US children. Immunogenicity data 
from the USA are obtained from a study by McBean et al (1988) in which three doses of tOPV were 
administered to infants in Maryland at 2, 4, and 18 months of age. Seroconversion rates following 
the second and third doses are based on the proportion of individuals with detectable antibodies at 
18  and  20  months  of  age,  respectively.  These  are  interpreted  here  as  seroconversion  on  the 
assumption that there was no exposure to live viruses aside from the administered vaccine, and that 
the persistence of maternal antibodies at 18 months of age was negligible. Abbreviations: PV1, type 1 
poliovirus; PV2, type 2 poliovirus; PV3, type 3 poliovirus; tOPV: trivalent oral poliovirus vaccine.
iii. Mucosal immunity
In addition to humoral immunity, exposure to live polioviruses elicits a local response at 
the  nasopharyngeal  and intestinal  mucosal  surfaces,  preventing  replication  at  these  sites 
following subsequent  viral  exposure (Hird and Grassly,  2012).  The most  widely adopted 
measure  of  poliovirus-specific  mucosal  protection  involves  administration  of  a  challenge 
dose of OPV, wherein the subsequent shedding of vaccine polioviruses in nasopharyngeal 
and stool samples signifies viral replication in the nasopharynx and gut, respectively, while 
the absence of shedding can be viewed as an indicator of mucosal protection.
Although  some  uncertainty  remains  regarding  the  immune  effectors  responsible  for 
poliovirus-specific mucosal immunity, secretory antibodies appear to play an important role. 
Following exposure to OPV, secretory IgA appears in the nasopharynx and duodenum after 
1–3 weeks (Ogra et al, 1968). This rise in intestinal antibody coincides with the decline in 
viral excretion (Valtanen et al, 2000). Following viral clearance, the titre of poliovirus-specific 
IgA in  stool  samples  has  been  shown  to  correlate  with  protection  against  subsequent 
intestinal replication (Onorato et al, 1991; Morimoto, 2001; Samoilovich et al, 2003), and a 
similar  relationship has  been observed between nasal  IgA and nasopharyngeal  shedding 
(Ogra and Karzon, 1971). A study performed among elderly individuals in the Netherlands 
also  found  that  the  presence  of  homotypic  circulating  IgA  antibodies  decreased  the 
likelihood of viral excretion following challenge with mOPV of serotypes 1 or 3 (Buisman et 
al,  2008).  However,  the  titre  of  secretory  or  serum  IgA required  for  protection  against 
poliovirus replication is unknown. Moreover, in contrast to serum neutralising antibodies, a 
standardised assay for the detection of poliovirus-specific IgA is currently lacking.
It is likely that the variation in OPV-induced humoral immunity observed in different 
geographic  settings  also  extends  to  mucosal  protection,  particularly  given  that  vaccine 
poliovirus replication is correlated both with seroconversion and the induction of secretory 
antibody responses. However, data to support this case are undermined by several factors. 
First, mucosal immunity to OPV has not been as extensively studied as humoral immunity, 
particularly  in  low-income countries  (Hird  and Grassly,  2012).  Second,  among challenge 
studies that have examined mucosal immunity, factors such as the nature of the challenge 
dose and the age at which it is administered have varied considerably (Kok et al, 1992; WHO, 
1996; Jafari et al, 2014; John et al, 2014). The latter is particularly relevant – in contrast to 
humoral immunity, wherein seroconversion can be interpreted as an all-or-nothing response 
that  is  durable  over  many  years,  mucosal  immunity  wanes  over  time,  enabling  OPV-
immunised individuals to be re-infected (Smith et al, 1976; Onorato et al, 1991). During a 
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retrospective  analysis  of  AFP surveillance  data  in  India,  Grassly  et  al  (2012)  observed a 
marked increase in the odds of shedding challenge virus among individuals who had not 
received a dose of OPV for more than 6 months compared with those who had received a 
dose in the past 40 days, suggesting that significant waning of mucosal protection occurs 
within  a  year  of  vaccination.  Finally,  although failure  to  shed  vaccine  viruses  following 
challenge is widely considered as an indicator of mucosal immunity, there are (as considered 
in greater detail below) a range of factors that may inhibit replication of vaccine polioviruses. 
Thus, if shedding after OPV challenge is observed to be lower in a certain population, it may 
be incorrect to infer that mucosal immunity must be higher in these individuals.
iv. Cell-mediated immunity
In addition to the induction of humoral immunity, OPV has been shown to elicit a cell-
mediated immune response, including the production of poliovirus-specific CD4+ and CD8+ 
T cells (Katrak et al, 1991; Wahid et al, 2005). T cell responses display cross-reactivity among 
poliovirus serotypes, and may therefore confer a degree of heterotypic immunity (Katrak et 
al, 1991). However, in contrast to humoral immunity, cell-mediated responses do not appear 
to be a prerequisite for viral clearance. In particular, while B cell immunodeficiencies such as 
hypogammaglobulinaemia have consistently  been linked with the  long-term excretion of 
vaccine polioviruses after OPV administration (Martin et al, 2000; MacLennan et al, 2004), 
this is not the case for T cell immunodeficiencies such as HIV (Hennessey et al, 2005).
v. Efficacy
The efficacy of  IPV was determined on the basis  of  one of  the largest  field trials  in 
history, wherein approximately 400,000 individuals were randomly assigned to receive IPV 
or placebo, and an additional 200,000 vaccinated individuals were followed up alongside 
unvaccinated  children  (Francis  et  al  [1955],  as  cited  by  Plotkin  and  Vidor  [2008]).  No 
comparable study has been performed for OPV (nor, indeed, would it have been ethical to do 
so  given the  availability  of  IPV).  However,  the  efficacy of  OPV has  been determined in 
several studies by comparing the vaccination histories of paralytic poliomyelitis cases with 
those of controls. These have predominantly taken one of two forms: case–control studies 
following poliovirus outbreaks (e.g., Deming et al, 1992) and retrospective analyses of AFP 
databases in which poliomyelitis cases are compared with cases of non-polio AFP (e.g., Grassly 
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et al, 2006). A summary of per-dose protective efficacy estimates against type 1 poliovirus 
from a selection of these studies is provided in Table 1.2. 
Notably, data regarding the protective efficacy of OPV come almost exclusively from 
low-income  countries.  There  is  limited  scope,  therefore,  to  compare  efficacy  estimates 
between  high-  and  low-income  settings,  though  it  would  be  reasonable  to  assume  that 
discrepancies in OPV immunogenicity are reflected by similar disparities in efficacy given 
that humoral immunity is  a well-established correlate of protection against poliomyelitis. 
Estimates derived from AFP surveillance databases do, however, provide insight into within-
country variation in OPV efficacy that is pertinent both to the polio endgame and the topic of 
this thesis. During an analysis of more than 96,000 AFP cases recorded in India between 1997 
and 2005,  Grassly et  al  (2006)  observed a decrease in the odds of  paralytic  poliomyelitis 
consistent  with  a  constant  probability  of  protection  per  dose  of  tOPV.  While  a  per-dose 
efficacy of 13% was observed across the whole of India for type 1 poliovirus, when a separate 
analysis was performed to delineate OPV response in the northern states of Uttar Pradesh 
and Bihar – responsible for the majority of poliomyelitis cases in India since 1997 despite 
intensive vaccination efforts – per-dose efficacy estimates were 9% for Uttar Pradesh, 18% for 
Bihar,  and 21% for the rest of India.  Similar results were observed for protective efficacy 
against type 3 poliovirus. Thus, the authors concluded that the persistence of polio in India 
in 2005 was attributable, in part, to within-country variation in OPV efficacy. Mangal et al 
(2014)  applied a  similar  approach when examining factors  underlying the  persistence  of 
!     s30
Table 1.2.  Per-dose protective efficacy of oral  poliovirus vaccine against  paralytic  poliomyelitis 
attributable to type 1 poliovirus.
Per-dose efficacy, % (95% CI)
Country Method mOPV bOPV tOPV Ref.
Gambia Outbreak-CC - - 68 (27–86) Deming et al (1992)
Oman Outbreak-CC - - 30 (-234–85) Sutter et al (1991)
India AFP-CC - - 13 (10–16) Grassly et al (2006)a
India (Uttar Pradesh) AFP-CC 30 (19–39) - 11 (7–14) Grassly et al (2007)a
Nigeria AFP-CC 67 (39–82) - 16 (10–21) Jenkins et al (2008)
Afghanistan/Pakistan AFP-CC 35 (16–49) 23 (10–35) 13 (6–19) O’Reilly et al (2012)
Nigeria AFP-CC 32 (26–38) 30 (20–38) 19 (16–23) Mangal et al (2014)
Abbreviations:  AFP-CC,  case–control  study  conducted  within  acute  flaccid  paralysis  surveillance 
database;  bOPV, bivalent oral  poliovirus vaccine;  CI,  confidence interval;  mOPV, monovalent oral 
poliovirus vaccine; Outbreak-CC, case–control study conducted following outbreak of poliomyelitis; 
tOPV, trivalent oral poliovirus vaccine.
a Data overlap.
poliomyelitis in Nigeria, revealing markedly lower protective efficacy of tOPV and mOPV in 
northern versus southern states.
vi. Inactivated poliovirus vaccine
Before moving on from polio,  it  is worth briefly considering the extent to which the 
geographic discrepancies in vaccine immunogenicity outlined above extend to IPV. When 
three doses of this vaccine are administered to infants in high-income countries at 2, 4, and 6 
months of age, seroconversion to all three serotypes is consistently observed in more than 
95%  of  individuals  (Aristegui  et  al,  2003;  Plotkin  and  Vidor,  2008;  Tapiero  et  al,  2013). 
Seroconversion rates may fall short of these levels when IPV is administered in low-income 
countries using the Expanded Programme on Immunisation (EPI) schedule (6, 10, and 14 
weeks of age) – one study adopting this schedule in Thailand, for example, documented 
seroconversion rates of 67%, 65%, and 94% for serotypes 1, 2, and 3, respectively (WHO, 
1996). However, it is likely that these findings largely reflect differences in the timing and 
interval of IPV administration, and the influence of these factors on the titre of maternal 
antibodies at the time of vaccination. The presence of elevated titres of maternal antibodies 
(e.g.,  1  in  64  or  greater)  has  been  shown  to  have  a  marked  inhibitory  effect  on  IPV 
immunogenicity (Kok et al, 1992; WHO, 1996). Accordingly, the earlier IPV is administered, 
the less time maternal antibodies will have had to decay, and the greater their inhibitory 
capacity. This notion is supported by a study conducted in Puerto Rico in which infants were 
randomly assigned to receive IPV at 6, 10, and 14 weeks of age or 2, 4, and 6 months of age – 
while seroconversion was observed in more than 99% of infants for all three serotypes using 
the  latter  schedule,  the  EPI  schedule  induced seroconversion  in  86%,  86%,  and 97% for 
serotypes 1, 2, and 3, respectively (Dayan et al, 2007).
Variation in maternal antibody titres among populations may therefore influence the 
immunogenicity of IPV during early infancy (as discussed below with reference to OPV). 
This variation has not been well quantified; however, it is feasible that titres will tend to be 
higher in countries where mothers have recently been exposed to circulating wild or vaccine 
polioviruses (SAGE, 2013b). 
Once maternal antibody titres have decayed, IPV induces a robust systemic immune 
response irrespective of geographic setting, and has proven highly immunogenic in regions 
where the performance of OPV is compromised. This was recently illustrated during a study 
conducted in Uttar Pradesh, India – a state previously linked with impaired OPV efficacy 
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(Grassly et al, 2006) – in which children up to 10 years of age were randomised to receive 
IPV,  bOPV,  or  no  vaccine  (Jafari  et  al,  2014).  Seroconversion  to  type  1  poliovirus  was 
observed in 83%, 98%, and 96% of IPV recipients and 14%, 13%, and 42% of bOPV recipients 
aged  6–11  months,  5  years,  or  10  years,  respectively.  Similar  seroconversion  rates  were 
observed  among  IPV  recipients  for  serotypes  2  and  3  (82–100%).  Thus,  while  the 
immunogenicity of IPV may be impeded by maternal antibodies in early infancy, it appears 
that  the injected vaccine does not face the same barriers to vaccine performance in low-
income countries observed for its oral counterpart.
vii. Seasonal variation in oral poliovirus vaccine performance
In addition to the geographic variation observed in the immunogenicity of OPV, marked 
seasonal  variation  in  vaccine  performance  has  been  documented  –  a  fact  that  will  be 
important to bear in mind when considering the factors shaping oral vaccine performance 
below. In particular, among infants in the Gambia who received four doses of tOPV starting 
at 6 weeks of age, seroconversion rates for all  three serotypes declined as the number of 
doses received during the rainy season increased (Cirne et al, 1995). Seroconversion to type 3 
poliovirus was observed in 84% of infants who received all doses outside the rainy season 
compared with 51% of those who received three of  more doses within the rainy season. 
Similar  trends  in  vaccine  efficacy  were  subsequently  observed  in  a  case–control  study 
conducted among children in the Gambia paralysed during an outbreak of type 1 poliovirus 
(Deming et al, 1997), while a marked reduction in OPV take was observed among Indian 
children immunised between April and September (warmer months that coincide with the 
high season for enterovirus transmission) (Grassly et al, 2012).
viii. Conclusions
For  more  than  half  a  century,  OPV  has  been  at  the  forefront  of  efforts  to  control 
poliovirus transmission owing to its low cost, ease of use, and ability to induce systemic and 
mucosal  immunity.  However,  the  immunogenicity  of  OPV  in  low-income  countries  has 
consistently  been  shown to  fall  short  of  the  robust  immune response  observed in  high-
income  countries.  Moreover,  within  countries  in  which  polio  has  proven  most  resilient, 
significant variation in OPV efficacy between regions has been implicated in sustaining viral 
circulation.  This  variation  in  the  efficacy  of  OPV  continues  to  stand  in  the  way  of  the 
eradication endgame as we move ever closer to polio’s extinction.
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1.3. Rotavirus
As we prepare for the synchronised withdrawal of one oral vaccine, another is in the 
process of being rolled out across the globe. The target is rotavirus – a disease that infects the 
majority of the world’s infants before the end of their third year of life, and a leading cause of 
severe gastroenteritis in high- and low-income countries alike (Clark et al, 2008; Estes and 
Greenberg, 2013).
1.3.1. Classification and pathogenesis
The potential role of viruses in the aetiology of diarrhoeal illness did not come to light 
until 1972, when a viral agent was identified as the cause of an outbreak of acute gastroenteritis 
in  the  US  city  of  Norwalk,  Ohio  (the  virus  was  subsequently  termed  Norwalk  virus) 
(Kapikian et al, 1972). Human rotaviruses were discovered soon after, following the use of 
electron microscopy to identify viral particles in duodenal samples obtained from infants 
with acute gastroenteritis (Bishop et al, 1973). These 70-nm icosahedral viruses, which make 
up a distinct genus in the family Reoviridae, consist of an outer capsid, an inner capsid, and 
an inner core surrounding a genome that consists of 11 segments of double-stranded RNA. 
Rotaviruses can be separated into seven serogroups (A to G, of which groups A, B, and C 
have been documented in humans) based on the cross-reactivity of antisera obtained from 
hyperimmunised animals. Serogroup determinants are predominantly located in the highly 
immunogenic inner capsid protein VP6 (Estes and Greenberg, 2013). Genetic reassortment 
can occur among members of the same serogroup, but not between groups (Yolken et al, 1988). 
Rotavirus serogroup A accounts for the vast majority of the diarrhoeal disease burden in 
infants,  and  has  been  the  focus  of  vaccine  development  efforts  to  date.  As  with  other 
serogroups,  group  A rotaviruses  can  be  divided  into  multiple  serotypes  based  on  the 
composition  of  the  outer  capsid  proteins  VP4  and  VP7,  which  elicit  serotype-specific 
antibody responses (as well as cross-neutralising antibodies in some instances). Rotaviruses 
can be distinguished according to G serotype (based on the glycoprotein VP7) and P serotype 
(based on the protease-sensitive protein VP4). However, owing to extensive cross-reactivity 
between P serotypes when assessed by monoclonal or polyclonal antisera, strains are now 
more commonly discriminated according to VP4 genotype (signified in square brackets), as 
determined by nucleic acid sequencing. More than 60 combinations of G and P serotypes 
have been shown to cause diarrhoeal disease. Although a small number of strains, including 
G1P[8],  G2P[4],  G3P[8],  G4P[8],  and  G9P[8],  account  for  the  majority  of  cases  globally 
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(Gentsch et al, 2005; Santos and Hoshino, 2005), other strains may be regionally important; 
for example, strain G8P[6] accounted for 42% of rotavirus cases observed during a study of 
children  with  acute  diarrhoea  in  Blantyre,  Malawi  (Cunliffe  et  al,  1999).  Moreover,  the 
distribution of serotypes within a region is not static – between 1999 and 2007, the proportion 
of rotavirus cases attributed to serotype G9 by Australia’s National Rotavirus Surveillance 
Program ranged annually from 7% to 75% (O'Ryan, 2009).
Rotaviruses are highly contagious, even in settings with high standards of hygiene and 
sanitation. Infected individuals may shed up to 100 billion viral particles per gram of stool 
(Flewett, 1983), while as few as 90 virions may be sufficient to establish a new infection in 
animal  models  (Payment  and  Morin,  1990) .  Transmission  is  predominantly  faecal–oral, 6
although  spread  via  respiratory  droplets  has  also  been  proposed  (Gurwith  et  al,  1981). 
Following ingestion, viruses replicate primarily in mature epithelial cells near the tips of the 
small  intestinal  villi.  In  contrast  to  the  gastroenteritis  induced  by  numerous  bacterial 
enteropathogens,  diarrhoea occurs with limited intestinal  inflammation.  Based on studies 
conducted in vitro and in animal models, disease pathogenesis has been linked with several 
distinct mechanisms, including malabsorption induced by the destruction of epithelial cells 
and the disruption of epithelial  cell  function (Boshuizen et al,  2003),  paracellular leakage 
caused by the disruption of tight junctions (Dickman et al, 2000), and the viral enterotoxin 
NSP4, which induces the secretion of chloride ions (and the consequent release of water) via 
a calcium-dependent signalling pathway (Ball et al, 2005). Viraemia may also occur, but has 
not been linked with any specific pathologic sequelae (Blutt et al, 2007). Additional details 
regarding the replication cycle and pathogenesis of rotavirus can be found in reviews by 
Estes and Greenberg (2013) and Desselberger (2014), among others.
1.3.2. Epidemiology
Among the myriad bacterial, viral, and eukaryotic diarrhoeal pathogens, rotavirus forms 
the greatest threat to human health. Exposure to the virus is universal – in the USA, evidence 
of prior rotavirus infection was apparent in more than 50% of infants aged 6–12 months and 
more than 90% of children aged 2–3 years prior to the introduction of rotavirus vaccination 
(Kapikian et al, 1978). Similarly, during a cohort study in Vellore, India, 81%, 96%, and 99% of 
 Although a minimum infectious dose of 100 virions is commonly cited for human infections, during 6
a human challenge study by Ward et al (1986), infection was observed at a minimum dose of 9 x 10-1 
focus forming units (ffu), with approximately 1.56 x 104 particles per ffu. No infections were observed 
at a dose of 9 x 10-2 or 9 x 10-3 ffu (each tested in seven volunteers). These findings suggest that a 
higher infectious dose (~104 particles) is typically required to establish infection.
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children had been infected by rotavirus by 1, 2, and 3 years of age, respectively (Gladstone et 
al, 2011). 
Rotavirus infections are more likely to be severe between 3 and 24 months of age. Prior 
to 3 months, infections are typically mild or asymptomatic (Chrystie et al, 1978; Fischer et al, 
2002),  which  may  relate  in  part  to  a  protective  effect  of  passively  acquired  maternal 
antibodies (Xu et al, 2005) and breastfeeding (Jayashree et al, 1988a; Plenge-Bonig et al, 2010). 
The first exposure to rotavirus after 3 months of age is often associated with mild or severe 
diarrhoea  (Velazquez  et  al,  1996).  Although  subsequent  infections  are  more  likely  be 
asymptomatic, re-infection rates are high – during the aforementioned cohort study in south 
India, 11% of infants had experienced five or more episodes of rotavirus by 3 years of age 
(Gladstone et al, 2011). Notably, the protective effect of prior rotavirus exposure may vary by 
setting  –  whereas  two  previous  infections  conferred  complete  protection  against  severe 
disease among infants in Mexico (Velazquez et al, 1996), the equivalent rate of protection in 
south India was 57% (Gladstone et al, 2011).
Prior to the introduction of rotavirus vaccination in the USA, the virus was responsible 
for an estimated 2.7 million cases of gastroenteritis each year, of which 55,000–70,000 resulted 
in hospitalisation (Payne et al, 2011). Rotavirus-associated gastroenteritis accounted for 20–60 
deaths among children under 5 years of age, and approximately US $1 billion in direct and 
indirect costs (Tucker et al, 1998). The per-capita disease burden is likely to be comparable in 
other high-income countries, although hospitalisation rates vary from approximately 250 per 
100,000 children under 5 years of age each year in Spain (Visser et al, 1999) to more than 800 
per 100,000 in Hungary and Australia (Ferson, 1996; Szucs et al, 1999). 
In  low-income countries,  rotavirus-associated disease  often ranks  among the  highest 
causes  of  infant  mortality.  Based  on  estimates  from  2004,  rotavirus  was  responsible  for 
475,000–580,000 deaths among children under 5 years of age, with more than half of these 
deaths occurring in just six countries – India, Pakistan, China, Nigeria,  Ethiopia, and the 
Democratic  Republic  of  Congo  (Parashar  et  al,  2009).  Estimated  rotavirus-associated 
mortality rates ranged from less than 1 per 100,000 children under 5 years of age (observed in 
50 countries) to 439 per 100,000 in Sierra Leone – a discrepancy attributable at least in part to 
variation in access to appropriate medical care, such as oral rehydration therapy. 
Thus, while rotavirus infection in the first few years of life is experienced by nearly all 
children  in  both  high-  and  low-income  countries  in  the  absence  of  vaccination,  the 
consequences of infection vary significantly by geographic setting, with the majority of deaths 
occurring in a small number of countries in sub-Saharan Africa and the Indian subcontinent.
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1.3.3. Rotavirus vaccines: development and implementation
It is remarkable to consider that by the time rotavirus was discovered in 1973, OPV had 
already been in use for more than a decade. As the significant disease burden of this novel 
pathogen became increasingly apparent, efforts to develop a vaccine accelerated swiftly, and 
human trials of rotavirus vaccine candidates began in the early 1980s. The first vaccine to be 
licensed,  Rotashield,  was a  tetravalent  vaccine consisting of  a  simian rotavirus strain (of 
serotype G3) alongside three simian–human reassortant strains (one each for serotypes G1, 
G2, and G4) containing human VP7 genes. After proving safe and efficacious during trials 
conducted in the USA (Bernstein et al, 1995; Rennels et al, 1996), Finland (Joensuu et al, 1997), 
and elsewhere (Clark et al, 2008), Rotashield was licensed in the USA in 1998. However, use 
of  this  vaccine  would  be  short-lived.  Less  than  a  year  after  licensure,  Rotashield  was 
withdrawn after being linked with an increased risk of intussusception – a rare condition 
characterised by intestinal obstruction following the folding of one section of the bowel into 
another (Murphy et al, 2001).
Rotashield  has  since  been  replaced  by  RotaTeq  (developed  by  Merck)  and  Rotarix 
(developed  by  GlaxoSmithKline),  which  were  approved  in  the  USA in  2006  and  2008, 
respectively. Like Rotashield, RotaTeq is an animal–human reassortant vaccine. It consists of 
four  strains  (one  each  for  serotypes  G1,  G2,  G3,  and  G4)  containing  human VP7  genes 
expressed by a bovine rotavirus (the Wistar Calf 3 [WC3] strain), and one strain in which 
WC3 is reassorted to express a human VP4 gene of genotype P[8]. Rotarix, on the other hand, 
comprises a single human rotavirus strain of serotype G1P[8] – the most common serotype of 
circulating wild-type rotavirus – obtained from a child in Cincinnati,  USA, and passaged 
multiple times through monkey kidney cells (Bernstein et al, 1998) . Three other vaccines – 7
the  Lanzhou  lamb  rotavirus  vaccine,  a  lamb  rotavirus  strain  licensed  in  China  in  2000; 
Rotavin,  a human strain licensed in Vietnam in 2007;  and Rotavac,  a naturally occurring 
human–bovine reassortant G9P[11] strain (termed 116E) licensed in India in 2014 – are also 
being used to combat rotavirus, but are currently licensed only for national markets.
In 2006, the WHO recommended that rotavirus vaccination be included in the routine 
immunisation programmes of all countries in Europe, North America, and Latin America 
based on the results of clinical trials confirming the safety and protective efficacy of Rotarix 
(in a two-dose series) and RotaTeq (in a three-dose series) in these regions (Ruiz-Palacios et 
 A nice coincidence:  the Rotarix strain traces back to a child being treated during the 1988–1989 7
rotavirus  season  at  the  Cincinnati  Children’s  Hospital  –  the  same  hospital  where  Albert  Sabin 
developed OPV several decades earlier (Cincinnati Children's Hospital Medical Center, 2010).
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al,  2006;  Vesikari  et  al,  2006;  WHO,  2007).  These  recommendations  were  subsequently 
expanded to include all regions following the completion of trials that confirmed the efficacy 
(albeit  variable,  as  considered further  below) of  rotavirus vaccination in Asia  and Africa 
(WHO, 2009; Armah et al, 2010; Madhi et al, 2010; Zaman et al, 2010). The implementation of 
rotavirus vaccines has expanded steadily since – an effort aided by funding from Gavi, which 
currently  identifies  rotavirus  vaccination  as  a  ‘cornerstone  objective’  (Gavi,  2016).  As  of 
January 2016, 80 countries (including 37 countries eligible for Gavi support) have introduced 
rotavirus vaccination into their national routine immunisation programmes (Figure 1.3).
1.3.4. Variation in rotavirus vaccine performance
i. Efficacy
Whereas much of our data regarding variation in the performance of OPV is based on 
immunogenicity, a primary endpoint of several placebo-controlled trials of rotavirus vaccines 
has been the protective efficacy of immunisation against rotavirus-associated gastroenteritis. 
In a systematic review and meta-analysis by Soares-Weiser et al (2012), which included 41 
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Figure 1.3. The global roll-out of rotavirus vaccines in national immunisation programmes. Data 
were  obtained from PATH (2016).  Rotavirus  vaccination status  is  displayed as  of  January 2016. 
Among  countries  that  have  implemented  vaccination  schemes,  57  have  introduced  Rotarix 
(including  31  of  the  37  Gavi-eligible  countries),  19  have  introduced  RotaTeq,  and  four  have 
introduced both vaccines. Vaccination has also been introduced in pilot or regional programmes in 
Canada, the Philippines, and Thailand.
Rotarix RotaTeq Rotarix/RotaTeq
Created with mapchart.net ©
rotavirus vaccine trials overall, this was identified as an outcome in 21 trials of Rotarix and 
eight trials of RotaTeq. While the particulars vary from study to study, the following would 
be typical of these trials: infants are enrolled at the age of 6–12 weeks and administered a full 
course  of  either  vaccine  or  placebo,  with  the  former  typically  comprising  two  doses  of 
Rotarix or three doses of RotaTeq, separated by an interval of 4–10 weeks; these individuals 
are then followed up for a period of up to 2 years of active surveillance involving regular 
(often  weekly)  meetings  with  trial  staff;  during  any  episodes  of  gastroenteritis  in  this 
surveillance period, severity is determined based on pre-defined criteria (usually the Vesikari 
severity score [Ruuska and Vesikari, 1990]) and stool samples are collected and assessed for 
the presence of rotavirus, generally by enzyme-linked immunosorbent assay (ELISA); finally, 
the relative risk of rotavirus-associated gastroenteritis in vaccine versus placebo recipients is 
used to calculate the protective efficacy of the vaccine . 8
Estimates  of  the  1-year  efficacy  of  Rotarix  against  severe  rotavirus-associated 
gastroenteritis among the clinical trials reviewed by Soares-Weiser et al (2012) are provided 
in Table 1.3. Combining results across studies in low-mortality countries (WHO strata A and 
B) , Rotarix had an efficacy of 86% (range, 74–97%) for up to 1 year of follow-up, and 85% 9
(range, 78–96%) for up to 2 years. By contrast, in high-mortality countries (stratum E), the 
vaccine had an efficacy of 63% (range, 45–78%) for up to 1 year, and just 42% (range, 38–59%) 
for up to 2 years of  follow-up,  suggesting not  only that  Rotarix performance is  severely 
impaired  in  these  environments,  but  that  protection  wanes  more  swiftly.  Comparable 
discrepancies in protective efficacy and duration of protection have been observed during 
clinical trials of RotaTeq, suggesting that similar barriers to vaccine performance affect both 
of these vaccines (Soares-Weiser et al, 2012).
Notably,  despite  containing  only  one  strain  of  rotavirus  (G1P[8]),  Rotarix  has  been 
shown to confer both homotypic and heterotypic protection. Among infants in Malawi and 
South Africa, protection against severe rotavirus-associated gastroenteritis was equivalent for 
G1 versus non-G1 serotypes up to 1 year of age (Madhi et al, 2010), while efficacy in excess of 
90% was observed for serotypes G1, G2, G3, and G9 up to 2 years of age among infants in 
several  countries in Asia (Phua et  al,  2009).  However,  in a multi-centre study performed 
across Latin America and Finland, Ruiz-Palacios et al (2006) observed a protective efficacy 
 Vaccine efficacy = (1 - relative risk) x 1008
 Based on the strata A to E defined by the WHO, wherein stratum A has very low mortality rates in 9
children under 5 years of age (quintile 1), strata B and C have low mortality rates (quintiles 2 and 3), 
and strata D and E have high mortality rates (quintiles 4 and 5) (WHO, 2003).
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for severe gastroenteritis of 91% against fully homotypic strains (G1P[8]), 87% against partly 
heterotypic strains (G3P[8], G4P[8], and G9P[8]), and 45% against fully heterotypic strains 
(G2P[4]). Thus, while Rotarix clearly confers a degree of heterotypic protection, this may be 
lower for viruses that differ from the vaccine at both G and P epitopes.
ii. Immunogenicity
In contrast to poliovirus, wherein the presence of neutralising antibodies in serum is an 
established correlate of protection against paralytic disease, the immunological correlates of 
protection against rotavirus remain equivocal (Clarke and Desselberger, 2015). The titres of 
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Table 1.3. Efficacy of Rotarix against severe rotavirus-associated gastroenteritis (up to 1 year).
Studya Location
Mortality 
group
Cases of severe 
RVGE (n/N)
RR (95% CI) VERV1 Placebo
Bernstein et al (1999) USA A 2/108 9/107 0.22 (0.05–1.00) 78
Vesikari et al (2007) Czech Republic, 
Finland, Germany, 
Italy, Spain
A 5/2572 60/1302 0.04 (0.02–0.10) 96
Phua et al (2009) Hong Kong, 
Singapore, Taiwan
A 0/5263 15/5256 0.03 (0.00–0.54) 97
Salinas et al (2005) Brazil, Mexico, 
Venezuela
B 27/1392 34/454 0.26 (0.16–0.42) 74
GlaxoSmithKline 
(2008)
Argentina, Brazil, 
Dominican Republic, 
Honduras, Panama
B 7/4211 19/2099 0.18 (0.08–0.44) 82
Ruiz-Palacios et al 
(2006)
Argentina, Brazil, 
Chile, Colombia, 
Dominican Republic, 
Finland, Honduras, 
Mexico, Nicaragua, 
Panama, Peru, 
Venezuela 
A, B, D 12/9009 77/8858 0.15 (0.08–0.28) 85
Summary (strata A/B) 0.14 (0.07–0.26) 86
Madhi et al (2010) Malawi E 52/1182 47/591 0.55 (0.38–0.81) 45
Madhi et al (2010) South Africa E 16/2116 36/1050 0.22 (0.12–0.40) 78
Steele et al (2010) South Africa E 5/379 3/96 0.42 (0.10–1.74) 58
Summary (stratum E) 0.37 (0.18–0.75) 63
Data are from clinical trials included in a systematic review by Soares-Weiser et al (2012). Infection 
rates and risk ratios are those reported in Analysis 1.1 of this review. Abbreviations: CI, confidence 
interval; RR, risk ratio; RV1, Rotarix; RVGE, rotavirus-associated gastroenteritis; VE, vaccine efficacy.
a Major publication, as cited by Soares-Weiser et al (2012), is indicated here.
both serum and faecal IgA have been shown to reflect the level of rotavirus-specific IgA in 
the  duodenum,  and  can  therefore  be  viewed  as  markers  of  antibody  responses  at  the 
intestinal mucosal surface (Hjelt et al, 1985; Grimwood et al, 1988). Elevated titres of serum 
neutralising antibodies (Chiba et al,  1986; Ward et al,  1992),  serum IgA (Hjelt et al,  1987; 
O'Ryan et al, 1994), serum IgG (O'Ryan et al, 1994), and faecal IgA  (Matson et al, 1993) have 
all been shown to correlate with protection against infection and/or severe gastroenteritis 
following natural rotavirus exposure, although symptomatic infection may still occur among 
individuals with high antibody titres (including serum IgA titres of 1 in 400 and serum IgG 
titres in excess of 1 in 6,400) (Velazquez et al, 2000). These findings likely reflect a failure to 
fully delineate the effectors involved in rotavirus immunity. Studies in animal models have 
highlighted the potential importance of cytotoxic T cells targeting conserved viral epitopes 
(Offit and Dudzik, 1989), while memory B cells expressing gut-homing markers have been 
shown to correlate weakly with protection in humans (Rojas et al, 2007).
Despite their equivocal value as protective correlates, serum antibody responses have 
been considered in a subset of vaccinees during several efficacy trials of Rotarix and RotaTeq. 
These efforts have focused predominantly on rotavirus-specific serum IgA (determined by 
ELISA), though several trials of RotaTeq have also examined serotype-specific neutralising 
antibodies  (Armah  et  al,  2010;  Zaman  et  al,  2010).  To  confuse  matters,  definitions  of 
seroconversion have differed according to the vaccine being investigated – while a  post-
vaccination  IgA concentration  of  ≥20  U/mL has  been  used  to  define  seroconversion  to 
Rotarix (Vesikari et al, 2007; Madhi et al, 2010), a three-fold increase between pre- and post-
vaccination titres has been adopted in RotaTeq trials (Vesikari et al, 2006; Zaman et al, 2010). 
Nonetheless, these immunogenicity studies have helped to corroborate the geographic 
trends in vaccine performance observed for efficacy endpoints. In a systematic review by 
Patel et al (2013), mean seroconversion rates following two doses of Rotarix were 87%, 74%, 
and  53%  across  studies  conducted  in  countries  with  low  (WHO  stratum  A),  medium 
(stratum  B),  and  high  child  mortality  rates  (strata  D  and  E),  respectively,  and  post-
vaccination IgA concentrations followed a similar trend. Combining data across Rotarix and 
RotaTeq, the authors observed a significant correlation between post-vaccination IgA titre/
concentration and efficacy (with an R2 of 0.56). Moreover, lower IgA titres were associated 
with a greater drop-off in protective efficacy in the second year after vaccination (with post-
vaccination concentrations of >90 U/mL generally indicative of sustained protection). The 
absence of serological and efficacy data from the same individual vaccinees precluded the 
examination of more precise thresholds of protection in this review. Overall, these findings 
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suggest that while serum IgA levels may not be a perfect correlate of protection, they provide 
a useful indicator of the marked discrepancies in vaccine performance between high- and 
low-income settings. 
iii. Vaccine take
The link between the replication of vaccine viruses and seroconversion is less clearcut 
for oral rotavirus vaccines than for OPV (see section 1.2.3). I will refer to this outcome as 
‘take’ in the following chapters, although rotavirus vaccine trials have often used this term to 
encompass  either  seroconversion  or  post-vaccination  viral  shedding (Salinas  et  al,  2005). 
Following challenge with live rotavirus, the shedding of higher quantities of rotavirus has 
been linked with greater increases in serum neutralising antibody titre (Ward et al, 1986), 
thus supporting the link between viral replication efficiency and immunogenicity. Similarly, 
during clinical trials of Rotarix, the presence of rotavirus antigens in stool samples collected 
approximately 1 week after vaccination has been observed in 50–80% of infants following the 
first dose of vaccine and 4–18% following the second dose (Cortese et al, 2009) – rates that are 
broadly consistent with dose-specific estimates of seroconversion (Vesikari et al, 2004; Salinas 
et  al,  2005).  Although  few  clinical  trials  of  Rotarix  have  reported  on  vaccine  take,  it  is 
reasonable to suspect that the geographic variation observed in the immunogenicity of this 
vaccine also applies to the replication efficiency of vaccine rotaviruses. By contrast, Yen et al 
(2011a) observed rotavirus antigen in the stool samples of just 21% of US infants within the 9 
days following their first dose of RotaTeq. Given the high immunogenicity and efficacy of 
RotaTeq in this setting, it would appear that vaccine take is not as relevant an indicator of 
RotaTeq response as it is for OPV and Rotarix.
iv. Post-licensure effectiveness
The  final  form  of  data  pertinent  to  the  geographic  variation  in  rotavirus  vaccine 
performance is the effectiveness of Rotarix and RotaTeq in countries where they have been 
implemented in routine immunisation programmes. Increasingly, studies have been able to 
examine  vaccine  effectiveness  by  comparing  the  vaccination  histories  of  individuals 
hospitalised  for  rotavirus-associated  gastroenteritis  with  those  of  uninfected  controls 
(Correia et al, 2010; Wang et al, 2010; Staat et al, 2011) – analogous to the case–control studies 
conducted within AFP surveillance  databases  for  OPV.  These  post-licensure  effectiveness 
studies have largely recapitulated the findings of large-scale studies of vaccine efficacy, while 
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also highlighting the protection conferred by a partial vaccination series. The receipt of a full 
series of RotaTeq has generally been shown to protect more than 90% of infants in high-
income countries,  while  effectiveness  in  the  range  of  69–93% has  been  observed  after  a 
partial series (Patel et al, 2012b). By contrast, during a case–control study in Nicaragua, the 
same vaccine had an effectiveness of 44% after a full series (Patel et al,  2009a). Similarly, 
vaccine effectiveness after two doses of Rotarix has been estimated to be in excess of 97% 
among  children  in  Spain,  compared  with  57%  and  64%  in  South  Africa  and  Malawi, 
respectively (Groome et al, 2014b; Bar-Zeev et al, 2015). As observed in vaccine efficacy trials, 
Rotarix has been shown to protect against both homotypic and heterotypic strains, although 
effectiveness  appears  to  be  lower  and  may  wane  more  rapidly  for  heterotypic  viruses 
(Correia et al, 2010; Patel et al, 2013b; Bar-Zeev et al, 2015). Data regarding the herd effects of 
immunisation (inferred based on the incidence of rotavirus-associated disease in children too 
old  to  be  vaccinated)  have  been  variable  –  whereas  significant  indirect  protection  after 
rotavirus vaccine introduction was recently documented in Moldova (Gheorghita et al, 2016) 
and Armenia (Sahakyan et al, 2016), such effects were absent in South Africa (Groome et al, 
2016) and Zambia (Mpabalwani et al, 2016).
v. Conclusions
Overall, it is clear that oral rotavirus vaccines suffer from similar deficits in performance 
in  low-income  countries  as  OPV.  Data  from  large-scale  trials  have  highlighted  severe 
discrepancies  in the efficacy and immunogenicity of  Rotarix  and RotaTeq in low- versus 
high-income  countries,  and  protection  wanes  more  rapidly  in  the  former.  As  rotavirus 
vaccines are rolled out in routine immunisation programmes across the globe, these deficits 
are likely to impede the control of rotavirus-associated disease in regions that endure its 
greatest burden.
1.4. Other oral vaccines
Before discussing the mechanisms that might account for geographic variation in oral 
vaccine performance, it is worth noting that this phenomenon is not restricted to vaccines 
targeting  poliovirus  and  rotavirus.  Indeed,  several  oral  vaccines  targeting  bacterial 
enteropathogens have demonstrated similar trends in immunogenicity and/or efficacy. 
As noted in the preface to this chapter, a live-attenuated oral Shigella vaccine candidate 
(referred  to  as  SC602)  was  both  reactogenic  and  immunogenic  among  adults  in  North 
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America,  but displayed limited immunogenicity among children or adults in Bangladesh 
(WHO, 2006; Levine et al, 2007). Oral cholera vaccines may face similar obstacles in endemic 
settings. A single dose comprising 5 x 108 colony-forming units (CFU) of the live-attenuated 
cholera vaccine candidate CVD 103-HgR  was sufficient to induce seroconversion (defined 10
as a significant rise in vibriocidal antibodies) in more than 90% of North American adults 
(Levine et al, 1988; Kotloff et al, 1992); however, at the same dose, Su-Arehawaratana et al 
(1992) observed seroconversion in less than 50% of Thai soldiers during a series of studies 
conducted between 1988 and 1991 . A study among Indonesian children 5–9 years of age 11
documented similar deficiencies in immunogenicity following a single CVD 103-HgR dose at 
5 x 108 CFU (with seroconversion in 16% of recipients), although the administration of an 
elevated dose (5 x 109 CFU) elicited seroconversion in 75–87% (Suharyono et al, 1992). While 
these findings suggest that increasing the dose of inoculum may partly overcome the barriers 
to  CVD  103-HgR  performance  observed  in  low-income  countries,  estimates  of  vaccine 
efficacy when administered at  elevated doses have produced mixed results  (Richie et  al, 
2000; Calain et al, 2004).
CVD 103-HgR was licensed in Switzerland in 1991, and was subsequently approved in 
several other countries for use in individuals traveling to high-risk regions. However, the 
licensure process was never completed in the USA, and manufacture of the vaccine ceased in 
2004. Two oral cholera vaccines are in use today – Dukoral, a monovalent vaccine comprising 
killed  whole  cells  of  V.  cholerae  serogroup  O1  along  with  recombinant  cholera  toxin  B 
subunit; and Shanchol, a bivalent vaccine containing killed whole cells of serogroups O1 and 
O139. Vaccination is largely restricted to emergency response (for example, following the 
recent cholera outbreak in Haiti [Ivers et al, 2012]), and the WHO has been maintaining a 
stockpile of the two vaccines for this purpose since 2012 (WHO, 2013). The degree to which 
Dukoral and Shanchol efficacy varies by geographic setting is unclear given that the use of 
these vaccines has largely been restricted to cholera-endemic countries or outbreak response. 
Notably, the vaccines have proven efficacious in both of these applications (Lucas et al, 2005; 
Shin et al, 2011; Luquero et al, 2014; Ivers et al, 2015), and Shanchol recently demonstrated a 
cumulative 5-year protective efficacy of 65% during a cluster-randomised trial in Kolkata, 
India, with no evidence of a significant drop-off in protection over time (Bhattacharya et al, 
 CVD 103-HgR consists of a strain of V. cholerae (classical Inaba 569B) in which the enzymatically 10
active A subunit  of  cholera toxin has been deleted.  The vaccine also contains a gene for mercury 
resistance, which serves as a marker for the modified strain.
 Intriguingly, the vaccine was more immunogenic among civilians, although the seroconversion rate 11
in this group (63%) still fell short of the response rates observed in Europe and North America.
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2013). It is worth noting, however, that during an immunogenicity study conducted among 
children up to 12 years of age, a vaccine similar in composition to Dukoral induced higher 
vibriocidal antibody titres in Swedish than in Nicaraguan individuals (Hallander et al, 2002).
In a review by Levine (2010), the live-attenuated Salmonella Typhi vaccine Ty21a, which 
is licensed in more than 50 countries, was highlighted as a “notable exception” to the trend of 
impaired oral vaccine performance in low-income countries on the basis of efficacy data from 
Chile, Egypt, and Indonesia. However, comparable data from industrialised countries are not 
available for this vaccine. Moreover, among the studies cited by Levine (2010), efficacy was 
considerably greater in Egypt (96% over 3 years of follow-up among children 6–7 years of 
age) than in Indonesia (42–53% over 30 months of follow-up among individuals 3–44 years of 
age),  suggesting  that  important  geographic  variation  in  efficacy  may  still  exist  for  this 
vaccine (Wahdan et al, 1982; Simanjuntak et al, 1991).
Overall, it is clear that oral vaccines targeting both viral and bacterial enteropathogens 
must contend with significant deficits in performance in low- versus high-income countries. 
These discrepancies present a clear obstacle not only to the effective use of available vaccines 
targeting poliovirus, rotavirus, and cholera, but to the development of novel oral vaccines 
targeting major enteric infections such as norovirus, astrovirus, Shigella, Campylobacter, and 
ETEC. Identifying the barriers to oral vaccine performance, and in due course the means to 
circumvent them, thus presents a crucial challenge to the control of enteric disease.
1.5. Explaining variation in oral vaccine performance
So far in this chapter, I have reviewed the considerable (and growing) body of evidence 
to  suggest  that  oral  vaccine  performance is  impeded in  low-income countries.  Efforts  to 
elucidate the biological mechanisms responsible for this phenomenon date back to the early 
field trials  of  OPV.  In  the  remainder  of  this  chapter,  I  will  summarise  what  is  currently 
understood regarding the causes of variation in oral vaccine performance, and highlight the 
gaps in this understanding that the present thesis aims to address.
1.5.1. Transplacental antibodies
As noted above, newborn infants passively acquire serum antibodies from their mothers 
via the placenta. These antibodies, which are predominantly of class IgG (Cohen and Norins, 
1968),  are  actively  transported  across  the  outer  cell  layer  of  the  placenta  via  a  specific 
receptor, termed the neonatal Fc receptor (Roopenian and Akilesh, 2007). IgG titres in cord 
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blood and infant sera have been shown to correlate closely with titres in maternal serum (Da 
Silva et al, 1958; Moon et al, 2016), while IgA and IgM antibodies are either absent or occur in 
trace  amounts  (Cohen  and  Norins,  1968).  Following  placental  transfer,  rotavirus-  and 
poliovirus-specific  antibodies  decay  with  a  half-life  of  3–4  weeks  (Gelfand  et  al,  1960; 
Robertson, 1993; Behrend et al, 2014; Moon et al, 2016). When acquired at a starting titre of 1 
in 1,024 or greater, poliovirus-specific antibodies typically remain detectable for at least 9–12 
months post birth (Da Silva et al, 1958).
As with so many of the issues that have remained central to the OPV research agenda, 
the  potential  impact  of  maternal  antibodies  on vaccine  immunogenicity  was  highlighted 
during the First International Conference on Live Poliovirus Vaccines in 1959, when Konald 
Prem from the University of Minnesota described an impaired response to tOPV (in this case 
using strains developed at Lederle Laboratories) among newborn infants with elevated titres 
(>1 in 32) of passively acquired antibodies (Prem et al, 1959). This effect has consistently been 
demonstrated in field trials of tOPV since (Cirne et al, 1995; Asturias et al, 2007; Chandir et 
al,  2014;  Estivariz  et  al,  2015),  with  the  greatest  inhibitory  effect  typically  observed  for 
serotype 3 (Asturias et al, 2007; Estivariz et al, 2015). Among infants in Brazil who received 
tOPV  at  0,  6,  10,  and  14  weeks  of  age,  type  3  seroconversion  was  observed  in  70%  of 
individuals who had a baseline homotypic antibody titre of less than 1 in 64, but only 29% of 
those with a baseline titre of at least 1 in 256 (Cirne et al, 1995). Similarly, passively acquired 
serum antibodies have been observed to confer protection against natural rotavirus infection 
(Xu et  al,  2005)  and to  reduce  the  immunogenicity  of  oral  rotavirus  vaccines,  including 
Rotarix (Moon et al, 2016), RotaTeq (Becker-Dreps et al, 2015), and strain 116E (Appaiahgari 
et al, 2014).
The mechanisms by which maternal antibodies interfere with oral vaccine performance 
remain uncertain. Although serum IgG may passively transfer across the intestinal mucosa 
(termed transudation), it is unlikely to reach sufficient concentrations to directly inhibit the 
replication of vaccine viruses (Siegrist, 2003). Inhibition of serum antibody responses may 
instead occur during the downstream processing of antigens from replicating viruses.  As 
highlighted by Siegrist (2003), these antigens may be exposed to maternal antibodies during 
transit to lymph nodes, masking them from B cell receptors. Antigen–antibody complexes are 
also readily taken up by antigen-presenting cells,  preventing exposure to B cell  receptors 
while still enabling T cell responses to be elicited (the latter have demonstrated a greater 
resistance to inhibition by maternal antibodies for parenteral vaccines [Gans et al, 1998]). In 
both cases, the degree of inhibition would be expected to correlate with the titre of passive 
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antibodies, which is consistent with observations for OPV (Cirne et al, 1995) and rotavirus 
vaccine (Appaiahgari et al, 2014).
Irrespective of the precise mechanism, the inhibitory influence of maternal antibodies on 
serological response to OPV and oral rotavirus vaccines is clear. The degree to which this 
contributes  to  geographic  trends  in  vaccine  performance  is  less  certain.  Although cross-
sectional  surveys of  poliovirus-  and rotavirus-specific maternal  antibody titres have been 
carried  out  at  individual  sites  (Chan  et  al,  2011;  John  et  al,  2011),  direct  comparison  of 
multiple sites using standardised methods are currently lacking for either disease (although 
such studies have been conducted for breastmilk, as detailed below). In the case of OPV, 
recent exposure to live viruses – either circulating wild viruses or vaccine viruses shed by 
OPV recipients  –  is  likely  to  be  more  common among mothers  in  low-income countries 
(where OPV is widely implemented), which may boost the titre of serum antibodies that are 
passed  on  to  newborns.  Similarly,  maternal  exposure  to  natural  rotavirus  infection,  and 
consequent boosting of serum antibody titres, will be greatest in high-transmission settings, 
enhancing the potential influence of passively acquired antibodies.
Discrepancies  in  vaccine performance by geographic  setting may therefore  be  partly 
attributable  to  variation in the titre  of  passively acquired antibodies.  However,  there are 
several aspects of this phenomenon that maternal antibodies cannot explain, including: (i) 
the  significant  within-country  variation in  OPV efficacy observed during studies  of  AFP 
surveillance databases in India and Nigeria, wherein the majority of doses would have been 
received during SIAs (and thus after the waning of passively acquired antibodies) (Grassly et 
al,  2006;  Mangal et  al,  2014);  (ii)  the impaired immunogenicity of tOPV observed among 
Indian infants 3–12 months of age who were seronegative to all three types of poliovirus at 
enrolment (John and Jayabal, 1972) ; and (iii) the significant discrepancies in CVD 103-HgR 12
immunogenicity among adults in high- versus low-income countries (section 1.4).
1.5.2. Breastfeeding
Breastmilk has the capacity to decrease the titre of vaccine viruses that reach the gut 
owing to the presence of neutralising antibodies (predominantly of class IgA) and of innate 
immune factors such as lactadherin and lactoferrin (Patel et al, 2009b). This may, in turn, 
 After one dose of tOPV, seroconversion to serotypes 1, 2, and 3 was observed in 15%, 60%, and 30% 12
of these infants, respectively – considerably lower than the seroconversion rates observed after one 
dose of tOPV among North American children with a high prevalence of pre-vaccination antibodies 
(McBean et al, 1988).
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contribute to geographic variation in oral vaccine performance. Moon et al (2010) observed 
rotavirus-specific IgA and neutralising antibody titres to be significantly higher in breastmilk 
obtained from Indian mothers  compared with mothers  from the USA, with intermediate 
titres observed in samples from Vietnam and South Korea. The researchers observed similar 
discrepancies in the levels of lactoferrin, lactadherin, rotavirus-specific IgA, and neutralising 
antibodies in breastmilk obtained from Indian and South African women when compared 
with  North  American  women  (Moon  et  al,  2013).  Although  no  analogous  studies  have 
recently been performed for poliovirus, Zaman et al (1993) documented significantly higher 
IgA titres specific to type 1 virus in breastmilk samples obtained from unvaccinated women 
from  Pakistan  compared  with  OPV-immunised  women  from  Japan  or  IPV-immunised 
women from Sweden, and it is likely that similar discrepancies between endemic and non-
endemic settings persist today.
In spite of these marked differences in antibody titres, findings regarding the impact of 
breastfeeding on vaccine performance are less than clearcut. In the case of OPV, Lepow et al 
(1961) documented a marked reduction in the excretion of vaccine viruses in breastfed versus 
non-breastfed neonates immunised shortly after birth. Other studies have observed similar 
trends  when  OPV  is  administered  during  the  first  few  days  of  life  (Sabin  et  al,  1963), 
suggesting that the elevated antibody titres in colostrum may interfere with the replication of 
vaccine polioviruses. Later in infancy, the picture is more ambiguous – while an increase in 
the  duration  of  breastfeeding  was  associated  with  a  decrease  in  seroconversion  rate 
(significant  for  serotype  3)  following  four  doses  of  tOPV  among  infants  in  Brazil,  no 
significant  differences  in  either  shedding or  seroconversion were  observed following the 
administration of type 1 mOPV to breastfed versus non-breastfed infants in Uganda (Domok 
et al, 1974). Among Indian infants between 6 and 51 weeks of age, withholding breastfeeding 
for 3–6 hours before and after vaccination did not impact the immunogenicity after one or 
three doses of tOPV (compared with infants breastfed within the 30 minutes prior to each 
dose) (John et al, 1976). To confuse matters further, a recent trial in Bangladesh documented a 
significant  increase  in  type  1  seroconversion  in  association  with  exclusive  breastfeeding 
following the administration of tOPV at 6, 10, and 14 weeks of age (Estivariz et al, 2015), and 
is  not  alone  in  highlighting  the  potential  benefits  of  breastfeeding  for  OPV  response 
(Pickering et al, 1998; Haque et al, 2014). 
Studies of oral rotavirus vaccines have similarly failed to establish a clear inhibitory (or 
beneficial) effect of breastfeeding on vaccine performance. While several trials have observed 
a  reduction  in  immunogenicity  among  breastfed  infants  (Rennels,  1996),  the  effect  has 
!     s47
typically been modest, and recent trials in India, Pakistan, and South Africa have failed to 
document  a  significant  change in  seroconversion rate  in  conjunction with the temporary 
withholding of breastfeeding immediately before and after vaccination (Groome et al, 2014a; 
Rongsen-Chandola et al, 2014; Ali et al, 2015).
It is possible that the conflicting findings of these studies reflect contradictory influences 
of breastfeeding on vaccine immunogenicity. On the one hand, IgA antibodies and innate 
immune factors may inhibit the replication of vaccine viruses – an effect that is likely to be 
particularly  potent  during  the  neonatal  period  given  the  elevated  titres  of  antibodies  in 
colostrum. However, breastfeeding may also prevent enteric infections (Bilenko et al, 2008), 
promote  the  maturation  of  the  infant  immune  system  (M'Rabet  et  al,  2008),  and  buffer 
vaccine viruses from gastric acid (Rennels, 1996), which together may alleviate or indeed 
reverse the inhibitory effects of breastmilk IgA.
1.5.3. Host genetics
The potential contribution of host genetics to variation in vaccine response has garnered 
increasing  interest  as  sequencing  technologies  have  become  more  widely  available.  In 
particular,  candidate  gene  and genome-wide  association  studies  have  helped to  uncover 
genetic variants that influence the performance of vaccines targeting measles, rubella, and 
hepatitis  B,  among others  (Mentzer  et  al,  2015;  Milet  et  al,  2016).  An important  role  for 
genetic variation in shaping the immune response to OPV is supported by a study of twin 
pairs in the Gambia who received tOPV at 0, 1, 2, 3, and 9 months of age (Newport et al, 
2004).  Based  on  the  titre  of  serotype  1  neutralising  antibodies  in  monozygotic  versus 
dizygotic twins at 5 months of age, the authors estimated that heritability may account for 
60% of the variation in OPV response. It is worth noting, however, that factors influencing 
antibody titre after immunisation may not be the same as those influencing seroconversion, 
which is the primary outcome of interest in the chapters that follow. 
A recent genome-wide association study was conducted among infants in Bangladesh to 
identify genetic variants that may contribute to variation in OPV response (Wojcik, 2013). 
This distinguished several suggestive associations for single-nucleotide polymorphisms on 
chromosome 7 (of which the top-ranking fell upstream of the gene SHH) and chromosome 14 
(of which the top-ranking fell downstream of the gene MAPK1IP1L), and also highlighted the 
potential  importance of  genes  involved in  histone modification.  However,  these  findings 
have not been independently validated and should thus be treated with caution. 
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Studies considering the impact of genetic variation on rotavirus vaccine response are 
currently lacking. However, recent findings suggest that variation in the phenotype of histo-
blood group antigens (HBGAs) – previously linked with susceptibility to noroviruses and 
several  other  enteropathogens  (Flores  and  Okhuysen,  2009)  –  may  influence  clinical 
outcomes following natural rotavirus exposure (Imbert-Marcille et al, 2014; Van Trang et al, 
2014). Specifically, it appears that individuals with a non-secretor HBGA phenotype may be 
resistant to infection with P[8] rotavirus genotypes (Imbert-Marcille et al, 2014). The extent to 
which HBGA phenotype impacts the efficacy of oral rotavirus vaccines remains a topic of 
ongoing research, albeit one that is beyond the scope of the present thesis.
1.5.4. Malnutrition and micronutrient deficiencies
Malnutrition is  common in  the  world’s  poorest  countries,  and as  noted above,  may 
contribute  to  more than half  of  deaths among children under 5  years  of  age worldwide 
(Caulfield et  al,  2004).  The detrimental  effects  of  malnutrition may arise  in part  through 
abnormalities in immune function – including deficits in antibody production, complement 
formation, and thymic function, among others – which have been linked both with impaired 
growth (e.g., stunting and wasting) and deficiencies in specific micronutrients, such as zinc, 
iron, and vitamin A (Scrimshaw and SanGiovanni, 1997; Hughes and Kelly, 2006). In light of 
these  immunological  deficits,  there  has  been  much interest  in  the  possible  link  between 
malnutrition and vaccine performance in low-income countries. To date, these efforts have 
failed to uncover a consistent link between the two (Savy et al, 2009; Prendergast, 2015). In 
the  case  of  OPV,  a  recent  study  among infants  in  Bangladesh  documented  a  significant 
decrease in type 3 poliovirus antibody titres in conjunction with malnutrition (as defined by 
a  weight-for-age  Z  score  of  <-2)  after  at  least  three  doses  of  OPV  (Haque  et  al,  2014). 
However, other studies in India (Chopra et al, 1989) and Nigeria (Greenwood et al, 1986) 
have failed to uncover an association between weight and OPV immunogenicity. Similarly, 
supplementation  with  vitamin  A did  not  significantly  impact  OPV  seroconversion  rates 
during trials in Bangladesh, Indonesia, and Ghana (Rahman et al, 1998; Semba et al, 1999; 
Newton et al,  2005), while the receipt of zinc supplements – which are known to have a 
significant therapeutic effect during the treatment of acute gastroenteritis (Patro et al, 2008) – 
had no effect on OPV seroconversion during a recent placebo-controlled trial  in Pakistan 
(Habib et al, 2015). 
Data regarding the potential impact of malnutrition on oral vaccines other than OPV are 
limited,  although  supplementation  with  zinc  (but  not  vitamin  A)  significantly  boosted 
!     s49
vibriocidal antibody response among recipients of CVD 103-HgR in Bangladesh (Albert et al, 
2003).  Data  from  a  recent  trial  examining  the  impact  of  zinc  and/or  probiotic 
supplementation on the immunogenicity of Rotarix and OPV among infants in south India 
will be discussed further in Chapters 4 and 5 of this thesis (although the focus here will be on 
the association between the intestinal  microbiota and vaccine outcome).  Overall,  while it 
remains plausible  that  malnutrition and micronutrient  deficiencies  may contribute  to  the 
impaired performance of oral vaccines in low-income countries,  we currently lack robust 
data to support this notion.
1.5.5. Concurrent enteropathogens
Enteropathogen infections have long been recognised as a major cause of morbidity and 
mortality, and this burden is greatest in the low-income countries where oral vaccines are 
least immunogenic. Of the 7.6 million deaths among children under 5 years of age in 2010, 
diarrhoea accounted for approximately 10%, with the vast  majority of  these occurring in 
Africa and southeast Asia (Liu et al, 2012).
In  addition  to  symptomatic  disease,  the  pervasive  nature  of  asymptomatic  enteric 
infections in low-income countries has become increasingly apparent in recent years, placing 
the remarkable scale of enteropathogen transmission in a new light.  This is perhaps best 
illustrated by the MAL-ED study – a multi-centre cohort study in which children from eight 
low- and middle-income countries in Africa, Asia, and South America were followed for the 
first 2 years of life (Lang, 2010; Platts-Mills et al, 2015). The prevalence of common bacterial, 
viral,  and  eukaryotic  enteropathogens  was  assessed  in  stool  samples  collected  during 
episodes of diarrhoea as well as in non-diarrhoeal surveillance samples (collected at monthly 
intervals for the first year life, and every 3 months thereafter). This approach revealed the 
burden of enteropathogens to be considerable irrespective of diarrhoea status (Platts-Mills et 
al, 2015). Indeed, at least one pathogen was identified in 65% of non-diarrhoeal stools, while 
two pathogens were present in 29%. Infection intensity varied considerably across the study 
sites – in Naushero Feroze, Pakistan, more than one pathogen per stool was observed by 2 
months of age on average, and this rose to approximately two pathogens per surveillance 
sample by 1 year of age; by contrast, in Venda, South Africa, the mean number of pathogens 
per surveillance sample did not exceed one throughout the follow-up period. Considerable 
seasonal variation was also observed for several pathogens. Together, these findings, along 
with those of other recent studies that have sought to quantify the burden and aetiology of 
diarrhoeal  disease  (such  as  the  Global  Enteric  Multicenter  Study  [Kotloff  et  al,  2013]), 
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highlight the intense and varied burden of enteropathogens experienced by infants in low-
income countries from soon after birth.
Non-polio enteroviruses (NPEVs) were not considered by the MAL-ED study, but are an 
important  player  in  the  chapters  that  follow.  Like  diarrhoeal  pathogens,  NPEVs  occur 
frequently among infants living in low-income countries. Among children enrolled in a polio 
vaccine trial in Kenya, NPEV prevalence ranged from less than 30% at 2–3 months of age to 
over 70% at 8–9 months (Kok et al, 1992). Although studies in high-income countries have 
occasionally documented comparably high NPEV infection rates (e.g., ~40% during an OPV 
trial conducted in Italy [Nardi et al, 1966]), the prevalence of these viruses tends to fall well 
short of the rates observed in low-income settings. Indeed, NPEVs were identified in only 
one of 203 children aged between 3 months and 5 years during the first trial of ‘balanced’ 
tOPV conducted in Canada in 1961 (Robertson et al, 1962).
Do NPEVs and other enteropathogens interfere with the performance of oral vaccines? 
As noted above, OPV response varies by season in tropical settings, and diminished vaccine 
take has been shown to coincide with the high season of enterovirus transmission in India 
(Grassly et al,  2012).  Although these seasonal variations are consistent with an inhibitory 
effect  of  concurrent  infections  on OPV,  direct  evidence  of  enteropathogen interference  is 
more conflicting. In the spring of 1958, a trial of OPV was conducted in Mexico in which a 
reduction in both seroconversion and vaccine take was observed in infants infected with 
NPEVs at the time of vaccination, suggesting that existing viruses may interfere with the 
establishment  of  vaccine  polioviruses  in  the  intestinal  tract  of  OPV recipients  (Benyesh-
Melnick et al, 1959). These and other similar findings during early studies of OPV gave rise 
to a firm conviction in the inhibitory effect of enteric pathogens on vaccine response, and led 
Albert Sabin to conclude the following during the First International Conference on Live 
Poliovirus Vaccines (Sabin, 1959):
“It is obvious from these observations and from others to be reported here … that the 
high incidence of naturally occurring enteric viruses among children living under poor 
conditions  of  sanitation  and  hygiene,  especially  in  subtropical  and  tropical  climates, 
presents a special problem in the successful utilization of live poliovirus vaccine under 
these conditions.” 
In  spite  of  this  initial  certainty,  subsequent  efforts  to  determine  the  impact  of 
enteropathogens  on  OPV have  yielded  contradictory results  –  while  several  studies  have 
supported the inhibitory effects of NPEVs (Japan Live Poliovaccine Research Commission, 
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1966;  Triki  et  al,  1997),  bacterial  enteropathogens (Mahmoud et  al,  1976),  and concurrent 
diarrhoea (Posey et al, 1997), others have refuted these effects (John and Christopher, 1975; 
Kok et al, 1992). During a large field trial involving two doses of tOPV in Toluca, Mexico, 
Sabin himself observed seroconversion rates of 96%, 96%, and 72% for serotypes 1, 2, and 3, 
respectively,  despite  the  presence  of  NPEVs  in  more  than  50% of  children  in  the  study 
population before the trial commenced (Sabin et al, 1960). In light of these conflicting data, 
the  relative  contribution  of  NPEVs  and  other  enteric  infections  to  the  phenomenon  of 
impaired OPV immunogenicity in low-income countries remains uncertain.  
Data regarding the impact of enteric infections on vaccines other than OPV are limited. 
During a placebo-controlled trial in Ecuador, treatment with albendazole (an anthelmintic) 
prompted an increase in seroconversion rates  and vibriocidal  antibody titres  following a 
subsequent dose of CVD 103-HgR among children with ascariasis, highlighting the potential 
inhibitory effect of eukaryotic pathogens on oral vaccine immunogenicity (Cooper et al, 2000). 
Given that OPV has been co-administered alongside oral rotavirus vaccines in a number of 
trials, the potential interference between these attenuated viruses has garnered considerable 
interest (Patel et al, 2012a). Notably, while co-administration does not appear to inhibit the 
immunogenicity  of  OPV,  rotavirus-specific  seroconversion  rates  and antibody titres  have 
consistently been lower when either Rotarix or RotaTeq are administered with OPV than 
without, particularly following the first dose of rotavirus vaccine (Rennels, 1996; Patel et al, 
2012a).  Thus,  the  continued  use  of  OPV  during  routine  immunisation  in  low-income 
countries (as opposed to the IPV-only schedules generally adopted in high-income countries) 
may contribute to the geographic discrepancies observed in rotavirus vaccine performance.
In addition to the influence of co-administered Sabin viruses, the potential inhibitory 
effect of natural enterovirus exposure on Rotarix outcome was highlighted during a recent 
study  among  infants  in  Bangladesh  (Taniuchi  et  al,  2016) .  Herein,  the  quantity  of 13
enteroviruses  at  the  time  of  immunisation  was  negatively  correlated  with  the 
immunogenicity and efficacy of the rotavirus vaccine – an effect that was not observed for 
any other viral, bacterial, or eukaryotic enteropathogens. Since no association was observed 
between the quantity  of  Sabin polioviruses  and Rotarix  outcome,  the inhibitory effect  of 
enteroviruses in this study was ascribed principally to NPEVs. The degree to which these 
findings (published late in the write-up of this thesis) are representative of the risk factors for 
rotavirus vaccine failure in other low-income settings remains to be seen.
 Notably, this study adopted the same PCR-based methods of enteropathogen detection adopted in 13
Chapters 4, 5, and 6.
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A central aim of the present thesis is to address the gaps in our current understanding of 
the  relationship  between  enteropathogen  infections  and  oral  vaccine  response,  first  by 
integrating data from past studies of OPV in a systematic review and meta-analysis (Chapter 
2),  and  subsequently  by  using  novel  diagnostic  methods  to  clarify  the  influence  of 
enteropathogen exposure on the immunogenicity of OPV and Rotarix (Chapters 4, 5, and 6). 
Potential mechanisms that might account for an inhibitory effect of enteropathogens on oral 
vaccines will be considered during the discussion of these data.
1.5.6. The bacterial microbiota
The  potential  influence  of  the  intestinal  microbiota  on  oral  vaccine  response  is  not 
restricted to concurrent enteropathogens. Indeed, there is good reason to suspect that the 
microbiota as a whole (commensal and pathogenic) may play an important role in shaping 
our  immune  response  to  these  vaccines,  and  it  is  this  possibility  that  forms  the  second 
principal line of enquiry in the present thesis. 
The intestinal microbiota is a diverse and crowded community comprising an estimated 
100 trillion prokaryotes  (the  bacterial  microbiota)  (Whitman et  al,  1998),  an even greater 
number of  bacteriophages  and eukaryotic  viruses  (the  virome),  and an array of  protists, 
yeasts, fungi, and helminths (the eukaryome). Although this thesis focuses predominantly on 
the  bacterial  microbiota,  the  potential  contribution  of  the  virome  and  eukaryome  to 
geographic discrepancies in oral vaccine outcome should not be discounted. Indeed, both 
vary markedly by geographic setting (Holtz et al, 2014; Parfrey et al, 2014), and both have 
been shown to  influence  development  of  the  mammalian immune system and intestinal 
homeostasis (Kernbauer et al, 2014; Lukes et al, 2015).
A more detailed introduction to the laboratory and bioinformatic methods adopted to 
assess the bacterial microbiota will be provided in Chapter 3. Here, I will restrict my focus to 
two key questions: what is known about the development of the bacterial microbiota in early 
infancy?  And  what  might  lead  us  to  suspect  that  the  composition  of  the  microbiota 
contributes to the discrepancies in oral vaccine performance between high- and low-income 
countries?
i. Development of the bacterial microbiota
The  timing  of  first  microbial  colonisation  of  the  infant  gut  has  been  the  subject  of 
considerable debate in recent years (Rodriguez et al, 2015). While it was previously believed 
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that the foetus develops in an environment that is kept sterile by the placental barrier, this 
view has been challenged by the detection of bacteria in umbilical cord blood (Jimenez et al, 
2005),  amniotic  fluid (Bearfield et  al,  2002),  and placental  tissue (Aagaard et  al,  2014)  of 
healthy newborns. Genetically labeled Enterococcus strains administered orally to pregnant 
mice  have  been  shown  to  appear  in  both  amniotic  fluid  and  meconium  (the  first  stool 
produced following birth), suggesting that members of the maternal oral or gut microbiota 
may be transmitted directly to neonates during gestation (Jimenez et al, 2005; Jimenez et al, 
2008). However, the extent of prenatal colonisation and health implications of this microbial 
exposure remain uncertain (Rodriguez et al, 2015).
Following any intrauterine exposure,  the next  major  colonisation opportunity occurs 
during delivery. The meconium microbiota of neonates born via vaginal delivery has been 
shown to overlap in composition with the vaginal microbiota of their mothers (with major 
genera  including  Prevotella,  Lactobacillus,  and  Sneathia),  while  that  of  neonates  born  by 
caesarean  section  more  closely  resembles  the  skin  microbiota  of  mothers  (including  a 
predominance of  Staphylococcus,  Acinetobacter,  and  Micrococcineae)  (Dominguez-Bello et  al, 
2010).  These initial  differences in composition according to delivery mode may form the 
basis  of  longer-term  discrepancies  in  the  bacterial  microbiota,  including  a  delay  in 
Bacteroidetes colonisation and a decrease in Clostridia abundance among infants delivered 
by caesarean section (Salminen et al, 2004; Jakobsson et al, 2014). Contrary to this notion, 
however,  several  studies  have  observed  the  microbiota  composition  of  infants  born  via 
vaginal delivery and caesarean section to converge over the first 6 months of life (Trosvik et 
al, 2010; Dogra et al, 2015). 
Other important sources of early colonisation include exposure to the mother’s faecal 
microbiota during delivery, which may enable transmission of Enterobacteriaceae, among 
other  taxa  (Rodriguez  et  al,  2015);  contact  with  the  mother’s  skin,  enabling  transfer  of 
Staphylococcus species (prominent early colonisers that are swiftly outcompeted over the first 
few months of life) (Subramanian et al, 2014; Rodriguez et al, 2015); and breastmilk, which 
contains a complex bacterial community encompassing several hundred species, rich in the 
genera Streptococcus,  Staphylococcus,  Weisella, Leuconostoc,  and Lactococcus (Hunt et al, 2011; 
Cabrera-Rubio et al, 2012). 
Following these initial colonisation events, the gut microbiota remains in a state of near-
constant  flux  and  maturation  for  the  first  2–3  years  of  life,  with  diversity  increasing 
constantly (Koenig et al, 2011; Schloss et al, 2014; Subramanian et al, 2015). Factors known to 
influence this process include gestational age, diet, maternal health status, host genetics, and 
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(as detailed below) geographic location (Rodriguez et al, 2015). Overall, the maturation of the 
microbiota can be thought of as a process of ecological succession, with early colonisers that 
are  predominantly  facultative  anaerobes  (e.g.,  Staphylococcus,  Lactococcus,  and 
Enterobacteriaceae) fostering changes in the infant gut, including a decrease in redox potential, 
that  enable  colonisation  by  obligate  anaerobes  (e.g.,  Bifidobacterium  and  Clostridium) 
(Rodriguez et al, 2015). Gradual progressions are punctuated by major shifts in composition 
that  coincide  with  changes  in  diet,  antibiotic  usage,  and  infection  –  as  elegantly 
demonstrated by a 2.5-year case study in which faecal samples from a single infant  were 
collected at  regular  intervals  from birth onwards (Koenig et  al,  2011).  During this  study, 
sequencing of  the  highly  conserved 16S  rRNA gene –  encoding the  16S  ribosomal  RNA 
subunit  –  was  used  to  determine  the  composition  of  the  bacterial  microbiota,  while 
metagenomic analysis (encompassing composition and function) of a subset of samples was 
conducted  via  shotgun  sequencing.  This  revealed  an  early  microbiota  (coinciding  with 
exclusive breastfeeding) dominated by Firmicutes and enriched in genes involved in lactate 
utilisation. A shift in diet to include formula and solid foods at approximately 4 months of 
age  was  associated  with  an  abrupt  expansion  of  the  phylum  Bacteroidetes,  while  the 
cessation of breastfeeding and shift to an adult diet was associated with the establishment of 
a more stable microbial community capable of performing the core metabolic functions of the 
adult microbiome, including vitamin biosynthesis and the breakdown of polysaccharides. 
Other events, including a fever at 3 months of age and the treatment of an ear infection with 
cefdinir  (a  broad-spectrum  oral  cephalosporin  antibiotic)  at  1  year  of  age,  were  also 
associated with temporary shifts in community composition and functional profile. 
The maturation of  the infant  microbiota culminates  in a  diverse and stable  bacterial 
community after approximately 3 years (Yatsunenko et al, 2012). Estimates of the number of 
species  present  in  a  typical  adult  gut  vary  according  to  the  depth  of  sampling  and the 
definition of ‘species’ adopted: while a minimum of 160 species per individual is often cited 
based  on  a  metagenomic  study  of  European  adults  (Qin  et  al,  2010),  with  sufficient 
sequencing depth more than 1,500 operational taxonomic units (OTUs) – typically defined as 
sequences with at least 97% identity spanning one or more hypervariable regions of the 16S 
rRNA gene – have been observed in samples from healthy adults (Yatsunenko et al, 2012).
ii. Potential influence of the bacterial microbiota on oral vaccines
As noted above, the infant microbiota is in a state of profound flux for the first 2–3 years 
of  life  –  a  time  encompassing  the  administration  of  oral  vaccines  during  routine 
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immunisation and (in the case of  OPV) SIAs.  Several  lines of  reasoning suggest  that  the 
composition of  the gut  microbiota may contribute to geographic  trends observed in oral 
vaccine performance. I shall tackle each of these in turn below.
(1) The bacterial microbiota shapes the development of the infant immune system
 To  date,  much of  our  understanding  regarding  the  relationship  between the  bacterial 
microbiota and the immune system comes from the study of  germ-free animals or those 
colonised by defined microbial  communities  (termed gnotobiotic  animals).  Although this 
may be a somewhat blunt approach for assessing what is  undoubtedly a complex set  of 
interactions,  it  has  nonetheless  provided a  clear  indication  of  the  importance  of  the  gut 
microbiota to the development and function of the mammalian immune system. Germ-free 
mice harbour gross structural abnormalities in the gut-associated lymphoid tissue, including 
a decrease in the number of IgA-producing plasma cells, a reduction in the size of Peyer’s 
patches, and a decrease in the number of intraepithelial lymphocytes (for a more complete 
account, refer to Smith et al [2007]). The activation of innate immune receptors (e.g., Toll-like 
receptors) by microbial signals has been shown to enhance epithelial cell proliferation and 
the repair of epithelial damage (Pull et al, 2005; Hooper et al, 2012). Specific bacterial taxa 
have also been shown to promote the expansion of distinct immune cell populations – for 
example, segmented filamentous bacteria trigger the accumulation of CD4+ Th17 cells in the 
small intestine (Ivanov et al, 2009), while members of the genus Clostridium have been shown 
to induce CD4+ regulatory T cells in the colonic mucosa (Atarashi et al,  2011).  Microbial 
metabolites such as short-chain fatty acids may interact with host immune cells to produce 
similar immunomodulatory effects (Arpaia et al, 2013).
The reach of the gut microbiota goes beyond the intestinal mucosa (Hooper et al, 2012). 
Germ-free animals have fewer plasma cells in systemic circulation, fewer germinal centres, 
and diminished serum antibody responses to bacterial antigens (Smith et al, 2007). The risk 
of  atopic  disease has been linked with composition of  the gut  microbiota  during critical 
windows of early childhood in both mice and humans (Russell et al, 2013; Arrieta et al, 2015). 
New  interactions  between  the  microbiota  and  the  immune  system  are  constantly  being 
uncovered (e.g., Gomez de Aguero et al, 2016), highlighting the myriad ways in which the 
immune system has evolved to shape and respond to the body’s microbial inhabitants. While 
these findings may be insufficient to directly tie the microbiota with oral vaccine response, 
they  do  establish  a  robust  link  between  the  composition  of  the  gut  microbiota  and  the 
maturation and functional capacity of the immune system in early infancy.
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(2) The bacterial microbiota facilitates viral colonisation of the intestinal mucosa
In addition to its role in shaping the development of the mammalian immune system, 
the bacterial  microbiota has been shown to facilitate  the replication and persistence of  a 
number of enteric viruses (Pfeiffer and Virgin, 2016). Again, relevant data regarding these 
‘transkingdom interactions’ are derived largely from animal models,  including germ-free, 
antibiotic-treated,  and  immunodeficient  mice.  In  the  case  of  poliovirus,  depletion  of  the 
bacterial  microbiota  by  antibiotics  has  been  shown  to  inhibit  viral  replication  and 
pathogenesis  in  mice  (Kuss  et  al,  2011),  while  in  vitro  virus  infectivity  is  enhanced  by 
exposure  to  live  bacteria  (both  Gram-negative  and  Gram-positive),  killed  bacteria,  and 
bacterial surface polysaccharides such as lipopolysaccharide and peptidoglycan (Kuss et al, 
2011). These polysaccharides have been shown to increase the thermal stability of virions as 
well as enhance attachment to the poliovirus receptor (Robinson et al, 2014), suggesting that 
polioviruses  have  evolved  to  exploit  microbiota-derived  signals  in  order  to  colonise  the 
intestinal  mucosa.  Analogous  effects  have  been  reported  for  rotavirus,  which  exhibits 
reduced infectivity and pathogenicity in antibiotic-treated mice (Uchiyama et al,  2014). In 
spite of this, treated mice exhibited higher titres of rotavirus-specific serum IgG, serum IgA, 
and faecal IgA compared with untreated mice, highlighting the complexity of interactions 
between the microbiota and the immunogenicity of enteric viruses.
Thus, there is a growing body of evidence reflecting the importance of transkingdom 
interactions to enteric virus colonisation and infectivity.  It  is  worth noting, however,  that 
while microbiota-derived signals may be necessary for viral infection, it is by no means clear 
that variation in microbiota composition translates to variation in viral (and viral vaccine) 
outcomes, especially given that signals such as lipopolysaccharide and peptidoglycan would 
be readily available in the infant gut irrespective of geographic setting.
(3) Composition of the infant microbiota varies by geographic location
In order to account for the observed variation in oral vaccine performance between high- 
and low-income countries, it is necessary for the composition of the infant microbiota to vary 
geographically. Such variation has been amply demonstrated in several recent studies. By 
sequencing the V4 hypervariable region of the 16S rRNA gene in 531 individuals aged 0–83 
years from the USA, Venezuela, and Malawi, Yatsunenko et al (2012) observed considerable 
differences  in  microbiota  composition  according  to  location,  with  particularly  marked 
separation  between  US  individuals  and  those  from  Venezuela  and  Malawi.  These 
!     s57
discrepancies were evident among adults and infants (under 6 months of age). Using the 
Random Forests machine-learning algorithm (discussed further in Chapter 3), the researchers 
identified  28  OTUs  that  discriminated  US  from  non-US  infants,  and  23  OTUs  that 
distinguished  Venezuelan  from  Malawian  infants  (with  several  members  of  the  family 
Enterococcaceae  enriched  in  the  former).  Compositional  differences  were  mirrored  by 
discrepancies in the functional profile of the infant microbiome, as determined by shotgun 
sequencing of faecal samples. In particular, several genes involved in vitamin biosynthesis 
(especially vitamin B2) and carbohydrate metabolism were enriched among Malawian and 
Venezuelan  compared  with  US  infants,  suggesting  that  functional  differences  in  the 
microbiota may reflect discrepancies in diet and vitamin availability. 
Several  other  studies  have  documented  variation  in  microbiota  composition  when 
comparing individuals from different regions (De Filippo et al, 2010; Grzeskowiak et al, 2012; 
Nakayama et al, 2015). Using fluorescence in situ hybridisation and flow cytometry, Fallani et 
al (2010) highlighted the possible existence of a ‘geographic gradient’ across Europe in the 
composition of the faecal microbiota at 6 weeks of age, with northern countries characterised 
by the enrichment of the genus Bifidobacterium and several Clostridium species, and southern 
countries  by  the  enrichment  of  Bacteroides  and  Lactobacillus,  among  others.  Notably,  the 
differences observed between countries exceeded the variation among samples due to delivery 
mode and feeding method (breast fed, formula fed, or mixed). While these and other similar 
findings are consistent with the presence of broad-scale latitudinal gradients in microbiota 
composition (Suzuki and Worobey, 2014), it has also been suggested that similarities in host 
lifestyle  may  link  the  bacterial  microbiota  of  individuals  from  geographically  disparate 
settings.  Indeed,  Pehrsson  et  al  (2016)  recently  compared  faecal  microbiota  data  from 
individuals in Peru, El Salvador, Venezuela, Malawi, and the USA, and documented marked 
clustering of microbiota composition according to whether hosts had an ‘urban industrial’, 
‘peri-urban industrialising’, ‘rural agriculturalist’, or ‘hunter–gatherer’ lifestyle.
Together,  these  findings  highlight  the  substantial  variation that  occurs  in  microbiota 
composition according to geographic setting and lifestyle – variation that is undoubtedly 
sufficient to account for all or some of the discrepancies observed in oral vaccine performance.
(4) Preliminary data support a link between the microbiota and oral vaccine response
A recent study among infants in Bangladesh immunised at 0, 6, 10, and 14 weeks of age 
provides  the  first  direct  evidence  of  a  potential  link  between  the  composition  of  the 
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microbiota and the immune response to OPV (Huda et al, 2014). The V4 region of the 16S 
rRNA gene was sequenced via Illumina Miseq to determine the diversity and composition of 
the  microbiota  in  48  infants  at  6,  11,  and  15  weeks  of  age.  This  revealed  the  relative 
abundance  of  the  phylum  Actinobacteria  at  15  weeks  to  be  positively  correlated  with 
poliovirus-specific  IgG  concentration  in  serum  and  CD4+  T  cell  stimulation  index  (also 
measured at 15 weeks).  The quantity of several members of the genus Bifidobacterium,  as 
determined by quantitative PCR, was also correlated with poliovirus-specific T cell response, 
highlighting the potential  influence of  these taxa on vaccine immunogenicity.  It  is  worth 
noting, however, that the study did not adopt the standard microneutralisation assay during 
the measurement of OPV response (section 1.2.3), and may therefore have failed to capture 
discrepancies  in  microbiota  composition  that  influence  seroconversion  to  the  vaccine. 
Moreover,  overall  microbiota  diversity  within  samples  (alpha  diversity),  compositional 
overlap between samples (beta diversity), and OTU-level differences in relative abundance 
were not reported in relation to OPV response . While this study provides a preliminary 14
validation of the potential  role of  the microbiota in shaping OPV immunogenicity,  much 
uncertainty remains regarding the nuances and key players in this relationship.
Several  other  studies  lend  support  to  the  hypothesised  link  between  microbiota 
composition and oral vaccine response. Small bowel bacterial overgrowth, as measured by 
hydrogen breath test, was associated with a decrease in vibriocidal antibody titre following 
one dose of CVD 103-HgR among children in Chile (Lagos et al, 1999), while an increase in 
microbiota  diversity  was  linked  with  a  higher  CD8+  T  cell  response  (but  not  humoral 
response)  among individuals  who received four doses of  the oral  typhoid vaccine Ty21a 
(Eloe-Fadrosh  et  al,  2013),  albeit  among  only  six  vaccinees.  Owing  to  the  increased 
availability  of  high-throughput  sequencing  technologies,  it  is  reasonable  to  expect  that 
numerous studies in the coming years will probe further into the influence of the microbiota 
on vaccine immunogenicity (both oral and parenteral).
iii. The bacterial microbiota as a marker for other risk factors of oral vaccine failure
In light of its impact on both the development of the infant immune system and the 
infectivity of  viral  pathogens,  it  is  reasonable to hypothesise that  the composition of  the 
bacterial microbiota may directly influence the outcomes of oral immunisation. However, it 
is also possible that the intestinal flora might act as a diagnostic or prognostic marker for 
 See Chapter 3 for further details regarding these measures.14
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other risk factors of oral vaccine failure. In particular, significant shifts in the composition 
and  diversity  of  the  bacterial  microbiota  have  been  documented  in  conjunction  with 
malnutrition (Smith et al, 2013; Dinh et al, 2016), current or recent diarrhoea (Subramanian et 
al,  2014),  and chronic inflammation of the gut (Manichanh et  al,  2006;  Fava and Danese, 
2011),  among  others.  Given  that  the  present  thesis  aims  to  characterise  the  association 
between the composition of the bacterial microbiota and oral vaccine outcome among infants 
in south India, as opposed to the mechanisms of vaccine failure in animal models or in vitro 
systems,  it  will  be  important  to  bear  these  potential  indirect  effects  in  mind during  the 
chapters ahead.
1.5.7. Environmental enteropathy
At  the  intersection  of  the  mucosal  immune  system,  the  intestinal  microbiota,  and 
enteropathogen exposure is a pervasive condition termed ‘environmental enteropathy’ (EE). 
This  subclinical  disorder  was  first  recognised  in  the  1960s,  when  jejunal  biopsies  of 
individuals from Thailand (Sprinz et al, 1962), Pakistan (Lindenbaum et al, 1966), and several 
other developing countries revealed structural abnormalities of the intestinal architecture to 
be  a  frequent  occurrence  among  asymptomatic  individuals.  EE  is  characterised  by  the 
flattening of  intestinal  villi,  an increase in crypt depth,  nutrient  malabsorption,  intestinal 
inflammation (including an influx of inflammatory cells into the lamina propria), increased 
gut permeability, and bacterial translocation across the gut wall, among other physiological 
and  immunologic  manifestations  (Korpe  and  Petri,  2012;  Prendergast  and  Kelly,  2012). 
Although the precise aetiology of this condition is unclear, exposure to enteropathogens is 
thought to be crucial. As noted by Korpe and Petri (2012): 
“Constant exposure to fecal–oral contamination, and sustained episodes of self-limited 
infectious gastroenteritis, may lead to a perpetual state of small bowel injury. This injury 
could cause hyperstimulation of  the mucosal  immune system and result  in the small 
bowel pathology that has been described.”
The characteristics of EE may begin to appear soon after birth, and thereby have the 
potential to overlap with the administration of oral vaccines during routine immunisation – 
in  a  study  conducted  in  south  India,  finger-like  villi  were  observed  in  small  intestinal 
biopsies of stillborn foetuses; however, some degree of villous blunting was evident within 
the first 30 days of life in the majority of infants, while more severe manifestations of EE 
were apparent by 8 weeks of age (Chacko et al, 1969). Brown et al (2015) recapitulated the 
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features of EE by administering a cocktail of microbes (including a mixture of Bacteroidales 
species and E. coli) to malnourished mice, thereby implicating diet and microbial exposure in 
the aetiology of this condition. EE also displays a degree of seasonality – during a 3-year 
cohort study involving more than 200 adults in Zambia, marked seasonal variations were 
observed in villous height, gut permeability, and carbohydrate absorption (Kelly et al, 2004).
Owing to the pervasive nature of EE and its apparent link with chronic inflammation 
and other alterations of intestinal immune function, this condition has been hypothesised to 
play a key role in explaining the impaired response to oral vaccines in low-income settings 
(Serazin et  al,  2010;  Korpe and Petri,  2012;  Keusch et  al,  2014).  A key difficulty faced in 
unravelling this potential association is how best to measure and define EE. Owing to the 
invasive nature of intestinal biopsies, studies of EE have increasingly adopted alternative 
means  of  identifying  the  subclinical  condition  from  blood  or  stool  samples,  including 
markers  of  gut  inflammation  (e.g.,  faecal  calprotectin,  myeloperoxidase,  and  lactoferrin), 
microbial translocation (e.g., faecal neopterin and soluble CD14 in serum or plasma), and 
mucosal  permeability (e.g.,  faecal  α1-antitrypsin and reg1B in serum).  Although a recent 
study observed significant associations between several of these EE biomarkers and serum 
antibody  titres  to  Rotarix  and  OPV  among  infants  in  Bangladesh  (Naylor  et  al,  2015), 
individual  markers  were  often  not  consistent  in  the  direction  of  their  association,  either 
across the oral vaccines (e.g., reg1B, which was positively associated with Rotarix response 
but negatively associated with type 3 poliovirus response), or across different timepoints for 
the same vaccine (e.g., soluble CD14, which differed in the direction of its association with 
type  1  poliovirus  response  when  measured  at  6  and  18  weeks  of  age).  The  relative 
importance of EE in shaping the immune response to oral vaccines thus remains uncertain. 
Moreover, establishing the extent of this association is made all  the more difficult by the 
inevitable  overlap  of  EE  with  several  other  hypothesised  causes  of  oral  vaccine  failure, 
including enteropathogen exposure and malnutrition. 
1.5.8. The infectious agent
The nature of exposure to the targeted pathogen may have an important contribution to 
geographic variation in the protective efficacy of oral vaccines. As noted above, while Rotarix 
is capable of inducing both homotypic and heterotypic immunity, protection appears to be 
lower when individuals are exposed to viral strains that differ from the vaccine at both G and 
P epitopes (Ruiz-Palacios et al, 2006). Such exposure may be more frequent in low-income 
countries, where the circulation of unusual rotavirus strains is more common (Ramachandran 
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et al, 1996; Gentsch et al, 2005; Moyo et al, 2014). Variation in transmission intensity may also 
be relevant to vaccine response. Following a trial of Ty21a in Indonesia, Simanjuntak et al 
(1991) highlighted the possibility that an increase in the infectious inoculum (“more frequent 
inoculations  of  greater  numbers  of  bacteria”)  in  this  high-transmission setting may have 
contributed to the lower efficacy observed compared with earlier trials in Chile and Egypt. 
Similarly,  an  increase  in  the  infectious  load following extensive  flooding was  implicated 
during  a  large  outbreak  of  type  1  paralytic  poliomyelitis  within  a  highly  immunised 
population in South Africa between 1987 and 1988 (Schoub et al, 1992). 
In the case of rotavirus, exposure to natural infection in the neonatal period is common, 
particularly in settings with a high transmission intensity. One study performed in an urban 
hospital in India observed rotavirus shedding in 36% of infants within the first 3 days of life 
(Jayashree  et  al,  1988b).  In  a  review  of  Rotarix  trials,  Cunliffe  et  al  (2014)  documented 
baseline  rotavirus-specific  IgA seropositivity  rates  of  0–9%  among  studies  conducted  in 
Europe and North America and 0–26% among studies in Asia, Africa, and Latin America 
(given  that  transfer  of  IgA antibodies  across  the  placenta  is  negligible,  the  presence  of 
rotavirus-specific IgA in serum can be seen as indicator of prior viral exposure). Neonatal 
exposure has been linked with a reduction in the severity (but not frequency) of subsequent 
rotavirus infection (Bishop et al,  1983; Vethanayagam et al,  2004), albeit not in all studies 
(Banerjee et al, 2007). Notably, a reduction in vaccine immunogenicity among seropositive 
infants was recently observed during studies of Rotarix conducted in Zambia (Chilengi et al, 
2016) and Bangladesh (Emperador et al, 2016), suggesting that the induction of rotavirus-
specific  immunity  following  neonatal  viral  exposure  may  contribute  to  the  impaired 
immunogenicity of rotavirus vaccines in high-transmission settings.
1.6. Knowledge gaps and hypotheses
Significant deficits in the immunogenicity of oral vaccines targeting poliovirus, rotavirus, 
and several  other  enteropathogens have consistently  been documented in settings where 
they might confer the greatest public health benefit. The biological mechanisms responsible for 
this phenomenon have not been fully elucidated, in part because a range of interconnected 
factors are undoubtedly involved. In the present thesis, I will focus on just one aspect of this 
broader  tapestry  –  the  influence  of  the  intestinal  microbiota.  In  particular,  I  will  aim to 
answer two central questions. Do bacterial, viral, or eukaryotic enteropathogens influence 
the immunogenicity and replication efficiency of OPV or oral rotavirus vaccine? And is the 
composition of the commensal bacterial flora associated with response to these vaccines?
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Although the potential inhibitory effect of concurrent enteropathogens on OPV has been 
considered in a number of previous trials (section 1.5.5),  the influence of these infections 
(particularly non-viral infections) remains uncertain. Meanwhile, limited data are currently 
available regarding the potential effect of enteropathogens on the immunogenicity of oral 
rotavirus vaccines. I have attempted to clarify the impact of concurrent pathogens on the 
immunogenicity  of  OPV  and  oral  rotavirus  vaccine  by  exploiting  recent  advances  in 
molecular diagnostics. Specifically, in Chapter 4 of this thesis, I will describe how TaqMan 
array  cards  –  comprising  384-well  arrays  of  singleplex  real-time  PCR assays  targeting  a 
multitude of common bacterial, viral, and eukaryotic enteropathogens (Liu et al, 2013) – were 
used to examine the influence of concurrent infections on response to Rotarix among infants 
in  a  low-income  community  in  south  India.  The  same  approach  was  then  extended  to 
examine the impact of enteropathogens on OPV response, first within the same cohort of 
infants  (Chapter  5)  and  subsequently  among  infants  6–11  months  of  age  enrolled  in  a 
randomised, placebo-controlled trial examining the impact of oral azithromycin treatment on 
the immunogenicity of mOPV3 (Chapter 6). By comparing pathogen burden according to 
vaccine outcome in each of these study populations, I sought to test the hypothesis that the 
presence of enteropathogens at the time of immunisation inhibits the immunogenicity of oral 
vaccines  targeting  poliovirus  and  rotavirus,  and  thereby  contributes  to  the  geographic 
variation observed in the efficacy of these vaccines.
The  potential  influence  of  the  bacterial  microbiota  on  oral  vaccine  immunogenicity 
might take one of several forms. First, specific taxa may interact with vaccine strains in either 
an inhibitory or beneficial way (analogous to keystone species that impact their ecosystem in 
a  manner disproportionate  to  their  relative abundance).  In  the case of  allergic  atopy,  for 
example, it was recently observed that a decrease in the relative abundance of four genera 
(Faecalibacterium, Lachnospira, Rothia, and Veillonella) at 3 months of age was associated with a 
significant increase in the risk of developing asthma later in childhood (Russell et al, 2013). 
While there are some data to suggest that members of the genus Bifidobacterium may have a 
beneficial effect on OPV response (Huda et al, 2014), further investigation of the potential 
impact of ‘keystone taxa’ on OPV and other oral vaccines is certainly warranted. In Chapters 
4, 5, and 6, I will describe how sequencing of the 16S rRNA gene within the faecal samples of 
infants  in  south  India  was  used  to  identify  whether  specific  taxa  differed  in  relative 
abundance according the outcome of Rotarix or OPV. Owing to the relative novelty of this 
line  of  enquiry,  there  were limited existing data  regarding the potential  identity  of  such 
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discriminant  taxa .  However,  taking cues from the published literature on inflammatory 15
bowel disease (IBD), we hypothesised a priori  that failure to respond to the oral vaccines 
would be associated with an elevated abundance of Proteobacteria – a phylum containing 
numerous pathogenic species (including Campylobacter, Shigella, and the assorted pathotypes 
of diarrhoeagenic E. coli) that has consistently been implicated in the onset of Crohn’s disease 
and other chronic inflammatory conditions of the gut (Carvalho et al, 2012; Mukhopadhya et 
al, 2012). 
In addition to the influence of specific taxa, the immune response to oral vaccines may 
be shaped by a broader shift (or ‘dysbiosis’ ) of the gut’s microbial community. Such shifts 16
have been documented in association with a broad range of pathologies, including IBD (Fava 
and  Danese,  2011),  obesity  (Turnbaugh  et  al,  2009),  diabetes  (Larsen  et  al,  2010),  and 
malnutrition (Smith et al, 2013), among others (Balter, 2012). It is reasonable to suspect that 
analogous  broad-scale  discrepancies  in  microbiota  composition  might  also  be  apparent 
among infants at risk of oral vaccine failure. This possibility was tested – both in relation to 
oral rotavirus vaccine (Chapter 4) and OPV (Chapters 5 and 6) – by assessing the overall 
diversity and composition of the bacterial microbiota in faecal samples collected from infants 
in south India at the time immunisation. Specifically, we hypothesised that failure to respond 
to oral vaccination would be associated with a reduction in the diversity of the bacterial 
microbiota,  as  observed in  conjunction with malnutrition (Subramanian et  al,  2014),  IBD 
(Manichanh et al, 2006), and acute gastroenteritis (Mai et al, 2006; Chang et al, 2008).
1.6.1. General versus specific effects
While the trend of impaired performance in low-income countries appears to be general 
to oral vaccines, the underlying mechanisms responsible for this phenomenon may not be. 
OPV and Rotarix are both composed of attenuated viruses that are capable of replicating and 
inducing an immune response in the intestinal mucosa, but target different cell types and 
elicit  different  immune  effectors.  It  is  reasonable  to  suspect  that  certain  risk  factors  for 
vaccine failure may be shared across these oral  vaccines,  such as the inhibitory effect  of 
passively acquired maternal antibodies, while others may be specific to a particular vaccine 
 The study by Huda et al (2014) was not published until after we had designed the 16S rRNA gene 15
sequencing work described in Chapters 4 and 5.
 The term ‘dysbiosis’ is somewhat nebulous, but is often used to describe a significant change in 16
microbiota diversity or composition in conjunction with a particular pathology. I will  refrain from 
using it further in this thesis owing to its lack of a replicable definition as a diagnostic entity.
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or  vaccine  strain.  For  example,  it  may  transpire  that  HBGA phenotype  influences  the 
infectivity of P[8] rotavirus genotypes, but not other attenuated strains of this virus. Thus, a 
secondary aim of this thesis is to determine the extent to which the association between the 
intestinal microbiota and vaccine outcome is shared across Rotarix and OPV.
1.6.2. Objectives
i) To integrate published data regarding the impact of concurrent infections on OPV 
response via systematic review and meta-analysis (Chapter 2);
ii) To  introduce  the  laboratory  and  bioinformatic  methods  adopted  in  subsequent 
chapters for the assessment of (i) bacterial, viral, and eukaryotic enteropathogens, 
and (ii) the composition of the bacterial microbiota (Chapter 3);
iii) To assess the impact of concurrent enteropathogens and the bacterial microbiota on 
the immunogenicity and take of Rotarix and tOPV doses co-administered to infants 
in south India at 6 and 10 weeks of age (Chapters 4 and 5);
iv) To determine the proportion of failed vaccine seroconversions per dose of tOPV that 
can be attributed to enteropathogens in this setting (Chapter 5);
v) To  establish  whether  the  composition  of  the  bacterial  microbiota  influences  the 
immunogenicity  and  take  of  mOPV3  administered  to  6–11  month-old  infants  in 
south India (Chapter 6);
vi) To determine whether novel, persistent, or recently resolved enteropathogens differ 
in the extent to which they interfere with mOPV3 response (Chapter 6).
1.7. Conclusions
The central  issue of  this  thesis  –  why do oral  vaccines underperform in low-income 
countries? – has existed for more than half a century. Despite considerable effort, we are still 
some way from defining the biological mechanisms at the heart of this phenomenon, and 
further still  from establishing how best  to circumvent it.  My work set  out  to gain novel 
insight  into  this  aged  query  by  harnessing  recent  technological  advances  –  both  in  the 
detection of multiple enteropathogens using novel diagnostic methods and in the profiling of 
the bacterial flora via high-throughput sequencing. 
Before considering these novel techniques further, however, we shall first turn our gaze 
to what has gone before by applying a more traditional technique – the systematic review 
and meta-analysis.  
!     s65
Chapter 2: Influence of enteric infections on response to oral poliovirus vaccine: a 
systematic review and meta-analysis
2.1. Background
In 1959,  Albert  Sabin referred to enteric  infections as  a  “special  problem” facing the 
successful  implementation  of  OPV in  low-income countries  based  on  the  observation  of 
diminished or  delayed replication of  vaccine polioviruses  in  individuals  with concurrent 
viruses (Sabin, 1959). Not only are infections such as NPEVs more prevalent in regions where 
OPV is least immunogenic (Mangal et al, 2014), but within these regions, OPV outcomes are 
diminished during the high season of pathogen transmission (Grassly et al, 2012). In light of 
the inhibitory potential of enteropathogens, the WHO modified its immunisation policy in 
the mid-1980s to recommend that an additional OPV dose be given to children if they are 
immunised during an episode of gastroenteritis (WHO, 1986).
However,  as  highlighted  in  the  previous  chapter  (section  1.5.5),  data  regarding  the 
influence of enteric infections on OPV have yielded contradictory results – while several 
reports  have  emphasised  the  inhibitory  influence  of  concurrent  NPEVs  (Japan  Live 
Poliovaccine Research Commission, 1966; Triki et al, 1997), bacteria (Mahmoud et al, 1976), or 
diarrhoea (Posey et al,  1997),  others have refuted these effects (Kok et al,  1992; John and 
Christopher,  1975;  Sabin et  al,  1960).  The relative contribution of enteric infections to the 
impaired immunogenicity of OPV in low-income countries thus remains uncertain.
With this in mind, we carried out a systematic review and meta-analysis with the aim of 
clarifying the influence of enteric infections and diarrhoea on the odds of responding to OPV. 
The review also considered the potential effects of EE (the subclinical disorder associated 
with blunted intestinal villi, nutrient malabsorption, and intestinal inflammation described 
in  section  1.5.7),  which  has  been  widely  documented  among  individuals  in  low-income 
countries, and suggested as a possible cause of impaired oral vaccine performance (Korpe 
and Petri, 2012; Serazin et al, 2010).
2.1.1. Hypotheses
i) The  balance  of  evidence  in  the  published literature  supports  the  presence  of  an 
inhibitory effect of concurrent enteropathogens or diarrhoea on OPV response;
ii) This inhibitory effect is reflected by a decline in the relative odds of seroconversion 
and vaccine take per dose of OPV in infected versus uninfected individuals.
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2.2. Methods
2.2.1. Literature search
A literature  search  was  carried  out  in  October  2012  to  identify  published  articles 
examining  the  influence  of  concurrent  enteric  infections,  diarrhoea,  or  environmental 
enteropathy on response to OPV. Titles, key words, and abstracts in the citation databases 
PubMed and ISI Web of Knowledge were searched using the following term: “polio* and 
(oral or OPV) and (compet* or interfer* or diarrh* or entero* or enteric or coinfect* or bacter* 
or helminth* or parasit* or protozoa*) and (immunogen* or stool or excret* or shed* or sero* 
or serum or antibod* or efficac* or fec* or faec*)”. The asterisk symbols in this search term 
function as ‘wildcards’ enabling the matching of truncated words (e.g.,  “seroprevalence”, 
“seroconversion”,  and “serology” would all be matched by the search term “sero*”).
2.2.2. Screening of abstracts and titles
PRISMA guidelines were followed throughout the study selection process (Moher et al, 
2009).  Following  the  removal  of  duplicates,  the  titles  and  abstracts  of  studies  identified 
during the above search were evaluated for their relevance to the review topic. Articles were 
considered eligible  for  full-text  review if  their  abstracts  reported the delivery of  OPV to 
human recipients alongside the assessment of: (i) concurrent diarrhoea; (ii) concurrent enteric 
infection;  (iii)  enterovirus  excretion  or  faecal  sample  collection  at  or  near  the  time  of 
vaccination; (iv) EE; or (v) unspecified factors influencing or interfering with OPV response. 
Articles were excluded if they did not report on primary research or included fewer than ten 
OPV recipients. Among articles for which no abstracts were available, full-text copies were 
obtained if the title referred to OPV delivery alongside one of the five potential indicators of 
interference listed above. Eligible articles were obtained from electronic journals or from the 
holdings of the British Library (London, UK) or Wellcome Library (London, UK).
2.2.3. Search for additional studies
Additional studies were identified by scanning the text and bibliographies of articles 
being considered for full-text review. Articles were obtained if they were described as having 
examined the effect of non-polio enteric infections, diarrhoea, or EE on OPV response, or if 
their title referred to OPV and one of these potential sources of interference. Several complete 
conference proceedings were also scanned for potentially relevant studies (including the First 
International  Conference  on  Live  Poliovirus  Vaccines  [1959],  the  Second  International 
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Conference on Live Poliovirus Vaccines [1960], and the Fourth Scientific Conference of the 
Institute of Poliomyelitis and Virus Encephalitis [1960]), as were the text and bibliographies 
of a number of relevant articles identified during the review of abstracts or known to the 
authors (Gerichter et al, 1978; Oduntan et al, 1978; Salk, 1979; Sabin, 1980; Tulchinsky et al, 
1989; Patriarca et al, 1991; Fine and Carneiro, 1999; Grassly et al, 2007).
2.2.4. Inclusion and exclusion criteria
Studies were included in the review if they fulfilled the following criteria: (i) delivery of 
OPV in a prospective trial; (ii) reporting 0–7 days prior to OPV delivery of diarrhoea, NPEV 
excretion, other indicators of enteric co-infection, or markers of EE; and (iii) measurement of 
OPV response, including assessment of seroconversion or poliovirus-specific antibody titres 
within 8 weeks of OPV delivery, shedding of vaccine poliovirus between 1 and 4 weeks after 
immunisation  (hereafter  referred  to  as  vaccine  take),  or  intestinal  immunity  (including 
measurement of poliovirus-specific faecal IgA following vaccination or shedding of vaccine 
virus  after  OPV  challenge).  If  the  reporting  of  enteric  infections  spanned  the  7  days 
preceding vaccination, but was not limited to this window, the study was included. Studies 
were excluded if: (i) they included only immunocompromised individuals; (ii) fewer than ten 
individuals were present in either the infected or control group; (iii) OPV outcomes were not 
presented according to the presence or absence of concurrent infection, diarrhoea, or markers 
of  EE;  or  (iv)  the  reporting  of  concurrent  enterovirus  infection  did  not  distinguish 
polioviruses from NPEVs. Conference abstracts were excluded if a complete report of the 
study was already included in the review. If multiple eligible reports of the same trial were 
encountered, the most comprehensive report was used for data extraction, although other 
reports were consulted for relevant details where necessary. Several reports presented data 
from separate trials of mOPV and tOPV (Urasawa, 1964b; Ramos Alvarez, 1966) or of tOPV 
trials conducted in different countries (Cirne et al, 1995) − these were considered as separate 
studies during the analysis.  Publications in languages other than English were translated 
with the assistance of proficient speakers.
2.2.5. Data extraction
Data were extracted from eligible studies regarding the type, schedule, and potency of 
the administered OPV, the timing of sample collection or diarrhoea assessment, the collection 
method for  faecal  specimens,  the  laboratory  methods used for  the  assessment  of  enteric 
!     s68
viruses, and the criteria and methods used to assess serological response. Results presented 
only  in  graphical  form  were  digitised  and  data  extracted  using  Plot  Digitizer  software 
(version 2.6.2).  Where relevant, an effort was made to obtain supplementary details from 
authors  of  the  included studies,  although this  was  generally  not  feasible  given  that  the 
majority of trials were conducted more than 30 years ago.
2.2.6. Statistical analysis
i. Random-effects meta-analyses
Meta-analyses were conducted to examine the effects of concurrent NPEV infection and 
diarrhoea on the odds of seroconversion per dose of OPV, and of NPEVs on the odds of 
vaccine take. Intestinal immunity was not used as a measure of OPV response in any of the 
eligible  studies.  Studies  were  included  in  the  analyses  if  they  reported  the  number  or 
proportion of individuals demonstrating seroconversion or vaccine virus shedding after a 
given dose  of  OPV by serotype and according to  the  presence  or  absence  of  concurrent 
NPEVs  (excluding  poliovirus-infected  individuals)  or  diarrhoea.  In  several  studies  (e.g., 
Dardanoni et al, 1962; Ingram et al, 1962), data were presented for individual vaccinees or 
groups  of  vaccinees;  in  these  instances,  OPV  response  data  were  grouped  according  to 
infection status at the time of vaccination. If data were presented as proportions, the number 
of responders was inferred by rounding to the nearest whole number. An additional analysis 
was  conducted  to  compare  the  odds  of  seroconversion  after  multiple  OPV  doses  in 
individuals presenting with diarrhoea at the time of one or more doses with those free of 
diarrhoea at all doses. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were 
calculated  separately  for  each  serotype  on  a  log  scale  using  random-effects  models 
(DerSimonian  and Laird,  1986).  Heterogeneity  among studies  was  assessed using  the  χ2 
statistic. A continuity correction of 0.5 was used in trials with zero events in any comparison 
group. 
An important decision before undertaking these analyses was whether to use fixed-effect 
or  random-effects  meta-analytic  models.  As  noted by Borenstein  et  al  (2010),  fixed-effect 
models  assume  that  all  studies  are  estimating  a  common  effect  (the  fixed  effect),  with 
variability arising only due to sampling variation among studies. By contrast, random-effects 
models assume that there are two sources of variation among studies – variation in the effect 
size  being  estimated,  and  random  sampling  variation  in  the  estimation  of  these  effects. 
Owing to  the  marked differences  in  the  age  and location of  the  study populations,  and 
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discrepancies  in  the  timing  of  sample  collection  and  laboratory  techniques  adopted  (as 
discussed further below), it was reasonable to expect that a distribution of effects would be 
captured  by  the  included  studies.  Random-effects  models  were  therefore  deemed  more 
appropriate for these analyses. 
Following the estimation of serotype-specific effects, data across the three serotypes were 
combined  in  multi-level  meta-analytic  models  based  on  a  structural  equation  modelling 
approach (Cheung, 2014), incorporating study as a cluster effect. Overall ORs for the multi-
level models were calculated using maximum likelihood estimation, with likelihood-based 
CIs. Stratified analyses and mixed-effects meta-regression were used to assess the impact of 
serotype,  formulation (mOPV vs tOPV),  and trial  setting (low-,  lower-middle-,  or  upper-
middle-income vs high-income countries, as listed by the World Bank in April 2013) on effect 
size; the impact of each factor on model fit was assessed using the likelihood ratio test (LRT). 
Potential publication bias was assessed using funnel plots and Egger’s test (Egger et al, 
1997). Sensitivity analyses were performed to include studies with at least five individuals in 
the infected and control groups (rather than ten), and to include trials in which poliovirus-
infected individuals were not distinguished from NPEV-infected individuals. Analyses were 
conducted in the programming language R (using the packages meta and rmeta for serotype-
specific models, and metaSEM for multi-level models) and using Review Manager software 
(RevMan 5.2).
ii. A note on multi-level models
The decision to use multi-level meta-analytic models in this study revolves around their 
capacity to reflect hierarchies in the structure of the data when estimating the overall OR 
across serotypes. Crucially, it would not be appropriate to treat data for separate poliovirus 
serotypes from an individual study as independent given that they were collected from the 
same group of vaccine recipients. By incorporating study as a ‘cluster effect’ within a multi-
level modelling approach, it was possible to account for this pseudoreplication (analogous to 
including study as a random effect within a mixed-effects regression model). We used the R 
package metaSEM – which implements random-effects meta-analyses as structural equation 
models  (as  described by Cheung [2014])  –  to  fit  the  multi-level  models  described above 
owing to its ability to recapitulate serotype-specific OR estimates obtained using standard 
random-effects models (as implemented in the R packages meta  and rmeta)  as well  as its 
capacity to compare the fit of nested models using the LRT.
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2.3. Results
2.3.1. Study selection
The literature search led to the identification of 203 articles of potential relevance to the 
review. Among these articles, 28 fulfilled the criteria for inclusion in the review, reporting on 
25 distinct trials of OPV. Figure 2.1 presents a flow chart of the study selection process, while 
a summary of the eligible studies is provided in Table 2.1.  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Figure 2.1.  Flow chart of study selection process.  A study by Swartz et al  (1972b) was initially 
classified as eligible, but was subsequently re-classified based on details in a separate report by the 
authors  (Swartz  et  al,  1972a),  which clarified that  the presence of  NPEV infections in  the week 
following (as opposed to preceding) OPV delivery had been used as an indicator of  concurrent 
infection. Abbreviations: NPEVs, non-polio enteroviruses; OPV, oral poliovirus vaccine.
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Legend  to  Table  2.1.  Abbreviations:  BA,  enteric  bacteria;  DI,  diarrhoea;  EE,  environmental 
enteropathy; EU, eukaryotic parasites; GMT, geometric mean titre; H, high; IG, income group; IPV, 
inactivated poliovirus vaccine; JLPRC, Japan Live Poliovaccine Research Commission; L, low; LM, 
lower middle; m, months; mOPV, monovalent oral poliovirus vaccine; NA, not reported; NP, non-
polio enteroviruses; OPV, oral poliovirus vaccine; SER, seroconversion; tOPV, trivalent oral poliovirus 
vaccine; UM, upper middle; VI, other enteric viruses (non-enteroviruses); w, weeks; y, years.
a Where multiple reports describing the same trial fulfilled the eligibility criteria for inclusion in the 
review, the most comprehensive report is indicated here.
b Income status designated by the World Bank in April 2013.
c The total number of OPV recipients recruited in each trial is indicated; however, the influence of 
enteric infections was often examined in a subset of the total study population.
d Outcomes are listed if they were reported within the eligible timeframe (i.e., within 8 weeks of 
vaccination for seroconversion and within 4 weeks for vaccine take) and compared according to the 
presence or absence of infection at the time of vaccine delivery; other OPV outcomes may have 
been  reported  in  each  study,  but  not  with  respect  to  enteric  infection  or  within  the  eligible 
timeframe.
e Three doses of mOPV were delivered in the order type 1, type 3, type 2.
f The  study  reported  on  a  collaborative  trial  of  mOPV  involving  27  laboratories  across  Japan, 
commencing in May 1961; data from preceding eligible reports, using the same vaccine formulation 
and also commencing in May 1961 (by Takatsu [1962],  Urasawa [1964a],  and Urasawa [1964b]) 
were assumed to be included in or to overlap with this later and more comprehensive report in 
order  to  avoid the  risk  of  duplicating data  from individual  vaccinees.  However,  the  study by 
Urasawa (1964b) also reported on a trial of tOPV, which was included in the analysis separately.
g Data regarding vaccine take were obtained from the report by Monaci et al (1965), which included 
a subset of the children under 5 years of age reported on by Nardi et al (1966) and an additional 70 
vaccinees between 6 and 10 years of age.
2.3.2. Concurrent non-polio enteroviruses
i. Serological response
Sixteen eligible studies reported serological response to OPV according to the presence 
or absence of concurrent NPEVs (Table 2.2). Across nine studies eligible for inclusion in the 
meta-analysis  (all  involving  delivery  of  Sabin  vaccine),  the  presence  of  NPEVs  had  a 
significant inhibitory effect on seroconversion rates for type 1 poliovirus (OR 0.44, 95% CI 
0.23–0.84), but not types 2 or 3 (OR 0.53, 95% CI 0.19–1.46 and OR 0.56, 95% CI 0.27–1.12, 
respectively; Figure 2.2).  Overall,  the reduction in per-dose seroconversion among NPEV-
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infected individuals approached significance (summary OR 0.47, 95% CI 0.20−1.04). There 
was no evidence of marked publication bias (Egger’s test, P values >0.05 for each serotype; 
Figure 2.3). Serotype did not significantly influence effect size (LRT, P = 0.680). Significant 
heterogeneity  in  ORs across  studies  was  observed for  each serotype (χ2,  P values  0.002, 
<0.001, and 0.001 for type 1, 2, and 3 data, respectively) and for the overall OR (χ2, P <0.001).
When the meta-analysis was stratified according to OPV formulation (mOPV vs tOPV), 
NPEV-associated interference was significant for each serotype following the administration 
of mOPV (summary OR 0.17, 95% CI 0.07−0.42) but not tOPV (summary OR 0.92, 95% CI 
0.45−1.86; Table 2.3). The impact of formulation on effect size was significant (LRT, P = 0.008). 
A separate subgroup analysis revealed that interference was generally greater among studies 
conducted in low- or middle-income than high-income countries (Table 2.3), although the 
impact of trial setting was not significant (LRT, P = 0.181). A sensitivity analysis including 
studies with a minimum of five individuals in the infected and control groups did not alter 
the outcomes of this meta-analysis (Table 2.3). 
ii. Impact of concurrent non-polio enteroviruses across multiple doses of oral poliovirus vaccine
A limited number of trials examined the influence of NPEV infections at the time of one 
or more doses on seroconversion rates after multiple doses of tOPV. Maldonado et al (1997) 
reported a significant decrease in type 1 seroconversion rate after two doses of tOPV among 
infants in Mexico presenting with concurrent NPEVs (including any infection identified in 
stool samples 1 week before, at the time of, or 1 week after OPV delivery) compared with 
those free of NPEV infections. By contrast, Kok et al (1992) did not observe a significant effect 
of  concurrent  NPEVs on  the  antibody levels  obtained after  three  doses  of  tOPV among 
children in Kenya, while John and Christopher (1975) did not observe significant inhibition 
of seroconversion among NPEV-infected children in India who were seronegative to one or 
more  poliovirus  serotypes  upon receipt  of  a  second dose  of  tOPV.  Heterogeneity  in  the 
reporting of these trials precluded the synthesis of data across studies.
iii. Concurrent enteroviruses
Studies  were  not  included  in  the  primary  analysis  if  the  reporting  of  concurrent 
enterovirus infection did not distinguish poliovirus infections (wild-type or vaccine-derived) 
from NPEVs. This specification was included to avoid the risk of biasing the results in favour 
of an interference effect, given the inter-serotype interference that is known to arise between 
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the vaccine poliovirus strains (Patriarca et al, 1991). However, we performed a sensitivity 
analysis  to incorporate studies in which the reporting of  data did not enable poliovirus-
infected individuals to be excluded. 
Following the inclusion of six additional studies (Campillo Sainz et al, 1962; Paul et al, 
1962;  Poliomyelitis  Commission of the Western Region Ministry of Health,  Nigeria,  1966; 
Peradze et al, 1968; Domok et al, 1974; Domok and Balayan, 1976), significant inhibition of 
per-dose seroconversion was evident for type 1 poliovirus (OR 0.51, 95% CI 0.34−0.75) but 
not for types 2 or 3 (OR 0.67, 95% CI 0.33−1.36 and OR 0.58, 95% CI 0.33−1.02, respectively). 
Inhibition of  per-dose seroconversion was significant  overall  (summary OR 0.55,  95% CI 
0.33−0.89; Table 2.3).  Heterogeneity was significant for each poliovirus serotype (P values 
0.012, <0.001, and 0.001 for type 1, 2, and 3 data, respectively) and for the overall OR (P 
<0.001).  During  meta-regression,  effect  size  did  not  differ  significantly  according  to 
poliovirus serotype (LRT, P  = 0.434),  trial  setting (LRT, P = 0.303),  or – in contrast to the 
primary analysis – formulation (mono-, bi-, or tri-valent OPV; LRT, P = 0.248). Inclusion of one 
extra study (Paul et al, 1962) in the analysis of vaccine take did not markedly change the 
results (Table 2.3). Since the primary focus of this review was to assess the impact of non-
polio  enteric  infections  on  OPV  response,  poliovirus-infected  individuals  were  still 
excluded  from  this  sensitivity  analysis  where  possible.  The  proportion  of  enteroviruses 
accounted for  by  polioviruses,  where  reported,  varied from less  than 10% (Poliomyelitis 
Commission of  the Western Region Ministry of  Health,  Nigeria,  1966) to more than 50% 
(Campillo Sainz et al, 1962). 
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Legend  to  Table  2.2.  Abbreviations:  2x,  two  samples;  3x,  three  samples;  d,  days;  IR,  infected 
responders; IT, infected total; JLPRC, Japan Live Poliovaccine Research Commission; Led, Lederle; m, 
months;  mAb,  maternal  antibody;  MI,  metabolic  inhibition  assay;  MN,  microneutralisation  assay; 
mOPV,  monovalent  oral  poliovirus  vaccine;  N,  neutralisation  assay;  NA,  not  reported;  OPV,  oral 
poliovirus vaccine; SM, suckling mice; TCID50, median tissue culture infective doses; tOPV, trivalent 
oral poliovirus vaccine; UR, uninfected responders; UT, uninfected total; w, weeks.
a Studies reporting the use of rectal swabs are indicated as ‘swab’. All other faecal sampling methods 
are listed as ‘stool’.
b Other  tests  included  assays  for  haemagglutination/haemagglutination-inhibition,  infection  of 
suckling and adult cotton rats, ELISA, RNA–RNA hybridisation, and electron microscopy.
c Antibody  titres  are  expressed  as  the  reciprocal  of  the  minimum  dilution  producing  virus 
neutralisation.
d Dose-specific take data from this study were not included in the meta-analysis as the age range of 
NPEV-infected  individuals  (1−4  months)  did  not  match  that  of  uninfected  individuals  (3−4 
months); the younger age of infected individuals may therefore be responsible for the differences 
observed between these groups.
e Additional details were obtained from a report by Voroshilova et al (1960).
f The total number of uninfected individuals was not reported directly by the authors; however, 33 
children under 4 years of age (the age range in which the influence of NPEVs on OPV take was 
examined) lacked any virus during the pre-vaccination survey. This was therefore used as the total 
number of uninfected controls during the meta-analysis.
g Any poliovirus excretion within the 4-week period after vaccine delivery (rather than the full study 
period of 10 weeks) was considered as indicative of vaccine take.
h This  study  was  not  included  in  the  primary  analysis  as  eight  individuals  excreting  type  3 
poliovirus at the time of vaccination were not excluded from the data. 
i Methods  were  assumed  to  follow  those  described  in  a  prior  publication  by  the  same  author 
(Urasawa, 1964a).
j The study reported outcomes relative to the presence or absence of NPEVs for vaccine take at 2 and 
4 weeks after OPV delivery, and seroconversion 4 and 8 weeks after vaccination; in both cases, the 
4-week data were available for more individuals, and were therefore used in the meta-analysis. The 
reporting of concurrent NPEVs in this study spanned the period immediately before and after 
vaccination.
k Data regarding vaccine take were obtained from a report by Monaci et al (1965).
l Additional details were obtained from a report by Sabin (1980).
m Additional details were obtained from reports by John and Jayabal (1972) and John (1975). The 
presented  data  were  summed  across  ditypic  and  tritypic  seronegative  individuals;  data  for 
monotypic seronegative individuals were not reported according to poliovirus serotype.  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Figure 2.2. Forest plot of the impact of concurrent non-polio enterovirus infections on the odds of 
seroconversion per dose of oral poliovirus vaccine. ORs and 95% CIs, calculated using random-
effects models, are presented for each serotype by boxes and black lines, with box area proportional 
to study weight. Summary ORs are indicated by diamonds, the width of which represents the 95% 
CI. Abbreviations: CI, confidence interval; JLPRC, Japan Live Poliovaccine Research Commission; 
mOPV, monovalent oral poliovirus vaccine; OR, odds ratio; tOPV, trivalent oral poliovirus vaccine.
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B
C
Figure 2.3. Funnel plots. Data are presented for (A) serotype 1, (B) serotype 2, and (C) serotype 3, 
and correspond to the forest plot depicted in Figure 2.2. Abbreviations: OR, odds ratio; SE (log OR), 
standard error of log odds ratio.
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iv. Vaccine take
Nine studies reporting vaccine take according to the presence or absence of NPEVs were 
eligible for inclusion in the meta-analysis (Figure 2.4). Sabin vaccine was used in each study 
(where  specified).  As  with  serological  response,  a  significant  decrease  in  the  odds  of 
shedding  in  NPEV-infected  individuals  was  observed  for  serotype  1  (OR  0.50,  95%  CI 
0.28−0.89) but not types 2 or 3 (OR 0.59, 95% CI 0.30−1.13 and OR 0.67, 95% CI 0.26−1.71, 
respectively). There was no evidence of marked publication bias (Egger’s test, P values >0.05 
for each serotype). Overall, the reduction in shedding among NPEV-infected individuals was 
not  significant  (summary  OR  0.58,  95%  CI  0.26−1.24).  The  impact  of  serotype  was  not 
significant  following  meta-regression  (LRT,  P  =  0.489).  Heterogeneity  among studies  was 
significant for serotypes 2 and 3 (χ2, P values 0.081, 0.015, and 0.001 for type 1, 2, and 3 data, 
respectively), and for the overall OR (χ2, P <0.001). Again, stratification of the meta-analysis 
according to vaccine formulation revealed that NPEV-associated interference was greater for 
mOPV than tOPV (LRT, P = 0.032), and in low- or middle-income than high-income countries 
(LRT, P = 0.019; Table 2.3).
v. Impact of specific non-polio enteroviruses
Seven studies  reported the influence of  NPEVs on OPV take and/or seroconversion 
according to the presence of specific pathogens (Levine and Goldblum, 1960; Dardanoni et al, 
1962; Ingram et al, 1962; Urasawa, 1964b; Spano and Dardanoni, 1965) or pathogen groups 
(Fang-Cho, 1960; John and Christopher, 1975). Although the numbers of individuals affected 
by  particular  NPEVs  were  generally  small,  the  findings  of  four  studies  merit  particular 
mention. Ingram et al (1962) documented vaccine response in a US nursery following the 
delivery of type 1 mOPV during an epidemic of echovirus 14 (a species B enterovirus). The 
virus did not inhibit  seroconversion or vaccine take, although the study included just 25 
vaccinees. Urasawa (1964b) reported an inhibitory effect of Coxsackie B5 virus (also a species 
B enterovirus)  on both take and serological  response following the delivery of  mOPV to 
individuals in Japan; however,  Coxsackie B5 virus did not inhibit  serological response to 
tOPV (Figure 2.2). During a study in China involving one dose of tOPV, interference with 
seroconversion was similar for different subgroups of NPEVs (Coxsackie A, Coxsackie B, or 
echovirus/other viruses) (Fang-Cho, 1960). On the other hand, John and Christopher (1975) 
observed no interference with seroconversion among children in India irrespective of the 
subgroup of NPEV present at the time of tOPV administration. Overall, we observed no clear 
evidence to support the particular inhibitory effect of any specific NPEV or NPEV group.
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Figure 2.4. Forest plot of the impact of concurrent non-polio enterovirus infections on the odds of 
vaccine  take  per  dose  of  oral  poliovirus  vaccine.  See  Figure  2.2  for  additional  details. 
Abbreviations:  CI,  confidence  interval;  JLPRC,  Japan  Live  Poliovaccine  Research  Commission; 
mOPV, monovalent oral poliovirus vaccine; OR, odds ratio; tOPV, trivalent oral poliovirus vaccine.
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2.3.3. Concurrent diarrhoea
i. Serological response
Four  of  the  included  trials  considered  the  influence  of  concurrent  diarrhoea  on 
serological response to tOPV (Table 2.4), of which two were eligible for inclusion in the meta-
analysis  (Figure  2.5).  Both  studies  involved  the  delivery  of  Sabin  strains.  Concurrent 
diarrhoea was associated with a significant decrease in per-dose seroconversion rates for 
serotypes 2 and 3 (OR 0.52, 95% CI 0.34–0.80 and OR 0.45, 95% CI 0.26–0.78, respectively), 
but not type 1 (OR 0.92, 95% CI 0.60–1.40). Overall, the impact of diarrhoea on dose-specific 
seroconversion was significant (summary OR 0.61, 95% CI 0.38−0.87). The difference in effect 
size among serotypes approached significance (LRT, P = 0.067). Heterogeneity among studies 
was not significant for any serotype (χ2, P values >0.05) or overall (χ2, P = 0.207). 
We carried out a separate analysis to assess the impact of experiencing diarrhoea at the 
time of one or more doses on overall seroconversion after multiple tOPV doses (Figure 2.6). 
Overall, a significant decline in the odds of seroconversion was observed in children who 
experienced at least one concurrent diarrhoeal episode (summary OR 0.68, 95% CI 0.48−0.93). 
As  with  the  dose-specific  seroconversion data,  this  interference  effect  was  significant  for 
serotypes 2 and 3 (OR 0.47, 95% CI 0.28–0.79 and OR 0.59, 95% CI 0.44–0.79, respectively), 
but not type 1 (OR 1.05, 95% 0.71–1.55). Heterogeneity among studies was not significant for 
any serotype (χ2, P values >0.05) or overall (χ2, P = 0.154). Effect size differed significantly 
according to serotype (LRT, P  = 0.024). It should be noted that two other studies did not 
observe a significant impact of concurrent diarrhoea on serological response after multiple 
doses of tOPV, but were not suitable for inclusion in this analysis (Kok et al, 1992; Myaux et 
al,  1996).  There  were  insufficient  studies  to  formally  assess  publication  bias  regarding 
diarrhoea-associated interference.
ii. Vaccine take
One trial,  conducted in  Egypt  by  Mahmoud et  al  (1976),  examined the  influence  of 
concurrent  diarrhoea  on  OPV  take.  Over  a  3-week  period  after  OPV  delivery,  vaccine 
shedding was observed in 1/10 (10%) children with diarrhoea at the time of immunisation 
and 9/14 (64%) of those without diarrhoea.
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Figure  2.6.  Forest  plot  of  the  impact  of  concurrent  diarrhoea  on  the  odds  of  seroconversion 
following multiple doses of oral poliovirus vaccine. See Figure 2.2 for additional details. Data were 
obtained from one article (Cirne et al, 1995), reporting on separate trials of trivalent OPV in Brazil 
(WHO 1995a) and the Gambia (WHO 1995b). The reporting of concurrent diarrhoea spanned the 
2-week period preceding vaccination. Abbreviations: CI, confidence interval; OR, odds ratio; tOPV, 
trivalent oral poliovirus vaccine.
Figure 2.5. Forest plot of the impact of concurrent diarrhoea on the odds of seroconversion per 
dose of oral poliovirus vaccine. See Figure 2.2 for additional details. Abbreviations: CI, confidence 
interval; OR, odds ratio; tOPV, trivalent oral poliovirus vaccine. 
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2.3.4. Other enteropathogens
We identified only five studies that reported the effect of enteric infections other than 
NPEVs on response to OPV (Myaux et al, 1996; Maldonado et al, 1997; Triki et al, 1997; Faden 
and  Duffy,  1992;  Mahmoud  et  al,  1976).  Although  several  other  studies  used  isolation 
techniques  permissive  to  the  detection  of  adenoviruses  or  reoviruses  (e.g.,  John  and 
Christopher, 1975; Spano and Dardanoni, 1965), either the infections were not observed in 
pre-vaccination samples or their impact on OPV response was not reported.
During a study in Bangladesh, Myaux et al (1996) examined rectal swabs for rotavirus 
antigen before delivery of the first of three tOPV doses. Among 11 individuals positive for 
rotavirus with complete  follow-up data,  lower seroconversion rates  were observed to all 
three serotypes following one dose of OPV compared with uninfected individuals, although 
differences were not significant.
Maldonado et al (1997) examined the combined influence of concurrent viral pathogens 
(including NPEV, adenovirus 40/41, astrovirus, and rotavirus infections) and enteric bacteria 
on seroconversion rates  across  two doses  of  tOPV among infants  in  Mexico.  Concurrent 
infections were generally more frequent among non-responders compared with responders 
at each dose, and were linked with a diminished response to serotypes 1 and 2 at the second 
dose.  Antibody titres  for  serotypes 1  and 2  were significantly  lower among infants  with 
concurrent viral or bacterial infections compared with those lacking infections after the first 
dose  of  OPV,  and  for  type  2  poliovirus  after  the  second  dose.  Notably,  in  spite  of  the 
significant interference effects  for type 1 and 2 poliovirus observed in this  study,  overall 
seroconversion  rates  for  these  serotypes  after  two  doses  of  tOPV  were  86%  and  97%, 
respectively. Corresponding seroconversion rates for type 3 poliovirus were only 61% after 
two  doses,  though  no  significant  interference  effect  for  concurrent  enteropathogens  was 
observed for this serotype.
Triki et al (1997) measured the influence of enteric bacteria and eukaryotic parasites on 
serological response to tOPV among infants in Tunisia. Overall seroconversion rates were 
high in this study,  with only 16 out of  114 individuals failing to seroconvert  to all  three 
serotypes after three doses. Among individuals with incomplete seroconversion, a significant 
increase  in  the  frequency  of  eukaryotic  parasites  −  including  Candida  albicans,  Candida 
tropicalis, and Giardia intestinalis − was observed (5/16 [31%], compared with 12/98 [12%] in 
those with complete  seroconversion).  The prevalence of  enteric  bacteria,  rotaviruses,  and 
adenoviruses did not differ significantly between these groups. It should be noted, however, 
that stool samples were obtained both at the time of vaccination and during intervening 
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episodes of diarrhoea in this study; the reporting of enteropathogen prevalence therefore 
included, but was not limited to, infections coinciding with OPV delivery. 
In a US study examining the influence of concurrent enteric and nasopharyngeal viral 
pathogens (including NPEV, adenovirus, and rotavirus infections) on response to OPV and/or 
enhanced-potency  IPV,  Faden  and  Duffy  (1992)  reported  detectable  antibodies  to  each 
poliovirus serotype in all participants after three vaccine doses, irrespective of immunisation 
schedule  (OPV  alone,  IPV  alone,  or  combined).  Compared  with  uninfected  controls, 
individuals with viral infections had similar serum neutralising antibody, nasopharyngeal 
neutralising antibody, and nasopharyngeal IgA titres following the delivery of tOPV doses at 
either 4 or 12 months of age, though a modest decrease in serum antibody titres was evident 
for the latter dose among infected individuals.
Finally,  in  the  trial  by  Mahmoud et  al  (1976)  described  above,  in  which  concurrent 
diarrhoea was observed to reduce OPV take among children in Egypt, each case of diarrhoea 
was attributed to Shigella infection.
Overall, while these findings provide some indication of a potential inhibitory effect of 
enteric bacteria or eukaryotic parasites on serological response to OPV, the extent of this 
interference remains uncertain owing to the small number and heterogeneous nature of the 
available studies.
2.3.5. Environmental enteropathy
No  studies  encountered  in  this  review  examined  the  influence  of  EE  on  OPV 
immunogenicity or take.
2.4. Discussion
The potential link between enteropathogen exposure and the impaired immunogenicity 
of OPV in low-income countries has been the subject of a varied and conflicted literature that 
dates back to the earliest days of the vaccine’s implementation. This systematic review and 
meta-analysis was carried out with the aim of integrating the findings of this extensive body 
of work, and thereby determine which direction the balance of evidence leans when it comes 
to  the  impact  of  enteropathogens  on  OPV.  Overall,  the  review  supports  the  role  of 
enteropathogens  as  a  risk  factor  for  impaired  OPV  response  –  for  type  1  poliovirus,  a 
significant reduction in the odds of both seroconversion and vaccine poliovirus replication 
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for  a  given  dose  of  OPV  was  observed  in  NPEV-infected  compared  with  -uninfected 
individuals, while concurrent diarrhoea was associated with a decrease in seroconversion for 
serotypes 2 and 3. Enteropathogens other than NPEVs may also interfere with the immune 
response to OPV, but have been considered by only a small number of studies to date. 
Significant heterogeneity in the extent of  NPEV-associated interference was observed 
among studies included in this review. Factors that may contribute to this include vaccine 
potency,  age  at  vaccination,  collection  method  for  faecal  samples,  and  viral  isolation 
methods,  which varied widely among studies.  Of  particular  note  is  the  starting dilution 
adopted during neutralisation assays,  which has previously been shown to influence the 
seroconversion rates observed for tOPV (Patriarca et al, 1991) – this varied from the use of 
undiluted sera to 1 in 10 dilutions among the included studies.
Stratification  of  the  analysis  revealed  that  interference  with  both  take  and 
seroconversion was generally greater following the delivery of mOPV than tOPV, and in 
trials conducted in low- or middle-income as opposed to high-income countries. Trends were 
consistent  across  serotypes.  These  stratified  findings  should  be  interpreted  with  caution 
given the small number of studies in each subgroup, and the potential for individual studies 
with marked interference effects (e.g., Ramos-Alvarez, 1961) to exert a strong influence on a 
particular  subgroup.  Nonetheless,  they  raise  the  possibility  that  mOPV  may  be  more 
susceptible than tOPV to the influence of enteric infections. This observation might reflect the 
dynamics of competition between enteroviruses coinciding in the gut – in particular, while 
an  existing  NPEV infection  may have  a  marked inhibitory  effect  on  a  single  attenuated 
vaccine strain in mOPV, the additive effect on top of the inter-serotype interference arising 
between poliovirus strains in tOPV may be smaller. 
The disparity observed according to trial setting suggests that infants in low- or middle-
income countries may be more susceptible to the inhibitory effect of concurrent NPEVs on 
OPV – potentially indicative of differences in the strains of circulating enteroviruses or the 
heightened prevalence of comorbidities such as acute malnutrition, which might influence 
the outcomes of NPEV-associated interference. One must also consider the possibility that 
infants  in  low-income countries  with other  risk factors  for  OPV non-response (including 
malnutrition and EE, among others) may simply be more susceptible to NPEV infections, 
and that the apparent association between NPEVs and impaired OPV response is not causal.
At present, we can only speculate as to the potential mechanisms that may account for 
the observed interference effects.  Although NPEVs do not  use the poliovirus receptor  to 
access cells,  following entry these viruses might compete for cellular factors required for 
!     s90
replication  (i.e.,  direct  interference  at  a  cellular  level).  The  potential  for  species  C 
enteroviruses  to  infect  the  same cells  as  polioviruses  is  supported by the  observation of 
recombinant strains in cVDPVs (Jegouic et al, 2009; Combelas et al, 2011). In vitro studies of 
viral co-infection have demonstrated a decline in poliovirus replication in cells infected with 
NPEVs (Hsiung, 1961), although this effect is absent for certain NPEV serotypes (Crowell, 
1963). Interference by NPEVs or other enteric pathogens might also arise indirectly via the 
induction of  non-specific innate antiviral  immunity.  Type I  and III  interferons have been 
shown to play an important role in the innate immune response to enterovirus infections 
(Deonarain et al, 2004; Lind et al, 2014; Reid and Charleston, 2014). As such, the induction of 
these innate immune mediators by an existing viral infection might inhibit the replication of 
an attenuated vaccine poliovirus. In the case of diarrhoea, interference may also involve a 
reduction in the gut’s mucosal surface area (and hence access to poliovirus receptors) and an 
increase in the rate of gastrointestinal transit following OPV administration.
The inhibitory effect of NPEVs was more pronounced for type 1 poliovirus than types 2 
or  3,  while  the  opposite  was  true  of  diarrhoea-associated  interference.  Although  the 
differences were generally not significant following meta-regression, these findings suggest 
that the extent of interference may differ among poliovirus serotypes, and that this specificity 
may  vary  according  to  the  nature  of  the  concurrent  infection.  The  notion  that  Sabin 
polioviruses  of  serotype  1  may  be  more  susceptible  to  interference  by  concurrent 
enteroviruses is also consistent with the need for an elevated potency of this serotype within 
the tOPV formulations currently in use.
The relative influence of individual NPEVs or NPEV groups on OPV response remains 
unclear based on the available evidence. While Urasawa (1964b)  highlighted the potential 
inhibition of mOPV response by Coxsackie B5 virus, this pathogen did not interfere with 
seroconversion following tOPV delivery. Moreover, studies carried out in India (John and 
Christopher,  1975)  and  China  (Fang-Cho,  1960)  documented  comparable  seroconversion 
rates in individuals infected with Coxsackie A viruses, Coxsackie B viruses, and echoviruses 
at the time of tOPV delivery, albeit with small numbers of individuals in each group. It is 
worth noting that since the studies included in this review were published, the classification 
of enteroviruses has shifted to reflect the molecular properties of this group of viruses. Based 
on the sequence of the VP1 gene, human enteroviruses can be separated into four major 
clusters – species A through D (Oberste et al, 1999; Oberste and Pallansch, 2005). Although 
polioviruses are typically listed as a separate species owing to their distinct pathogenicity, 
they  fall  within  the  same  genetic  cluster  as  species  C  enteroviruses.  It  is  tempting  to 
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speculate that species C enteroviruses might therefore induce a greater interference effect on 
vaccine polioviruses. As noted above, recombination between species C viruses and OPV 
occurs relatively frequently, suggesting that the viruses have similar cell tropism (Jegouic et 
al, 2009; Combelas et al, 2011). However, whether or not these similarities give rise to an 
increased capacity for interference with OPV replication has not yet been assessed.
2.4.1. Limitations
Several limitations of the present review should be acknowledged. By considering the 
impact of enteric infections 0–7 days preceding OPV delivery, the study did not account for 
the possible effects of the stage of enterovirus infection on the outcomes of co-infection (e.g., 
whether infections have reached peak multiplication within the intestinal tract [Drozdov and 
Shirman,  1961])  or  the  potential  influence  of  infections  arising  after  OPV  delivery 
(Voroshilova et al, 1960b; Swartz et al, 1972a; Swartz et al, 1972b) . In addition, past exposure 17
to  enteropathogens  might  induce  inflammatory  changes  and  other  alterations  in  innate 
immune function within the intestinal mucosa that affect OPV response even in the absence 
of concurrent infection, or give rise to a state of mucosal or systemic immune tolerance that 
diminishes  OPV  response.  As  noted  in  the  previous  chapter,  EE  has  been  linked  with 
exposure to enteropathogens, and may contribute to the impaired immunogenicity of OPV in 
low-income settings (Korpe and Petri, 2012). However, we encountered no studies reporting 
on the association between markers of this subclinical condition and OPV response before 
October 2012. Findings published since the completion of this systematic review have thus 
far  failed  to  observe  a  consistent  association  between  EE  biomarkers  and  oral  vaccine 
outcome (Naylor et al, 2015). 
Another important consideration is the general tendency of the included studies to focus 
on a specific group of enteric pathogens. Only two studies examined the influence of both 
viral and non-viral pathogens on OPV response (Triki et al, 1997; Maldonado et al, 1997), 
while the use of only monkey kidney cells for enterovirus detection by several trials would 
result in certain NPEV infections (e.g., several Coxsackie A viruses) going undetected within 
the  study  population  (Lee  et  al,  1965).  Given  the  pervasive  nature  of  enteropathogens 
(Kotloff et al, 2013; Platts-Mills et al, 2015), it is likely that many individuals classified as 
‘uninfected’  during  the  present  analysis  harboured  undetected  pathogens  at  the  time  of 
vaccination. This could result in an underestimate of the association between NPEV infection 
 The potential discrepancy between the inhibitory effect of novel, persistent, and recently resolved 17
infections is an issue we shall consider in Chapter 6. 
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and  vaccine  non-response.  Conversely,  co-infection  with  other  enteropathogens  among 
individuals harbouring NPEVs may be common given the shared risk factors for pathogen 
exposure. An effect of these co-infections may be captured by the meta-analyses reported 
above, which would bias our findings in the opposite direction.
2.4.2. Assessment of study quality
An issue I  faced during the assessment of  eligible studies was how best  to evaluate 
study quality or the risk of bias. For the analysis of NPEVs, for instance, the influence of 
infections  on vaccine  response  was  generally  reported as  a  secondary outcome within  a 
larger  trial  of  OPV (e.g.,  Japan Live Poliovaccine Research Commission,  1966).  Although 
several tools exist for the assessment of quality in observational studies (Sanderson et al, 
2007), their applicability to the studies in this review was questionable. To use the example of 
the Newcastle–Ottawa quality assessment scale for cohort studies (Wells et al, 2014), criteria 
were either not applicable (e.g., “demonstration that outcome of interest was not present at 
start of study” cannot be applied to seroconversion given that this was defined based on the 
comparison of pre- and post-vaccination samples) or would have given the same score to all 
studies (e.g., for “selection of the non-exposed cohort” [i.e., individuals without NPEVs or 
diarrhoea], all studies would have been listed as “drawn from the same community as the 
exposed  cohort”).  The  ability  of  such  criteria  to  meaningfully  discriminate  the  included 
studies according to their risk of bias is therefore equivocal. 
This  is  not  to  say that  meaningful  differences in study quality  were absent.  While  I 
considered the possibility of formulating a customised set of criteria with which to judge 
study quality, the inferences that could be made based on the application of an unvalidated 
tool would be limited. Accordingly, I opted to assess the risk of publication bias using funnel 
plots and Egger’s test, and to extract detailed information regarding study size, laboratory 
methods, and outcome definitions (presented in the tables above), thereby enabling readers 
to  assess  the  relative  validity  of  the  included studies  based on  relevant  aspects  of  their 
design.
2.4.3. Conclusions
As a whole, the present review supports the hypothesised link between enteropathogens 
and the impaired response to OPV in low-income countries. In particular, there is a sizeable 
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body of evidence from the 1960s to suggest that existing NPEVs have an inhibitory effect on 
the immunogenicity and take of vaccine polioviruses. 
Of  the  25  studies  included  in  this  review,  it  is  interesting  to  note  that  none  were 
performed in the last 15 years. Why the question has dropped out of fashion is not entirely 
clear, though this may relate to the costly, labour-intensive efforts required to detect enteric 
viruses using culture-based methods (when OPV was first introduced, the identification of 
enteroviruses required up to 2 weeks of cell culture), as well as a gradual shift away from the 
early conviction in the importance of concurrent infections as an inhibitor of OPV response 
(John  and  Christopher,  1975;  Patriarca  et  al,  1991).  Given  recent  advances  in  molecular 
diagnostics, the detection of enteropathogens is no longer the cumbersome task it once was. 
There is considerable potential, therefore, to return to the question of whether viral, bacterial, 
and eukaryotic enteropathogens contribute to the impaired immunogenicity of OPV in low-
income countries. We also have the potential to expand our view beyond the role of specific 
pathogens and consider the broader influence of the intestinal microbiota, including both its 
commensal and pathogenic constituents. 
It is these issues that form the foundation for the remainder of this thesis.
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Chapter 3: Assessing the intestinal microbiota: laboratory and bioinformatic methods
3.1. Background
The systematic review described above validates the inhibitory effect of enteropathogens 
on the immunogenicity of oral vaccines. However, the review also highlights notable gaps in 
our  understanding  of  this  phenomenon.  While  it  appears  that  NPEVs  are  capable  of 
interfering with the immunogenicity and take of OPV, these infections form only a portion of 
the pathogen spectrum to which infants living in low-income countries are exposed (Kotloff 
et al, 2013; Platts-Mills et al, 2015). Few studies have considered the potential influence of 
other  viral,  bacterial,  or  eukaryotic  enteropathogens  on  OPV  response.  Meanwhile,  as 
alluded to in Chapter 1, there are currently limited published data regarding the impact of 
enteropathogens on the performance of oral rotavirus vaccines.
In the remainder of this thesis, I will describe several lines of enquiry that have sought to 
clarify the relationship between the intestinal microbiota and oral vaccine immunogenicity. 
These analyses revolved around two distinct but related themes – the assessment of multiple 
enteropathogens via real-time PCR and the high-throughput sequencing of the 16S rRNA 
gene. Here, I will introduce the key laboratory and bioinformatic methods adopted in the 
chapters  that  follow.  Specifically,  I  will  provide  an  overview  of:  (i)  the  detection  of 
enteropathogens via real-time PCR using TaqMan array cards (TACs); (ii) the preparation of 
the 16S rRNA gene amplicon libraries (of which four were sequenced during the course of 
this thesis); (iii) the bioinformatic analysis pipeline adopted for processing of the resulting 
16S rRNA gene sequences; and (iv) the primary comparisons of interest during analysis of 
the bacterial microbiota data, including the prediction of vaccine outcome using the Random 
Forests machine-learning algorithm. Specific details on how these methods were applied to 
examine the relationship between the intestinal microbiota and oral vaccine immunogenicity 
are described in later chapters.
3.2. The TaqMan array card
The principle method of enteropathogen detection adopted in this thesis involved the 
use  of  TACs .  Each  card  consists  of  a  384-well  array  of  singleplex  real-time  reverse 18
transcription  PCR (RT-PCR)  assays.  Originally  developed  for  studies  of  gene  expression 
 Other  assays  for  the  detection  of  specific  enteropathogens  (including  Sabin  polioviruses  and 18
rotavirus) are described where relevant in the following chapters.
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(Lossos  et  al,  2004),  TACs  have  since  been  customised  for  a  wide  range  of  purposes, 
including  the  detection  of  respiratory  pathogens  (Kodani  et  al,  2011)  and  potential 
bioterrorism agents (Rachwal et al, 2012). The cards used in the studies described below were 
specifically developed for the detection of enteropathogens by researchers at the University 
of Virginia (Charlottesville, USA), and have demonstrated high sensitivity and specificity for 
this purpose (Liu et al, 2013; Liu et al, 2014). Eight samples were assessed per card, with 48 
discrete  assays  per  sample  spanning  a  comprehensive  range  of  bacterial,  viral,  and 
eukaryotic enteropathogens. A full list of targets is provided in Table 3.1.
3.2.1. Nucleic acid extraction
Extraction of DNA and RNA was performed from 200 mg of stool using the QIAamp 
DNA Stool Mini Kit (Qiagen). The Qiagen extraction protocol was modified to include an 
initial bead-beating step of 2–3 minutes using 500-'m glass beads (a process that has been 
shown to increase the yield of DNA from bacterial and eukaryotic enteropathogens [Halstead 
et al,  2013]), after which samples were heated to 90–95°C for 5 minutes. The final elution 
volume was 200 'l,  of which 100 'l  was transferred to a tube containing 100 'l  of RNA 
storage solution (AM7001, Ambion). The resulting total nucleic acid samples were stored at 
-70°C until testing. Extrinsic controls for DNA (106 copies of phocine herpesvirus [PhHV]) 
and RNA (107 copies of MS2 bacteriophage) were spiked into the lysis buffer at the start of 
the  procedure  to  monitor  extraction  and  amplification  efficiency.  A negative  extraction 
control was included in each batch to monitor cross-contamination.
3.2.2. Enteropathogen detection
 Procedures for the TAC assay have previously been described (Liu et al, 2013). Briefly, 
for each sample, we mixed 40 'l of the extracted total nucleic acid with 50 'l of AgPath-ID 
RT-PCR buffer,  4 'l  of AgPath-ID one-step enzyme mix, and 6 'l  of nuclease-free water. 
Reaction mixtures were added to each of the eight loading ports of the TAC (one per sample), 
which was centrifuged twice at 1,200 RPM for 1 minute. Cards were then sealed and the 
loading ports removed. RT-PCR was performed for the 384-well array on a QuantStudio 12K 
Flex system (Applied Biosystems). Cycle conditions were as follows: 45°C for 20 minutes; 
95°C for 10 minutes; and 45 cycles of 95°C for 15 seconds and 60°C for 1 minute.
Diarrhoeagenic E. coli subgroups were examined using multiple targets and defined as 
follows: enteroaggregative E. coli (EAEC), aatA and/or aaiC; enteropathogenic E. coli (EPEC), 
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Table 3.1. TaqMan array card targets.
Target Gene Reference
Controls
MS2a - Rolfe et al (2007)
PhHVa - Liu et al (2013)
Hs99999901-s1 18S rRNA gene Manufacturer control
Bacterial targets
Bacteria (any) 16S rRNA gene Rousselon et al (2004)
Aeromonas Aerolysin Liu et al (2013)
Bacteroides fragilis EGBF       Modified from Merino et al (2011)
Campylobacter Cpn60               Designed based on Hill et al (2006)
Campylobacter jejuni/coli cadF Cunningham et al (2010)
Clostridium difficile tcdB Liu et al (2013)
EAEC aaiC   Boise et al (2008)
EAEC aatA   Boise et al (2008)
EPEC eae Liu et al (2013)
EPEC bfpA Liu et al (2013)
ETEC LT Hidaka et al (2009)
ETEC ST Liu et al (2013)
Helicobacter pylori ureC Designed based on Shukla et al (2011)
Mycobacterium tuberculosis IS6110 Halse et al (2010) 
Salmonella ttr Malorny et al (2004)
Shigella/EIEC ipaH Vu et al (2004)
STEC stx1 Liu et al (2013)
STEC stx2 Hidaka et al (2009)
Vibrio cholerae lyA Liu et al (2013)
Eukaryotic targets
Ancylostoma Ribosomal gene Basuni et al (2011)
Ascaris Ribosomal gene     Modified from Wiria et al (2010)
Cryptosporidiuma Ribosomal gene Liu et al (2013)
Cryptosporidium typing Lib13 Hadfield et al (2011)
Cyclospora Ribosomal gene Verweij et al (2003)
Enterocytozoon bieneusi Ribosomal gene Verweij et al (2007)
Entamoeba histolytica 18S Verweij et al (2004)
Encephalitozoon intestinalis Ribosomal gene Verweij et al (2007)
Giardia 18S Verweij et al (2004)
Giardia typing tpi     Modified from Almeida et al (2010)
Isospora Ribosomal gene ten Hove et al (2008)
Necator Ribosomal gene Basuni et al (2011)
Strongyloides Ribosomal gene Verweij et al (2009)
Trichuris Ribosomal gene Liu et al (2013)
Viral targets
Adenovirus serotypes 40/41 Fiber gene Jothikumar et al (2005)
Adenovirus Hexon Heim et al (2003)  
Astrovirus Capsid Liu et al (2013)
Enterovirus 5’ UTR    Modified from Oberste et al (2010)
Norovirus genogroup 1 ORF1-2    Modified from Kageyama et al (2003)
Norovirus genogroup 2 ORF1-2 Kageyama et al (2003)
Rotavirusa NSP3 Zeng et al (2008)
Sapovirus RdRp Liu et al (2013)
Adapted  from  Grassly  et  al  (2016).  Abbreviations:  EAEC,  enteroaggregative  Escherichia  coli;  EIEC, 
enteroinvasive E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; LT, heat-labile enterotoxin; 
PhHV, phocine herpesvirus; ST, heat-stable enterotoxin; STEC, Shiga toxin-producing E. coli. 
a Assay carried out in duplicate for each sample.
eae  and/or bfpA;  ETEC,  heat-stable  enterotoxin and/or heat-labile  enterotoxin;  and Shiga 
toxin-producing E. coli (STEC), stx1 and/or stx2. The presence of adenovirus was determined 
based on amplification of the pan-adenovirus or serotype 40/41 targets, while norovirus was 
defined as  the  detection  of  either  genogroup 1  or  genogroup 2  targets.  The  presence  of 
Campylobacter,  Giardia,  and Cryptosporidium was determined based on the amplification of 
genus-  or  species-specific  targets.  Based  on  these  criteria,  we  distinguished  between  31 
distinct enteropathogens in each sample.
3.2.3. Interpretation and analysis
Upon completion of the TAC assay, each of the 48 singleplex reactions per sample gave 
rise either to an exponential amplification curve or no amplification (Figure 3.1). Each TAC 
target has a fluorescence threshold predetermined by the assay developers. The threshold 
cycle (Ct) value for an amplification curve is the reaction cycle at which the curve crosses this 
threshold, wherein a lower Ct value signifies a higher copy number for the target in question. 
A Ct value of 35 was generally adopted as a uniform cut-off for pathogen detection based on 
previous  standardisation  of  the  TAC  assay  (Liu  et  al,  2013).  We  visually  inspected  the 
amplification curve of each RT-PCR assay with a Ct value of less than 35 to ensure that an 
exponential (S-shaped) reaction curve was apparent. If a non-exponential rise in fluorescence 
was observed (indicative of a gradual shift in the signal of the reaction dyes as opposed to 
amplification from template DNA), the reaction baseline (encompassing the period before 
the exponential rise in the amplification curve) was manually adjusted to correct this.
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Figure 3.1. TaqMan array card amplification curves. Targets were considered positive if the Ct value – 
at which the amplification curve crosses the threshold (dotted) line – was less than 35, as exemplified 
by targets 1 and 2 in the example above. Abbreviation: Ct, threshold cycle.
3.3. 16S rRNA gene sequencing
A summary  of  the  16S  rRNA gene  sequencing  pipeline  adopted  in  the  following 
chapters  –  from stool  sample through to  the preparation of  a  table  of  OTU counts  with 
taxonomic assignments – is provided in Figure 3.2. Details regarding the specific steps of this 
pipeline are provided below.
3.3.1. Nucleic acid extraction
A separate extraction from stool samples was performed for sequencing of the 16S rRNA 
gene. Again, DNA was extracted from 200 mg of stool using the QIAamp DNA Stool Mini 
Kit. The Qiagen protocol was modified to include an incubation step at 37°C for 10 minutes 
with  1.67  'l  of  lysozyme  (30  mg/ml),  13  'l  of  mutanolysin  (11.7  U/'l),  and  3  'l  of 
lysostaphin (4.5  U/'l)  –  an enzyme cocktail  that  has been shown to improve taxonomic 
representativeness  during  studies  of  mock  bacterial  communities  (Yuan  et  al,  2012). 
Incubation was carried out  using a  plate  thermo–shaker  (PST-60HL-4,  Biosan)  set  at  250 
RPM.  Following  incubation,  we  added  10  'l  of  proteinase  K,  50  'l  of  sodium  dodecyl 
sulphate (10%), and 20 'l of RNase A (1 mg/ml) to each sample prior to a second incubation 
step (this time in a water bath) at 70°C for 10 minutes. Samples were subsequently vortexed 
at  high speed with 370 mg of  500-'m glass  beads (added to samples at  the start  of  the 
protocol)  for  5  minutes.  At  the  end  of  the  extraction  procedure,  the  final  elution  was 
performed using 50 'l of buffer AE. A negative control was included in each extraction batch. 
3.3.2. Library preparation
The protocol for the preparation of the 16S rRNA gene V4 hypervariable region libraries 
was adapted by Dr Anna Zekavati (Imperial Biomedical Research Centre Genomics Facility, 
Hammersmith  Hospital,  London)  from a  protocol  developed by Balamurugan Ramadass 
(Department of Gastrointestinal Sciences, Christian Medical College, Vellore) and colleagues 
(Dinh et al, 2016). Analogous methods targeting the 16S rRNA gene V4 region have been 
widely adopted during studies of acute malnutrition (Subramanian et al, 2014), geographic 
variation  in  microbiota  composition  (Yatsunenko et  al,  2012),  and IBD (Davenport  et  al, 
2014),  among  others.  Before  conducting  the  full  experiments  described  in  the  following 
chapters, we validated the laboratory methods – from PCR through to sequencing – during a 
pilot study of 48 faecal DNA samples.
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Figure 3.2. 16S rRNA microbiota analysis pipeline. The pipeline is separated into (A) laboratory 
steps  and  (B)  bioinformatic  steps.  The  Unix  commands  illustrate  the  key  steps  involved  in 
preparation of the OTU table. Abbreviations: OTU, 97%-identity operational taxonomic unit; qPCR, 
quantitative PCR.
The V4 region of the 16S rRNA gene was amplified via PCR in triplicate for each sample 
using primers  515F (5’-GTGCCAGCAGCCGCGGTAA-3’)  and 806R (5’-GGACTACCAGG-
GTATCTAAT-3’). Primers also contained Illumina adapter sequences, primer pads (to adjust 
the overall melting temperature of the primer [Kozich et al, 2013]), and linker sequences (that 
are  not  complementary to  the  16S rRNA gene at  the  corresponding site),  as  detailed by 
Caporaso et al (2012). Each reverse primer contained a unique 12-bp Golay barcode to enable 
multiplexed sequencing. The reaction mixture comprised 11 'l of distilled water, 10 'l of 
2.5X  HotMasterMix  (5  Prime),  1  'l  each  of  forward  and  reverse  primers  at  10  'M 
(Invitrogen), and 2 'l of template DNA. Cycle conditions were as follows: 95°C for 2 minutes; 
20 cycles of 94°C for 30 seconds, 52°C for 45 seconds, and 65°C for 5 minutes; and a final 
extension  of  65°C  for  15  minutes  (Dinh  et  al,  2016).  Following  PCR,  products  from  the 
triplicate assays were combined, purified using the QIAquick PCR Purification Kit (Qiagen), 
visualised using gel electrophoresis (Figure 3.3), and quantified via Qubit fluorometer with 
broad-range assay reagents (Life Technologies). A no-template control was included in each 
batch of PCR and up to two of these controls were included in each sequencing run.
PCR products to be sequenced in a given MiSeq run were pooled in equimolar quantities 
(300 ng per sample)  and 1X TE buffer  added to make up a total  volume of  4  ml.  Since 
extraction and no-template controls did not yield sufficient PCR product to be detected by 
Qubit, these products were added to the pool in a quantity equivalent to the lowest volume 
being added for a faecal DNA amplicon (personal communication, Dr Michael Cox, National 
Heart and Lung Institute, Imperial College London). 10 ml of 100% ethanol and 600 'l of 5 M 
NaCl were added to the pooled library, which was vortexed lightly and stored overnight at 
-20°C. The library was subsequently divided evenly into ten Eppendorf tubes, which were 
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Figure 3.3. Amplification of the 16S rRNA gene V4 region. Purified PCR products were visualised 
under UV light on a 2% agarose/TAE gel containing ethidium bromide. The bands depicted in this 
gel are approximately 400 bp in length. Abbreviations: C, extraction control; NT, no-template control; 
S, faecal DNA sample. 
centrifuged for 30 minutes at full speed (14,000 g). Following the removal of supernatant, the 
pellets were washed with 800 'l  of 70% ethanol, centrifuged for 5 minutes at full speed, 
allowed to air-dry for  10 minutes,  then resuspended in 20 'l  of  EB buffer  (Qiagen)  and 
pooled. 100 'l of this pool was subsequently run on a 1.5% agarose gel and the band excised 
then purified using the QIAquick Gel Extraction Kit (Qiagen; Figure 3.4). 
The eluted library was quantified using the KAPA Library Quantification Kit (KK4824, 
KAPA Biosystems) on a 7500 Fast real-time PCR system (Applied Biosystems) and diluted to 
a  concentration of  2  nM . The size distribution of  amplicons was verified using a  High 19
Sensitivity  DNA Kit  on  an  Agilent  2100  BioAnalyzer  (Figure  3.4C)  or  (for  the  library 
described  in  Chapter  6)  using  a  D1000  ScreenTape  on  an  Agilent  2200  TapeStation.  The 
library  was  then  sequenced  via  Illumina  MiSeq,  following  the  151  x  151  base  pair  (bp) 
protocol described by Caporaso et al (2012). This method includes the spiking of libraries 
with phi X (bacteriophage) control DNA to enable calculation of sequencing error rate and to 
improve the accuracy of base calls, which is impaired during the sequencing of amplicons 
owing to the limited diversity observed among sequences (Caporaso et al, 2012). For each 
run, the final mixture consisted of 60% library DNA and 40% phi X DNA.
 We initially quantified the pooled library via Qubit. Although successfully applied during the pilot 19
study, this approach subsequently led to a failed MiSeq run in which all of the reads mapped to the 
phi X control genome, suggesting severe under-representation of the 16S rRNA gene amplicons. The 
use  of  quantitative  PCR resolved this  issue.  Thus,  it  appears  that  Qubit  had failed  to  accurately 
quantify the yield of adapter-ligated amplicons within the eluted library. Despite much consideration 
of the issue, the reasons for this discrepancy elude me.
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Figure 3.4. Purification of the pooled 16S rRNA gene amplicons via gel extraction. (A) The pooled 
library was visualised under UV on a 1.5% agarose/TAE gel containing ethidium bromide. (B) After 
the band had been cut out using a scalpel, the same gel was imaged to verify that the band had been 
accurately excised. (C) The size distribution of the library was verified using a High Sensitivity DNA 
Kit on a 2100 BioAnalyzer or equivalent approach. The peak corresponding to the 16S rRNA gene 
amplicon library is signalled by an asterisk. Abbreviations: bp, base pairs; FU, fluorescence units.
*
3.3.3. Merging of paired-end reads
Sequence data were automatically demultiplexed by the MiSeq analysis software. The 
sequencing output thus consisted of two ‘fastq’ files for each sample – one containing 151-bp 
forward reads (into the V4 region from primer 515F) and the other containing 151-bp reverse 
reads  (from  primer  806R).  Each  sequence,  in  turn,  has  three  key  pieces  of  information 
associated with it: (i) a sequence identifier, containing information such as the instrument 
name, run ID, and the coordinates of the cluster within the MiSeq flow cell (which are used 
to match paired reads); (ii) the string of base calls; and (iii) a corresponding string of quality 
(or ‘phred’) scores, which signal the probability that the base call was erroneous (Illumina, 
2014).  For  example,  the  character  ‘?’,  indicating  a  quality  score  of  30,  signals  an  error 
probability of 0.001. The fastq format is illustrated as follows:
@M01823:172:000000000-A8EYD:1:1101:12988:1798 1:N:0:41 sequence identifier
TACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGCGTA… base calls
+
CCCCCFFCCFCDGGGGGGGGGGHGGGGGHHHHHHHGG… quality scores
Forward and reverse reads from each sample were assembled into contiguous sequences 
(or ‘contigs’) using FLASH – an algorithm implemented via the Unix command line that 
assembles paired reads and retains a quality score for each base (Magoc and Salzberg, 2011). 
A  minimum  overlap  size  of  25  bp  was  specified  during  this  assembly  process  –  a 
conservative  estimate  given that  the  median length  of  the  assembled reads  was  253  bp, 
indicating a typical overlap between paired reads of 49 bp. A length-filtering step was then 
performed to exclude assembled reads outside of  the target  range (253 ± 15 bp) using a 
customised Unix script (adapted from code published by Ziemann [2012]; Figure 3.2).
3.3.4. Sequence processing in Qiime
Assembled sequences were analysed using Qiime (MacQiime version 1.8.0) – a suite of 
bioinformatic processing tools written in the programming language Python that are tailored 
to  the  analysis  of  microbiota  data  (Caporaso  et  al,  2010b).  Several  commands  in  the 
bioinformatic pipeline were adapted from a shell script published by Nelson et al (2014). 
Qiime commands were implemented via the Unix command line using customised shell 
scripts.  Unless  otherwise  specified,  default  parameter  settings  were  applied  when 
implementing the commands described below.
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i. Quality filtering
Quality  filtering  was  performed  using  the  Qiime  function  split_libraries_fastq.py.  We 
applied  the  filtering  criteria  previously  validated  by  Bokulich  et  al  (2013),  but  with  an 
elevated quality  score  of  ≤19 to  define low-quality  base  calls  (corresponding to  an error 
probability of >0.01). These criteria retain contigs with: (i) no ambiguous base call (i.e., calls 
that could not be assigned as A, C, G, or T); (ii) no more than three consecutive low-quality 
bases; and (iii) a minimum number of consecutive high-quality bases spanning at least 75% 
of the total sequence length.  
ii. OTU picking
After  quality  filtering,  we  clustered  sequences  into  OTUs.  A  threshold  of  ≥97% 
nucleotide  identity  is  typically  adopted  to  define  OTUs  in  sequence-based  microbiota 
analyses (Navas-Molina et  al,  2013).  However,  there are several  distinct  approaches with 
which to group sequences into these 97%-identity clusters. During ‘closed-reference’ OTU 
picking, sequences are matched to a reference database (e.g., the Greengenes database of 16S 
rRNA gene sequences [DeSantis et al,  2006a]) and any sequences without a match in the 
database are discarded. This approach is computationally efficient and enables OTUs to be 
directly compared from study to study if the same database is used. By discarding sequences 
without a match, however, potentially relevant data are lost. The use of ‘open-reference’ OTU 
picking  makes  up  for  this  drawback  by  initially  matching  sequences  with  a  reference 
database, then grouping any remaining sequences into novel clusters (or ‘de novo OTUs’).
In  our  study,  however,  we  adopted  a  de  novo  OTU-picking  strategy.  This  approach 
assigns contigs into clusters based solely on their sequence identity (i.e., without use of a 
reference  database).  Although  computationally  intensive,  de  novo  OTU  selection  benefits 
from  using  all  available  sequence  data  and  avoids  the  tendency  of  reference-based 
approaches to overestimate the number of OTUs present in a set of sequences (which we 
observed  while  testing  the  bioinformatics  pipeline).  In  particular,  databases  such  as 
Greengenes contain reference OTUs with a given level of similarity (e.g.,  97%) across the 
entire 16S rRNA gene (~1,500 bp).  However,  within the V4 region targeted in our study, 
reference OTUs may have >99% sequence identity. As a result,  sequences that would fall 
within the same OTU during de novo selection have the potential to be assigned to separate 
OTUs by reference-based methods. Other researchers have documented similar issues with 
reference-based methods of OTU selection (Nelson et al, 2014; Westcott and Schloss, 2015).
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To pick de novo OTUs, we initially concatenated the contigs from different samples, then 
clustered these sequences using the ‘uclust’ algorithm (via the Qiime command pick_otus.py). 
This algorithm is described in full by Edgar (2010). Briefly, sequences are initially sorted by 
abundance . The most abundant sequence then becomes the ‘seed’ of the first OTU. For each 20
subsequent sequence, the existing database of seeds is examined to determine if there is a 
match of ≥97% (using the algorithm ‘usearch’). If a match is found, the sequence is assigned 
to that OTU (for this reason, uclust is referred to as a ‘greedy’ algorithm). If there is no match 
at a 97% threshold, the sequence becomes a new seed. In each iteration of this algorithm, the 
search of the seed database ceases as soon as a match is found. However, seed sequences are 
sorted based on the number of unique ‘words’ (in our case, 12-bp sequences) they share with 
the query sequence, such that the first match is typically the most similar sequence in the 
existing database (Edgar,  2011).  At the end of  this  process,  all  sequences are assigned to 
OTUs that fulfil the following criteria: (i) all sequences within an individual OTU have ≥97% 
identity with the seed sequence; and (ii) all seed sequences have <97% identity.
iii. Alignment, chimera checking, and taxonomy assignment
Having  assigned  all  sequences  to  OTUs,  reference  sequences  from  each  OTU  were 
selected using the function pick_rep_set.py. We then generated a multiple alignment of these 
sequences  using  PyNAST  (DeSantis  et  al,  2006b;  Caporaso  et  al,  2010a)  and  identified 
potential chimeras using the algorithm ChimeraSlayer (Haas et al, 2011). These steps were 
achieved by implementing the functions align_seqs.py  and parallel_identify_chimeric_seqs.py, 
respectively.  Chimeras are  artefacts  of  PCR that  contain more than one parent  sequence. 
Although they may be formed by a range of mechanisms, the majority are thought to arise 
following incomplete extension from a primer during the PCR amplification cycle, which 
enables  partially  extended  strands  to  prime  extension  from  a  heterologous  site  during 
subsequent cycles (Smyth et al, 2010). The removal of chimeric sequences is crucial to avoid 
the artificial inflation of bacterial diversity estimates during microbiota analyses.
To assign a taxonomic classification to each OTU, we used the naïve Bayesian Ribosomal 
Database Project (RDP) classifier developed by Wang et al (2007), as implemented via the 
function parallel_assign_taxonomy_rdp.py.  The RDP classifier makes taxonomic assignments 
from  kingdom  through  to  species  level  and  provides  a  confidence  estimate  for  each 
assignment. We adopted a minimum confidence threshold of 0.8. The rank of classification 
 This is a modification of the algorithm originally described by Edgar (2010), wherein sequences are 20
sorted by length as opposed to abundance.
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(kingdom, phylum, etc.) assigned by this approach may vary from OTU to OTU – thus, while 
some sequences can be assigned a species-level classification above the confidence threshold 
of 0.8, others can be assigned only as far as, for example, class or order.
Notably, the use of reference sequences corresponding to the 16S rRNA hypervariable 
region  of  interest  has  previously  been  shown  to  improve  the  depth  and  confidence  of 
taxonomic classification during studies of the bacterial microbiota (Werner et al, 2012). We 
therefore used customised reference files comprising the V4 region of the Greengenes 97%-
identity  OTU  sequences  (version  2013/08)  during  alignment,  chimera  checking,  and 
taxonomic assignment. A V4-specific alignment was initially generated by identifying the 
locations  of  the  primers  515F  and  806R  in  the  NAST-aligned  Greengenes  reference  file, 
trimming the alignment 15-bp upstream and downstream of the primer locations using the 
function pcr.seqs in mothur  (Schloss et  al,  2009),  and removing common gaps using the 21
function filter.seqs  (analogous to the approach adopted by Nelson et al  [2014] to generate 
reference files specific to the V4–V5 region of the 16S rRNA gene). The resulting file was used 
as a basis for alignment and chimera checking in the pipeline outlined above. Alignment 
characters were removed to generate an unaligned set of V4 sequences, which was used to 
retrain the RDP classifier during taxonomic classification.
iv. Phylogenetic tree
To prepare a phylogenetic tree of the V4 sequences, we created a new alignment of OTU 
reference sequences by implementing the Qiime function align_seqs.py with default settings 
(using a Greengenes alignment spanning the entire 16S rRNA gene as a reference instead of 
the  V4-specific  file  described  above).  It  was  then  possible  to  filter  this  alignment  while 
applying the ‘Lane mask’ (Lane, 1991) by implementing the function filter_alignment.py with 
default parameter settings. The filtering of alignments involves the removal of gap characters 
that are common to all sequences. Crucially, by applying the Lane mask during this process, 
it is also possible to filter out nucleotide positions that demonstrate too much variability to 
be useful when generating a phylogeny (in practice, the Lane mask comprises a series of 0s 
and 1s, wherein 1s correspond to the positions in the 16S rRNA gene alignment that should 
be ignored when generating a phylogenetic tree). After filtering the alignment in this way, a 
phylogenetic tree was prepared using FastTree (Price et al, 2009) – the default tree-building 
algorithm implemented by the Qiime function make_phylogeny.py.
 Like  Qiime,  mothur  is  a  package  of  bioinformatics  analysis  tools  tailored  for  the  analysis  of 21
microbiota sequence data.
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v. OTU table
To conclude the bioinformatics pipeline, an OTU table was constructed using the Qiime 
functions make_otu_table.py and biom convert. This table contains a column for each sample 
and a row for each OTU, with each cell indicating the number of assembled contigs for a 
given  sample  that  were  assigned  to  the  corresponding  OTU.  Unaligned  or  chimeric 
sequences were removed during the construction of this table. OTUs representing <0.005% of 
sequences  were  also  removed  by  applying  the  function  filter_otus_from_otu_table.py,  as 
recommended by Bokulich et al (2013). 
3.3.5. Interpretation and analysis
After processing sequences via the pipeline outlined above, our analyses centred around 
detecting  discrepancies  in  the  diversity  and  composition  of  the  bacterial  microbiota 
according to vaccine response. In each analysis, the OTU table was randomly subsampled – a 
process  termed  ‘rarefaction’  –  to  standardise  sequencing  depth  across  samples.  Rarefied 
versions  of  the  filtered  OTU  table  were  generated  using  the  Qiime  function 
multiple_rarefactions.py.  Specific  details  regarding  statistical  analyses  are  described  in  the 
following chapters; however, the key outcomes of interest are introduced briefly below. 
i. Alpha diversity
For the assessment of alpha (within-sample) diversity, we determined the OTU count (a 
measure of taxonomic richness) and Shannon index (a composite of richness and evenness) 
using  the  Qiime  functions  multiple_rarefactions.py,  alpha_diversity.py,  and  collate_alpha.py. 
Mean OTU count and Shannon index for each sample across ten independent rarefactions at 
a given depth served as the input for analyses. 
ii. Beta diversity
Weighted  and  unweighted  Unifrac  distances  were  used  to  assess  beta  diversity 
(divergence between microbial communities). As noted by Lozupone et al (2007), the Unifrac 
distance  between  two  samples  is  a  measure  of  “the  fraction  of  the  branch  length  in  a 
phylogenetic tree that leads to descendants in either, but not both, of the two communities”. 
Accordingly,  the greater the overlap in composition between two samples,  the lower the 
Unifrac  distance  between  them.  By  comparing  distances  across  multiple  samples,  it  is 
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possible to assess the degree to which the overall composition of the bacterial microbiota 
clusters according to an outcome of interest (e.g., vaccine response). Unifrac distances can 
either be weighted by the relative abundance of the bacterial taxa (weighted Unifrac) or not 
(unweighted Unifrac)  –  whereas  weighted Unifrac  distances  are  influenced primarily  by 
changes  in  the  most  abundant  taxa  within  the  samples  being  compared,  unweighted 
distances capture changes in the presence/absence of low-abundance taxa (Chen et al, 2012).
We  used  the  Qiime  function  beta_diversity.py  to  calculate  weighted  and  unweighted 
Unifrac distances between samples in the analyses described below. The phylogenetic tree 
generated  by  the  function  make_phylogeny.py  (see  above)  served  as  the  basis  of  these 
calculations. Unifrac distances were visualised using principal coordinates analysis (via the 
function principal_coordinates.py). The clustering of samples according to outcomes of interest 
was  then  assessed  using  the  adonis  function  –  a  non-parametric  permutation-based  test 
(implemented in  the R package vegan)  that  partitions  sums of  squares  within a  distance 
matrix between variables and residuals in a manner equivalent to multivariate analysis of 
variance (Oksanen et al, 2015).
iii. Taxon relative abundance
To distinguish whether individual taxa discriminated individuals according to vaccine 
outcome  (as  suggested  in  the  ‘keystone  taxa’  hypothesis  outlined  in  section  1.6),  we 
examined  whether  phylum-,  class-,  and  OTU-level  differences  in  relative  abundance 
distinguished  responders  from  non-responders.  To  account  for  the  highly  skewed 
distribution  of  taxon  relative  abundances  observed  across  samples,  we  performed  these 
analyses using non-parametric tests, including a bootstrapped t statistic and Wilcoxon’s rank 
sum test (as described in relevant sections of the chapters that follow). To reduce the risk of 
type  I  error  given  the  multitude  of  taxa  present  in  samples,  P  values  for  each  set  of 
comparisons (phylum-, class-,  or OTU-level)  were adjusted via Benjamini–Hochberg false 
discovery rate (FDR) correction (Benjamini and Hochberg, 1995).
iv. Random Forests
The  Random  Forests  machine-learning  algorithm  has  increasingly  been  applied  in 
studies of the gut microbiota as a means of assessing the degree to which individuals can be 
discriminated according to an outcome of interest based on the composition of their bacterial 
flora  (e.g.,  Yatsunenko et  al,  2012;  Subramanian  et  al,  2014).  First  described  by  Breiman 
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(2001), Random Forests functions by building multiple classification trees from a set of input 
variables  (in  our  case,  1,000  trees  were  generated  for  each  analysis  from an  input  table 
containing the relative abundances of OTUs). Each tree is generated from a subset of samples 
equivalent  in  size  to  the original  dataset  but  picked at  random with replacement  (i.e.,  a 
bootstrap  sample).  As  such,  approximately  a  third  of  samples  are  left  out  for  each  tree 
(referred to as the ‘out-of-bag’ samples).  For categorical outcome variables, trees are then 
built as follows:
i) A subset of the M available variables (of size √M by default) is selected (e.g., out of 
135 OTU abundances, 12 are chosen at random);
ii) The variable that enables the best possible separation of samples according to the 
outcome of interest (e.g., responders vs non-responders) is selected  – this variable 22
is used to split the first node of the tree;
iii) Steps (i) and (ii) are repeated for each daughter node;
iv) This process continues until all nodes contain either one individual or one class of 
individual (e.g., vaccine responders).
A benefit of Random Forests is that the available data do not need to be divided into 
training and validation subsets. Instead, each tree is used to predict the class of out-of-bag 
samples. At the end of the run, each sample will have been left out of approximately a third 
of the trees in the forest (a result of the bootstrap sampling that occurs before each tree is 
generated). Thus, in a forest of 1,000 trees, there will be in excess of 300 ‘votes’ for the class of 
each  sample.  The  class  that  receives  the  majority  of  these  votes  is  then  assigned as  the 
predicted outcome of the sample (Breiman and Cutler, 2004). A summary of the tree-building 
process and out-of-bag classification procedure is provided in Figure 3.5.
We focused on two key outputs of the Random Forest algorithm. First, we calculated the 
overall out-of-bag classification accuracy of the forest (i.e.,  the percentage of samples that 
were assigned to the correct class). For each analysis, this value was compared to the baseline 
accuracy of the model, wherein all samples are assigned to the majority class. Second, we 
considered the estimated ‘importance’ of each variable, calculated as follows:
i) For a given tree, the values of the variable are randomly permuted in the out-of-bag 
samples;
ii) Each out-of-bag sample is run down the classification tree to obtain a predicted class;
 Random Forests applies the Gini splitting rule, which attempts to isolate the majority class from the 22
remainder of the data at each node in the classification tree.
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iii) The proportion of votes for the correct class in the permuted out-of-bag dataset is 
subtracted from the proportion of votes for the correct class in the untouched data;
iv) This process is repeated for each tree in the forest, enabling the mean decrease in 
classification accuracy to be calculated (Breiman and Cutler, 2004).
Crucially,  important  variables  will  give  rise  to  a  greater  decrease  in  the  predictive 
accuracy of the tree when permuted in this way.
Random Forests has been shown to confer high predictive accuracy when applied to a 
variety of different data forms (Gislason et al, 2006; Cutler et al, 2007), including microbiota 
data (Subramanian et al, 2014). The algorithm is capable of handling ‘wide’ data (containing 
more  predictors  than  observations),  making  it  well  suited  to  the  analysis  of  OTU 
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Figure 3.5. Random Forests: tree building and out-of-bag sample classification. (A) The Random 
Forests algorithm functions by selecting multiple bootstrap samples of the input data. (B) In each of 
these  bootstrap  samples,  approximately  a  third  of  the  input  samples  are  left  ‘out-of-bag’.  (C) 
Classification trees are generated for each bootstrap sample, as described in the main text. During 
this  process,  a  subset  of  the potential  predictors is  considered at  each node.  (D) The out-of-bag 
samples are then run down each tree; for a given sample, the class that receives the majority of votes 
across the forest is its predicted outcome. (E) Each node of the tree corresponds to a threshold in one 
of the input variables (in our case, the relative abundance of an OTU). Abbreviation: OTU, 97%-
identity operational taxonomic unit. 
abundances.  Moreover,  in  contrast  to  the  analyses  of  alpha diversity,  beta  diversity,  and 
relative taxon abundance described above, classification trees have the capacity to capture 
complex interactions among the input variables.
3.4. Mock community profile
In  the  final  MiSeq  run  of  this  thesis  (described  in  Chapter  6),  we  sequenced  PCR 
products amplified from two mock communities obtained from BEI Resources (Manassas, 
USA): HM-782D, comprising genomic DNA derived from a community of 20 bacterial strains 
with  an  even  rRNA operon  count  per  organism  (BEI  Resources,  2012a);  and  HM-783D, 
comprising genomic DNA from the same community but with an uneven (‘staggered’) rRNA 
operon count per organism (BEI Resources, 2012b).
The sequencing data obtained from these communities were analysed via the pipeline 
described above. We restricted our attention to the mock community with an even rRNA 
operon  count  per  organism  during  the  ensuing  analyses.  Among  the  16,860  sequences 
obtained  from  this  sample  after  quality  filtering,  we  excluded  OTUs  with  a  relative 
abundance of <0.1%, then matched the remaining OTUs (n = 18) to their corresponding taxa 
in the mock community based on genus-level taxonomic classifications or (where the mock 
community contained multiple strains in the same genus) using BLAST (Johnson et al, 2008).
The relative  abundances  of  these  taxa  were  generally  consistent  with  their  expected 
values  (Figure  3.6).  Although  we  observed  no  sequences  corresponding  to  the  strain 
Propionibacterium  acnes  and  under-representation  of  strains  in  the  genera  Enterococcus, 
Deinococcus,  and Rhodobacter,  these findings are consistent with the biases documented in 
previous studies using the primers 515F and 806R (Nelson et al, 2014).
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Figure 3.6. Mock community composition. Data are displayed for the mock community with an 
even rRNA operon count per organism (HM-782D, BEI Resources).
3.5. Conclusions
Recent  advances  in  molecular  diagnostics  and  high-throughput  sequencing  have 
enabled the composition of the intestinal microbiota – including both pathogenic microbes 
and the commensal bacterial flora as a whole – to be characterised with a sensitivity and 
depth that was not possible when OPV was first developed. These advances, in turn, provide 
us with novel opportunities for understanding the potential contribution of the intestinal 
microbiota to the impaired performance of oral vaccines in low-income settings. 
In this chapter, I have introduced the laboratory and bioinformatic methods that form 
the foundation of the investigations that follow; in the next, I will describe how they were 
put to use to characterise the intestinal flora of infants who received Rotarix and tOPV as 
part of a clinical trial in south India.  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Chapter 4: Influence of enteropathogens and the bacterial microbiota on response 
to oral rotavirus vaccine: a case–control study in south India
4.1. Background
During the course of the systematic review described in Chapter 2, a clinical trial was 
being  carried  out  in  Vellore,  India,  led  by  researchers  at  the  Christian  Medical  College 
(ClinicalTrials.gov identifier NCT01616693). The primary aim of this study was to assess the 
impact  of  zinc  and/or probiotic  supplementation on the immunogenicity  of  Rotarix  and 
tOPV when co-administered to infants at 6 and 10 weeks of age. Crucially, stool samples 
were collected on the day of each vaccine dose and stored at -70°C. These samples provided 
us  with  an  opportunity  to  conduct  a  nested  case–control  study  comparing  the  pre-
vaccination intestinal microbiota – including the burden of bacterial, viral, and eukaryotic 
enteropathogens as well as the overall composition of the bacterial flora (assessed via 16S 
rRNA gene sequencing) – according to whether or not infants responded to the oral vaccines. 
In doing so, we could test the hypothesis that the composition of the intestinal microbiota is 
associated with the immunogenicity and take of oral rotavirus vaccine and tOPV.
In this chapter,  I  will  present the results of these endeavours with respect to Rotarix 
response. These analyses will then be extended to consider OPV outcome in Chapter 5. The 
influence of probiotic supplements on the composition of the bacterial microbiota, which was 
considered  as  a  secondary  objective,  will  also  be  briefly  described.  Where  applicable, 
findings are reported according to STROBE guidelines (von Elm et al, 2007).
4.1.1. Hypotheses
i. Enteropathogen burden
i) The presence and number of enteropathogens (bacterial, viral, or eukaryotic) at the 
time of immunisation is associated with a significant reduction in the likelihood of 
responding to Rotarix and tOPV (based either on seroconversion or take);
ii) The replication of vaccine polioviruses is negatively correlated with the replication 
of vaccine rotaviruses.
ii. Bacterial microbiota
i) Failure to respond to Rotarix and tOPV (based either on seroconversion or take) is 
associated with a decrease in the diversity of the bacterial microbiota;
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ii) Oral vaccine responders have a bacterial microbiota composition that is distinct from 
non-responders, as inferred by Unifrac distances and the discriminatory capacity of 
Random Forest models;
iii) These  shifts  are  driven  in  part  by  an  elevated  abundance  and  diversity  of 
Proteobacteria among non-responders compared with responders.
4.2. Vellore
Before describing the methods adopted in this study, a brief tangent is warranted to 
consider  the  setting in  which the  trial  took place.  Vellore  is  a  city  with  a  population of 
approximately 40,000 located in Tamil Nadu, a state in the southern-most tip of the Indian 
subcontinent.  Temperatures  range from 18°C in December to  44°C in May (Kattula  et  al, 
2014),  and  the  city  experiences  a  mean  annual  rainfall  of  approximately  1,000  mm  (by 
comparison, London has a mean annual rainfall  of less than 600 mm [Met Office, 2016]). 
Rainfall is at its peak between August and November (the northeast monsoon season). 
The clinical trial took place among residents of Chinnallapuram, a densely populated 
semi-urban slum area in the southwest of Vellore. Within this and adjacent areas, the most 
common  occupation  is  the  production  of  ‘beedis’  –  hand-made  cigarettes  consisting  of 
tobacco  wrapped  in  dried  leaves  (Kattula  et  al,  2014).  Homes  in  Chinnallapuram  are 
predominantly  built  from  permanent  materials  such  as  bricks  and  concrete,  although 
‘kutcha’  houses  (made  from  mud  brick,  thatch,  or  other  low-quality  materials)  are  not 
uncommon (Sarkar et al, 2013). Residents have access to a local urban health clinic, and a 
government hospital is located approximately 5 km away. Also within a few kilometres of 
the area is the Christian Medical College, a 2,500-bed hospital in the centre of Vellore, as well 
as  its  two  outreach  centres  –  the  Low  Cost  Effective  Care  Unit  and  the  Department  of 
Community Health and Development. Infants living in Chinnallapuram and adjacent areas 
are known to experience a considerable burden of gastrointestinal disease – within a cohort 
of 176 children, Sarkar et al (2013) documented 4.0 episodes of gastrointestinal illness per 
child-year in the first year of life, and 2.5 episodes in the second year. Stunting, defined as a 
height-for-age Z score of <-2, was observed in approximately 30% of children at 2 years of 
age. Caesarean section accounts for 6–18% of births (Gladstone et al, 2008; Kattula et al, 2014).
Several factors may contribute to the high incidence of enteropathogens observed among 
infants  in  Vellore.  High  rates  of  rotavirus  shedding  have  been  documented  in  neonatal 
nurseries at the Christian Medical College, likely via perinatal transmission or exposure to 
contaminated surfaces (Ramani et al, 2008). Microbial contamination of municipally supplied 
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water  is  ubiquitous  (Brick  et  al,  2004),  and is  enhanced by  household  storage  practices, 
wherein water is routinely kept for up to several weeks in wide-mouthed containers and 
consumed without  additional  treatment.  Close  contact  with  animals,  poor  hand hygiene 
practices,  overcrowding,  and  lack  of  access  to  functioning  toilets  may  also  enhance  the 
likelihood of enteropathogen exposure (Collinet-Adler et al, 2015; Kattula et al, 2015).
The central role of Vellore in the history of polio research is also worth highlighting. In 
particular, studies led by Professor Thekkekara Jacob John in the 1970s were among the key 
works to shed light on the impaired immunogenicity of OPV in low-income, tropical settings 
(John, 1976). These studies notably did not support the inhibitory effect of NPEVs on OPV 
response, as is evident in Figure 2.2 (John and Christopher, 1975). 
4.3. Methods
4.3.1. Study population
Samples were obtained from a clinical trial that set out to assess the impact of daily 
supplements of zinc and/or probiotics on the immunogenicity of oral rotavirus vaccine and 
tOPV in early infancy. At the time of writing, a full report of the trial is pending (Lazarus et 
al, manuscript in preparation). In brief, between 18 July 2012 and 22 February 2013 a total of 
620  infants  living  in  Chinnallapuram  were  recruited  to  the  trial  at  5  weeks  of  age. 
Participants  were  assigned  at  random  to  receive  one  of  four  treatment  regimens:  (i) 
supplements  of  zinc  (5  mg  of  zinc  sulphate  heptahydrate)  and  probiotics  (Lactobacillus 
rhamnosus GG capsules containing 1010 organisms) administered daily from 5 to 11 weeks of 
age;  (ii)  zinc  supplements  and  probiotic  placebo;  (iii)  probiotic  supplements  and  zinc 
placebo; and (iv) zinc placebo and probiotic placebo. All participants received Rotarix at 6 
and 10 weeks of age and tOPV at 6, 10, and 14 weeks of age. Infants also received routine 
vaccines according to the national schedule in India, including tOPV at birth. Serum anti-
rotavirus VP6 IgA antibodies were measured at 6 and 14 weeks of age using an antibody-
sandwich enzyme immunoassay (Ward et al, 2004). Response to Rotarix was defined as a 
four-fold increase in serum anti-VP6 IgA titre  or detection of antibodies at ≥20 U/ml in 23
previously seronegative infants. Anti-poliovirus neutralising antibody titres were assessed at 
the  same  timepoints  using  the  standardised  microneutralisation  method  (WHO,  1997). 
Response to tOPV was defined as an increase in poliovirus serotype 3 neutralising antibody 
titre from <1:8 to ≥1:8 or a four-fold rise in titre, assuming a decay in pre-vaccination titre 
 Strictly  speaking,  these  antibody  measures  are  concentrations  rather  than  titres;  however,  for 23
simplicity I will use the term ‘titres’ when referring to both rotavirus and poliovirus antibody levels.
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with a half-life of 28 days. Stool samples were collected on the day of and 4 and/or 7 days 
after the 6- and 10-week vaccine doses. All study procedures were completed by 25 April 
2013. Key features of the trial design are highlighted in Figure 4.1. The study was supported 
by funding from the Department of Biotechnology (India) and PATH. 
4.3.2. Enteropathogen testing
Enteropathogen testing was carried out in the Department of Gastrointestinal Sciences at 
the Christian Medical College, Vellore. My role in the laboratory work is clarified above (p6).
i. Primary outcome and sample size calculation
Following completion of the trial, we devised a nested case–control study to assess the 
impact of concurrent enteropathogens on oral rotavirus vaccine immunogenicity. Our initial 
objective was to examine the impact of harbouring ≥1 enteropathogen at either 6 or 10 weeks 
of age on the odds of seroconverting to rotavirus. However, since the sensitive detection of 
multiple  enteropathogens  via  TACs  had  not  previously  been  conducted  in  this  study 
population, we used an interim analysis of enteropathogen prevalence to inform final sample 
size calculations. Herein, we selected 112 individuals (14 who seroconverted to rotavirus and 
14 who failed to seroconvert from each of the four study arms) and performed the extraction 
and TAC assay for the 6- and 10-week stool samples of this subset (according to the methods 
described in Chapter 3). Without unblinding study arm or vaccine outcome, the prevalence 
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Figure  4.1.  Zinc/probiotic  supplementation  trial  design.  The  additional  laboratory  assays 
undertaken  as  part  of  the  nested  case–control  study  described  in  this  chapter  are  indicated. 
Abbreviations: TAC, Taqman array card; tOPV, trivalent oral poliovirus vaccine; w, weeks.
of  enteropathogens  at  6  and  10  weeks  of  age  was  determined.  Five  individuals  were 
excluded at each timepoint owing to insufficient sample availability or the absence of RNA 
targets (including MS2) in the TAC assay. The interim analysis revealed a high prevalence of 
EAEC (67/107 [63%] at 6 weeks and 70/107 [65%] at 10 weeks) and enteroviruses (74/107 
[69%] at 6 weeks and 78/107 [73%] at 10 weeks) – we subsequently confirmed that Sabin 
viruses accounted for the majority of the latter, as described below. Rotavirus infections were 
observed in 3/107 (3%) 6-week samples and 1/107 (1%) 10-week samples. Infections other 
than EAEC, enterovirus, and rotavirus were observed in 48/107 (45%) and 44/107 (41%) of 6- 
and 10-week samples, respectively, and were present during at least one of the two doses in 
68/105 (65%) individuals.  By contrast,  when enteroviruses  and EAEC were included,  ≥1 
enteropathogen was observed at 6 or 10 weeks in 104/105 (99%) infants.
In  light  of  the  high  prevalence  of  EAEC  and  enteroviruses,  as  well  as  the  limited 
association between EAEC and diarrhoea in previous studies using analogous methods of 
pathogen detection (Taniuchi et al, 2013; Platts-Mills et al, 2014), we decided to omit these 
pathogens  from  the  primary  outcome  analyses.  Rotavirus  infections  were  also  excluded 
given that – in contrast to the hypothesised inhibitory effect of enteropathogens – one would 
expect  natural  rotavirus  exposure  or  shedding  of  vaccine  rotaviruses  to  be  positively 
correlated with  rotavirus  seroconversion.  We estimated that  the  inclusion of  at  least  150 
infants who seroconverted to rotavirus (hereafter referred to as ‘responders’) and 150 infants 
who failed to seroconvert (‘non-responders’) would provide 80% power to detect a reduction 
in the odds of rotavirus seroconversion (with an OR of ≤0.5 and an α of 0.05) in conjunction 
with the presence of ≥1 enteropathogen (excluding EAEC, enterovirus, and rotavirus) at 6 or 
10 weeks of age, assuming an overall infection rate of 65% in a study population comprising 
50% responders and 50% non-responders (Dupont and Plummer, 1990).
ii. Eligibility criteria and TaqMan array card assay
Trial participants were considered eligible for the study if they received supplements or 
placebo, received both doses of Rotarix and tOPV, and provided paired serum samples (n = 
563). To meet sample size requirements, we included all eligible infants who seroconverted to 
rotavirus, subject to constraints in sample availability (n = 162, of whom 52 received zinc and 
probiotics, 35 received zinc alone, 39 received probiotics alone, and 36 received placebo). For 
each arm, we selected an approximately equivalent number of non-responders at random (to 
account  for  the  potential  confounding  of  study  arm  with  infection  status  and 
seroconversion).  The  final  study  population  is  summarised  in  Table  4.1.  Infants  were 
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excluded if either the 6- or 10-week stool sample lacked sufficient material for nucleic acid 
extraction (<200 mg) . Pre-vaccination samples for the 6- and 10-week vaccine doses were 24
tested for each individual. In each sample, the presence of 31 enteropathogens was assessed 
using TACs, as described in Chapter 3.
Samples were considered eligible for the analysis if they were positive for PhHV and at 
least one RNA target (MS2 or other). The extraction and assay were repeated for samples that 
failed to meet these criteria. If repetition failed to yield an eligible assay, the sample was 
excluded from the analyses. A Ct value of 35 was used as a uniform cut-off for pathogen 
detection. If a pathogen target was present at a Ct of <35 in the negative extraction control, 
the extraction batch was repeated. The order in which samples were extracted and analysed 
was randomised,  and the nature of  samples (responder vs non-responder,  6-  vs 10-week 
sample,  and study arm) was blinded.  A no-template control  was assessed approximately 
once per week to monitor laboratory contamination.
 Since the preparation of 200-mg aliquots, nucleic acid extraction, and TAC assays were carried out 24
in tandem, there were several instances in which it  became apparent that the 6- or 10-week stool 
sample collected from an infant lacked sufficient material for nucleic acid extraction only after the 
TAC assay for the corresponding pre-vaccination sample had been completed. In these instances, the 
completed assays were retained in the final analyses.
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Table 4.1. Summary of study population.
Treatment group
Trial population 
(per protocol)
No. in enteropathogen 
subset
No. in 16S rRNA 
microbiota subset
Total
Rotarix 
responders (%) Total
Rotarix 
responders (%) Total
Rotarix 
responders (%)
Zinc/probiotics 137 54 (39.4) 105 52 (49.5) 38 19 (50.0)
Zinc only 143 40 (28.0) 69 35 (50.7) - -
Probiotics only 136 42 (30.9) 78 39 (50.0) 69 35 (50.7)
Placebo 135 37 (27.4) 73 36 (49.3) 63 31 (49.2)
Overall 551 173 (31.4) 325 162 (49.8) 170 85 (50.0)
Five individuals in the enteropathogen study were excluded from the final analyses as they did not 
complete the study per protocol – two received zinc and probiotics (of whom one seroconverted to 
rotavirus); one received zinc alone (a responder); and two received probiotics alone (of whom one 
seroconverted to rotavirus).  Two infants were excluded from the microbiota analyses (both non-
responders who received probiotics alone) – one did not complete the study per protocol, while the 
other  was  excluded owing to  a  clerical  error  that  led  to  the  incorrect  samples  being  extracted. 
Protocol deviations included the receipt of OPV outside of the study clinic, failure to visit the study 
clinic  within  the  pre-specified  window  period,  and  the  omission  of  ≥6  days  of  test  article 
(supplement/placebo) consumption.
iii. Detection of Sabin polioviruses among enterovirus-positive samples
In addition to the assessment of enteropathogens using TACs, we tested for the presence 
of Sabin polioviruses in all samples positive for the pan-enterovirus target during the TAC 
assay.  This  was  achieved  using  a  multiplex  real-time  one-step  RT-PCR  assay  for 
simultaneous detection of all three Sabin types that has previously been described (Taniuchi 
et al,  2015).  Viral RNA was extracted from a 20% stool suspension in minimum essential 
medium using the QIAxtractor (Qiagen) – an automated nucleic acid purification system – 
with Vx reagents. Positive controls for each serotype, a negative control, and a no-template 
control were included in each run.
iv. Detection of rotavirus shedding
To examine the impact of the intestinal microbiota on Rotarix replication (or ‘take’), we 
quantified viral shedding in stool samples collected pre-vaccination and 4 and 7 days after 
administration of the 6-week dose of Rotarix using a real-time RT-PCR assay targeting the 
rotavirus VP6 gene. Infants were included in this analysis if  their 6-week pre-vaccination 
sample had been successfully assayed via TAC. RNA was extracted from 200 'l of 10% stool 
suspension  using  the  QIAxtractor  (Qiagen)  with  Vx  reagents.  Reverse  transcription  was 
performed  with  random  primers  (Pd(N)6  hexamers;  Invitrogen)  using  Moloney  murine 
leukaemia virus reverse transcriptase (Superscript II MMLV RT; Invitrogen). Real-time PCR 
was then conducted on an ABI PRISM 7500 thermal cycler (Applied Biosystems) using the 
primers 5’-GACGGVGCRACTACATGGT-3’ and 5’-GTCCAATTCATNCCTGGTG-3’ (Sigma–
Aldrich), which amplify a 379-bp region of the VP6 gene, and the probe 5’-(FAM)-CCACC-
RAAYATGACRCCAGC-NGTA-NFQ-MGB-3’  (Applied Biosystems) (Iturriza Gomara et  al, 
2002; EuroRotaNet, 2009). For calibration of the assay, a standard curve was generated from a 
ten-fold dilution series representing between 101 and 108 copies of a plasmid containing the 
VP6 gene of a rotavirus G1P[8] strain. Rotavirus shedding was defined as the presence of 
>100 viral copies per reaction either 4 or 7 days after vaccination. Infants shedding above this 
threshold on the day of vaccination were excluded.
4.3.3. 16S rRNA gene sequencing
In a subset of 170 infants (85 infants who seroconverted to rotavirus and 85 who failed to 
seroconvert), we assessed the composition of the bacterial microbiota by sequencing the V4 
hypervariable region of the 16S rRNA gene in stool samples collected prior to the 6- and 
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10-week vaccine doses (340 samples in total). This sample size was not informed by a specific 
power  calculation,  but  represented  a  pragmatic  optimum  given  the  trade-off  between 
increased multiplexing and decreased sequencing depth (with the aim of achieving >2,000 
sequences per sample).  Infants were considered for the microbiota subset if  eligible TAC 
assays (positive for PhHV and at least one RNA target) had been performed for both 6- and 
10-week samples and if sufficient stool material for DNA extraction was available at both 
timepoints. During selection of the microbiota subset, we included all eligible individuals 
who  received  only  placebos  and  all  who  received  probiotics  with  zinc  placebo.  The 
remaining individuals were selected at random from recipients of both zinc and probiotics. 
This enabled us to assess the impact of probiotic supplementation on the microbiota as a 
secondary objective.
The laboratory procedures and bioinformatic analysis pipeline for sequencing of the 16S 
rRNA gene V4 region are described in Chapter 3. DNA extraction was carried out in the 
Department of Gastrointestinal Sciences at the Christian Medical College, Vellore. Samples 
were then transferred to the UK, where library preparation was carried out in the Imperial 
Biomedical  Research  Centre  Genomics  Facility  at  Hammersmith  Hospital,  London. 
Completed libraries were submitted to the Medical Research Council Clinical Sciences Centre 
Genomics Facility at Hammersmith Hospital for sequencing via Illumina MiSeq. 
The order of samples for nucleic acid extraction, PCR, and sequencing was randomised. 
Samples were split across two MiSeq runs, each containing 190 samples (180 samples, eight 
extraction controls, and two no-template controls in the first run; 160 samples, six extraction 
controls,  two  no-template  controls,  and  22  technical  replicates  in  the  second).  Technical 
replicates  included  sequencing  replicates  (using  the  same  PCR  product;  n  =  8);  PCR 
replicates (using different reverse primers on the same MiSeq run; n = 5); replicates of both 
PCR and sequencing (using different reverse primers on different MiSeq runs; n = 5); and 
amplicons obtained from template DNA extracted without enzyme incubation (included for 
exploratory purposes only; n = 5).
4.3.4. Statistical analysis
i. Enteropathogen burden
The  primary  outcome  of  this  study  was  the  association  between  rotavirus 
seroconversion (as a categorical dependent variable) and the presence of ≥1 enteropathogen 
(excluding EAEC, enterovirus,  and rotavirus) at 6 or 10 weeks of age,  as determined via 
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logistic regression. Individuals were excluded from the analysis if they did not complete the 
study  per  protocol.  As  secondary  outcomes,  we  compared  the  prevalence  of  individual 
pathogens, pathogen groups (bacterial, viral, eukaryotic, or any), mixed infections (defined 
as >1 enteropathogen), and concurrent diarrhoea (defined as ≥3 loose stools in a 24-hour 
period within the 7 days preceding vaccination) according to oral rotavirus vaccine response 
(serological responders vs non-responders and shedders vs non-shedders) at each dose using 
the χ2 test or Fisher’s exact test (the latter applied if there were <5 infected or uninfected 
individuals in either of the groups being compared). For prevalence estimates, 95% CIs were 
calculated using the Clopper–Pearson exact method (Clopper and Pearson, 1934). Rotavirus 
infections were excluded from analyses of mixed infections, pathogen groups, and pathogen 
count. To examine the impact of pathogen abundance on vaccine outcome, we compared Ct 
values for TAC targets present in at least 1% of the study population according to vaccine 
outcome using Wilcoxon’s rank sum test; a one-unit decrease in Ct corresponds to a two-fold 
increase in target copy number. Wilcoxon’s rank sum test was also used to compare the total 
pathogen count at each dose according to vaccine outcome. P values of 0.05 were considered 
significant. For comparisons of prevalence or abundance for individual TAC targets present 
in at least 1% of the study population, P values were adjusted via Benjamini–Hochberg FDR 
correction.
NPEVs were  defined as  the  presence  of  an enterovirus  in  the  absence  of  any Sabin 
viruses – a definition that assumes equal sensitivity of the pan-enterovirus and Sabin-specific 
assays. We compared NPEV prevalence at each dose according to rotavirus vaccine outcome 
using the χ2 test. Since our assays did not allow distinction of samples positive for both Sabin 
viruses and NPEVs from those positive for just one of these viruses, infants harbouring any 
Sabin virus were excluded from comparisons of NPEV prevalence. 
The association between rotavirus seroconversion and rotavirus take was assessed using 
the  χ2  test.  To  provide  a  preliminary  indication  of  the  impact  of  poliovirus  replication 
following the birth dose of tOPV on the take of Sabin viruses administered at 6 weeks of age 
in this study population, we compared the shedding of enteroviruses (and of each Sabin 
serotype) at 10 weeks of age (i.e., 4 weeks after vaccination) according to whether ≥1 Sabin 
serotype was present in pre-vaccination samples (also using the χ2 test) .25
Across  the  6-  and 10-week doses,  we assessed the  cumulative  impact  of  concurrent 
infections on the odds of seroconversion among individuals with eligible samples (positive 
 A more in-depth analysis of factors impacting the immunogenicity and take of OPV in this study 25
population is described in Chapter 5.
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for  PhHV  and  at  least  one  RNA target  at  both  doses)  via  logistic  regression.  For  each 
pathogen group (bacterial,  viral, eukaryotic, or any), we assessed the number of doses in 
which ≥1 infection was present (0, 1, or 2) as a categorical explanatory variable. As with the 
primary outcome analysis outlined above, we excluded EAEC, enterovirus, and rotavirus 
infections in these logistic regression models. Owing to the limited number of individuals 
infected with ≥1 viruses (excluding enterovirus) or ≥1 eukaryote at both doses (six and two, 
respectively), we combined across infants infected at one or both doses for these pathogen 
groups. All analyses were carried out in the programming language R.
ii. Bacterial microbiota: alpha diversity, beta diversity, and relative taxon abundance
After processing sequences via the bioinformatic pipeline described in Chapter 3, we 
observed a minimum of 3,726 sequences per sample. To standardise sequencing depth across 
samples, all comparisons were carried out at a depth of 3,500 sequences per sample. Our 
primary outcome during assessment of the bacterial microbiota was the association between 
within-sample diversity (OTU count and Shannon index as continuous dependent variables) 
and  rotavirus  vaccine  response  (seroconversion  or  shedding),  as  determined  via  linear 
regression.  MiSeq  run  was  included  as  a  covariate  to  account  for  potential  run-to-run 
variation. Separate analyses were performed to examine the association between rotavirus 
vaccine response and the number of OTUs within the phylum Proteobacteria at each dose. 
These  phylum-specific  OTU  counts  were  determined  using  the  Qiime  functions 
filter_taxa_from_otu_table.py and alpha_diversity.py.
To  assess  divergence  between  bacterial  communities  (beta  diversity)  according  to 
vaccine  outcome,  we  calculated  weighted  and  unweighted  Unifrac  distances  between 
samples in ten rarefied OTU tables containing 3,500 sequences per sample. Mean Unifrac 
distances were visualised using principal  coordinates  analysis.  The clustering of  samples 
according to vaccine outcome and individual was assessed using the adonis function in the R 
package vegan, with 9,999 permutations stratified by MiSeq run. Unifrac distances between 
the  6-  and  10-week  samples  from  each  individual  were  also  used  as  an  indicator  of 
microbiota  stability.  These  distances  were  compared according to  vaccine  outcome using 
Wilcoxon’s rank sum test.
To  identify  potential  phylum-,  class-,  and  OTU-level  differences  in  relative  taxon 
abundance  according  to  vaccine  outcome,  we  used  a  non-parametric  test  based  on  a 
bootstrapped  t  statistic  (implemented  in  the  R  package  permute).  For  each  taxon,  a 
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distribution of 9,999 t statistics was generated by randomly permuting the outcome assigned 
to  each  sample.  The  non-parametric  P  value  was  then  determined  by  calculating  the 
proportion  of  permuted  t  statistics  greater  than  or  equal  to  the  observed  t  statistic. 
Permutations were stratified by MiSeq run. Taxa were assessed if they were present in at 
least 2% of samples being compared. Since failure to respond to Rotarix was hypothesised a 
priori  to  be  associated  with  an  elevated  abundance  of  Proteobacteria,  P  values  of  <0.05 
(phylum- and class-level) or <0.005 (OTU-level) were considered significant for comparisons 
of  this  phylum in pre-vaccination samples.  For  all  other  taxa,  P values for  each level  of 
comparison (phylum, class, or OTU) were adjusted via Benjamini–Hochberg FDR correction, 
and adjusted P values of <0.05 considered significant.
We prioritised the placebo-only and probiotics-only study arms in our 16S rRNA gene 
sequencing study to enable the impact of probiotic supplementation on the microbiota to be 
assessed as a secondary objective. Accordingly, we repeated the aforementioned analyses of 
alpha diversity, beta diversity, and relative taxon abundance to compare the composition of 
the bacterial microbiota between recipients of placebo alone (n = 63) with those who received 
probiotics with zinc placebo (n = 69). 
iii. Random Forests
An overview of the Random Forests machine-learning algorithm is provided in Chapter 
3.  We  fitted  Random  Forest  models  to  discriminate  infants  according  to:  (i)  rotavirus 
seroconversion; (ii) rotavirus take; and (iii) receipt of probiotics (probiotics only vs placebo 
only) .  Separate  analyses  were  carried  out  for  6-  and  10-week  samples.  Models  were 26
implemented  in  the  R  package  randomForest,  with  1,000  trees  per  forest  and  all  other 
parameters at  their  default  values.  A table of  OTU relative abundances (determined at  a 
depth of 3,500 sequences per sample) served as input, and OTUs were included as predictors 
if they were present in at least 2% of the samples being compared. For each comparison, 
mean out-of-bag classification accuracy and variable  importance  scores  were  determined 
over 100 iterations of the algorithm (analogous to the approach adopted by Subramanian et 
al [2014]). Significance of the model fit was assessed by generating 999 null models in which 
class labels were randomly assigned to the input variables and determining the proportion of 
null models with a classification accuracy greater than the mean accuracy of the fitted model. 
 Since  the  L.  rhamnosus  GG probiotic  strain  appeared to  correspond to  a  single  OTU,  we fitted 26
separate Random Forest models either with or without this OTU in order to clarify the impact of 
probiotic supplementation on taxa other than the administered strain.
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Since  the  tree-building  process  in  Random  Forests  is  tailored  towards  isolating  the 
majority class, the algorithm has a tendency to perform poorly if classes are imbalanced (e.g., 
if the number of non-shedders greatly outweighs the number of shedders) (Chen et al, 2004). 
Under-sampling of the majority class has been shown to improve classification accuracy of 
minority class members when applying several machine-learning algorithms (Drummond 
and Holte, 2003), including Random Forests (Chen et al, 2004). Accordingly, if the majority 
class contained more than 60% of observations (as was the case in the analysis of vaccine 
take),  we performed a  separate  analysis  in  which a  random subset  of  samples  from the 
majority class equal in size to the minority class was selected for each of the 100 iterations of 
the Random Forest algorithm.
iv. Variation between MiSeq runs
In the 13 samples sequenced in both MiSeq runs, we compared the number of OTUs, 
Shannon index, and phylum-, class-, and OTU-level relative abundances between replicates 
at  a  depth  of  3,500  sequences  per  sample  using  Wilcoxon’s  signed-rank  test.  During 
comparisons of taxon abundance, P values for each set of comparisons (phylum-, class-, or 
OTU-level)  were  adjusted  via  Benjamini–Hochberg  FDR  correction.  The  clustering  of 
sequencing replicates based on weighted and unweighted Unifrac distances was visualised 
using principal coordinates analysis, and the proportion of variance explained by MiSeq run 
and technical replicate assessed using the adonis function.
v. Sensitivity analyses
For  comparisons  of  vaccine  outcome  with  respect  to  enteropathogen  burden,  we 
performed sensitivity analyses in which: (i) lower Ct cut-offs (30, 25, and 20) were used to 
assess the presence or absence of TAC targets; (ii) samples lacking amplification of MS2 were 
excluded (to examine the impact of variation in the extraction efficiency of RNA targets); 
(iii) individuals positive for rotavirus-specific IgA at baseline were excluded (to account for 
the potential impact of prior rotavirus exposure on the outcomes of concurrent infection); 
and (iv) infants who experienced a robust response to vaccination (defined as both a four-
fold rise in serum IgA titre and a post-vaccination titre of >90 U/ml) were compared with 
those  who  were  seronegative  post-vaccination  (titre  <20  U/ml)  or  experienced  a  fall  in 
antibody titre between pre- and post-vaccination samples. A post-vaccination IgA titre of 
>90 U/ml has previously been suggested as an indicator of  sustained protection against 
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severe rotavirus-associated gastroenteritis (Patel et al, 2013a), and was therefore used as to 
define a robust serological response here.
In each sensitivity analysis, we repeated the primary outcome comparison (considering 
the  impact  of  harbouring  ≥1  enteropathogen at  6  or  10  weeks  on  the  odds  of  rotavirus 
seroconversion).  We  also  compared  the  proportion  of  responders  and  non-responders 
infected  with  EAEC,  ≥1  bacteria  other  than  EAEC,  enteroviruses,  ≥1  virus  other  than 
enterovirus, ≥1 eukaryote, ≥1 infection of any kind (either including or excluding EAEC and 
enterovirus), or mixed infections at 6 weeks of age, 10 weeks of age, or at both timepoints. To 
examine the potential influence of treatment group on the primary outcome comparison, we 
fitted  separate  logistic  regression  models  in  which  we  added  interaction  terms  between 
enteropathogen infection status and (i) zinc supplementation (zinc vs no zinc); (ii) probiotic 
supplementation (probiotics vs no probiotics); and (iii) study arm.
The same sensitivity  analyses  were  performed (where  applicable)  to  analyses  of  the 
bacterial microbiota. In each case, we examined discrepancies in alpha diversity (number of 
OTUs  and  Shannon  index)  and  beta  diversity  (cluster  significance  based  on  adonis) 
according to seroconversion status at a depth of 3,500 sequences per sample.
4.4. Results
4.4.1. Oral rotavirus vaccine immunogenicity
Out of 551 individuals who completed the study per protocol, 173 (31%) seroconverted 
to  rotavirus.  Supplementation  with  either  zinc  or  probiotics  alone  did  not  significantly 
improve rotavirus seroconversion rates compared with placebo (χ2, P values >0.05; Table 4.1); 
however,  a  modest  but  significant  increase  in  seroconversion  rate  was  observed  among 
infants who received both supplements compared with those who received neither (χ2, P = 
0.036) (Lazarus et al, manuscript in preparation).
4.4.2. Association between concurrent enteropathogens and seroconversion
i. Primary outcome
We assessed the presence of enteropathogens using TACs in a total 325 infants (Table 
4.1),  of  whom 320 completed the trial  per  protocol.  Among per-protocol  individuals,  we 
obtained eligible TAC assays (positive for PhHV and at least one RNA target) for 6-week 
samples in 313 infants, 10-week samples in 316 infants, and 6- and 10-week samples in 309 
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infants  (including  155  [50%]  responders  and  154  [50%]  non-responders).  In  infants  with 
eligible assays at both timepoints, pathogen exposure did not significantly influence the odds 
of rotavirus seroconversion: ≥1 infection (excluding EAEC, enterovirus, and rotavirus) was 
observed at either 6 or 10 weeks of age in 70/154 (45%) non-responders and 78/155 (50%) 
responders (OR 1.22, 95% CI 0.78–1.90). 
ii. Secondary outcomes
The prevalence of enteropathogens present in at least 1% of the study population at the 
time of each vaccine dose is displayed in Figures 4.2A and 4.2B by rotavirus seroconversion 
status  (see  Table  4.2  for  the  frequency  and  abundance  of  all  TAC  targets).  EAEC  and 
enteroviruses were the predominant infections at each timepoint. EAEC was identified in 
150/313 (48%) 6-week samples and 180/316 (57%) 10-week samples, and was present in a 
similar  proportion  of  responders  and  non-responders  at  each  dose  (χ2,  P  values  >0.05). 
Enteroviruses were observed in 217/313 (69%) 6-week samples and 237/316 (75%) 10-week 
samples.  The  majority  of  enterovirus-positive  samples  (155/217  [71%]  at  6  weeks  and 
176/235 [75%] at 10 weeks ) contained one or more Sabin serotypes, reflecting the routine 27
administration of OPV in this population, including at birth. The prevalence of enteroviruses, 
Sabin polioviruses,  and NPEVs did not  differ  significantly between responders and non-
responders at either dose (χ2, P values >0.05; Figure 4.3). However, enterovirus abundance 
was greater among responders than non-responders at 6 weeks of age (Ct, 29.5 ± 4.5 vs 31.0 ± 
4.1, Wilcoxon’s rank sum, FDR-corrected P = 0.042; Table 4.2).
Other  enteropathogens  were  generally  more  common  in  responders  than  non-
responders  at  6  weeks  of  age  (Figure  4.2A),  although  no  individual  comparisons  of 
prevalence  or  abundance  were  significant  after  FDR  adjustment  (Table  4.2).  Combining 
across pathogens, ≥1 infection (excluding EAEC, enterovirus, and rotavirus) was observed in 
56/156 (36%) responders and 37/157 (24%) non-responders at 6 weeks (χ2, P = 0.017). This 
discrepancy can be attributed primarily to bacterial pathogens, which were more common in 
responders than non-responders (40/156 [26%] vs 21/157 [13%]; χ2, P = 0.006), albeit only 
when EAEC was excluded (Figure 4.2A). These differences were no longer apparent at 10 
weeks  of  age  (Figure  4.2B).  The  proportion  of  individuals  infected  with  ≥1  viral  or  ≥1 
eukaryotic  enteropathogen  did  not  differ  significantly  between  responders  and  non-
responders at either dose.
 The detection of Sabin viruses was not performed for two 10-week samples that were positive for 27
enterovirus.
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Figure 4.2. Association between concurrent pathogens and rotavirus vaccine immunogenicity. The 
prevalence of concurrent pathogens is displayed for Rotarix doses administered at (A) 6 weeks and 
(B) 10 weeks of age. Pathogens present in at least 1% of the study population are included. (C, D) The 
number of pathogens and prevalence of mixed infections are displayed at (C) 6 weeks and (D) 10 
weeks of age. Mean pathogen counts are indicated by dotted lines. Rotaviruses were excluded from 
analyses of pathogen groups, mixed infections, and pathogen count. (E) Compared with individuals 
clear  of  infection  at  both  doses,  an  increase  in  the  odds  of  seroconversion  was  evident  among 
individuals with ≥1 infection at both doses. ORs and 95% CIs are indicated. EAEC, enterovirus, and 
rotavirus infections were excluded. * P <0.05. Abbreviations: Bac, bacteria; EAEC, enteroaggregative 
Escherichia coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; EV, enterovirus; Euk, 
eukaryote; OR, odds ratio; RV1, Rotarix; Vir, virus; w, weeks.
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We  observed  up  to  six  pathogens  per  sample  in  this  study.  Mixed  infections  were 
observed in a similar proportion of rotavirus vaccine responders and non-responders at 6 
weeks (73/156 [47%] vs 74/157 [47%]; χ2, P = 0.862) and 10 weeks (90/158 [57%] vs 95/158 
[60%];  χ2,  P  = 0.568).  Likewise,  total  pathogen count did not differ  significantly between 
responders and non-responders at either dose (Wilcoxon’s rank sum, P values >0.05; Figures 
4.2C and 4.2D).
The infections observed in this study were largely subclinical. Concurrent diarrhoea was 
documented in <5% of individuals at both 6 and 10 weeks of age. This proportion did not 
differ significantly between responders and non-responders at either 6 weeks (6/173 [3%] vs 
12/378 [3%];  χ2, P = 0.857) or 10 weeks (7/173 [4%] vs 17/378 [4%];  χ2, P = 0.810).
iii. Pathogen prevalence over successive Rotarix doses 
Compared with individuals clear of infections at both 6 and 10 weeks, we observed a 
significant increase in the odds of seroconversion when ≥1 concurrent infection was present 
at both doses (OR 2.25, 95% CI 1.15–4.41; Figure 4.2E) – an effect that was absent among 
individuals infected during only one of the two vaccine doses (OR 0.91, 95% CI 0.55–1.50). A 
similar  trend was apparent  among infants  harbouring bacterial  infections at  one or  both 
doses (OR 1.32, 95% CI 0.76–2.31 and OR 1.98, 95% CI 0.93–4.23, respectively). The presence 
of ≥1 virus or ≥1 eukaryote during at least one dose did not significantly impact the odds of 
seroconversion (OR 0.82, 95% CI 0.48–1.41 and OR 0.85, 95% CI 0.28–2.58, respectively).
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Figure 4.3.  Association between enterovirus subgroups and rotavirus vaccine immunogenicity. 
Data  are  displayed  for  Rotarix  doses  administered  at  (A)  6  weeks  and  (B)  10  weeks  of  age. 
§  comparison  of  enterovirus  prevalence  among  infants  negative  for  all  Sabin  serotypes. 
Abbreviation: NPEV, non-polio enterovirus; RV1, Rotarix; w, weeks.
4.4.3. Dose 1 rotavirus vaccine take
Among  the  313  per-protocol  infants  in  which  6-week  pre-vaccination  samples  were 
successfully assayed via TAC, the measurement of rotavirus shedding on the day of and 4 
and 7 days after vaccination was carried out in 288 (92%) – stool samples were lacking at one 
or  more timepoint  for  the remaining individuals.  Rotavirus shedding at  >100 copies  per 
reaction on day 0 was observed in 10/288 (3%) individuals. In the remaining infants, we 
observed  shedding  at  up  to  4.2  million  copies  per  reaction  in  the  week  following 
immunisation,  although  shedding  at  >1,000  copies  per  reaction  was  rare  (Figure  4.4B). 
Shedding at >100 copies per reaction at either day 4 or 7 was observed in 66/278 (24%) 
infants. Rotavirus seroconversion was observed in 46/66 (80%) shedders and 95/212 (45%) 
non-shedders (χ2, P <0.001).
4.4.4. Association between concurrent enteropathogens and vaccine take
After  adjusting  for  multiple  comparisons,  we  observed  no  association  between  the 
prevalence of enteropathogens at 6 weeks of age and dose 1 Rotarix take (Figure 4.5A; Table 
4.3). Pathogen count was comparable in shedders and non-shedders (1.7 ± 0.9 [mean ± s.d.] vs 
1.5 ± 1.0; Wilcoxon’s rank sum, P = 0.282), as was the prevalence of mixed infections (35/66 
[53%] vs 100/212 [47%]; χ2, P = 0.405). However, enterovirus abundance was significantly 
greater in shedders than non-shedders (Ct, 28.8 ± 4.3 vs 30.5 ± 4.3; Wilcoxon’s rank sum, 
FDR-corrected P = 0.046; Table 4.3) – an effect that appears to be attributable in part to a 
greater prevalence of Sabin viruses in the pre-vaccination samples of shedders (Figure 4.6A). 
By contrast, at 10 weeks of age, enteroviruses were observed in 39/65 (60%) and 166/210 
(79%) rotavirus shedders and non-shedders, respectively (χ2, FDR-corrected P = 0.014). This 
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Figure  4.4.  Rotavirus  shedding  at  6  weeks  of  age.  (A)  Rotavirus  shedding  in  pre-vaccination 
samples. (B) The proportion of individuals shedding on the day of and 4 and 7 days after the first 
dose of Rotarix. Abbreviation: RV, rotavirus.
A                      B
discrepancy encompasses differences in the prevalence of Sabin viruses (present in 29/64 
[45%] and 122/209 [58%] shedders and non-shedders, respectively; χ2, P = 0.066) as well as 
NPEVs (9/35 [26%] vs 43/87 [49%]; χ2, P = 0.017; Figure 4.6B). We also observed a significant 
reduction in the shedding of Sabin viruses at 10 weeks of age among individuals harbouring 
≥1 Sabin serotype at 6 weeks, potentially indicative of interference with the take of OPV 
given at 6 weeks of age by poliovirus replication following the birth dose of OPV (Figure 
4.6C).  Aside from a degree of  residual  rotavirus shedding,  no other  discrepancies  in  the 
prevalence of TAC targets were evident among rotavirus shedders versus non-shedders at 10 
weeks  of  age  (Figure  4.5B;  Table  4.3).  Diarrhoea  in  the  week preceding vaccination  was 
observed in 3/66 [5%] and 8/212 [4%] of shedders and non-shedders, respectively (Fisher’s 
test, P = 0.726). 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Figure 4.5. Association between concurrent pathogens and dose 1 rotavirus vaccine take. Data are 
displayed for samples collected at (A) 6 weeks and (B) 10 weeks of age. Pathogens present in at least 
1% of the study population are included. Rotaviruses were excluded from analyses of pathogen 
groups, mixed infections, and pathogen count. * P <0.05; ** P <0.005. Abbreviations: Bac, bacteria; 
EAEC, enteroaggregative Escherichia coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. 
coli; Euk, eukaryote; EV, enterovirus; RV, rotavirus; STEC, Shiga toxin-producing E. coli; Vir, virus; w, 
weeks.
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4.4.5. Association between bacterial microbiota composition and rotavirus vaccine outcome
i. Composition of the bacterial microbiota
We sequenced the V4 region of the 16S rRNA gene in 340 samples from 170 individuals 
(of which two were excluded from the final analyses, as detailed in Table 4.1). After quality 
filtering, we obtained 25,254 ± 13,091 (mean ± s.d.) sequences per sample, encompassing 153 
97%-identity OTUs. The overall composition of the bacterial microbiota was broadly similar 
at 6 and 10 weeks of age (Figure 4.7A), and a small number of taxa were dominant across 
samples (Figure 4.7B).
ii. Alpha diversity
We observed no significant differences in OTU count – across all taxa (Figure 4.8A) or 
within the phylum Proteobacteria (Figure 4.8B) – or Shannon index (Figure 4.8C) between 
rotavirus vaccine responders and non-responders at either dose (linear regression, P values 
>0.05). However, individuals who shed rotavirus after the 6-week Rotarix dose harboured a 
greater number of OTUs at the time of vaccination (linear regression, P = 0.007; Figure 4.8D) 
– a discrepancy that was still evident among these individuals at 10 weeks of age (linear 
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Figure 4.6. Association between enterovirus subgroups and dose 1 vaccine take. Viral shedding is 
displayed at (A) 6 weeks and (B) 10 weeks of age according to the shedding of rotavirus in the week 
following the first dose of Rotarix. (C) Viral shedding at 10 weeks of age is displayed according to 
whether or not ≥1 Sabin serotype was present at 6 weeks of age. § comparison of enterovirus 
prevalence among infants negative for all Sabin serotypes; * P  <0.05;  ** P <0.005; *** P <0.0005. 
Abbreviations: EV, enterovirus; NPEV, non-polio enterovirus; RV, rotavirus; Sabin+, positive for ≥1 
Sabin serotype; Sabin-, negative for all Sabin serotypes; w, weeks.
regression, P = 0.027). This observation was attributable in part to a greater number of OTUs 
in the phylum Proteobacteria among shedders (Figure 4.8E).  No significant differences in 
Shannon index were observed between shedders and non-shedders at either 6 or 10 weeks 
of age (P values >0.05; Figure 4.8F). A summary of alpha diversity analyses is provided in 
Table 4.4.
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Figure 4.7. Composition of the bacterial microbiota among vaccine recipients. (A) Phylum- and 
genus-level composition of the bacterial microbiota at 6 and 10 weeks of age. (B) Top  20 OTUs based 
on mean relative abundance among 6-week samples.  The abundance distribution of all  OTUs is 
displayed in the inset. When ranked by decreasing mean relative abundance, 18 OTUs accounted for 
>95%  of  the  observed  microbiota  in  these  samples.  Abbreviations:  CRA,  cumulative  relative 
abundance; OTU, 97%-identity operational taxonomic unit; w, weeks.
B
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Figure 4.8. Association between microbiota diversity and rotavirus vaccine response. (A) Mean 
OTU count (± s.d.) at multiple rarefaction depths, (B) OTU count within the phylum Proteobacteria, 
and (C) Shannon index according to rotavirus seroconversion status. Proteobacteria-specific OTU 
counts and Shannon index were calculated at a depth of 3,500 sequences per sample. Mean values 
for these measures in each group are indicated. (D, E, F) The same comparisons are displayed with 
respect to Rotarix take following the first (6-week) dose of vaccine. * P <0.05. Abbreviations: OTU, 
97%-identity operational taxonomic unit; RV, rotavirus; RV1, Rotarix; w, weeks.
A             B   C 
iii. Beta diversity
We observed no significant difference in bacterial community composition according to 
seroconversion status based on unweighted or weighted Unifrac distances (adonis, P values 
>0.05; Figure 4.9). Although a modest shift in composition was evident in the pre-vaccination 
microbiota according to whether or not infants shed rotavirus after the 6-week Rotarix dose 
based on unweighted Unifrac (adonis, P = 0.032; Figure 4.9C), this accounted for only a small 
portion of the variance among samples (R2 = 0.012).
The 6-  and 10-week samples of  each individual  tended to cluster  together based on 
unweighted Unifrac (adonis, R2 = 0.635 and P <0.001; Figure 4.10A) and weighted Unifrac 
(adonis,  R2 = 0.644 and P  <0.001).  When within-subject Unifrac distances were used as a 
measure of microbiota stability, we observed no significant differences in stability according 
to seroconversion status (Wilcoxon’s rank sum, P values 0.889 and 0.557 for unweighted and 
weighted Unifrac, respectively; Figure 4.10B) or dose 1 take (Wilcoxon’s rank sum, P values 
0.644  and  0.527  for  unweighted  and  weighted  Unifrac,  respectively;  Figure  4.10C).  A 
summary of beta diversity analyses is provided in Table 4.5.
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Table 4.4. Summary of alpha diversity analyses.
Comparison
Number of OTUs Number of OTUs (Proteobacteria) Shannon index
Age 
(w) Na Nb
Effect 
size SE P
Effect 
size SE P
Effect 
size SE P
MiSeq run - 13 13 - - 0.152 - - - - - <0.001
RV1 seroconversion 6 85 83 0.078 1.066 0.942 0.026 0.313 0.935 0.072 0.092 0.436
10 85 83 -0.612 1.029 0.553 -0.054 0.312 0.863 0.020 0.082 0.804
Dose 1 RV1 take 6 37 116 3.558 1.298 0.007 0.841 0.387 0.031 0.111 0.115 0.338
10 37 116 2.759 1.234 0.027 0.896 0.387 0.022 0.164 0.101 0.105
Probioticsc 6 67 63 2.206 1.173 0.062 - - - 0.110 0.107 0.307
10 67 63 1.105 1.178 0.350 - - - -0.021 0.094 0.826
Sensitivity analyses
RV1 seroconversion 
(titre >90 U/ml)
6 36 69 0.454 1.404 0.747 - - - 0.098 0.128 0.446
10 36 69 0.159 1.380 0.909 - - - 0.016 0.111 0.887
RV1 seroconversion 
(IgA-)
6 67 57 0.017 1.228 0.989 - - - -0.004 0.104 0.968
10 67 57 -0.772 1.198 0.520 - - - 0.008 0.095 0.937
With the exception of MiSeq run, which was assessed via Wilcoxon’s signed-rank test, the impact of each factor 
on the specified measure of alpha diversity was assessed via linear regression, with MiSeq run included as a 
covariate. Abbreviations: IgA-, analysis restricted to individuals negative for rotavirus-specific IgA at baseline; 
OTU, 97%-identity operational taxonomic unit; RV, rotavirus; RV1, Rotarix; SE, standard error; w, weeks.
a Number of responders/shedders/probiotics recipients/Miseq run 1 samples.
b Number of non-responders/non-shedders/placebo recipients/Miseq run 2 samples.
c Compares probiotics-only with placebo recipients. 
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Figure 4.9. Clustering of samples according to rotavirus vaccine response. Unweighted Unifrac 
distances  between samples,  visualised via  principal  coordinates  analysis,  are  displayed at  (A)  6 
weeks and (B) 10 weeks according to seroconversion status,  and (C) according to rotavirus take 
following the 6-week vaccine dose. Mean values for principal coordinate 1 are indicated by dotted 
lines. (D, E, F) The same comparisons are displayed for weighted Unifrac distances. Abbreviations: 
PC, principal coordinate; RV, rotavirus; RV1, Rotarix.
A            B            C
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Figure 4.10. Association between microbiota stability and rotavirus vaccine response. (A) Clustering 
of 6- and 10-week samples within each individual based on unweighted Unifrac distances. Six sample 
pairs are highlighted. (B, C) Within-subject Unifrac distances, used as an indicator of microbiota 
stability, are displayed according to (B) seroconversion status and (C) vaccine take. Mean values in 
each group are indicated. Abbreviations: PC, principal coordinate; RV, rotavirus; RV1, Rotarix.
A                B    C
iv. Taxon relative abundance
No significant  phylum-,  class-,  or  OTU-level  differences  in  taxon relative abundance 
were  observed  according  to  rotavirus  seroconversion  status  –  either  within  the  phylum 
Proteobacteria (Figure 4.11A) or across all taxa (non-parametric t test, FDR-corrected P values 
>0.05).  Similar results were observed with respect to vaccine take (Figure 4.11B) – one OTU 
in the phylum Proteobacteria (family Enterobacteriaceae) was significantly more abundant in 
the pre-vaccination samples of shedders compared with non-shedders (Table 4.6); however, 
no other phylum-, class-, or OTU-level differences in abundance distinguished these infants. 
At  10  weeks  of  age,  an  increase  in  the  relative  abundance  of  Bacteroidetes  and 
Verrucomicrobia (specifically the classes Bacteroidia and Verrucomicrobiae)  was observed 
among infants who shed rotavirus following the 6-week Rotarix dose compared with non-
shedders  (Table  4.6).  These  findings  were  driven  in  part  by  the  enrichment  of  an  OTU 
classified as Parabacteroides distasonis among shedders (Table 4.6).
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Table 4.5. Summary of beta diversity analyses.
Comparison Age (w)
Unweighted Unifrac Weighted Unifrac
R2 P R2 P
MiSeq runa - 0.017 0.992 0.006 0.946
Technical replicate IDa - 0.858 <0.001 0.987 <0.001
Study ID - 0.635 <0.001 0.644 <0.001
RV1 seroconversion 6 0.006 0.605 0.003 0.733
10 0.005 0.815 0.004 0.533
Dose 1 RV1 take 6 0.012 0.032 0.015 0.149
10 0.015 0.003 0.006 0.452
Probioticsb 6 0.012 0.021 0.008 0.322
10 0.013 0.014 0.003 0.741
Sensitivity analyses
RV1 seroconversion (titre >90 U/ml) 6 0.007 0.920 0.003 0.814
10 0.007 0.868 0.008 0.423
RV1 seroconversion (IgA-) 6 0.007 0.758 0.009 0.348
10 0.006 0.863 0.003 0.718
See Table 4.4 for details regarding the number of infants included in each comparison. The impact of 
each factor on the specified measure of beta diversity was assessed using the function adonis in the 
R  package  vegan;  9,999  permutations  were  included  in  each  comparison.  Abbreviations:  IgA-, 
analysis restricted to individuals negative for rotavirus-specific IgA at baseline; OTU, 97%-identity 
operational taxonomic unit; RV1, Rotarix; w, weeks.
a Comparison includes 13 samples sequenced in both the first and second MiSeq runs.
b Compares probiotics-only with placebo recipients. 
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Figure 4.11. Pre-vaccination Proteobacteria abundance by rotavirus vaccine response. Results are 
displayed  according  to  (A)  seroconversion  status  and  (B)  dose  1  vaccine  take.  Mean  relative 
abundance for each group is indicated by a horizontal line, while prevalence is indicated by a cross. 
Abbreviation: RV, rotavirus; RV1, Rotarix; w, weeks.
A                                 B
Table 4.6. Summary of significant differences in taxon abundance.
Level Taxonomic classification
OTU 
ID
Age 
(w)
Relative 
abundance 
(%) in group 1 
(mean ± s.d.) 
Relative 
abundance 
(%) in group 2 
(mean ± s.d.) P FDR P
RV1 seroconversion
NS
Dose 1 RV1 take Non-shedders Shedders
OTU Enterobacteriaceae sp. 745 6 0.003 ± 0.010 0.010 ± 0.018 0.004a -
P Verrucomicrobia 10 0.007 ± 0.053 0.600 ± 3.064 0.003 0.019
P Bacteroidetes 10 2.730 ± 8.129 7.434 ± 14.917 0.009 0.027
C Verrucomicrobiae 10 0.007 ± 0.053 0.600 ± 3.064 0.002 0.019
C Bacteroidia 10 2.730 ± 8.129 7.434 ± 14.917 0.008 0.046
OTU Parabacteroides distasonis 23512 10 0.011 ± 0.074 0.431 ± 1.242 0.0003 0.039
Probiotics Placebo Probiotics
OTU Lactobacillus zeae 21300 6 0.045 ± 0.182 0.659 ± 1.008 0.0001 0.014
OTU Lactobacillus zeae 21300 10 0.116 ± 0.315 0.912 ± 1.540 0.0001 0.013
OTU Actinomyces 21955 10 0.0005 ± 0.004 0.013 ± 0.032 0.0002 0.013
Groups were compared using a non-parametric t  test stratified by MiSeq run. Abbreviations: C, 
class;  FDR,  adjusted  by  Benjamini–Hochberg  false  discovery  rate  correction;  NS,  no  significant 
differences; OTU, 97%-identity operational taxonomic unit; P, phylum; RV1, Rotarix; w, weeks.
a P value was not adjusted as taxon was within the phylum Proteobacteria, hypothesised a priori to 
be associated with vaccine outcome.
v. Random Forests
Random Forest models based on OTU abundance data failed to accurately distinguish 
infants according to rotavirus seroconversion status (Figure 4.12A). Across 100 iterations of 
the algorithm, Rotarix response was predicted with a mean accuracy of 43.4% and 45.7% 
based on OTU abundances at 6 and 10 weeks, respectively (baseline accuracy: 50.6%). The 
models  conferred no significant  improvement in predictive accuracy compared with null 
models in which outcomes were randomly assigned to the input data (P values >0.05). When 
using  the  full  dataset  (comprising  37  shedders  and  116  non-shedders),  Random  Forests 
similarly failed to distinguish infants according to vaccine take following the 6-week dose of 
Rotarix (Figure 4.12B; P values >0.05), with the majority of shedders (>93% on average) being 
misclassified  as  non-shedders  using  both  6-  and  10-week  data.  However,  the  algorithm 
performed  somewhat  better  when  a  balanced  dataset  comprising  all  shedders  and  37 
randomly selected non-shedders was used for each iteration of the Random Forest algorithm. 
This led to a predictive accuracy of 61.4% and 60.9% for 6- and 10-week data, respectively 
(baseline  accuracy:  50.0%;  P values  0.038  and  0.040;  Figure  4.12C).  Variables  with  mean 
importance scores of >0.001 for the latter models are displayed in Figure 4.13.
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Figure  4.12.  Predictive  accuracy  of  Random  Forest  models.  Mean  accuracy  (±  s.d.)  across  100 
iterations of the Random Forest algorithm are displayed for models predicting (A) seroconversion 
status, (B) dose 1 vaccine take (full data), (C) dose 1 vaccine take using balanced data (including 37 
shedders and 37 non-shedders in each iteration of  the algorithm),  and (D) receipt  of  probiotics. 
Dotted lines indicate baseline accuracy, wherein all individuals are assigned to the majority class. 
OTU 21300 corresponds to the Lactobacillus strain that was enriched among probiotics recipients 
(section 4.4.6). * P <0.05; *** P <0.0005. Abbreviations: OTU, 97%-identity operational taxonomic unit; 
RV, rotavirus; RV1, Rotarix; w, weeks.
A      B                              C                                D
4.4.6. Impact of probiotics on the bacterial microbiota
The influence of probiotic supplementation on the bacterial microbiota was modest. A 
single OTU, classified as Lactobacillus zeae, was significantly more abundant among probiotics 
compared with placebo recipients at 6 weeks (relative abundance, 0.659 ± 1.008% [mean ± 
s.d.]  vs  0.045 ± 0.182%; non-parametric  t  test,  FDR-corrected P = 0.014;  Table 4.6;  Figure 
4.14A) and 10 weeks (relative abundance, 0.912 ± 1.540% vs 0.116 ± 0.315%; non-parametric t 
test,  FDR-corrected  P  =  0.013).  Given  the  clear  discrepancies  in  the  prevalence  and 
abundance of this OTU according to treatment group, it  is reasonable to conclude that it 
corresponds to the probiotic strain (the Greengenes database used for taxonomic assignment 
in this study does not contain a specific sequence for L. rhamnosus). An OTU in the genus 
Actinomyces  was  also  enriched  in  probiotics  recipients  at  10  weeks  of  age  (Table  4.6). 
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Figure 4.13. Highest ranking taxa by Random Forest importance score for prediction of rotavirus 
vaccine take. Data are displayed for models predicting dose 1 vaccine take using balanced data (Figure 
4.12C). Mean importance scores (± s.d.) were calculated over 100 iterations of the Random Forest 
algorithm. Separate analyses were carried out for 6- and 10-week samples. Abbreviation: w, weeks.
However,  no other phylum-, class-,  or OTU-level differences in taxon relative abundance 
distinguished probiotics from placebo recipients at either timepoint (non-parametric t test, 
FDR-corrected P values >0.05).
Receipt  of  probiotics  was  not  associated with  a  significant  change in  OTU count  or 
Shannon index (Table 4.4; Figure 4.14B). A shift in microbiota composition among recipients 
of probiotics was apparent based on unweighted Unifrac distances (adonis, P values 0.021 
and 0.014 at  6 and 10 weeks,  respectively;  Figure 4.14C),  but accounted for only a small 
proportion of variance among samples (R2, 0.012 and 0.013 at 6 and 10 weeks, respectively; 
Table 4.5). No significant clustering was apparent when using weighted Unifrac distances 
(adonis, P values >0.05 at both doses). 
The  outputs  of  Random Forests  were  consistent  with  these  findings  (Figure  4.12D). 
Models predicted the receipt of probiotics with a mean accuracy of 79.4% and 76.7% at 6 and 
10 weeks, respectively (baseline accuracy: 51.5%) – a significant improvement in fit compared 
with null models (P values <0.001). However, when separate models were fitted in which the 
OTU  corresponding  to  the  probiotic  strain  was  excluded,  this  predictive  capacity  was 
abrogated (mean accuracy, 54.1% and 58.0% at 6 and 10 weeks, respectively; P values >0.05). 
In  line  with  these  findings,  the  probiotic  strain  had  a  mean  importance  score  that  far 
outweighed that of any other OTUs when models were fitted using full data (Figure 4.15). 
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Figure 4.14. Impact of probiotic supplements on the bacterial microbiota. (A) Receipt of probiotics 
resulted in enrichment of a single OTU (classified as L. zeae). Mean relative abundance of this OTU in 
each group is indicated by a horizontal line, while prevalence is indicated by a cross. (B) OTU count 
according to treatment group. Mean values in each group are indicated. (C) Clustering of samples 
according to treatment group. Unweighted Unifrac distances between 6-week samples, visualised 
via principal coordinates analysis,  are displayed. Mean values for principal coordinate 1 in each 
group are indicated by dotted lines. *** P <0.0005 prior to FDR adjustment. Abbreviations: OTU, 
97%-identity operational taxonomic unit; PC, principal coordinate; w, weeks.
4.4.7. Negative controls
Combining across the 14 extraction controls and four no-template controls included in 
the two sequencing runs, we obtained a total of 58 sequences at the end of the analysis pipeline 
(4.1 sequences per control sample on average), suggesting that any contamination of laboratory 
reagents  or  cross-contamination  during  sample  handling  was  negligible.  Among  these 
sequences, 53 (91%) corresponded to the five most abundant OTUs among faecal samples.
4.4.8. Comparison of technical replicates
Thirteen samples were sequenced in both MiSeq runs. Measures of alpha diversity were 
generally consistent among these technical replicates (Figures 4.16A and 4.16B), although a 
decrease  in  Shannon index  was  evident  among samples  in  the  second MiSeq run when 
assessed by Wilcoxon’s signed-rank test (P <0.001). No significant shift in beta diversity was 
evident according to MiSeq run (Table 4.5). As would be expected, replicability was generally 
higher among samples in which the same PCR product was sequenced than those in which 
PCR  was  repeated  (Figures  4.16C  and  4.16D).  Technical  replicate  ID  accounted  for  the 
majority of variance among these 26 samples based on Unifrac distances (adonis, R2, 0.858 
and 0.987 for unweighted and weighted distances, respectively). Significant differences in 
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Relative abundance 
(%), placebo group
(mean ± s.d.) 
Relative abundance 
(%), probiotics group 
(mean ± s.d.)
0.045 ± 0.182 0.659 ± 1.008
5.051 ± 8.787 1.771 ± 5.485
0.015 ± 0.035 0.003 ± 0.018
48.630 ± 29.782 48.834 ± 23.573
2.048 ± 3.256 3.515 ± 5.142
0.006 ± 0.015 0.019 ± 0.051
0.005 ± 0.011 0.010 ± 0.028
8.176 ± 9.667 9.492 ± 9.357
0.116 ± 0.315 0.912 ± 1.540
4.293 ± 8.244 1.302 ± 3.633
0.000 ± 0.004 0.013 ± 0.032
0.045 ± 0.118 0.139 ± 0.275
0.015 ± 0.027 0.027 ± 0.033
0.028 ± 0.034 0.049 ± 0.048
0.000 ± 0.000 0.256 ± 1.241
0.204 ± 0.304 0.258 ± 0.551
0.022 ± 0.057 0.005 ± 0.013
0.008 ± 0.015 0.018 ± 0.026
0.018 ± 0.052 0.001 ± 0.006
0.016 ± 0.023 0.027 ± 0.041
0.010 ± 0.039 0.001 ± 0.007
0 0.05 0.1
Lactobacillus zeae (21300)
Enterobacteriaceae sp. (17699)
Lactobacillus (2983)
Bifidobacterium adolescentis (14490)
Streptococcus (20859)
Streptococcus infantis (19950)
Bifidobacteriaceae sp. (3406)
Streptococcus (6490)
Lactobacillus zeae (21300)
Enterobacteriaceae sp. (17699)
Actinomyces (21955)
Actinomyces (12939)
Bacteria (other) (23692)
Streptococcus (1846)
Collinsella (4633)
Staphylococcus (14371)
Enterobacteriaceae sp. (10049)
Bifidobacterium (14600)
Peptoniphilus (11238)
Streptococcus (6456)
Streptococcus (13947)
Importance score 
(mean decrease in accuracy)
6w
10w
Figure 4.15. Highest ranking taxa by Random Forest importance score for prediction of probiotic 
treatment. Mean importance scores (± s.d.) were calculated across 100 iterations of the Random Forest 
algorithm. Separate analyses were carried out for 6- and 10-week samples. Abbreviation: w, weeks.
relative abundance of the phyla Actinobacteria and Firmicutes were evident according to 
MiSeq run, although no OTU-level differences were apparent after FDR correction (Table 
4.7). While these observations point to the potential influence of run-to-run variation on our 
findings, the effect appears to be modest.
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Figure 4.16. Comparison of technical replicates. Concordance between technical replicates is shown 
for (A) number of OTUs, (B) Shannon index, (C) unweighted Unifrac distances, and (D) weighted 
Unifrac distances. The same PCR product was re-sequenced in eight of these samples (closed circles), 
while PCR was repeated for the remaining five (open circles).  Abbreviations:  OTU, 97%-identity 
operational taxonomic unit; PC, principal coordinate.
Table 4.7. Significant differences in taxon abundance among technical replicates.
Taxonomic 
classification
Relative abundance 
(%) in run 1 
(mean ± s.d.) 
Relative abundance 
(%) in run 2 
(mean ± s.d.) P FDR P
Phylum
Actinobacteria 49.877 ± 26.893 54.543 ± 27.722 0.0002 0.001
Firmicutes 18.081 ± 11.156 15.114 ± 11.027 0.0007 0.002
Class
Bacilli 14.244 ± 12.690 11.490 ± 11.783 0.0002 0.001
Actinobacteria 46.022 ± 28.969 49.600 ± 30.454 0.0002 0.001
OTU
NS
Phylum-, class-, and OTU-level differences in abundance among the 13 samples included in both 
MiSeq  runs  were  assessed  using  Wilcoxon’s  signed-rank  test.  Abbreviations:  FDR,  adjusted  by 
Benjamini–Hochberg  false  discovery  rate  correction;  NS,  no  significant  differences;  OTU,  97%-
identity operational taxonomic unit.
4.4.9. Sensitivity analyses
i. Threshold cycle
When lower Ct cut-off values were adopted for pathogen detection (corresponding to 
higher copy numbers of the RNA/DNA targets), the primary outcome was unchanged (Table 
4.8). We observed a significantly greater prevalence of enteroviruses in Rotarix responders 
than non-responders at 6 weeks of age (Ct 30, 89/156 [57%] vs 57/157 [36%]; χ2, P <0.001; 
Figure 4.17A) –  a  finding consistent  with the analyses of  pathogen abundance described 
above (Table 4.2) – and a decrease in the prevalence of EAEC at this timepoint (Ct 20, 10/156 
[6%] vs 23/157 [15%]; χ2, P = 0.018). Other associations were largely unchanged (Figure 4.17), 
although the increased proportion of responders infected with ≥1 pathogen at both doses 
observed using a Ct cut-off of 35 was no longer significant at lower thresholds.
ii. Antibody titre
Among per-protocol infants included in the enteropathogen survey, 67 experienced a 
four-fold rise in rotavirus-specific serum IgA titre and had a post-vaccination titre in excess 
of 90 U/ml. When we compared these individuals to those who were seronegative post-
vaccination or experienced a fall  in antibody titre,  associations between TAC targets and 
vaccine  outcome  were  similar  to  those  observed  using  standard  seroconversion  criteria 
(Table 4.8) – these ‘robust responders’ were more likely than non-responders to harbour ≥1 
bacterial enteropathogen (excluding EAEC) at 6 weeks of age (17/67 [25%] vs 17/136 [13%]; 
χ2, P = 0.021), and a borderline-significant increase in the likelihood of being infected with ≥1 
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Table 4.8. Summary of sensitivity analyses.
Proportion with ≥1 pathogen at 6 or 10 weeks, 
n/N (%)
Sensitivity analysis Responders Non-responders OR (95% CI)
Primary outcome 78/155 (67.8) 70/154  (45.5) 1.22 (0.78–1.90)
Ct 30 48/155 (31.0) 47/154 (30.5) 1.02 (0.63–1.66)
Ct 25 27/155 (17.4) 26/154 (16.9) 1.04 (0.57–1.88)
Ct 20 7/155 (4.5) 4/154 (2.6) 1.77 (0.51–6.19)
IgA titre >90 U/ml 33/67 (49.3) 58/133 (43.6) 1.26 (0.70–2.26)
MS2+ 54/128 (42.1) 59/121 (48.8) 1.30 (0.79–2.15)
IgA- 51/110 (46.4) 57/114 (50.0) 1.16 (0.68–1.95)
Abbreviations:  CI,  confidence  interval;  Ct,  threshold  cycle;  IgA-,  analysis  restricted  to  infants 
negative for rotavirus-specific IgA at baseline; MS2+, analysis restricted to infants with MS2-positive 
samples at 6 and 10 weeks of age; OR, odds ratio.
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Figure  4.17.  Impact  of  threshold  cycle  on  the  association  between concurrent  pathogens  and 
rotavirus vaccine immunogenicity. The proportion of infants infected with the specified pathogen 
or pathogen group at (A) 6 weeks, (B) 10 weeks, and (C) both timepoints is displayed. Rotavirus 
infections were excluded. * P <0.05; ** P <0.005; *** P <0.0005. Abbreviations: Ct, threshold cycle; 
EAEC, enteroaggregative Escherichia coli; EV, enterovirus; RV1, Rotarix.
enteropathogen at both doses (largely driven by bacterial infections) was observed in these 
individuals (13/67 [19%] vs 35/133 [10%]; χ2, P  = 0.056). No significant associations were 
observed between viral or eukaryotic TAC targets and vaccine outcome as defined in this 
way.  Similarly,  comparisons  of  alpha  and  beta  diversity  did  not  reveal  any  significant 
discrepancies  in  the  composition  or  diversity  of  the  bacterial  microbiota  among  robust 
responders versus non-responders  (Tables 4.4 and 4.5).
iii. Treatment group interactions
In  the  primary  outcome  analysis,  we  assessed  the  impact  of  harbouring  ≥1 
enteropathogen at either 6 or 10 weeks on the odds of rotavirus seroconversion via logistic 
regression. We fitted separate logistic regression models to examine potential  interactions 
between  enteropathogen  infection  status  and  treatment  group  (zinc  supplementation, 
probiotic supplementation, or study arm). No significant interaction terms were observed 
(data  not  shown),  suggesting  that  the  association  between  concurrent  infections  and 
rotavirus seroconversion was not influenced by treatment group.
iv. Other sensitivity analyses
The  observed  associations  between  concurrent  enteropathogens  and  rotavirus 
seroconversion status were largely unchanged by excluding samples negative for MS2 (the 
extrinsic  RNA control)  or  excluding  individuals  who were  positive  for  rotavirus-specific 
serum  IgA at  baseline  (observed  in  167/551  [30%]  infants  who  completed  the  trial  per 
protocol) (Table 4.8). In both instances, responders were significantly more likely than non-
responders to harbour ≥1 enteropathogen (excluding EAEC and enterovirus) at both doses 
(χ2, P values <0.05) – an effect attributable primarily to discrepancies in the prevalence of 
bacterial infections, which were significantly more common among responders at 6 weeks of 
age (χ2, P values <0.05). When considering MS2-positive samples, non-responders were more 
likely than responders to harbour EAEC at both doses (50/128 [39%] vs 33/121 [27%]; χ2, P = 
0.049) – a result that was also apparent in the primary analysis when using a Ct cut-off of 30 
(Figure 4.17C). Likewise, comparisons of alpha and beta diversity were largely unaltered by 
the exclusion of infants positive for rotavirus-specific serum IgA at baseline (Tables 4.4 and 
4.5).
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4.5. Discussion
Throughout infancy, individuals living in tropical, low-income countries are exposed to 
a diverse array of enteropathogens. In Chapter 2, the inhibitory potential of these pathogens 
on  the  replication  efficiency  and  immunogenicity  of  OPV  was  highlighted  during  a 
systematic  review and meta-analysis.  Among infants  in  south  India  with  a  considerable 
burden of  enteropathogens,  we did  not  observe  a  similar  inhibitory  effect  of  concurrent 
infections on the immunogenicity of Rotarix doses administered at 6 and 10 weeks of age. 
Indeed, individuals harbouring ≥1 bacterial infection at the time of both doses were more 
likely to respond serologically to this vaccine.
The potential for concurrent infection with bacterial enteropathogens to have a beneficial 
impact  on  vaccine  immunogenicity  is  not  without  precedent.  Oh  et  al  (2014)  recently 
demonstrated that sensing of the bacterial microbiota via the pattern recognition receptor 
TLR5 significantly improved the immunogenicity of inactivated influenza vaccine in mice, 
while  double-mutant  heat-labile  enterotoxin  derived  from  ETEC  enhanced  the  mucosal 
immune response observed during a Phase I clinical trial of an oral inactivated ETEC vaccine 
candidate (Lundgren et al,  2014).  The induction of Toll-like receptor signalling and other 
inflammatory mediators by concurrent enteropathogens may have had a similar adjuvant 
effect in our study. However, given that rotavirus vaccine immunogenicity is considerably 
greater in high-income countries, where infants experience a low burden of enteropathogens, 
we consider such a mechanism to be unlikely. 
An alternative explanation for the elevated burden of bacterial pathogens among Rotarix 
responders  relates  to  the  replication  of  co-administered  vaccine  polioviruses.  Rotavirus 
shedding following the 6-week vaccine dose was negatively correlated with OPV take – an 
observation  consistent  with  an  inhibitory  effect  of  OPV  on  the  replication  of  vaccine 
rotaviruses (Patel et al, 2012a). Given their potential to interfere with OPV take, the presence 
of  concurrent  bacteria  may  have  enhanced  the  immunogenicity  of  Rotarix  in  this  study 
population  by  blocking  the  replication  of  co-administered  Sabin  viruses.  Notably,  the 
discrepancy in bacterial enteropathogen burden according to rotavirus vaccine outcome was 
most pronounced for the first (6-week) vaccine dose, which is also when the inhibitory effect 
of OPV on Rotarix appears to be greatest (Patel et al, 2012a). In Chapter 5, I will expand 
further  on the association between concurrent  enteropathogens and response to tOPV in 
these infants, which may further elucidate this possibility. 
It  is  worth  noting  that  the  association  between  bacterial  pathogens  and  rotavirus 
seroconversion was contingent  on the exclusion of  EAEC, which we chose to  omit  from 
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primary  comparisons  because  of  its  very  high  prevalence  and  limited  association  with 
diarrhoea in previous studies using similar methods of pathogen detection (Taniuchi et al, 
2013; Platts-Mills et al, 2014). When lower Ct cut-off values were adopted (corresponding to 
an elevated copy number), we observed a significantly greater prevalence of EAEC in non-
responders at 6 weeks of age – a finding consistent with an inhibitory effect of EAEC on 
rotavirus vaccine immunogenicity that appears to contradict the trend observed for other 
bacterial enteropathogens. However, we did not observe any significant differences in the 
abundance of EAEC when Ct values were directly compared according to seroconversion 
status or vaccine take. Overall, our findings highlight several possible associations of modest 
effect  size  between  bacterial  enteropathogens  and  rotavirus  vaccine  response,  though  it 
appears unlikely that bacterial infections form a major driving force behind the diminished 
immunogenicity of Rotarix observed in this study population.
Rotarix responders exhibited a greater burden of enteroviruses (and more specifically 
Sabin viruses) at 6 weeks of age – an effect that was clearest when considering vaccine take. 
These enteroviruses can be attributed primarily to the residual replication of Sabin viruses 
administered  at  birth,  although  secondary  transmission  of  vaccine  polioviruses  later  in 
infancy cannot be excluded. Thus, it appears that infants who experienced robust replication 
of one or more Sabin viruses following their birth dose of tOPV were more likely to respond 
to Rotarix during this study. Again, this observation may relate to the replication of Sabin 
viruses  co-administered  with  Rotarix.  OPV  take  was  significantly  lower  among  infants 
positive for Sabin viruses at 6 weeks of age, which may reflect either an inhibitory effect of 
the replicating Sabin viruses on the 6-week OPV dose, or the existence of poliovirus-specific 
mucosal protection among individuals who experienced extensive replication following the 
birth dose of tOPV. By either mechanism, existing polioviruses may have enhanced Rotarix 
response by inhibiting the replication of co-administered OPV. Factors influencing the take of 
Sabin viruses administered at birth are unclear, although maternal antibodies (including IgG 
transferred across the placenta and IgA in colostrum) are likely to be important (Sabin et al, 
1963). A conceptual model outlining the potential interactions between OPV and rotavirus 
vaccine doses administered in early infancy is provided in Figure 4.18.
At  10  weeks  of  age,  an  increased  prevalence  of  enteroviruses  was  evident  among 
individuals who failed to shed rotavirus following the 6-week vaccine dose. Notably, both 
Sabin viruses and NPEVs appear to have contributed to this discrepancy. While an elevated 
prevalence  of  Sabin  viruses  among  rotavirus  non-shedders  would  fit  neatly  within  the 
conceptual  model  described  above,  the  negative  association  between  Rotarix  take  and 
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subsequent  NPEV  infection  is  more  surprising.  The  potential  for  intestinal  viruses  to 
interfere with one another is  one of  the central  tenets  of  this  thesis.  Thus,  it  is  certainly 
possible that replicating vaccine rotaviruses may have an inhibitory effect on NPEVs, or that 
NPEVs arising after vaccine delivery may interfere with Rotarix take – a notion validated by 
the apparent inhibitory effects of NPEVs on Rotarix recently documented among infants in 
Bangladesh (Taniuchi et al, 2016). However, it is also important to recognise the risk of over-
interpreting these findings given key limitations in how they were attained. In particular, we 
did  not  target  NPEVs  with  a  specific  diagnostic  assay,  but  defined  these  viruses  as  the 
presence of an enterovirus detected via TAC in the absence of any Sabin serotypes. Since this 
approach did not allow us to identify samples positive for both Sabin viruses and NPEVs, we 
excluded infants positive for the former when assessing the impact of NPEVs on vaccine 
response. Not only did this approach limit the NPEV-specific analyses to a subset of infants 
that  may  not  be  representative  of  the  broader  population,  but  in  light  of  the  extensive 
shedding of Sabin polioviruses, it essentially entailed omitting half of the study population 
when assessing the potential impact of NPEVs (at least one Sabin serotype was identified in 
50% and 56% of infants at 6 and 10 weeks of age, respectively). No other viral TAC targets 
(assessed via specific assays in every sample) differed according to rotavirus shedding status, 
and we observed no significant association between NPEV prevalence and seroconversion 
status.
Approximately  30%  of  the  infants  in  this  study  were  positive  for  rotavirus-specific 
serum IgA at 6 weeks of age, indicative of high exposure to rotavirus during the neonatal 
period.  The  exclusion  of  seropositive  infants  from  the  analyses  did  not  influence  the 
associations  observed  between  concurrent  enteropathogens  and  vaccine  outcome. 
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Figure 4.18.  Conceptual  model  of  interactions between oral  rotavirus and poliovirus vaccines 
administered in early  infancy.  *  outcome not  measured in  this  study.  Abbreviations:  OPV,  oral 
poliovirus vaccine; RV, rotavirus; RV1, Rotarix; tOPV, trivalent oral poliovirus vaccine; w, weeks.
Discrepancies in pathogen burden were similarly unchanged when we adopted an elevated 
threshold antibody titre to define seroconversion. Thus, it is reasonable to conclude that the 
presence of enteropathogens did not represent a risk factor for failure to achieve a robust 
antibody response following two doses of Rotarix in these infants. 
To what extent are these findings generalisable to other low-income settings linked with 
impaired oral vaccine response? Based on the findings of the MAL-ED study (see section 
1.5.5), the enteropathogen burden experienced by infants in Vellore appears to be typical of 
that  endured  in  other  developing  countries  (Platts-Mills  et  al,  2015).  However,  at  a 
seroconversion rate of 31% after two doses, the immunogenicity of Rotarix in this study was 
poor  even  by  the  standards  of  low-income  settings,  where  seroconversion  rates  of 
approximately 50% are typical (Patel et al, 2013a). Reasons for the poor immunogenicity of 
Rotarix in these infants are unclear, especially given that a previous trial of this vaccine in 
India yielded a seroconversion rate of 58% after two doses at 8 and 12 weeks of age (Narang 
et al, 2009). Based on the findings presented here, we can merely conclude that (with the 
possible  exception  of  co-administered  vaccine  polioviruses)  concurrent  infections  do  not 
appear to account for discrepancies in rotavirus vaccine performance among these infants. 
Notably, these results are broadly consistent with recent findings from Bangladesh, where an 
increase in the quantity of enteroviruses (but no other enteropathogens) was linked with a 
reduction in the odds of rotavirus seroconversion (Taniuchi et al, 2016).
Turning  our  attention  to  the  bacterial  flora  as  a  whole,  we  observed  no  consistent 
discrepancies  in  microbiota  composition,  diversity,  or  stability  according  to  rotavirus 
seroconversion status. Referring back to the ‘keystone taxa’ hypothesis outlined in Chapter 1, 
we did not identify any OTUs that differed significantly in abundance between responders 
and non-responders (either in the phylum Proteobacteria or across other taxa). Findings were 
more intriguing with respect to vaccine take. At both 6 and 10 weeks of age, the number of 
OTUs was significantly lower among infants who failed to shed rotavirus after the first dose 
of  Rotarix  (a  result  consistent  with  the  hypothesised  association  between  microbiota 
diversity and oral vaccine outcome), and a shift in overall microbiota composition according 
to shedding status was apparent based on unweighted Unifrac distances. In each instance, 
however,  the  size  of  the  observed  discrepancies  was  modest.  Likewise,  Random  Forest 
models based on OTU abundance data conferred only a small increase in predictive accuracy 
for rotavirus shedding status compared with baseline. Thus, our findings suggest that the 
bacterial microbiota – in as much as it  was captured by the sampling method, extraction 
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techniques, primers, and sequencing methods adopted – is not a key factor underpinning the 
variation in rotavirus vaccine response observed in this study population.
These findings certainly do not preclude an important role for the bacterial microbiota in 
shaping broader geographic trends in rotavirus vaccine immunogenicity. If the comparison 
of infants from Malawi, Venezuela, and the USA is representative of the geographic variation 
present in microbiota composition (Yatsunenko et al, 2012), it is likely that the taxonomic 
structure and functional profile of the gut flora among infants in this study population differ 
considerably  from  those  of  infants  living  in  high-income  countries.  Given  the  poor 
immunogenicity of Rotarix in this trial, it is possible that all infants harboured a bacterial 
community  structure  inhibitory  to  vaccine  virus  replication,  with  insufficient  variation 
among  individuals  to  distinguish  compositional  differences  pertinent  to  Rotarix  failure. 
Future studies on a broader geographic and sociodemographic scale may help to test this 
possibility.
The administration of probiotics had a minimal impact on the bacterial microbiota of 
these infants.  This is  perhaps best  illustrated by the failure of  Random Forest  models to 
accurately  distinguish  between  probiotics  and  placebo  recipients  when  the  OTU 
corresponding  to  the  L.  rhamnosus  GG  probiotic  strain  was  omitted.  Despite  the  daily 
administration  of  capsules  containing 1010 organisms,  the  enriched OTU accounted for  a 
mean relative abundance of <1% among probiotics recipients at both 6 and 10 weeks of age. 
Since these samples were collected within the window of supplement administration, it is 
unclear whether the presence of this strain represents successful colonisation of the intestinal 
microbiota or passive transit.
4.5.1. Limitations
A number of limitations relating to technical details of the laboratory work involved in 
this study merit brief consideration. First, amplification of the extrinsic RNA control MS2 
was not observed in a portion of samples run on the TACs (including approximately 10% of 
samples included in the final analysis). By contrast, the extrinsic DNA control PhHV was 
recovered  in  all  samples.  Although  inconsistency  in  MS2  amplification  is  potentially 
indicative of suboptimal extraction and amplification efficiency for RNA targets, based on 
recent correspondence with researchers in the Department of Gastrointestinal Sciences at the 
Christian Medical College, it transpires that the use of a new batch of MS2 in subsequent 
projects led to much more consistent recovery of the RNA control (personal communication, 
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Dr Ira Praharaj). It is therefore likely that the issue lay in the stability of the MS2 rather than a 
problem with the extraction protocol. Nonetheless, we conducted a sensitivity analysis in 
which we excluded samples lacking amplification of MS2. This did not alter the primary 
outcomes of the study.
A more  significant  drawback  concerns  the  16S  rRNA gene  V4-specific  primers.  The 
primer sequences published by Caporaso et al (2012) – 5’-GTGCCAGCMGCCGCGGTAA-3’ 
(515F) and 5’-GGACTACHVGGGTWTCTAAT-3’ (806R) – are degenerate at several positions, 
such that a mixture of similar oligonucleotides is added during PCR. For example, the letter 
M corresponds to inclusion of the nucleotides C or A at the relevant site in the primer, while 
H corresponds to A, C, or T. The degeneracy of these primers enables a greater number of 
bacterial 16S rRNA gene sequences to be targeted within a given DNA sample. In the present 
study, however, we used the best available non-degenerate variants of these primers. Thus, 
while  our  515F  primer  sequence  has  88,946  perfect  matches  within  the  V4-specific 
Greengenes reference file used in the analyses described above, the degenerate variants of 
the primer used by Caporaso et al (2012) have 90,495 perfect matches. The corresponding 
806R  primers  have  71,778  versus  88,473  matches,  respectively.  While  the  use  of  non-
degenerate primers may have reduced the taxonomic coverage of our sequencing pipeline, 
these biases would have impacted all samples equally, and therefore do not undermine any 
observed discrepancies in relative abundance or diversity in our analyses. It is also worth 
noting  that  these  constraints  play  out  within  the  context  of  biases  in  coverage  and 
amplification efficiency that exist regardless of whether or not degenerate primers are used 
(Hong et al,  2009; Wang and Qian, 2009).  During a study of mock bacterial communities 
using the degenerate V4 primer sequences described above, Nelson et al (2014) documented 
the under-representation of several taxa (e.g., members of the genera Propionibacterium and 
Pseudomonas)  and corresponding over-representation of others (e.g.,  Helicobacter species) – 
similar biases were apparent during the sequencing of mock bacterial communities using our 
non-degenerate primers, as described above (section 3.4). The existing biases are likely only 
to have been exacerbated in our study by the use of non-degenerate primers.
The comparison of technical replicates revealed a degree of variation according to MiSeq 
run  that  cannot  be  discounted.  The  sources  of  this  variation  are  unclear  given  that  the 
protocol, personnel, and sequencing facility were standardised across the two runs, but may 
include differences in reagent lot  and sequencing error rate,  among others.  Similar batch 
effects have been documented in previous studies involving high-throughput sequencing of 
the 16S rRNA gene, particularly those using pyrosequencing (Ge et al,  2014; Mutlu et al, 
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2014). Although replicability appears to be higher when using MiSeq (Lluch et al, 2015), the 
potential  influence of batch effects is  often not reported in studies that collate data from 
multiple  sequencing runs,  and I  suspect  that  the issue may be more widespread than is 
currently appreciated or reported. Notably, we accounted for potential batch effects during 
the design of  this  study by randomising the order  in  which samples  were assayed,  and 
during statistical analyses via the inclusion of MiSeq run as a covariate in regression models 
and a constraint in permutation-based tests. It is therefore unlikely that the observed run-to-
run variation  substantially  altered  the  outcomes  of  this  study.  Given the  opportunity  to 
repeat  the  investigation,  however,  I  would have obtained a  greater  number  of  barcoded 
reverse primers in order to increase the multiplexing capacity of the sequencing pipeline and 
thereby included all samples on a single run .28
Finally,  comparisons  of  the  bacterial  microbiota  with  respect  to  probiotic  treatment 
group were conducted within a subset of infants enriched in Rotarix responders (owing to 
the selection criteria of this nested case–control study), and thus not entirely representative of 
the underlying study population. However, considering that microbiota composition did not 
differ significantly according to seroconversion status in any of the comparisons described 
above, it is unlikely that the selection criteria introduced any major bias into our findings 
regarding the impact of L. rhamnosus GG administration on the bacterial flora.
4.5.2. Conclusions
There  are  currently  limited  published  data  regarding  the  impact  of  the  intestinal 
microbiota  on  response  to  oral  rotavirus  vaccine.  Overall,  our  findings  corroborate  the 
potential  inhibitory  effect  of  co-administered  vaccine  poliovirus  on  Rotarix  response. 
Contrary  to  expectations,  we  observed  a  greater  burden  of  enteropathogens  among 
individuals who seroconverted to rotavirus – an effect that may well have been mediated by 
an inhibitory influence of these infections on OPV take. This possibility will be considered 
further  in  the  following chapter.  Although we observed no significant  differences  in  the 
composition  of  the  bacterial  microbiota  according  to  vaccine  immunogenicity,  a  similar 
investigation on a broader geographic scale may yet reveal an important role for the bacterial 
(or indeed viral) microbiota in shaping rotavirus vaccine response.
 This is the approach adopted during the library preparation described in Chapter 6, wherein 295 28
samples were included on a single MiSeq run.
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Chapter 5: Influence of enteropathogens and the bacterial microbiota on response 
to oral poliovirus vaccine among infants in south India
5.1. Background
The findings presented in the previous chapter raised the possibility that  concurrent 
bacterial  enteropathogens  may  have  a  beneficial  impact  –  albeit  a  modest  one  –  on  the 
immunogenicity of Rotarix doses administered to infants in south India at 6 and 10 weeks of 
age. Was this effect mediated by an inhibitory effect of bacterial infections on the replication 
of  vaccine polioviruses  co-administered with Rotarix?  Here,  we shall  explore  this  notion 
further by examining the association between the intestinal microbiota and OPV outcome 
within  the  same  study  population.  Again,  both  the  burden  of  enteropathogens  and  the 
composition of the bacterial microbiota will be considered. As noted in the systematic review 
described in Chapter 2, few prior studies have reported on the association between non-viral 
pathogens and response to OPV, while the potential impact of the bacterial microbiota on 
either seroconversion or vaccine take has not been examined to date. The laboratory and 
statistical methods involved in these analyses have been outlined in detail above, and will 
not be repeated here. However, several relevant additions and amendments to the methods 
are described below.
5.1.1. Hypotheses
The primary hypotheses of this study are outlined in the previous chapter (section 4.1.1). 
In brief, our principal objective was to test the notion that failure to respond to OPV (based 
either on type 3 poliovirus seroconversion or the take of Sabin viruses) is associated with an 
increase in the prevalence and number of enteropathogens at the time of immunisation. We 
also  hypothesised  that  failure  to  respond  to  OPV  is  associated  with  a  decrease  in  the 
diversity of the bacterial microbiota, and a shift in taxonomic composition (driven in part by 
an  elevated  relative  abundance  of  Proteobacteria)  based  on  Unifrac  distances  and  the 
discriminatory capacity of Random Forest models.
5.2. Methods
5.2.1. Additional TaqMan array card assays
The subset of infants recruited to our primary enteropathogen survey included just 62 
individuals who failed to seroconvert to type 3 poliovirus. To increase our power to detect 
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the  influence  of  enteropathogens  on  OPV  immunogenicity,  we  extended  the  study 
population to  include all  other  OPV non-responders  with sufficient  6-  and 10-week pre-
vaccination stool samples (n = 30). Nucleic acid extraction and TAC assays were conducted 
for  these  samples  using  the  methods  described  in  Chapters  3  and  4  (albeit  without 
randomisation by OPV outcome). Thus, our final study population encompassed 263 OPV 
responders and 92 non-responders (a ratio of approximately 3:1), while the 16S rRNA gene 
sequencing  subset  comprised  138  responders  and  32  non-responders  (a  ratio  of 
approximately 4:1; Table 5.1).
5.2.2. Statistical analysis
i. Enteropathogen burden 
In  line  with  the  assessment  of  rotavirus  vaccine  response,  the  primary  outcome  of 
interest  in this study was the association between type 3 poliovirus seroconversion (as a 
categorical dependent variable) and the presence of ≥1 enteropathogen (excluding EAEC and 
enterovirus) at  6 or 10 weeks of  age,  as determined via logistic  regression.  Type 3 Sabin 
viruses have generally proven to be the least immunogenic component of tOPV (Patriarca et 
al, 1991). Response to this serotype was therefore used as a marker of OPV immunogenicity 
in  the  present  trial.  Seroconversion  was  defined  as  an  increase  in  poliovirus  serotype  3 
neutralising antibody titre from <1:8 to ≥1:8 or a four-fold rise in titre between 6 and 14 
weeks of age, assuming a decay in pre-vaccination titre with a half-life of 28 days. Secondary 
outcomes  followed those  described  in  section  4.3.4.  Rotavirus  infections  were  no  longer 
excluded from analyses of pathogen groups or mixed infections as – in contrast to Rotarix 
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Table 5.1. Summary of study population.
Treatment group
Trial population 
(per protocol)
No. in enteropathogen 
subset
No. in 16S rRNA 
microbiota subset
Total
PV3 
responders (%) Total
PV3 
responders (%) Total
PV3  
responders (%)
Zinc/probiotics 137 108 (78.8) 109 85 (78.0) 38 29 (76.3)
Zinc only 143 116 (81.1) 80 56 (70.0) - -
Probiotics only 136 112 (82.4) 83 61 (73.5) 69 55 (79.7)
Placebo 135 112 (83.0) 83 61 (73.5) 63 54 (85.7)
Overall 551 448 (81.3) 355 263 (74.1) 170 138 (81.2)
Six infants  in the enteropathogen subset  were excluded from the final  analyses as  they did not 
complete the study per protocol, while two infants were excluded from the microbiota analyses. See 
Table 4.1 for additional details. Abbreviation: PV3, type 3 poliovirus.
outcome  –  we  did  not  anticipate  these  infections  to  be  positively  correlated  with  OPV 
response. However, we excluded enteroviruses from analyses of mixed infections and total 
pathogen count owing to the high prevalence of Sabin viruses among enterovirus-positive 
samples and the likely confounding of Sabin virus shedding with OPV outcome measures. 
The association between rotavirus seroconversion and type 3 poliovirus seroconversion was 
assessed using the χ2 test.
Although the shedding of vaccine polioviruses in the week following immunisation was 
not assessed, we used the shedding of Sabin viruses at 10 weeks of age as an indicator of 
vaccine take following the 6-week dose of tOPV. Specifically, we examined the influence of 
the intestinal microbiota on: (i) the shedding of any Sabin serotype at 10 weeks of age; and 
(ii) the shedding of type 3 Sabin viruses at 10 weeks of age. Infants were considered eligible 
for the analysis of OPV take if their 10-week sample was positive for PhHV and at least one 
RNA target  during  the  TAC  assay,  and  was  successfully  assayed  for  Sabin  serotypes  if 
positive for enterovirus. Individuals were excluded if they did not meet these criteria.
ii. Population attributable fraction of vaccine non-response associated with enteropathogens
We extended our analyses of OPV outcomes by estimating the fraction of vaccine failure 
that can be attributed to the presence of concurrent pathogens. First, to determine per-dose 
seroconversion rates in infected versus uninfected individuals, we calculated the expected 
numbers of responders and non-responders in the trial population as a whole infected at: 
neither 6 nor 10 weeks (E0R for responders and E0NR for non-responders); at one of the two 
doses (E1R and E1NR); and at both doses (E2R and E2NR). These estimates were obtained by 
multiplying the observed numbers of responders in groups E0, E1, and E2 within the TAC 
subset by 1.79 (448/250) and the observed numbers of non-responders by 1.21 (103/85) to 
account for the sampling proportions in our enteropathogen survey . EAEC and enterovirus 29
infections were excluded at each dose. Assuming a constant probability of seroconversion 
per OPV dose for infected (pi) and uninfected individuals (pu), we then calculated (using the 
Solver function in Microsoft Excel) the values of pi and pu that would maximise the likelihood:
L(pu, pi | E0R, E1R, E2R) =  P(E0R | n0, p0) * P(E1R | n1, p1) * P(E2R | n2, p2)
where p0 (the probability of seroconversion in infants infected at neither dose) = 1 - (1 - 
pu)2, p1 (the probability of seroconversion in infants infected at one dose) = 1 - (1 - pu)(1 - pi), 
 Overall, we successfully assayed the 6- and 10-week samples of 250 of the 448 per-protocol OPV 29
responders and 85 out of the 103 non-responders.
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and p2 (the probability of seroconversion in infants infected at both doses) = 1 - (1 - pi)2; n0, 
n1, and n2 are the estimated numbers of individuals infected at neither, one, or both doses in 
the trial population; and the conditional probabilities are given by the binomial probability 
density function.
Per-dose seroconversion rates were then used to estimate the population attributable 
fraction  (PAF)  of  failed  type  3  poliovirus  seroconversions  associated  with  concurrent 
enteropathogens under different burdens of infection, as follows:  
 
where It (the per-dose non-response rate in the whole population) = (1 - fi)(1 – pu) + fi(1 - 
pi), fi is the proportion of the population infected per dose, and d is the number of doses 
administered. We estimated fi for this study population at 6 weeks of age by multiplying the 
observed numbers of  infected and uninfected responders  within the TAC subset  by 1.78 
(448/252) and the observed numbers of non-responders by 1.17 (103/88) to account for the 
sampling proportions of the 6-week TAC assays (as described above).
iii. Bacterial microbiota
The OTU table generated following the 16S rRNA gene sequencing pipeline described in 
the previous chapter served as the input for analyses of the bacterial microbiota. Once again, 
our primary outcome for these analyses was the association between within-sample diversity 
(OTU count and Shannon index as continuous dependent variables) and vaccine response 
(type 3 poliovirus seroconversion after the 6- and 10-week doses or shedding after the 6-
week dose), as determined via linear regression. Secondary outcomes included comparisons 
of  OTU  count  within  the  phylum  Proteobacteria,  sample  clustering  based  on  Unifrac 
distances, microbiota stability, and taxon relative abundance according to OPV outcome, as 
described  in  section  4.3.4.  We  also  tested  the  capacity  of  Random  Forest  models  to 
discriminate infants according to type 3 poliovirus seroconversion and OPV take.
To determine whether OTU count and the presence of  ≥1 bacterial enteropathogen at 6 
weeks of age were independently associated with the odds of OPV response (seroconversion 
after the 6- and 10-week doses or shedding of any Sabin viruses after the 6-week dose), we 
compared the effect size and significance of these explanatory variables in univariate versus 
multivariate logistic regression models (with OPV outcome as the dependent variable). No 
other variables were adjusted for in these multivariate models.
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PAF    = 
Itd - (1 - pu)d 
Itd
   = 
(overall risk of non-response) - (risk of non-response among uninfected)
(overall risk of non-response) 
iv. Sensitivity analyses
Sensitivity analyses were carried out in which: (i) lower Ct cut-offs (30, 25, and 20) were 
used  for  the  assessment  of  TAC targets;  (ii)  samples  lacking  amplification  of  MS2  were 
excluded; (iii) individuals positive for serum type 3 poliovirus antibodies at baseline were 
excluded (thus removing any infants with maternal antibodies or who had responded to the 
tOPV  dose  administered  at  birth);  and  (iv)  comparisons  were  stratified  by  rotavirus 
seroconversion status (to account for the enrichment of the study population with Rotarix 
responders).  Among infants  lacking  type  3  poliovirus  antibodies  at  6  weeks  of  age,  we 
compared individuals who failed to respond with those who developed antibody titres of 
≥1:256, thus enabling us to assess the impact of the intestinal microbiota on the extent of the 
serum antibody response (or relative immunogenicity) achieved by immunisation. Outcomes 
of interest during sensitivity analyses followed those described in section 4.3.4.
5.3. Results
5.3.1. Oral poliovirus vaccine immunogenicity
After tOPV doses administered at 6 and 10 weeks of age, 448 (81%) of the 551 infants 
who completed the study per protocol seroconverted to type 3 poliovirus (Lazarus et  al, 
manuscript  in  preparation).  No significant  differences  in  immunogenicity  were  observed 
across the study arms (χ2, P values >0.05 for all comparisons). Seroconversion to rotavirus 
was observed in 147/448 (33%) individuals who responded to OPV and 26/103 (25%) of 
those who did not (χ2, P = 0.136).
5.3.2. Association between concurrent enteropathogens and seroconversion
i. Primary outcome
Among individuals who completed the study per protocol, we obtained eligible TAC 
assays for 6-week samples in 340 infants, 10-week samples in 343 infants, and 6- and 10-week 
samples in 335 infants (including 85 [25%] infants who seroconverted to type 3 poliovirus 
and  250  [75%]  non-responders).  Exposure  to  ≥1  enteropathogen  (excluding  EAEC  and 
enterovirus)  at  6  or  10  weeks  of  age  was  observed  in  51/85  (60%)  non-responders  and 
120/250 (48%) responders (OR 0.62, 95% CI 0.37–1.01).
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ii. Secondary outcomes
The  prevalence  of  concurrent  enteropathogens  according  to  seroconversion  status  is 
indicated in Figures 5.1A and 5.1B for 6- and 10-week samples, respectively. Comparisons of 
pathogen abundance are summarised in Table 5.2. At 6 weeks of age, non-responders were 
more likely to harbour ≥1 enteropathogen (excluding EAEC and enterovirus) than infants 
who seroconverted (38/88 [43%] vs 68/252 [27%]; χ2,  P  = 0.005).  Although no individual 
pathogens  differed significantly  in  prevalence  or  abundance  according to  seroconversion 
status (Table 5.2), this discrepancy was driven predominantly by bacterial infections, which 
were significantly more common in non-responders than responders overall (29/88 [33%] vs 
42/252 [17%]; χ2, P = 0.001), albeit only when EAEC was excluded. At 10 weeks of age, the 
proportion of infants infected with ≥1 pathogen no longer differed significantly between non-
responders  and responders  (36/87 [41%] vs  93/256 [36%];  χ2,  P = 0.401);  however,  non-
responders were still more likely to harbour ≥1 bacterial infection (28/87 [32%] vs 55/256 
[21%]; χ2, P = 0.044). The proportion of individuals infected with ≥1 viral or ≥1 eukaryotic 
enteropathogen did not differ significantly between the two groups at either dose. 
Although the proportion of individuals shedding enteroviruses at either 6 or 10 weeks of 
age did not differ according to seroconversion status, responders were more likely than non-
responders to harbour ≥1 Sabin serotype at 6 weeks of age (130/252 [52%] vs 31/88 [35%]; χ2, 
P = 0.008; Figure 5.2A) – a discrepancy attributable primarily to type 2 Sabin viruses, which 
were shed by 115/252 (46%) responders and 21/88 (24%) non-responders (χ2, P <0.001). As 
expected, the replication of type 3 Sabin viruses after the 6-week dose of tOPV was positively 
correlated with seroconversion – shedding of this serotype 4 weeks after immunisation (i.e., 
at 10 weeks of age) was observed in 76/254 (30%) responders and 3/87 (3%) non-responders 
(χ2,  P  <0.001;  Figure  5.2B).  The  prevalence  of  NPEVs  (based  on  exclusion  of  Sabin 
polioviruses) was greater among non-responders than responders at 6 weeks (28/57 [49%] vs 
44/122 [36%]) and 10 weeks (30/56 [54%] vs 42/101 [42%]); however, these differences were 
not statistically significant (χ2, P values 0.097 and 0.149, respectively). 
Mixed infections, defined as the presence of >1 enteropathogen (excluding enterovirus) 
were more common in non-responders than responders at 6 weeks (26/88 [30%] vs 38/252 
[15%]; χ2, P = 0.003; Figure 5.1C) and 10 weeks (30/87 [34%] vs 57/256 [22%]; χ2, P = 0.024; 
Figure  5.1D).  The  total  number  of  pathogens  (excluding  enterovirus)  did  not  differ 
significantly between non-responders and responders at 6 weeks (1.1 ± 1.1 [mean ± s.d.] vs 
0.8 ± 0.8; Wilcoxon’s rank sum, P = 0.081) or 10 weeks (1.3 ± 1.2 vs 1.0 ± 0.9; Wilcoxon’s rank 
sum, P = 0.189).
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Figure  5.1.  Association  between  concurrent  pathogens  and  oral  poliovirus  vaccine 
immunogenicity. The prevalence of concurrent pathogens is displayed for tOPV doses administered 
at (A) 6 weeks and (B) 10 weeks of age. Pathogens present in at least 1% of the study population are 
included. (C, D) The number of pathogens and prevalence of mixed infections are displayed at (C) 6 
weeks and (D) 10 weeks of age. Enteroviruses were excluded from these analyses. Mean pathogen 
counts are indicated by dotted lines. (E) Compared with individuals clear of infection at both doses, 
a decrease in the odds of seroconversion was evident among individuals with ≥1 infection at both 
doses. ORs and 95% CIs are indicated. EAEC and enterovirus infections were excluded. * P <0.05; 
**  P  <0.005.  Abbreviations:  Bac,  bacteria;  EAEC,  enteroaggregative  Escherichia  coli;  EPEC, 
enteropathogenic E. coli;  ETEC, enterotoxigenic E. coli;  EV, enterovirus; Euk, eukaryote; OR, odds 
ratio; PV3, type 3 poliovirus; Vir, virus; w, weeks.
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Among  per-protocol  infants  in  the  study  population  as  a  whole,  the  proportion  of 
individuals with diarrhoea in the 7 days preceding vaccination did not differ according to 
type 3 poliovirus seroconversion status – concurrent diarrhoea was observed in 17/448 (4%) 
responders and 1/103 (1%) non-responders at 6 weeks (Fisher’s test, P = 0.219), while the 
corresponding  rates  at  10  weeks  of  age  were  20/448  (5%)  and  4/103  (4%),  respectively 
(Fisher’s test, P = 1.000).
iii. Pathogen prevalence over successive oral poliovirus vaccine doses 
Compared with individuals free of infections at both 6 and 10 weeks of age, a decrease 
in the odds of OPV response was evident with each additional dose in which ≥1 concurrent 
infection (excluding EAEC and enterovirus) was present (OR 0.72, 95% CI 0.41–1.27 and OR 
0.46, 95% 0.24–0.89 for infants infected at one and two doses, respectively; Figure 5.1E). A 
similar trend was evident when analyses were restricted to bacterial infections (OR 0.76, 95% 
CI 0.41–1.40 and OR 0.30, 95% CI 0.15–0.61, respectively). The presence of ≥1 virus or ≥1 
eukaryote during at least one dose did not significantly impact the odds of seroconversion 
(OR 0.76, 95% CI 0.44–1.32 and OR 0.53, 95% CI 0.17–1.66, respectively). 
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Figure  5.2.  Association  between  enterovirus  subgroups  and  oral  poliovirus  vaccine 
immunogenicity. Data are displayed for tOPV doses administered at (A) 6 weeks and (B) 10 weeks 
of age. § comparison of enterovirus prevalence among infants negative for all Sabin serotypes; * P 
<0.05; *** P <0.0005. Abbreviations: NPEV, non-polio enterovirus; PV3, type 3 poliovirus; w, weeks.
5.3.3. Oral poliovirus vaccine take
Shedding  of  ≥1  Sabin  serotype  was  observed  in  184/341  (54%)  individuals  in  the 
enteropathogen  subset  with  eligible  10-week  samples ,  while  shedding  of  type  3  Sabin 30
viruses was observed in 79/341 (23%).  Among shedders of ≥1 serotype,  Sabin viruses of 
types 1, 2, and 3 were observed in 69 (38%), 110 (60%), and 79 (43%) individuals, respectively 
(Figure 5.3A). The proportion of infants shedding Sabin viruses of serotypes 1 and 2 at 10 
weeks of age did not differ according to type 3 Sabin virus shedding status (χ2, P values 
>0.05; Figure 5.3B).
5.3.4. Association between concurrent enteropathogens and vaccine take
Eligible 6-week TAC assays were available for 333/341 (98%) infants included in the 
analysis  of  OPV  take.  In  line  with  the  results  observed  for  vaccine  immunogenicity, 
individuals who failed to shed ≥1 Sabin serotype were more likely than shedders to harbour 
≥1 bacterial pathogen (excluding EAEC) in pre-vaccination samples (43/155 [28%] vs 25/178 
[14%];  χ2,  P  =  0.002;  Figure 5.4).  This  discrepancy was individually  significant  for  EPEC 
(95/155 [14%] vs 5/178 [3%];  χ2,  FDR-corrected P = 0.002)  and was still  apparent across 
bacterial pathogens when EAEC was included (22/155 [61%] vs 90/178 [51%]; χ2, P = 0.049). 
We observed no significant differences in the prevalence of viral pathogens (including Sabin 
serotypes  and  NPEVs;  Figure  5.4E)  or  eukaryotes  among  6-week  samples  according  to 
shedding  status.  However,  mixed  infections  were  more  common  in  non-shedders  than 
 As noted in Chapter  4,  the detection of  Sabin viruses was not  performed for  two infants  with 30
enterovirus-positive 10-week TAC assays. These infants were excluded from analyses of OPV take.
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Figure 5.3. Shedding of Sabin serotypes at 10 weeks of age. (A) Prevalence of Sabin virus shedding 
by serotype at 10 weeks of age among shedders of ≥1 serotype (n = 184). (B) Prevalence of Sabin 
virus shedding according to type 3 virus shedding status. *** P <0.0005. Abbreviation: w, weeks.
shedders (39/155 [25%] vs 23/178 [13%]; χ2, P = 0.004; Figure 5.4C) and the total number of 
pathogens was greater in these individuals (1.0 ± 1.0 [mean ± s.d.] vs 0.7 ± 0.8; Wilcoxon’s 
rank sum, P = 0.008). At 10 weeks of age (i.e., concurrent with the measurement of Sabin 
viruses), non-shedders continued to harbour a greater burden of enteropathogens (including 
an increased prevalence of viral infections [excluding enterovirus] that was not apparent at 6 
weeks  of  age;  Figures  5.4B  and  5.4D).  However,  the  discrepancy  in  bacterial  infection 
prevalence  was  no  longer  significant  at  this  timepoint  (Figure  5.4B).  Comparisons  of 
prevalence  and  abundance  for  individual  TAC  targets  according  to  shedding  status  are 
summarised in Table 5.3.
When  analyses  were  restricted  to  type  3  Sabin  viruses,  we  observed  no  significant 
association in the prevalence of bacterial, viral, or eukaryotic infections at 6 weeks of age 
according to shedding status (Figure 5.5), although a borderline-significant increase in the 
likelihood of  harbouring  ≥1  bacterial  pathogen  (excluding  EAEC)  was  observed in  non-
shedders compared with shedders (58/256 [23%] vs 10/77 [13%]; χ2, P = 0.065). Shedders 
were more likely than non-shedders to harbour type 2 Sabin viruses at 6 weeks of age (39/77 
[51%] vs 95/256 [37%]; χ2, P = 0.034; Figure 5.5E), and were less likely to be infected with 
type 3 Sabin viruses (4/77 [5%] vs 35/256 [14%]; Fisher’s test, P = 0.044). At 10 weeks of age, 
we  observed  no  significant  discrepancies  in  pathogen  burden  (aside  from  an  elevated 
prevalence of enteroviruses) according to shedding status (Figures 5.5B and 5.5D). Moreover, 
aside from a decreased abundance of enteroviruses at 10 weeks of age among infants who 
failed to shed type 3 Sabin virus (Ct, 26.8 ± 2.8 vs 30.1 ± 4.5 in shedders and non-shedders, 
respectively;  Wilcoxon’s  rank  sum,  FDR-corrected  P  <0.001),  we  observed  no  significant 
difference  in  the  abundance  of  TAC targets  at  either  6  or  10  weeks  of  age  according to 
serotype 3 shedding status (FDR-corrected P values >0.05; data not shown).
The proportion of infants with diarrhoea in the week preceding the 6-week OPV dose 
did not differ significantly according to the shedding of Sabin viruses (7/184 [4%] vs 4/157 
[3%] in shedders and non-shedders of ≥1 serotype, respectively, and 2/79 [3%] vs 9/262 [3%] 
in shedders and non-shedders of serotype 3, respectively; Fisher’s test, P values >0.05).
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A
B
C                                               D                                               E
Figure 5.4. Association between concurrent pathogens and dose 1 oral poliovirus vaccine take. 
Pathogen prevalence is  displayed for samples collected at (A) 6 weeks and (B) 10 weeks of age 
according to the shedding of ≥1 Sabin serotype at 10 weeks of age. Pathogens present in at least 1% 
of the study population are included. (C, D) The number of pathogens and prevalence of mixed 
infections  are  displayed  at  (C)  6  weeks  and  (D)  10  weeks  of  age.  Mean  pathogen  counts  are 
indicated  by  dotted  lines.  Enteroviruses  were  excluded  from  these  analyses.  (E)  Prevalence  of 
enterovirus subgroups at 6 weeks of age according to the shedding of ≥1 Sabin serotype 4 weeks 
later. § comparison of enterovirus prevalence among infants negative for all Sabin serotypes; * P 
<0.05; ** P <0.005; *** P <0.0005. Abbreviations: Bac, bacteria; EAEC, enteroaggregative Escherichia 
coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; Euk, eukaryote; EV, enterovirus; 
NPEV, non-polio enterovirus; Vir, virus; w, weeks.
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A
Figure 5.5. Association between concurrent pathogens and dose 1 take of type 3 Sabin viruses. 
Pathogen prevalence is  displayed for samples collected at (A) 6 weeks and (B) 10 weeks of age 
according  to  the  shedding  of  type  3  Sabin  viruses  at  10  weeks  of  age.  (C,  D)  The  number  of 
pathogens and prevalence of mixed infections are displayed at (C) 6 weeks and (D) 10 weeks of age. 
Mean  pathogen  counts  are  indicated  by  dotted  lines.  Enteroviruses  were  excluded  from  these 
analyses. (E) Prevalence of enterovirus subgroups at 6 weeks of age according to the shedding of 
type 3 Sabin viruses 4 weeks later. § comparison of enterovirus prevalence among infants negative 
for all  Sabin serotypes; * P  <0.05; ** P  <0.005; *** P <0.0005. Abbreviations: Bac, bacteria; EAEC, 
enteroaggregative Escherichia coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; Euk, 
eukaryote; EV, enterovirus; NPEV, non-polio enterovirus; Vir, virus; w, weeks.
5.3.5. Attributable fraction of vaccine non-response associated with measured enteropathogens
If we assume our study population to be representative of the 103 non-responders and 
448 responders included in the trial as a whole, our data are consistent with a per-dose type 3 
poliovirus seroconversion rate  of  61.6% among uninfected individuals  and 48.0% among 
individuals  infected  with  ≥1  enteropathogen  (excluding  EAEC  and  enterovirus).  In  a 
population experiencing a 30% chance of infection at the time of OPV delivery (the estimated 
prevalence  of  infections  at  6  weeks  of  age  in  this  study  population),  this  disparity  in 
immunogenicity  would  result  in  9.5%  of  failed  type  3  poliovirus  seroconversions  being 
attributable to concurrent infection per OPV dose. The corresponding proportion would rise 
to 26.0% after three doses.  At an infection rate of  50%, the PAF of vaccine non-response 
associated with concurrent infection would increase to 14.9% per OPV dose and 38.5% after 
three doses (Figure 5.6).
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Figure  5.6.  Population  attributable  fraction  of  oral  poliovirus  vaccine  failure  associated  with 
concurrent infections. (A) Estimated per-dose seroconversion rates in infected versus uninfected 
individuals  in  this  study population.  (B)  PAF of  failed type 3  poliovirus  seroconversions under 
different burdens of infection. Abbreviations: PAF, population attributable fraction; tOPV, trivalent 
oral poliovirus vaccine.
A             B
5.3.6. Association between bacterial microbiota composition and oral poliovirus vaccine outcome
i. Alpha diversity
Among the 168 per-protocol infants included in the 16S rRNA gene sequencing subset, 
136 (81%) seroconverted to type 3 poliovirus, 99 (59%) shed ≥1 Sabin virus of any serotype at 
10 weeks of age, and 41 (24%) shed type 3 Sabin virus at 10 weeks of age . The baseline 31
composition of the bacterial microbiota in these infants is described above (section 4.4.5). 
Comparisons of microbiota diversity according to OPV outcome are summarised in Table 5.4. 
In contrast to the results observed for rotavirus vaccine, type 3 poliovirus seroconversion 
was associated with a modest but significant decrease in the number of OTUs present at the 
time of vaccination, although this discrepancy was only apparent at 6 weeks of age (linear 
regression, P values 0.005 and 0.688 for 6- and 10-week comparisons, respectively; Figure 
5.7). Similarly, OTU count was negatively correlated with the take of Sabin viruses following 
the 6-week dose of tOPV – a result that was significant when comparing infants who shed ≥1 
Sabin serotype at 10 weeks of age with those who did not (Table 5.4). Comparisons of OTU 
count  within  the  phylum  Proteobacteria  according  to  OPV  outcome  were  generally  not 
significant (Table 5.4), although the diversity of this phylum at 6 weeks of age was negatively 
correlated with the subsequent shedding of type 3 Sabin viruses (linear regression, P = 0.011). 
No  significant  differences  in  Shannon  index  were  observed  according  to  either 
seroconversion status or OPV take (Table 5.4).
ii. Beta diversity 
No significant clustering of bacterial community composition was evident according to 
OPV outcome (seroconversion or take) based on unweighted or weighted Unifrac distances 
(adonis,  P  values  >0.05;  Table  5.5;  Figure  5.8).  Similarly,  no  significant  difference  in 
microbiota community turnover (as inferred by the Unifrac distances between 6- and 10- 
week samples of each individual) were observed according to serological response to OPV, 
shedding of type 3 Sabin viruses, or shedding of ≥1 Sabin serotype (Wilcoxon’s rank sum, P 
values >0.05; data not shown). 
 Detection of Sabin serotypes was not performed for one individual in the microbiota subset who 31
was positive for enterovirus (via TAC assay) at 10 weeks of age. Accordingly, the analyses of OPV take 
in this section include 167 per-protocol infants.
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Table 5.4. Summary of alpha diversity analyses.
Comparison
Number of OTUs Number of OTUs(Proteobacteria) Shannon index
Age 
(w) Na Nb
Effect 
Size SE P
Effect 
Size SE P
Effect 
Size SE P
PV3 seroconversion 6 136 32 -3.763 1.314 0.005 -0.537 0.393 0.173 -0.098 0.117 0.402
10 136 32 -0.526 1.310 0.688 -0.072 0.397 0.856 -0.023 0.104 0.824
Dose 1 OPV take 
(≥1 Sabin)
6 99 68 -2.729 1.057 0.011 -0.238 0.316 0.453 -0.173 0.093 0.064
10 99 68 0.264 1.045 0.801 -0.202 0.318 0.527 -0.044 0.084 0.601
Dose 1 OPV take 
(Sabin 3)
6 41 126 -2.157 1.219 0.079 -0.846 0.355 0.018 -0.126 0.107 0.239
10 41 126 0.556 1.197 0.643 -0.064 0.365 0.861 -0.074 0.096 0.443
Sensitivity analyses
PV3 seroconversion 
(≥1:256 vs <1:8, 
sero- at baseline)
6 39 13 -4.265 2.285 0.068 - - - -0.073 0.197 0.712
10 39 13 -3.131 1.927 0.111 - - - -0.041 0.166 0.804
PV3 seroconversion 
(RV1 responders)
6 73 12 -4.420 2.031 0.032 - - - -0.204 0.168 0.229
10 73 12 -2.301 2.119 0.281 - - - -0.297 0.175 0.094
PV3 seroconversion 
(RV1 non-
responders)
6 63 20 -3.437 1.790 0.058 - - - -0.051 0.167 0.760
10 63 20 0.839 1.687 0.620 - - - 0.155 0.126 0.222
PV3 seroconversion 
(sero- at baseline)
6 72 13 -5.603 2.194 0.013 - - - -0.176 0.188 0.350
10 72 13 -3.752 2.151 0.085 - - - -0.104 0.169 0.538
The impact of each factor on the specified measure of alpha diversity was assessed via linear regression, with 
MiSeq run included as a covariate. Abbreviations: OTU, 97%-identity operational taxonomic unit; OPV, oral 
poliovirus vaccine; PV3, type 3 poliovirus; RV1, Rotarix; SE, standard error; sero-, seronegative; w, weeks.
a Number of responders/shedders.
b Number of non-responders/non-shedders.
Figure 5.7. Association between microbiota diversity and oral poliovirus vaccine immunogenicity. 
(A) Number of OTUs, (B) OTU count within the phylum Proteobacteria, and (C) Shannon index 
according  to  type  3  poliovirus  seroconversion  status.  Mean  values  (±  s.d.)  are  displayed. 
Proteobacteria-specific  OTU  counts  and  Shannon  index  were  calculated  at  a  depth  of  3,500 
sequences per sample. * P <0.05. Abbreviations: OTU, 97%-identity operational taxonomic unit; PV3, 
type 3 poliovirus; w, weeks.
A            B  C 
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Table 5.5. Summary of beta diversity analyses.
Comparison Age (w)
Unweighted Unifrac Weighted Unifrac
R2 P R2 P
PV3 seroconversion 6 0.007 0.213 0.009 0.173
10 0.004 0.589 0.001 0.941
Dose 1 OPV take (≥1 Sabin) 6 0.007 0.172 0.005 0.470
10 0.005 0.611 0.009 0.202
Dose 1 OPV take (Sabin 3) 6 0.007 0.289 0.003 0.636
10 0.005 0.696 0.005 0.408
Sensitivity analyses
PV3 seroconversion 
(≥1:256 vs <1:8, sero- at baseline)
6 0.017 0.712 0.029 0.202
10 0.019 0.537 0.010 0.686
PV3 seroconversion  
(RV1 responders)
6 0.018 0.035 0.020 0.163
10 0.014 0.229 0.010 0.404
PV3 seroconversion  
(RV1 non-responders)
6 0.014 0.264 0.007 0.630
10 0.012 0.426 0.002 0.915
PV3 seroconversion 
(sero- at baseline)
6 0.012 0.467 0.006 0.678
10 0.013 0.296 0.006 0.629
See Table 5.4 for details regarding the number of infants included in each comparison. The impact of 
each factor on the specified measure of beta diversity was assessed using the function adonis in the 
R package vegan; 9,999 permutations were included in each comparison. Abbreviations: OPV, oral 
poliovirus vaccine; PV3, type 3 poliovirus; RV1, Rotarix; sero-, seronegative; w, weeks.
A     B                   C 
Figure  5.8.  Clustering  of  samples  according  to  oral  poliovirus  vaccine  response.  Unweighted 
Unifrac distances between samples, visualised via principal coordinates analysis, are displayed at 
(A) 6 weeks and (B) 10 weeks according to seroconversion status, and (C) according to OPV take 
following the 6-week vaccine dose (≥1 Sabin serotype). Mean values for principal coordinate 1 are 
indicated by dotted lines. Abbreviations: PC, principal coordinate; PV3, type 3 poliovirus; w, weeks.
iii. Taxon relative abundance
Comparisons of relative taxon abundance according to OPV outcome are summarised in 
Table 5.6. At 6 weeks of age, we observed a significant increase in the relative abundance of 
bacteria  in  the  classes  Betaproteobacteria  and  Epsilonproteobacteria  among  OPV  non-
responders. However, these discrepancies were driven by a small number of individuals – 
Betaproteobacteria were observed in 3/32 (9%) non-responders and 4/134 (3%) responders, 
while Epsilonproteobacteria were observed in 3/32 (9%) and 2/134 (1%) individuals in these 
groups, respectively. We observed no other phylum-, class-, or OTU-level differences in taxon 
relative abundance at 6 or 10 weeks of age according to poliovirus seroconversion status – 
either within the phylum Proteobacteria  or  across all  other taxa.  Similarly,  no significant 
differences in relative abundance were observed at either 6 or 10 weeks of age according to 
the take of Sabin viruses (either of ≥1 Sabin serotype or of type 3) following the 6-week dose 
of tOPV (non-parametric t test, P values >0.05).
iv. Random Forests
Consistent with the lack of significant discrepancies in microbiota composition based on 
relative  taxon  abundance  or  Unifrac  distances,  Random  Forests  failed  to  accurately 
discriminate infants according to type 3 poliovirus seroconversion status or OPV take (Figure 
5.9), and no significant improvement in classification accuracy was observed compared with 
!     s173
Table 5.6. Summary of significant differences in taxon abundance.
Level Taxonomic classification
OTU 
ID
Age 
(w)
Relative 
abundance 
(%) in group 1 
(mean ± s.d.) 
Relative 
abundance 
(%) in group 2 
(mean ± s.d.) P FDR P
PV3 seroconversion Non-responders Responders
C Epsilonproteobacteria 6 0.584 ± 2.026 0.006 ± 0.066 0.006a -
C Betaproteobacteria 6 0.456 ± 2.198 0.006 ± 0.061 0.009a -
C Verrucomicrobiae 6 0.079 ± 0.353 0.001 ± 0.007 0.013 0.050
Dose 1 OPV take (≥1 Sabin)
NS
Dose 1 OPV take (Sabin 3)
NS
Groups were compared using a non-parametric t  test stratified by MiSeq run. Abbreviations: C, 
class;  FDR,  adjusted  by  Benjamini–Hochberg  false  discovery  rate  correction;  NS,  no  significant 
differences; OPV, oral poliovirus vaccine; OTU, 97%-identity operational taxonomic unit; PV3, type 
3 poliovirus; w, weeks.
a P value was not adjusted as the OTU was within the phylum Proteobacteria, hypothesised a priori 
to be associated with vaccine outcome.
null models (P values >0.05). Indeed, across 100 iterations of the Random Forests algorithm 
using OTU relative abundances at either 6 or 10 weeks of age as input variables, the 32 OPV 
non-responders were misclassified as responders in every instance, reflecting the tendency of 
the tree-building algorithm to assign individuals to the majority class when there is a lack of 
discriminatory power in the predictors. The random under-sampling of responders to match 
the number of non-responders during each iteration of the Random Forest algorithm did not 
improve the predictive accuracy of the models (Figure 5.9B). This was also the case when 
under-sampling was used to  generate  balanced datasets  with respect  to  the  shedding of 
serotype 3 Sabin viruses (Figure 5.9E).
v. Multivariate logistic regression
In  the  primary  analyses,  OPV  outcome  was  associated  with  both  the  presence  of 
concurrent bacterial pathogens (excluding EAEC) and the number of OTUs at 6 weeks of age 
(comparisons that were significant when considering either seroconversion or the shedding 
of any Sabin serotype). To determine whether these variables were independently associated 
with  OPV  outcome,  we  compared  the  results  of  univariate  logistic  regression  models 
(including each predictor  separately)  with multivariate  models  including both predictors 
(Table 5.7). Unfortunately, these analyses were constrained by the incomplete overlap of the 
microbiota  subset  with  the  enteropathogen  dataset  –  the  associations  between  bacterial 
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A          B               C                        D                        E
Figure 5.9.  Prediction of oral  poliovirus vaccine response using Random Forests.  Estimates of 
mean accuracy (± s.d.) based on 100 iterations of the Random Forests algorithm are displayed for 
models predicting (A) seroconversion status (full  data),  (B) seroconversion status using balanced 
data (including 32 responders and 32 non-responders in each iteration of the algorithm), (C)  shedding 
of ≥1 Sabin serotype at 10 weeks of age; (D) shedding of serotype 3 Sabin viruses at 10 weeks of age 
(full data), and (E) shedding of serotype 3 Sabin viruses using balanced data (including 41 shedders 
and 41 non-shedders in each iteration of the algorithm).  Dotted lines indicate baseline accuracy, 
wherein all individuals are assigned to the majority class. Abbreviations: PV3, type 3 poliovirus; 
w, weeks.
enteropathogens and OPV outcome were only significant when considering the TAC data as 
a  whole.  However,  the  association  between  OTU  count  and  OPV  outcome  (either 
seroconversion or take) was significant and had a consistent effect size in both univariate and 
multivariate  analyses,  suggesting that  the  link between microbiota  diversity  and vaccine 
response was independent of the presence of bacterial enteropathogens detected via TAC.
5.3.7. Sensitivity analyses
i. Threshold cycle
When Ct values of 30, 25, or 20 (as opposed to 35) were adopted as universal thresholds 
for  pathogen  detection,  a  more  marked  decrease  in  the  odds  of  type  3  poliovirus 
seroconversion was apparent in conjunction with the presence of ≥1 enteropathogen during 
at least one of the 6- or 10-week tOPV doses (Table 5.8). Indeed, in contrast to the primary 
outcome  analysis,  the  decrease  in  vaccine  immunogenicity  among  infected  infants  was 
statistically significant at each of these thresholds.  The discrepancies in the prevalence of 
bacterial  enteropathogens  at  6  and  10  weeks  of  age  according  to  seroconversion  status 
observed in the primary analyses were generally apparent at more stringent cut-offs (Figure 
5.10). Moreover, at a Ct cut-off of 25, non-responders were more likely than responders to 
harbour ≥1 viral pathogen (excluding enterovirus) at 6 weeks of age (6/88 [7%] vs 4/252 
[2%]; Fisher’s test, P = 0.022).
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Table 5.7. Multivariate logistic regression outputs.
Age 
(w)
Univariate Multivariate
Variable N OR (95% CI) P OR (95% CI) P
Model 1: PV3 seroconversion, full data
≥1 Bac (exc. EAEC) 6 340 0.41 (0.23–0.71) 0.001 - -
Model 2: PV3 seroconversion, microbiota subset
≥1 Bac (exc. EAEC) 6 168 0.65 (0.25–1.70) 0.382 0.79 (0.29–2.11) 0.635
OTU count 6 168 0.92 (0.86–0.98) 0.006 0.92 (0.86–0.98) 0.007
Model 3: Dose 1 OPV take (≥1 Sabin), full data
≥1 Bac (exc. EAEC) 6 333 0.43 (0.25–0.74) 0.002 - -
Model 4: Dose 1 OPV take (≥1 Sabin),  microbiota subset
≥1 Bac (exc. EAEC) 6 167 0.53 (0.24–1.21) 0.133 0.61 (0.27–1.41) 0.250
OTU count 6 167 0.94 (0.90–0.99) 0.012 0.94 (0.90–0.99) 0.019
ORs signify the change in the relative odds of responding to OPV in conjunction with: (i) the presence 
versus absence of concurrent infection; or (ii) the addition of one OTU. Aside from those listed, no 
other variables were included in the multivariate models. Abbreviations: Bac, bacteria; CI, confidence 
interval;  EAEC,  enteroaggregative  Escherichia  coli;  OR,  odds  ratio;  OTU,  97%-identity  operational 
taxonomic unit; PV3, type 3 poliovirus; w, weeks.
ii. Antibody titre
Among per-protocol infants in the enteropathogen survey who lacked type 3 poliovirus 
antibodies at enrolment (n = 104), 64 achieved a post-vaccination titre of ≥1:256. When these 
‘robust responders’ were compared with infants who failed to seroconvert (and were also 
seronegative at baseline),  the effect size of the primary outcome was consistent with that 
observed using standard seroconversion criteria  (Table  5.8),  albeit  with broader  CIs.  The 
increased prevalence of bacterial  pathogens,  mixed infections,  and infections of any kind 
(excluding enterovirus and EAEC) among non-responders observed in the primary analyses 
were still apparent (data not shown), and the scale of the discrepancies were comparable to 
those observed using standard seroconversion criteria. Comparisons of alpha diversity and 
beta  diversity  were  similarly  unchanged  when  comparing  robust  responders  with  non-
responders (Tables 5.4 and 5.5).
iii. Stratification by rotavirus seroconversion status
To  account  for  the  potential  introduction  of  bias  via  the  enrichment  of  our  study 
population with Rotarix responders, we examined the impact of stratifying the analysis by 
rotavirus seroconversion status. Irrespective of rotavirus vaccine outcome, the presence of ≥1 
enteropathogen at either 6 or 10 weeks of age was associated with a reduction in the odds of 
type  3  poliovirus  seroconversion,  albeit  non-significant  (Table  5.8).  Dose-specific 
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Table 5.8. Summary of sensitivity analyses.
Proportion with ≥1 pathogen at 6 or 10 weeks, 
n/N (%)
Sensitivity analysis Responders Non-responders OR (95% CI)
Primary outcome 120/250 (48.0) 51/85  (60.0) 0.62 (0.37–1.01)
Ct 30 71/250 (28.4) 37/85 (43.5) 0.51 (0.31–0.86)
Ct 25 39/250 (15.6) 22/85 (25.9) 0.53 (0.29–0.96)
Ct 20 6/250 (2.4) 9/85 (10.6) 0.21 (0.07–0.60)
≥1:256 vs <1:8, sero- 31/64 (48.4) 22/38 (57.9) 0.68 (0.30–1.53)
RV1 responders 66/131 (50.4) 17/24 (70.8) 0.42 (0.16–1.08)
RV1 non-responders 54/119 (45.4) 34/61 (55.7) 0.66 (0.35–1.23)
MS2+ 95/202 (47.0) 40/72 (55.6) 0.71 (0.41–1.22)
sero- 63/139 (45.3) 22/38 (57.9) 0.60 (0.29–1.25)
Abbreviations:  CI,  confidence interval;  Ct,  threshold cycle;  sero-,  seronegative at baseline;  MS2+, 
analysis restricted to infants with MS2-positive samples at 6 and 10 weeks of age; OR, odds ratio; 
RV1, Rotarix.
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Figure 5.10. Impact of threshold cycle on the association between concurrent pathogens and oral 
poliovirus vaccine immunogenicity. The proportion of infants infected with the specified pathogen 
or pathogen group at (A) 6 weeks, (B) 10 weeks, and (C) both timepoints is displayed. * P <0.05; ** P 
<0.005. Abbreviations: Ct, threshold cycle; EAEC, enteroaggregative Escherichia coli; EV, enterovirus; 
PV3, type 3 poliovirus.
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discrepancies in pathogen burden were also robust to Rotarix outcome. In particular, at 6 
weeks of age, the increased prevalence of bacterial infections among infants who failed to 
seroconvert to type 3 poliovirus was consistent across Rotarix responders (12/24 [50%] vs 
28/132 [21%]; χ2, P = 0.003) and non-responders (17/64 [27%] vs 14/120 [12%]; χ2, P = 0.010). 
Other  discrepancies  observed  in  the  primary  analyses  were  generally  conserved  across 
Rotarix  responders  and  non-responders,  although  tests  were  not  always  statistically 
significant within these stratified comparisons (data not shown). Comparisons of alpha and 
beta diversity were largely unaffected in this sensitivity analysis (Tables 5.4 and 5.5).
iv. Treatment group interactions
In the primary analysis, we observed a borderline-significant decrease in the odds of 
poliovirus seroconversion when ≥1 concurrent infection was present during at least one dose 
of tOPV (Table 5.8).  When we added interaction terms between enteropathogen infection 
status (presence vs absence of ≥1 concurrent infection at 6 or 10 weeks of age) and either zinc 
supplementation (zinc vs no zinc), probiotic supplementation (probiotics vs no probiotics), or 
study arm, no significant interactions were observed (data not shown).
v. Other sensitivity analyses
Associations between enteropathogen infection and type 3  poliovirus  seroconversion 
status were largely unchanged by the exclusion of samples lacking MS2 (Table 5.8). Dose-
specific  comparisons  of  pathogen prevalence  were  generally  consistent  with  the  primary 
analyses,  though  some  significant  discrepancies  became  borderline-significant  in  the 
sensitivity  analysis  and  vice  versa  (data  not  shown).  Similarly,  the  negative  correlation 
between  concurrent  enteropathogens  and  seroconversion  was  still  apparent  when 
individuals with type 3 poliovirus antibodies at enrolment (6 weeks of age) were excluded 
(such antibodies were observed in 264/551 [48%] infants in this study population). Although 
the reduction in the odds of seroconversion among infants infected during at least one OPV 
dose was not significant (Table 5.8),  non-responders were more likely than responders to 
harbour ≥1 enteropathogen (excluding EAEC and enterovirus) at both doses (11/38 [29%] vs 
16/139 [12%]; χ2, P = 0.008) – a discrepancy primarily attributable to an increased prevalence 
of bacterial infection (excluding EAEC) in these infants at 6 weeks (14/39 [36%] vs 19/140 
[14%];  χ2,  P  =  0.001),  10  weeks  (14/38  [36%]  vs  27/141  [19%];  χ2,  P  =  0.027),  or  both 
timepoints (10/38 [26%] vs 9/139 [6%]; χ2, P <0.001).
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5.4. Discussion
The findings presented above provide clear support for the notion that enteric infections 
have the capacity to inhibit OPV response. During vaccine doses administered at 6 and 10 
weeks of age, a higher burden of enteropathogens was observed in infants who failed to 
respond serologically to type 3 poliovirus, and an increase in the odds of non-response was 
apparent with each additional dose in which ≥1 enteropathogen was present.
A key novelty of this study was the assessment of multiple enteropathogens in each 
sample.  As  highlighted  in  the  systematic  review described  in  Chapter  2,  most  previous 
studies concerning the influence of enteric infections on OPV have focused on the role of 
NPEVs.  By contrast,  we used TACs to  assess  31 putative viral,  bacterial,  and eukaryotic 
infections, thus providing a comprehensive view of the pathogen burden present within each 
sample. This approach revealed a greater prevalence of mixed infections among OPV non-
responders, while also implicating concurrent bacterial infections as a potential determinant 
of oral vaccine response in early infancy – at both 6 and 10 weeks of age, non-responders 
were significantly more likely than responders to harbour ≥1 bacterial infection (excluding 
EAEC), while bacterial pathogens were negatively correlated with the replication of Sabin 
viruses administered at 6 weeks of age. Overall, our findings were consistent with per-dose 
seroconversion rates for type 3 poliovirus of 48% and 62% among infected and uninfected 
infants,  respectively  –  a  discrepancy  that  would  result  in  approximately  10%  of  failed 
seroconversions per dose of tOPV being attributable to concurrent enteropathogens at the 
infection rates observed in this study population.
A challenge with the use of PCR-based pathogen detection is the effective distinction of 
clinically  relevant  infections  from  low-level  infections  of  equivocal  significance.  The 
sensitivity of TACs has been shown to markedly exceed that of conventional enteropathogen 
assays (such as culture, antigen detection, and microscopy), particularly for bacterial targets 
(Liu et al, 2013). When TAC assays were used to compare pathogen burden in diarrhoeal 
versus pre-diarrhoeal stool samples, Platts-Mills et al (2014) observed significant associations 
between infection and disease only when pathogen quantity was considered. In the present 
study,  the  abundance  of  individual  enteropathogens  tended  to  be  comparable  between 
responders and non-responders. However, we also performed a semi-quantitative sensitivity 
analysis  in  which  more  stringent  Ct  cut-offs  were  adopted  for  pathogen  detection.  This 
revealed a more marked decrease in the odds of poliovirus seroconversion in conjunction 
with the presence of high copy-number pathogen infections. Moreover, the elevated burden 
of  enteropathogens among non-responders was no longer contingent on the exclusion of 
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EAEC when lower Ct cut-offs were applied. Together, these findings suggest that infections 
of greater severity may have a more pronounced inhibitory effect on OPV outcome.
Although bacterial enteropathogens have previously been linked with a reduction in the 
titre of antibodies induced by OPV (Maldonado et al, 1997; Taniuchi et al, 2016), this is the 
first  study to document a significant decrease in seroconversion rate in conjunction with 
bacterial infections during early infancy. Moreover, since the majority of infections in this 
study  occurred  in  the  absence  of  diarrhoea,  our  findings  implicate  subclinical  bacterial 
infections as a potential source of interference with OPV. The inhibitory effect of individual 
enteropathogens  was  generally  not  significant  after  correcting  for  multiple  comparisons. 
However,  whether  considering  seroconversion  or  vaccine  take,  ETEC,  EPEC,  and 
Campylobacter were consistently more prevalent among OPV non-responders, resulting in a 
significant interference effect when combining across bacterial enteropathogens. Given that 
the  mechanisms  of  pathogenesis  vary  widely  across  these  infections,  their  consistent 
influence on OPV (if we assume a causal relationship) is somewhat surprising. For instance, 
whereas ETEC adheres to the intestinal mucosa and elicits symptoms via the release of heat-
labile and heat-stable enterotoxins, EPEC attaches to the intestinal epithelium and induces 
characteristic  lesions  (termed  ‘attaching  and  effacing  lesions’)  via  the  destruction  of 
microvilli and the formation of dense plaques of actin (Hodges and Gill, 2010). In spite of 
their  different  modes  of  attack,  each  of  these  pathogens  has  potent  immunomodulatory 
properties  (Bahrami  et  al,  2011),  and it  is  certainly  plausible  that  they might  upregulate 
common innate immune mediators (e.g.,  type I or type III  interferons [Bierne et al,  2012; 
Long et al, 2014]) that inhibit the replication of vaccine polioviruses, even in the absence of 
overt diarrhoeal symptoms.
It is also possible, however, that the observed associations might arise in the absence of a 
direct  inhibitory  effect  of  bacterial  enteropathogens  on  OPV  response.  As  noted  above 
(section 2.4),  malnutrition,  EE,  and other  putative  risk  factors  for  OPV non-response are 
likely to be correlated with (or indeed caused by) early enteropathogen exposure, and it may 
well be these factors that are responsible for OPV non-response in this study population. This 
scenario would undermine estimates of  the fraction of  OPV non-response attributable to 
enteropathogens given that these assume a causal relationship to exist between concurrent 
infections and vaccine failure.
The elevated prevalence of type 2 Sabin viruses among responders at 6 weeks of age –
evident when considering either seroconversion or the take of type 3 Sabin viruses – is in 
keeping with previous studies of sequential tOPV administration. In particular, Morimoto 
!     s180
(2001) elegantly demonstrated that Sabin viruses of serotypes 1 and 2 tend to replicate at the 
expense of serotype 3 following primary exposure to tOPV. The ensuing serotype-specific 
mucosal immune response – likely mediated by secretory IgA – prevents the replication of 
these serotypes on subsequent tOPV exposure, enabling type 3 Sabin viruses to replicate. 
Similarly, in the present study, the observation of type 2 Sabin viruses at 6 weeks of age is 
likely to be indicative of replication following the birth dose of tOPV, or possibly community 
exposure. 
We cannot rule out the possibility that the birth dose of tOPV induced seroconversion to 
type  3  poliovirus  in  a  portion  of  infants  in  this  study  (though  a  recent  study  in  India 
documented  type  3  poliovirus  seroconversion  in  just  4%  of  infants  following  the 
administration of tOPV at birth [Sutter et al, 2010]). In such infants, one would not expect the 
antibody titre to decay between 6 and 14 weeks of age (as is the case for passively acquired 
maternal  antibodies),  thereby  invalidating  the  criteria  we  used  to  define  poliovirus 
seroconversion.  However,  when  we  excluded  infants  with  type  3  poliovirus-specific 
antibodies at baseline (encompassing both maternal antibodies as well as those induced by 
tOPV  at  birth),  the  discrepancies  in  pathogen  burden  between  responders  and  non-
responders were still apparent. Thus, prior tOPV exposure does not appear to have impacted 
the primary outcomes of this study.
In contrast to the results of the systematic and meta-analysis reported above, we did not 
observe a significant inhibitory effect of NPEVs on OPV response in this study population. 
However,  this  may  simply  reflect  a  lack  of  power  to  detect  such  an  effect  given  the 
limitations in the methods of NPEV detection adopted (as discussed in detail in section 4.5). 
These  limitations  notwithstanding,  at  both  6  and  10  weeks  of  age,  NPEVs  were  more 
common among infants who failed to seroconvert to type 3 poliovirus, and it is possible that 
a significant interference effect (and a greater PAF of vaccine non-response associated with 
concurrent infection) would have been observed had a more specific diagnostic assay for 
these viruses been adopted. The interaction between NPEVs and OPV response is one that 
we shall return to in the following chapter.
What are the implications of these analyses for the conceptual model linking OPV and 
oral  rotavirus vaccine outcome outlined in the previous chapter  (Figure 4.18)?  To briefly 
recap,  we  hypothesised  that  the  increased  burden  of  bacterial  enteropathogens  among 
Rotarix responders might reflect an inhibitory effect of these pathogens on OPV response, 
and a consequent reduction in interference between vaccine polioviruses and Rotarix. The 
findings presented in this chapter highlight an association between bacterial pathogens and 
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OPV response of equal scale but opposite direction to that observed for Rotarix (indeed, 
Figures 4.2A and 5.1A form neat mirror images), and are thus consistent with the proposed 
model.
Once again, we did not observe any strong associations between the composition of the 
bacterial microbiota and oral vaccine outcome: no significant shift in community structure 
was evident based on unweighted or weighted Unifrac distances; Random Forest models 
failed to accurately discriminate infants according to seroconversion status or vaccine take; 
and aside from a handful of class-level associations driven by a small number of individuals, 
no significant discrepancies in taxon relative abundance were observed with respect to OPV 
response. However, contrary to the hypothesised association between microbiota diversity 
and oral vaccine outcome, the number of OTUs present at 6 weeks of age was negatively 
correlated  with  OPV  response  (either  seroconversion  or  take)  –  a  result  that  is  (again) 
contradictory  to  the  relationship  observed  for  Rotarix.  Notably,  the  negative  association 
between OTU count and poliovirus seroconversion remained significant when this variable 
was  included  alongside  bacterial  pathogen  infection  status  during  multivariate  logistic 
regression. Although we cannot rule out confounding of OTU count with an alternative risk 
factor for vaccine failure, these findings raise the possibility that an increase in microbiota 
diversity may inhibit the immunogenicity of vaccine polioviruses.
As  noted  in  the  previous  chapter,  the  restricted  geographic  and  sociodemographic 
diversity of infants in this study population may have undermined our capacity to identify 
compositional differences in the bacterial microbiota that contribute to the discrepancies in 
oral vaccine immunogenicity between low- and high-income settings. It is also important to 
recognise that the microbiota subset was selected so as to balance the number of Rotarix 
responders and non-responders, and thus included just 32 infants who failed to seroconvert 
to type 3 poliovirus after two doses. A more in-depth analysis of the potential impact of the 
bacterial microbiota on OPV response will be described in the following chapter.
In contrast to the poor response observed for oral rotavirus vaccine, the seroconversion 
rate for type 3 poliovirus in this study population – at 81% after two tOPV doses – was high. 
Patriarca et al (1991) reported an average seroconversion rate for this serotype of 70% (range, 
40–100%)  after  three  doses  of  tOPV  among  studies  conducted  in  developing  countries, 
consistent with an average per-dose response rate of <35%. The extent to which our findings 
are representative of factors influencing OPV immunogenicity in other tropical, low-income 
settings  is  therefore  uncertain.  Nonetheless,  we estimated the  PAF of  OPV non-response 
associated with different burdens of enteric disease. Among infants in Vellore, our results 
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suggest that upwards of 25% of failed type 3 poliovirus seroconversions after three tOPV 
doses may be attributable to the enteropathogens measured in this study. In Afghanistan and 
Pakistan, where poliovirus remains endemic, the burden of enteropathogens in early infancy 
is likely to exceed that observed in the present study, as evidenced by the recent MAL-ED 
cohort study (Platts-Mills et al, 2015). At a per-dose infection rate of 50%, we estimate the 
PAF of OPV non-response associated with enteropathogens to be approximately 40% after 
three doses.
5.4.1. Conclusions
Overall, this study supports the link between concurrent enteric infections and impaired 
response to OPV, and emphasises the key role of enteropathogens as a barrier to the optimal 
use  of  OPV  in  regions  where  poliovirus  transmission  continues.  By  examining  multiple 
bacterial, viral, and eukaryotic infections, our findings are among the first to demonstrate 
this association in the context of the diverse array of pathogens to which infants living in 
tropical, low-income countries are exposed.  
!     s183
Chapter 6: Influence of the intestinal microbiota on oral poliovirus vaccine 
response among infants in south India treated with azithromycin or placebo in a 
randomised controlled trial
6.1. Background
Before continuing with the final research chapter of this thesis, it is worth briefly taking 
stock of where we stand. So far, I  have presented findings from a systematic review and 
meta-analysis that supported the inhibitory effect of concurrent enteropathogens – including 
NPEVs and diarrhoea – on the immunogenicity and take of OPV. In the previous chapter, we 
extended these  findings  by testing for  a  diverse  array of  bacterial,  viral,  and eukaryotic 
enteropathogens among infants in south India who received tOPV at 6 and 10 weeks of age. 
In doing so, we observed a marked increase in enteropathogen burden among OPV non-
responders  driven  primarily  by  asymptomatic  bacterial  infections.  Overall,  our  findings 
suggested that approximately 10% of failed type 3 poliovirus seroconversions per dose of 
tOPV might be attributable to enteric co-infections in this study population. 
Findings with regard to Rotarix, which we examined in the same group of infants, were 
more ambiguous. I do not intend to recap them here, but suffice it to say that we did not 
observe a significant inhibitory effect of enteropathogens on the immunogenicity or take of 
this vaccine, nor did we observe any marked discrepancies in the taxonomic composition of 
the 16S rRNA microbiota according to vaccine outcome. Although additional exploration of 
the factors that influence oral rotavirus vaccine response is certainly warranted, such work is 
beyond the scope of the present thesis. Our attention in the remaining pages lies solely with 
OPV.
6.1.1. The EVI trial
On  5th  August  2014,  enrolment  commenced  for  the  Enteric  infection  and  Vaccine 
Immunogenicity  (EVI)  study.  Conducted across  14  blocks  in  Vellore,  this  trial  set  out  to 
examine  the  impact  of  a  3-day  course  of  oral  azithromycin  on  the  immune  response 
following  a  subsequent  dose  of  mOPV3  among  6–11  month-old  infants  who  lacked 
immunity  to  type  3  poliovirus.  By  diminishing  the  burden  of  enteropathogens  prior  to 
vaccination, it was hoped that an increase in mOPV3 immunogenicity might be observed in 
azithromycin compared with placebo recipients. The primary outcomes of the EVI trial were 
recently  published  (Grassly  et  al,  2016).  Notably,  while  antibiotic  treatment  significantly 
reduced  the  prevalence  of  bacterial  enteropathogens  and  the  levels  of  several  faecal 
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biomarkers  of  intestinal  inflammation  (including  calprotecin,  myeloperoxidase,  and  α1-
antitrypsin),  it  did not  significantly  impact  OPV immunogenicity  –  among children who 
completed  the  trial  per  protocol,  seroconversion  was  observed  in  175/348  (50%) 
azithromycin recipients and 192/357 (54%) placebo recipients. 
In contrast to the findings presented in the previous chapter, the prevalence of bacterial 
enteropathogens did not differ significantly according to vaccine outcome in the EVI trial, 
suggesting that the determinants of OPV immunogenicity in early infancy may differ from 
those in older children. However, seroconversion was negatively impacted by the presence of 
viral pathogens (particularly enteroviruses, of which the vast majority can be assumed to be 
NPEVs in light of the low prevalence of Sabin polioviruses [<2%] among enterovirus-positive 
samples obtained on the day of vaccination). Immunogenicity was negatively correlated with 
age in this study population (seroconversion was observed in 227/408 [56%] infants aged 6–7 
months and 140/297 [47%] aged 8–11 months; Fisher’s test, P = 0.027). After adjusting for age, 
the  inhibitory  effect  of  viral  pathogen  count  on  the  odds  of  seroconversion  remained 
significant.
6.1.2. Objectives
The samples collected during the EVI study provided us with an opportunity to probe 
further into the relationship between the intestinal  microbiota and oral  vaccine outcome. 
First, by assessing the 16S rRNA microbiota in a subset of trial participants, we sought to 
determine  the  impact  of  azithromycin  on  the  bacterial  microbiota,  and  of  the  bacterial 
microbiota on the immune response to mOPV3. Although the latter was considered in the 
previous chapter, our sequencing data encompassed only 32 infants who failed to respond to 
OPV, and may therefore have lacked sufficient power to detect discrepancies in microbiota 
composition pertinent to vaccine outcome. Furthermore, considering that the gut’s bacterial 
community is in a constant state of maturation for the first 2 years of life (Yatsunenko et al, 
2012;  Subramanian  et  al,  2015),  the  impact  of  microbiota  composition  on  oral  vaccine 
outcome at 6–11 months of age (a window in which OPV is regularly administered during 
SIAs) may well differ from that at 1–2 months.
The second line of enquiry in this chapter concerns the turnover in the gut’s microbial 
residents. Since stool samples were collected on the day of vaccination and 14 days earlier, it 
was possible to assess how changes in pathogen prevalence in the two weeks preceding 
vaccination  impacted  response  to  OPV.  Specifically,  did  novel  enteropathogen  infections 
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inhibit  mOPV3 response to a  greater  extent  than persistent  infections (e.g.,  owing to the 
transient up-regulation of innate immune effectors [Juhela et al, 1999])? And how did the 
recent resolution of an enteric infection influence vaccine response? 
Finally, we sought to make inroads into the challenge of integrating different forms of 
data when assessing the determinants of oral vaccine immunogenicity. The data collected as 
part of the EVI trial are diverse and extensive, encompassing anthropometric measurements, 
sociodemographic variables, antibiotic usage, enteropathogen prevalence, and (following the 
additional assays described below) the composition of the bacterial microbiota. Using the 
Random Forest machine-learning techniques introduced in Chapter 3, we assessed whether 
combining these different forms of data enhanced our capacity to predict mOPV3 outcome.
6.1.3. Hypotheses
i) Treatment with azithromycin depletes the diversity of the bacterial microbiota;
ii) mOPV3 non-responders have a bacterial microbiota composition that is distinct from 
responders, as inferred by discrepancies in alpha diversity, sample clustering based 
on Unifrac distances, and the discriminatory capacity of Random Forest models;
iii) Novel enteropathogen infections inhibit mOPV3 response to a greater extent than 
persistent infections;
iv) Combining  different  modules  of  data  (enteropathogen  prevalence,  16S  rRNA 
microbiota  composition,  anthropometry,  etc.)  increases  the  capacity  of  Random 
Forest models to discriminate infants according to mOPV3 outcome.
6.2. Methods
6.2.1. Study population
A full description of the study design and laboratory methods adopted during the EVI 
trial was recently published by Grassly et al (2016). Briefly, the trial was performed among 
6–11 month-old infants in Vellore.  Individuals were initially screened for the presence of 
serum neutralising antibodies to type 3 poliovirus and considered eligible for the study if 
they  lacked  detectable  antibodies  at  a  dilution  of  1  in  8.  At  enrolment,  infants  were 
randomised 1:1 to receive a 3-day course of azithromycin (a broad-spectrum bacteriostatic 
macrolide antibiotic administered once daily at a dose of 10 mg/kg) or placebo, starting on 
study day 0. Two weeks later (day 14), all participants were given a single dose of mOPV3 
containing  at  least  105.8  median  cell  culture  infective  doses  of  Leon  12a,b  strain  type  3 
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poliovirus. The primary outcome was seroconversion to type 3 poliovirus, defined as the 
detection  of  neutralising  antibodies  at  a  dilution  of  1  in  8  or  higher  in  serum  samples 
collected 3 weeks after immunisation (day 35).  Stool samples collected on days 0 and 14 
(before  treatment  and  immunisation,  respectively)  were  tested  for  the  presence  of 
enteropathogens using TACs (see Table 3.1 for a list of targets). In a subset of individuals, 
including  291  infants  who  completed  the  trial  per  protocol,  biomarkers  of  intestinal 
inflammation (calprotecin, myeloperoxidase, neopterin, and α1-antitrypsin) were tested in 
stool samples collected at enrolment (day 0) and pre-vaccination (day 14). In the same subset, 
shedding of type 3 poliovirus was assessed 7 days after vaccination (day 21) as a measure of 
OPV take. Key features of the EVI trial are summarised in Figure 6.1, and a comparison of 
this study with the zinc/probiotic supplementation trial described in Chapters 4 and 5 is 
provided  in  Table  6.1.  Methods  for  the  extraction  of  nucleic  acids  and  set-up  of  TACs 
followed those described in Chapter 3. However, to place an emphasis on high copy-number 
infections, a Ct value of 30 was adopted as a universal threshold for pathogen detection. For 
consistency with the primary analyses, the same cut-off was applied where relevant in the 
present study. The trial was funded by the Bill & Melinda Gates Foundation.
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Figure 6.1. EVI trial design. Assays of enteropathogen burden and bacterial microbiota composition 
that form the basis of this chapter’s analyses are indicated. Abbreviations: TAC, TaqMan array card; 
mOPV3, monovalent type 3 oral poliovirus vaccine; PV3, type 3 poliovirus.
6.2.2. 16S rRNA gene sequencing
A subset of 120 infants (60 per study arm) out of the first 300 individuals enrolled in the 
study were selected at random for assessment of the bacterial microbiota. For each individual, 
we assessed stool samples collected before treatment (day 0) and pre-vaccination (day 14). We 
also  assessed  samples  collected  from  40  adults  cohabiting  with  trial  participants.  DNA 
extraction,  amplification  of  the  16S  rRNA gene  V4  region,  and  library  preparation  was 
performed as previously described (section 3.3) . Extraction and PCR for infant samples was 32
performed in batches of  24,  with each batch containing the day-0 and -14 samples of  12 
infants.  Individuals  were  randomly  assigned  to  extraction  batches.  All  extractions  were 
blinded with regard to study arm and outcome. For a small  number of samples (18/240 
infant samples and 10/40 adult samples), the initial PCR did not yield sufficient product for 
sequencing (<15 ng/'l), likely due to the presence of PCR inhibitors after DNA extraction 
(Schrader et al, 2012). PCR was repeated for these samples, but with the inclusion of 0.2 'l of 
bovine serum albumin (BSA) in the 25-'l reaction mixture. In all cases, PCR inhibition was 
overcome by the addition of BSA. Pooled amplicons were sequenced in a single MiSeq run 
containing 240 infant samples, 40 adult samples, 12 no-template extraction controls, and one 
no-template  PCR  control.  We  also  sequenced  PCR  products  amplified  from  two  mock 
communities, as described in section 3.4.
 In contrast to the 16S rRNA microbiota analyses described in Chapters 4 and 5, library preparation 32
was conducted in Imperial College London’s Medical School Building at St Mary’s Hospital.
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Table 6.1. Comparison of the zinc/probiotic supplementation trial and EVI trial.
Feature
Zinc/probiotic 
supplementation trial EVI trial
Setting Vellore, India Vellore, India
Age at enrolment 5 weeks 6–11 months
Enrolment criteria (baseline 
antibody titre)
- Negative for type 3 poliovirus 
antibodies
Treatment Zinc and probiotics,  
probiotics, zinc, or placebo; 
daily from 5–11 weeks 
Azithromycin or placebo; 
3-day course starting on 
study day 0
Oral vaccines Rotarix and tOPV at 6 and 10 
weeks
mOPV3 on study day 14
Primary outcome Seroconversion between 6 
and 14 weeks
Seroconversion between 
study days 0 and 35
Measurement of enteropathogens/
16S rRNA microbiota
6 and 10 weeks Study days 0 and 14
Abbreviations: mOPV3, type 3 oral poliovirus vaccine; tOPV, trivalent oral poliovirus vaccine.
Contig assembly, quality filtering, OTU picking, and other sequence processing steps 
followed the methods described above (section 3.3). Since adults accounted for a minority 
(40/280) of the stool DNA samples included in the MiSeq run, we divided the OTU table into 
infant and adult samples before removing OTUs that represented <0.005% of sequences, thus 
reducing the risk of erroneously excluding low-abundance OTUs specific to adult samples. 
These  infant-  and  adult-specific  OTU  tables  were  generated  using  the  Qiime  command 
filter_samples_from_otu_table.py. After filtering by abundance, the OTU tables were merged 
using the command merge_otu_tables.py.
6.2.3. Statistical analysis
i. Bacterial microbiota
After sequence processing, we observed a minimum of 7,708 sequences per sample. All 
analyses were performed at a rarefaction depth of 7,500 sequences per sample. We examined 
the  association  between  16S  rRNA microbiota  composition  and  the  following  variables: 
seroconversion, vaccine take (as inferred by the shedding of type 3 polioviruses 7 days after 
immunisation), study arm, and exposure to non-intervention antibiotics. All analyses of OPV 
outcome and antibiotic exposure were restricted to individuals who completed the study per 
protocol.  Consistent  with  previous  chapters,  our  primary  outcome  was  the  association 
between alpha diversity (OTU count and Shannon index) and oral vaccine outcome . For the 33
assessment of diversity within and between samples, we generated ten separate rarefactions 
at  a  depth  of  7,500  sequences  per  sample  and  calculated  mean  values  for  OTU  count, 
Shannon index,  and between-sample Unifrac distances (unweighted and weighted).  OTU 
count and Shannon index were compared according to OPV outcome and antibiotic exposure 
(as categorical explanatory variables) via linear regression, with age included as a covariate, 
and between infant  and adult  samples using Student’s  t  test.  Unweighted and weighted 
Unifrac  distances  were  visualised  using  principal  coordinates  analysis,  and  cluster 
significance assessed using the adonis function with 9,999 permutations. Age was included 
prior to OPV outcome or antibiotic exposure when implementing adonis, and significance 
determined based on sequential sums of squares.
Once again, we used Unifrac distance between day-0 and -14 samples from each infant 
as a measure of microbiota stability. Clustering of samples by individual was assessed using 
 Owing to the lack of significant discrepancies in Proteobacteria-specific OTU count in the analyses 33
described above, this was no longer included as a separate measure of alpha diversity. 
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adonis, and within- versus between-subject distances were compared using Wilcoxon’s rank 
sum test (wherein between-subject distances comprised the mean Unifrac distance of day-14 
samples obtained from other individuals for a given day-0 sample). Within-subject distances 
were compared according to study arm and OPV outcome using Wilcoxon’s rank sum test.
Phylum-, class-, and OTU-level discrepancies in taxon relative abundance were assessed 
according to OPV outcome and antibiotic  exposure using Wilcoxon’s rank sum test .  To 34
account  for  multiple  comparisons,  P values  were  adjusted  by  Benjamini–Hochberg  FDR 
correction  (applied  separately  at  each  taxonomic  rank  for  a  given  comparison).  OTUs 
associated with study arm or vaccine outcome were visualised using Interactive Tree of Life 
(Letunic and Bork, 2007).
Adult samples were included in this study to provide a population-specific baseline of 
the mature bacterial  microbiota.  For each infant sample,  we calculated the mean Unifrac 
distance  (both  unweighted  and  weighted)  of  the  microbiota  community  from  all  non-
cohabiting adults.  This distance was used as an indicator of relative microbiota maturity 
(‘microbiota  age’),  and  assessed  in  relation  to  study  arm  and  OPV  outcome  via  linear 
regression, with age as a covariate. 
Associations  between  infant  age,  microbiota  diversity  and  age,  and  the  number  of 
enteropathogens (calculated separately for bacteria, viruses, and eukaryotes) were assessed 
in day-0 samples using Spearman’s rank correlation coefficient (ρ). This metric was also used 
to identify OTUs that showed monotonic changes in relative abundance with increasing age 
at  enrolment.  To  assess  whether  multiple  antibiotic  exposures  had  an  additive  effect  on 
microbiota  diversity,  we  compared  day-14  OTU  count  and  Shannon  index  among 
azithromycin  recipients  according  to  exposure  to  any  non-intervention  antibiotic.  The 
potential association between non-intervention antibiotic use and study arm was assessed 
using  the  χ2  test.  All  analyses  were  performed  in  the  programming  language  R,  and 
associations with a P value of <0.05 were considered statistically significant.
ii. Novel, persistent, and resolved infections
To examine how changes in pathogen burden in the 14 days preceding immunisation 
influenced OPV outcome, we classified enteropathogens as absent (not detected on day 0 or 
  This  differs  from the  permutation-based t  test  used to  compare  taxon abundance  in  previous 34
chapters, wherein permutations were stratified by MiSeq run. Since all samples from the EVI trial 
were included in a single run, stratification was not necessary, and the use of Wilcoxon’s rank sum test 
was therefore appropriate (and more computationally efficient).
!     s190
14), resolved (present on day 0, absent on day 14), novel (absent on day 0, present on day 14), 
or persistent (present on days 0 and 14) – hereafter referred to as ‘infection subclasses’. For 
each  enteropathogen  and  pathogen  group  (≥1  virus,  ≥1  virus  excluding  enterovirus,  ≥1 
bacteria, ≥1 bacteria excluding EAEC, and ≥1 eukaryote), the impact of resolved, novel, and 
persistent infections on vaccine outcome (seroconversion or take as categorical dependent 
variables)  was  assessed  via  logistic  regression,  with  age  included  as  a  covariate .  For 35
individual pathogens, we fitted both univariate models (including infection subclasses for 
each enteropathogen in turn) and multivariate models (including infection subclasses for all 
pathogens),  and adjusted the resulting P values via Benjamini–Hochberg FDR correction. 
Aside  from  age,  no  other  variables  were  included  in  the  multivariate  models.  Infection 
subclasses  were  excluded  from  these  analyses  if  they  contained  fewer  than  ten  infants. 
Finally, for viral enteropathogens, we directly compared seroconversion and take according 
to  the  presence  of  novel  versus  persistent  infections  using  the  χ2  test.  If  a  significant 
discrepancy was observed for a given pathogen, we determined whether this was associated 
with a difference in pathogen abundance at day 14 by comparing (using Wilcoxon’s rank sum 
test) the Ct values of the TAC target between infants with novel versus persistent infections.
iii. Random Forests
The Random Forest machine-learning algorithm was used to classify infants according 
to study arm, seroconversion status, and vaccine take using four modules of data: (i) baseline 
characteristics  (demography,  growth,  and antibiotic  usage,  among others);  (ii)  concurrent 
pathogens; (iii) 16S rRNA microbiota composition; and (iv) all of the above. A summary of 
the  variables  included  in  each  module  is  provided  in  Table  6.2.  Classification  accuracy, 
variable importance, and model significance were assessed as described above (section 4.3.4).
iv. Multivariate logistic regression 
To assess whether Shannon index and viral infection status (presence of ≥1 virus on day 
14)  were  independently  associated  with  the  odds  of  OPV  response  (seroconversion  or 
shedding), we compared the effect size and significance of these explanatory variables in 
univariate versus multivariate logistic regression models. Age was included as a covariate in 
all univariate and multivariate models. No other variables were adjusted for.
 During comparisons of pathogen groups, persistent infections encompassed the presence of any 35
infection at days 0 and 14. Thus, the replacement of one pathogen with another (i.e., one resolved 
infection and one novel infection) would be categorised as a persistent infection.
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v. Sensitivity analyses
Sensitivity analyses were carried out in which: (i) comparisons were stratified by study 
arm; (ii) non-responders were compared with individuals who developed post-vaccination 
antibody titres of ≥1:256; (iii) the association between study arm and microbiota composition 
was assessed among infants with no exposure to non-intervention antibiotics; and (iv) the 
association between seroconversion and microbiota composition was assessed among infants 
with no antibiotic exposure (azithromycin or other). In each instance, we compared alpha 
diversity (number of OTUs and Shannon index) and beta diversity (sample clustering based 
on unweighted and weighted Unifrac distances) according to vaccine outcome or study arm 
in pre-vaccination (day-14) samples. Sensitivity analyses (i) and (ii) were also performed for 
comparisons of infection subclasses. Herein, we assessed the influence of resolved, novel, 
and  persistent  infections  with  ≥1  virus,  ≥1  virus  excluding  enterovirus,  ≥1  bacteria,  ≥1 
bacteria excluding EAEC, or ≥1 eukaryote on the odds of seroconversion or vaccine take. If 
fewer than ten individuals lacked infections at days 0 and 14 in a given comparison, resolved 
infections were used as the reference group in logistic regression models.
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Table 6.2. Random Forest input variables.
Module 1: Baseline characteristics
Age (months) on day of vaccination
Date of vaccination
Sex
Religion (Christian/Hindu/Muslim)
Mother’s education (illiterate/primary/middle/secondary/university graduate)
House type (concrete/tiled/thatched)
Weight-for-age Z score
Height-for-age Z score
Currently breastfed (yes/no)
Number of OPV doses received prior to enrolment
Receipt of antibiotics in the month before enrolment (yes/no)
Receipt of non-intervention antibiotics between days 0 and 14 (yes/no)
Concurrent diarrhoea on day 14 (yes/no)
Study arma
Module 2: Concurrent pathogens
Ct values for each TAC target served as input for the models. Targets were excluded if they were 
absent in all individuals. Where pathogens were assessed using multiple targets (see Table 3.1), the 
targets were included as separate predictors. Samples were assigned a value of 35 for a given target 
if no amplification was observed below this threshold.
Module 3: 16S rRNA microbiota
An OTU table comprising 7,500 sequences per sample served as input for the models. OTUs were 
included if they were present in at least 2% of individuals.
Abbreviations:  Ct,  threshold cycle;  OPV,  oral  poliovirus  vaccine;  OTU,  97%-identity  operational 
taxonomic unit; TAC, TaqMan array card.
a Excluded when study arm was the output of the Random Forest models.
6.3. Results
6.3.1. Microbiota at enrolment
We sequenced the 16S rRNA gene V4 region in 240 infant samples and 40 adult samples 
in this study. After contig assembly and quality filtering, we obtained 14,685 ± 2,386 (mean ± 
s.d.)  sequences  per  sample,  spanning  821  97%-identity  OTUs  (of  which  555  [68%]  were 
unique to adult samples). At enrolment, the infant microbiota was characterised by a small 
number of dominant taxa, evident at both genus level (Figure 6.2A) and OTU level (Figure 
6.2B). Whereas the top 20 OTUs among infants had a cumulative mean relative abundance of 
90.2%, the equivalent proportion in adults was 67.8% (Figure 6.2C).
Infant samples were significantly less diverse than adult samples (72.2 ± 14.7 vs 249.8 ± 
57.2 for OTU count and 2.72 ± 0.51 vs 4.59 ± 0.63 for Shannon index; Student’s t test, P values 
<0.001; Figure 6.2D), and clustered separately from adult samples based on unweighted and 
weighted Unifrac  distances  (adonis,  R2  of  0.297 and 0.375 for  unweighted and weighted 
Unifrac,  respectively;  P  values  <0.001;  Figure  6.2E).  With  increasing  age,  we  observed  a 
significant increase in the number of OTUs and Shannon index (Figure 6.2D; Table 6.3), and a 
decrease in Unifrac distance from adult samples (increase in ‘microbiota age’), reflecting a 
shift in composition towards a more ‘adult-like’ microbiota between 6 and 11 months of age 
(Figure 6.2F; Table 6.3) . The highest-ranking age-discriminatory OTUs among infants, as 36
determined by Spearman’s ρ, are summarised in Table 6.4.
A correlation matrix summarising the associations between age, microbiota composition, 
and pathogen burden at enrolment is provided in Table 6.3. Alongside the patterns described 
above, this matrix highlights the significant shifts in pathogen burden that occurred with 
increasing age in this study population. The number of bacterial pathogens, in turn, was 
associated with an increase in both diversity and maturity of the microbiota.
6.3.2. Impact of azithromycin on the bacterial microbiota
Of  the  120  infants  included  in  the  microbiota  subset,  114  completed  the  trial  per 
protocol .  No  significant  differences  in  alpha  diversity,  beta  diversity,  taxon  relative 37
abundance, or microbiota age distinguished azithromycin from placebo recipients at day 0 
(Figure 6.3; Tables 6.5 and 6.6). The receipt of a 3-day course of azithromycin resulted in a 
 Two adult samples were excluded from calculations of infant microbiota age as they had substantially 36
lower diversity and clustered separately from the remaining adult samples (Figures 6.2D and 6.2E).
 Protocol deviations are described by Grassly et al (2016).37
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B
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F
Figure  6.2.  Composition  of  the  bacterial  microbiota  at  enrolment.  (A)  Mean  relative  taxon 
abundance at genus level (infants) and phylum level (infants and adults). (B) Top  20 OTUs based on 
mean relative abundance among day-0 infant samples (n = 120).  (C) Top 20 OTUs among adult 
samples (n = 40). OTUs present in both (B) and (C) are indicated with an asterisk. The abundance 
distribution of all OTUs in these samples is displayed in the inset. (D) Number of OTUs by age. 
(C)  Unweighted Unifrac distances,  visualised via principal coordinates analysis,  for day-0 infant 
samples and adult samples. (E) Microbiota maturity, as determined by mean unweighted Unifrac 
distance from non-cohabiting adults, by age. Abbreviations: CRA, cumulative relative abundance; 
m, months; OTU, 97%-identity operational taxonomic unit; PC, principal coordinate.
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Table 6.3. Baseline associations between age, microbiota diversity and age, and pathogen burden.
Alpha diversity Unifrac distance from adults Number of pathogens
No. OTUs Shannon MD-U MD-W Bacteria Viruses Eukaryotes
Age (m) 0.56 (<0.001)
0.48 
(<0.001)
-0.56 
(<0.001)
-0.42
(<0.001)
0.24
(0.009)
No. OTUs 0.63 (<0.001)
-0.74 
(<0.001)
-0.48 
(<0.001)
0.38 
(<0.001)
Shannon -0.52(<0.001)
-0.69 
(<0.001)
0.22
(0.015)
MD-U 0.56(<0.001)
-0.36
(<0.001)
MD-W
Bacteria 0.23 (0.013)
Viruses 0.26 (0.004)
Eukaryotes
Analyses were performed on day-0 samples for the 120 infants included in the microbiota subset. Spearman’s ρ 
and associated P values are displayed for correlations with a P value of <0.05. Abbreviations: m, months; 
MD-U, mean distance (unweighted Unifrac);  MD-W, mean distance (weighted Unifrac);  OTU, 97%-identity 
operational taxonomic unit.  
Table 6.4. Top 20 age-discriminatory operational taxonomic units.
OTU 
ID
Prevalence (%) Relative abundance (mean % ± s.d.)
FDR PTaxonomy
<8 m
(n = 70)
≥8 m
(n = 50)
<8 m
(n = 70)
≥8 m
(n = 50) ρ P
Faecalibacterium prausnitzii* 9677 25.7 66.0 0.057 ± 0.154 0.844 ± 2.054 0.49 1.16E-08 2.85E-06
Lactobacillus ruminis 12511 30.0 62.0 0.871 ± 5.516 2.693 ± 5.754 0.44 5.12E-07 4.20E-05
Ruminococcaceae sp.* 19836 8.6 44.0 0.045 ± 0.289 0.067 ± 0.129 0.44 4.83E-07 4.20E-05
Faecalibacterium* 3866 4.3 30.0 0.001 ± 0.003 0.021 ± 0.054 0.42 1.75E-06 0.0001
Dorea formicigenerans* 13285 17.1 52.0 0.096 ± 0.360 0.207 ± 0.382 0.41 3.00E-06 0.0001
Faecalibacterium* 5200 8.6 32.0 0.003 ± 0.010 0.017 ± 0.043 0.37 3.26E-05 0.0011
Coprococcus* 18159 7.1 36.0 0.062 ± 0.370 0.257 ± 0.709 0.37 2.84E-05 0.0011
Ruminococcus gnavus* 9067 11.4 38.0 0.120 ± 0.566 0.615 ± 1.532 0.35 8.86E-05 0.0025
Blautia* 15230 7.1 34.0 0.093 ± 0.495 0.113 ± 0.301 0.35 9.28E-05 0.0025
Lachnospiraceae sp.* 15571 7.1 28.0 0.026 ± 0.135 0.042 ± 0.122 0.35 0.0001 0.0025
Blautia* 3067 17.1 44.0 0.022 ± 0.068 0.466 ± 1.135 0.34 0.0001 0.0031
Lactobacillus 2346 7.1 30.0 0.011 ± 0.074 0.035 ± 0.128 0.33 0.0002 0.0045
Lactobacillus 2549 7.1 28.0 0.038 ± 0.282 0.054 ± 0.120 0.33 0.0003 0.0047
Streptococcus infantis 5074 61.4 34.0 0.022 ± 0.031 0.008 ± 0.015 -0.33 0.0003 0.0047
Bifidobacterium adolescentis 19111 7.1 28.0 0.001 ± 0.005 0.016 ± 0.039 0.32 0.0004 0.0063
Ruminococcus* 4023 5.7 26.0 0.155 ± 1.033 0.379 ± 2.078 0.31 0.0005 0.0077
Lachnospiraceae sp.* 23320 4.3 20.0 0.004 ± 0.020 0.015 ± 0.048 0.31 0.0005 0.0079
Leuconostocaceae sp. 15235 32.9 58.0 0.018 ± 0.051 0.027 ± 0.050 0.30 0.0008 0.0115
Streptococcus 23667 11.4 32.0 0.004 ± 0.012 0.014 ± 0.029 0.30 0.0009 0.0121
Lactobacillus ruminis 19280 8.6 28.0 0.005 ± 0.018 0.015 ± 0.037 0.30 0.0010 0.0123
OTUs that showed monotonic changes in relative abundance with increasing age were identified based on 
Spearman’s ρ. The top 20 age-discriminatory taxa are displayed above. * OTU belongs to the class Clostridia. 
Abbreviations: FDR, adjusted by Benjamini–Hochberg false discovery rate correction; m, months; OTU, 97%-
identity operational taxonomic unit.
significant decrease in the number of OTUs observed on day 14 and a borderline-significant 
decrease in Shannon index (Figure 6.3A; Table 6.5). A shift in taxonomic composition was 
apparent  based on unweighted and weighted Unifrac distances (adonis,  P values <0.05), 
albeit with modest effect size (R2 of 0.020 and 0.022 for unweighted and weighted distances, 
respectively; Figures 6.3B and 6.3C; Table 6.6). These changes can be attributed primarily to 
phylum-, class-, and OTU-level decreases in the relative abundance of Proteobacteria and 
Verrucomicrobia among individuals treated with azithromycin (Figures 6.3D and 6.3E; Table 
6.7).  Within  the  latter  phylum,  all  sequences  mapped  to  a  single  OTU,  classified  as 
Akkermansia muciniphila.  Microbiota age, as inferred by mean Unifrac distance from adult 
samples, was comparable in azithromycin and placebo recipients at day 14 (0.826 ± 0.042 
[mean ± s.d.] vs 0.821 ± 0.051 for unweighted distances and 0.598 ± 0.041 vs 0.593 ± 0.042 for 
weighted distances; linear regression, P values 0.577 and 0.543, respectively).
6.3.3. Impact of non-intervention antibiotics on the bacterial microbiota
The use of antibiotics other than the study intervention in this population was common. 
Among infants who completed the study per protocol, 185/705 (26%) took oral antibiotics in 
the  month  before  enrolment  (which  was  delayed  until  after  infants  had  stopped  taking 
antibiotics), while 78/705 (11%) took antibiotics other than the intervention between days 0 
and 14. Pre-enrolment antibiotics, where known, included amoxicillin (n = 40), co-trimoxazole 
(n = 25), and cefixime (n = 21), among numerous others. Prior exposure to antibiotics was 
associated with a significant decline in the number of OTUs at day 0 (Table 6.5). However, 
this discrepancy was no longer apparent at day 14. In contrast to the effect of azithromycin, 
we  did  not  observe  any  significant  clustering  of  samples  according  to  pre-enrolment 
antibiotic exposure based on unweighted or weighted Unifrac (Table 6.6).  Similarly, there 
were no significant phylum-, class-, or OTU-level differences in taxon relative abundance at 
enrolment according to antibiotic exposure status (Wilcoxon’s rank sum, FDR-corrected P 
values >0.05). 
The  proportion  of  infants  exposed  to  non-intervention  antibiotics  did  not  differ 
significantly according to  study arm before enrolment  (89/348 [26%] vs  96/357 [27%] in 
recipients of azithromycin and placebo, respectively; χ2, P = 0.592) or between days 0 and 14 
(37/348 [11%] vs 41/357 [11%]; χ2, P = 0.718). Among azithromycin recipients included in the 
microbiota subset, exposure to any non-intervention antibiotics (either before enrolment or 
between days 0 and 14) was associated with a reduction in OTU count at day 14, albeit non-
significant (Table 6.5).
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Figure 6.3. Impact of azithromycin on the bacterial microbiota. (A) OTU count and Shannon index 
(mean ± standard error) according to study arm. (B) Unweighted and (C) weighted Unifrac distances 
between  day-14  infant  samples,  visualised  via  principal  coordinates  analysis.  Mean  values  for 
principal  coordinate 1  are indicated by dotted lines.  (D)  OTU-level  differences in relative taxon 
abundance  at  day  14  according  to  study  arm.  Bars  display  P values  on  a  negative  log10  scale. 
Comparisons with a P value of <0.05 prior to FDR correction are indicated. The tree was constructed 
from de novo OTU sequences spanning the V4 region of the 16S rRNA gene. Owing to the use of a 
relatively short (and hypervariable) segment of the 16S rRNA gene for tree construction, phyla do 
not always separate into discrete lineages. (E) Class-level differences in taxon abundance according 
to  study arm.  Values  beyond the  scale  of  the  y-axis  are  indicated in  red.  *  P  <0.05  (after  FDR 
correction for abundance comparisons); ** FDR-corrected P <0.005. Abbreviations: AZ, azithromycin; 
OTU,  97%-identity  operational  taxonomic  unit;  Rel.  abund.,  relative  abundance;  PC,  principal 
coordinate; PL, placebo.
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Table 6.6. Summary of beta diversity analyses.
Comparison
Unweighted 
Unifrac
Weighted 
Unifrac
Group Day R2 P R2 P
Age All 0 0.049 <0.001 0.034 0.003
Study ID All - 0.676 <0.001 0.651 <0.001
Azithromycin                All 0 0.006 0.901 0.003 0.935
All 14 0.020 <0.001 0.022 0.024
AB- 14 0.025 0.003 0.041 0.006
Pre-enrolment antibiotics All 0 0.012 0.070 0.008 0.477
All 14 0.011 0.165 0.015 0.116
Any non-intervention antibiotics AZ 14 0.017 0.485 0.029 0.143
PV3 seroconversion (≥1:8 vs <1:8)                 All 0 0.010 0.185 0.011 0.254
All 14 0.013 0.031 0.008 0.465
PL 14 0.021 0.141 0.012 0.682
AZ 14 0.019 0.295 0.009 0.772
PL/AB- 14 0.031 0.260 0.012 0.914
PV3 seroconversion (≥1:256 vs <1:8)                         All 14 0.015 0.252 0.017 0.234
PV3 take All 0 0.015 0.207 0.010 0.575
All 14 0.025 0.005 0.016 0.301
PL 14 0.034 0.137 0.024 0.523
AZ 14 0.035 0.110 0.019 0.604
See Table 6.5 for details regarding the number of infants included in each group. The impact of each 
factor on the specified measure of beta diversity was assessed using the function adonis in the R 
package vegan; 9,999 permutations were included in each comparison. Abbreviations: AB-, excludes 
individuals who received oral antibiotics other than the study intervention; AZ, azithromycin arm; 
PL, placebo arm; PV3, type 3 poliovirus.
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Table 6.7. Influence of azithromycin on taxon abundance.
OTU 
ID
Prevalence (%) Relative abundance (mean % ± s.d.)
FDR PTaxonomic classification
PL
(n = 58) 
AZ
(n = 56) 
PL
(n = 58) 
AZ
(n = 56) P
Phylum (all)
Proteobacteria - 100.0 98.2 15.889 ± 13.207 10.200 ± 15.401 0.0001 0.0008
Verrucomicrobia - 20.7 0.0 0.474 ± 3.092 0.000 ± 0.000 0.0004 0.0012
Fusobacteria - 37.9 21.4 0.151 ± 0.856 0.745 ± 4.609 0.0509 0.1189
Bacteroidetes - 89.7 83.9 5.163 ± 10.268 3.497 ± 7.518 0.1075 0.1882
Actinobacteria - 100.0 100.0 41.017 ± 17.551 44.353 ± 20.885 0.2114 0.2959
Firmicutes - 100.0 100.0 37.275 ± 19.016 41.177 ± 20.596 0.3268 0.3813
Other - 79.3 80.4 0.031 ± 0.031 0.028 ± 0.025 0.7529 0.7529
Class (P value <0.05 prior to FDR adjustment)
Gammaproteobacteria - 100.0 96.4 14.801 ± 13.270 9.812 ± 15.365 0.0002 0.0025
Verrucomicrobiae - 20.7 0.0 0.474 ± 3.092 0.000 ± 0.000 0.0004 0.0025
Deltaproteobacteria - 13.8 0.0 0.009 ± 0.031 0.000 ± 0.000 0.0042 0.0197
Betaproteobacteria - 24.1 7.1 0.030 ± 0.106 0.003 ± 0.014 0.0096 0.0335
OTU (P value <0.05 prior to FDR adjustment)
Escherichia coli 8711 100.0 96.4 12.087 ± 12.457 7.309 ± 13.258 0.0001 0.0133
Escherichia coli 154 74.1 42.9 0.047 ± 0.046 0.022 ± 0.046 0.0001 0.0133
Akkermansia muciniphila 15064 20.7 0.0 0.474 ± 3.092 0.000 ± 0.000 0.0004 0.0295
Enterobacteriaceae sp. 4144 58.6 30.4 0.020 ± 0.027 0.006 ± 0.012 0.0005 0.0329
Escherichia coli 23059 75.9 53.6 0.044 ± 0.046 0.024 ± 0.040 0.0012 0.0582
Escherichia coli 22660 67.2 42.9 0.031 ± 0.036 0.014 ± 0.020 0.0019 0.0796
Campylobacter 21529 19.0 1.8 1.037 ± 3.858 0.001 ± 0.005 0.0029 0.0868
Escherichia coli 17709 91.4 69.6 0.205 ± 0.304 0.118 ± 0.221 0.0035 0.0868
Streptococcus 9412 27.6 7.1 0.009 ± 0.019 0.002 ± 0.008 0.0036 0.0868
Lactobacillus mucosae 8341 34.5 12.5 1.044 ± 3.871 0.023 ± 0.124 0.0038 0.0868
Bilophila 8458 13.8 0.0 0.009 ± 0.031 0.000 ± 0.000 0.0042 0.0868
Megasphaera 6777 13.8 0.0 0.007 ± 0.021 0.000 ± 0.000 0.0042 0.0868
Fusobacterium 13808 20.7 3.6 0.020 ± 0.095 0.000 ± 0.002 0.0047 0.0868
Bifidobacterium 19019 39.7 14.3 0.010 ± 0.017 0.005 ± 0.013 0.0049 0.0868
Bacteroides fragilis 2616 75.9 62.5 3.258 ± 8.058 0.962 ± 2.839 0.0059 0.0969
Sutterella 23966 12.1 0.0 0.018 ± 0.088 0.000 ± 0.000 0.0077 0.1129
Parabacteroides gordonii 22351 12.1 0.0 0.017 ± 0.092 0.000 ± 0.000 0.0077 0.1129
Dorea 17630 6.9 25.0 0.028 ± 0.190 0.042 ± 0.127 0.0088 0.1199
Peptostreptococcus 18269 15.5 1.8 0.345 ± 1.839 0.000 ± 0.002 0.0092 0.1199
Lactobacillales sp. 15744 70.7 82.1 0.042 ± 0.069 0.068 ± 0.069 0.0105 0.1261
Clostridiaceae 3647 13.8 33.9 0.005 ± 0.015 0.043 ± 0.120 0.0107 0.1261
Ruminococcus 12123 10.3 28.6 0.005 ± 0.028 0.008 ± 0.021 0.0172 0.1936
Escherichia coli 16451 39.7 19.6 0.015 ± 0.031 0.006 ± 0.018 0.0222 0.2393
Campylobacter 2226 8.6 0.0 0.010 ± 0.036 0.000 ± 0.000 0.0259 0.2530
Bacteroides 14039 19.0 5.4 0.009 ± 0.029 0.001 ± 0.006 0.0259 0.2530
Veillonellaceae sp. 1769 15.5 3.6 0.017 ± 0.067 0.000 ± 0.002 0.0265 0.2530
Streptococcus 24037 65.5 44.6 0.035 ± 0.047 0.024 ± 0.048 0.0276 0.2538
Escherichia coli 22987 43.1 25.0 0.014 ± 0.024 0.007 ± 0.017 0.0314 0.2780
Bacteroides ovatus 19772 36.2 17.9 0.091 ± 0.319 0.066 ± 0.288 0.0403 0.3421
Alloiococcus 19997 22.4 8.9 0.005 ± 0.013 0.002 ± 0.006 0.0456 0.3421
Ruminococcus bromii 1870 6.9 0.0 0.163 ± 0.943 0.000 ± 0.000 0.0474 0.3421
Coriobacteriaceae sp. 20404 6.9 0.0 0.044 ± 0.266 0.000 ± 0.000 0.0474 0.3421
Megasphaera 22530 22.4 8.9 0.510 ± 1.577 0.235 ± 1.523 0.0479 0.3421
Parabacteroides distasonis 3968 24.1 10.7 0.075 ± 0.327 0.043 ± 0.303 0.0487 0.3421
Proteus 2389 13.8 3.6 0.029 ± 0.116 0.001 ± 0.005 0.0489 0.3421
No phylum-, class-, or OTU-level differences distinguished azithromycin from placebo recipients at enrolment 
(FDR-corrected P values >0.05). Abbreviations: AZ, azithromycin arm; FDR, adjusted by Benjamini–Hochberg 
false discovery rate correction; OTU, 97%-identity operational taxonomic unit; PL, placebo arm.
6.3.4. Association between bacterial microbiota composition and oral poliovirus vaccine outcome
At  enrolment  (14  days  prior  to  mOPV3 administration),  we  observed no  significant 
differences in alpha diversity, beta diversity, or relative taxon abundance among individuals 
who seroconverted to type 3 poliovirus compared with those who did not  (Figure 6.4A; 
Tables  6.5  and 6.6).  In  pre-vaccination  samples  (day  14),  an  increase  in  OTU count  and 
Shannon index was apparent in non-responders compared with responders; however, these 
discrepancies were not statistically significant (linear regression, P values 0.144 and 0.057, 
respectively;  Figure  6.4A;  Table  6.5).  A  modest  shift  in  pre-vaccination  community 
composition according to seroconversion status was evident based on unweighted but not 
weighted Unifrac  (adonis,  P  values  0.031 and 0.465,  respectively;  Figure 6.4B;  Table  6.6), 
albeit  accounting  for  only  a  small  proportion  of  variance  among  samples  (R2  =  0.013). 
Although we  observed  no  significant  phylum-,  class-,  or  OTU-level  differences  in  taxon 
abundance according to seroconversion status (Wilcoxon’s rank sum, FDR-corrected P values 
>0.05), several OTUs belonging to the class Clostridia were enriched in the day-14 samples of 
infants who failed to seroconvert (P values <0.05 prior to FDR adjustment; Figure 6.5; Table 
6.8). We also observed a decrease in unweighted Unifrac distance from adults (or increase in 
microbiota age) in non-responders compared with responders on day 14 (0.811 ± 0.050 [mean 
±  s.d.]  vs  0.833  ±  0.042  for  unweighted distances  and 0.587  ±  0.044  vs  0.601  ±  0.038  for 
weighted distances; linear regression, P values 0.011 and 0.098, respectively; Figure 6.4C). 
This  discrepancy  was  absent  on  day  0  (linear  regression,  P  values  0.323  and  0.220, 
respectively).
Similar results were obtained when comparing individuals according to vaccine take. 
On day 14, we observed a significant increase in OTU count and Shannon index among non-
shedders compared with shedders (Figure 6.4D; Table 6.5), significant clustering of samples 
was evident based on unweighted but not weighted Unifrac distances (Figure 6.4E; Table 
6.6), and non-shedders had a more adult-like microbiota than shedders (0.806 ± 0.052 vs 0.838 
± 0.046 for unweighted distances and 0.583 ± 0.048 vs 0.607 ± 0.038 for weighted distances; 
linear regression, P values 0.002 and 0.014, respectively; Figure 6.4F). The class Clostridia was 
also enriched in non-shedders compared with shedders on day 14 (relative abundance, 11.6 ± 
10.2% vs 5.6 ± 7.7%; Wilcoxon’s rank sum, FDR-corrected P = 0.044; Table 6.9).
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Figure 6.4. Association between microbiota composition and oral poliovirus vaccine response. 
(A)  OTU  count  and  Shannon  index  (mean  ±  standard  error)  according  to  type  3  poliovirus 
seroconversion status. (B) Unweighted Unifrac distances between day-14 (pre-vaccination) samples, 
visualised via principal coordinates analysis. Mean values for principal coordinate 1 are indicated by 
dotted lines.  (C) Relative microbiota maturity,  as inferred by mean unweighted Unifrac distance 
from  adult  samples,  according  to  seroconversion  status.  (D,  E,  F)  The  same  comparisons  are 
displayed with respect  to  vaccine take.  *  P  <0.05.  Abbreviations:  OTU, 97%-identity  operational 
taxonomic unit; PC, principal coordinate; PV3, type 3 poliovirus.
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Figure 6.5. Changes in taxon abundance associated with oral poliovirus vaccine response.  Bars 
display  P values  on a  negative  log10  scale.  Comparisons  with  a  P value  of  <0.05  prior  to  FDR 
correction are indicated. Abbreviation: PV3, type 3 poliovirus. 
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Table 6.8. Summary of taxon abundance comparisons according to type 3 poliovirus seroconversion status.
OTU 
ID
Prevalence (%) Relative abundance (mean % ± s.d.)
FDR PTaxonomic classification
sero+
(n = 62)
sero- 
(n = 52)
sero+
(n = 62)
sero-
(n = 52) P
Phylum (all)
Fusobacteria - 22.6 38.5 0.010 ± 0.027 0.958 ± 4.840 0.0457 0.2985
Bacteroidetes - 80.6 94.2 4.821 ± 10.722 3.777 ± 6.498 0.0853 0.2985
Other - 83.9 75.0 0.032 ± 0.026 0.027 ± 0.031 0.1749 0.4081
Proteobacteria - 98.4 100.0 13.296 ± 16.585 12.854 ± 11.819 0.4493 0.7862
Firmicutes - 100.0 100.0 38.633 ± 19.072 39.858 ± 20.838 0.7848 0.9660
Verrucomicrobia - 11.3 9.6 0.385 ± 2.976 0.070 ± 0.398 0.8517 0.9660
Actinobacteria - 100.0 100.0 42.824 ± 18.644 42.455 ± 20.126 0.9660 0.9660
Class (P value <0.05 prior to FDR adjustment)
Fusobacteria - 22.6 38.5 0.010 ± 0.027 0.958 ± 4.840 0.0457 0.2985
OTU (P value <0.05 prior to FDR adjustment)
Ruminococcaceae sp.* 19836 12.9 40.4 0.054 ± 0.207 0.190 ± 0.648 0.0017 0.2271
Bacteroides caccae 13096 9.7 34.6 0.206 ± 1.099 0.084 ± 0.215 0.0023 0.2271
Bacteroides 13617 17.7 42.3 0.107 ± 0.528 0.397 ± 1.164 0.0027 0.2271
Parabacteroides distasonis 3968 8.1 28.8 0.025 ± 0.150 0.099 ± 0.435 0.0052 0.3228
Streptococcus 25262 100.0 98.1 5.025 ± 4.876 3.732 ± 4.925 0.0069 0.3414
Streptococcus 18919 71.0 46.2 0.032 ± 0.039 0.021 ± 0.037 0.0097 0.3503
Coprococcus* 22483 4.8 21.2 0.012 ± 0.079 0.013 ± 0.039 0.0099 0.3503
Lactobacillus 11591 27.4 9.6 0.023 ± 0.078 0.019 ± 0.112 0.0194 0.4005
Streptococcus infantis 5074 53.2 32.7 0.017 ± 0.025 0.007 ± 0.014 0.0196 0.4005
Bacteroides uniformis 1419 17.7 36.5 0.108 ± 0.514 0.116 ± 0.385 0.0209 0.4005
Coprococcus* 9446 4.8 17.3 0.007 ± 0.044 0.259 ± 0.853 0.0260 0.4005
Collinsella 4136 1.6 11.5 0.001 ± 0.005 0.028 ± 0.119 0.0277 0.4005
Megasphaera* 19218 1.6 11.5 0.000 ± 0.003 0.148 ± 0.704 0.0277 0.4005
Lachnospiraceae sp.* 13505 32.3 51.9 0.019 ± 0.045 0.047 ± 0.106 0.0277 0.4005
Streptococcus 2401 25.8 44.2 0.010 ± 0.022 0.033 ± 0.072 0.0281 0.4005
Bacteroides ovatus 19772 19.4 36.5 0.085 ± 0.381 0.072 ± 0.174 0.0283 0.4005
Clostridium* 23959 1.6 11.5 0.000 ± 0.003 0.034 ± 0.162 0.0287 0.4005
Lachnospiraceae sp.* 26629 16.1 34.6 0.008 ± 0.035 0.011 ± 0.026 0.0295 0.4005
Fusobacteriaceae sp. 12902 11.3 26.9 0.005 ± 0.018 0.805 ± 4.779 0.0307 0.4005
Actinomycetales 15867 48.4 30.8 0.012 ± 0.017 0.006 ± 0.009 0.0376 0.4481
Lachnospiraceae sp.* 23320 9.7 23.1 0.003 ± 0.009 0.017 ± 0.044 0.0379 0.4481
Lachnospiraceae sp.* 1106 4.8 17.3 0.007 ± 0.046 0.007 ± 0.017 0.0408 0.4498
Streptococcus 17841 71.0 76.9 0.061 ± 0.109 0.086 ± 0.097 0.0454 0.4498
Coprococcus* 18159 17.7 32.7 0.231 ± 1.190 0.396 ± 1.210 0.0468 0.4498
Streptococcus 25593 33.9 51.9 0.015 ± 0.028 0.026 ± 0.039 0.0469 0.4498
Clostridiaceae sp.* 3647 16.1 32.7 0.026 ± 0.108 0.020 ± 0.051 0.0497 0.4498
* OTU belongs to the class Clostridia. Abbreviations: FDR, adjusted by Benjamini–Hochberg false discovery 
rate correction; OTU, 97%-identity operational taxonomic unit; sero+, responders; sero-, non-responders.
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Table 6.9. Summary of taxon abundance comparisons according to type 3 poliovirus take.
OTU 
ID
Prevalence (%) Relative abundance (mean % ± s.d.)
FDR PTaxonomic classification
shed+
(n = 42) 
shed-
(n = 33) 
shed+
(n = 42) 
shed-
(n = 33) P
Phylum (all)
Bacteroidetes - 78.6 100.0 4.383 ± 9.604 4.408 ± 7.486 0.0734 0.4600
Verrucomicrobia - 19.0 6.1 0.578 ± 3.614 0.096 ± 0.498 0.1314 0.4600
Proteobacteria - 97.6 100.0 15.236 ± 18.064 11.557 ± 12.988 0.3615 0.5913
Actinobacteria - 100.0 100.0 41.777 ± 20.422 44.672 ± 17.791 0.4226 0.5913
Other - 81.0 75.8 0.028 ± 0.024 0.026 ± 0.032 0.4980 0.5913
Fusobacteria - 19.0 27.3 0.032 ± 0.150 0.009 ± 0.022 0.5068 0.5913
Firmicutes - 100.0 100.0 37.966 ± 21.086 39.233 ± 20.560 0.7462 0.7462
Class (P value <0.05 prior to FDR adjustment)
Clostridia - 100.0 100.0 5.646 ± 7.668 11.558 ± 10.208 0.0031 0.0435
OTU (P value <0.05 prior to FDR adjustment)
Ruminococcus gnavus* 9067 14.3 45.5 0.067 ± 0.216 1.532 ± 2.522 0.0010 0.1544
Lachnospiraceae sp.* 23320 7.1 36.4 0.002 ± 0.007 0.021 ± 0.041 0.0013 0.1544
Bacteroides caccae 13096 7.1 36.4 0.073 ± 0.452 0.339 ± 1.421 0.0019 0.1544
Lachnospiraceae sp.* 5031 2.4 24.2 0.000 ± 0.002 0.017 ± 0.047 0.0037 0.2279
Ruminococcus gnavus* 20675 66.7 84.8 1.370 ± 6.785 1.895 ± 1.895 0.0056 0.2574
Lachnospiraceae sp.* 26629 14.3 42.4 0.009 ± 0.042 0.016 ± 0.031 0.0069 0.2574
Streptococcus 23667 19.0 45.5 0.005 ± 0.016 0.017 ± 0.027 0.0084 0.2574
Clostridium* 23959 0.0 15.2 0.000 ± 0.000 0.052 ± 0.202 0.0099 0.2574
Bifidobacterium adolescentis 25246 42.9 15.2 0.014 ± 0.026 0.003 ± 0.009 0.0100 0.2574
Streptococcus 25916 7.1 30.3 0.008 ± 0.043 0.009 ± 0.020 0.0110 0.2574
Eggerthella lenta 3636 35.7 63.6 0.046 ± 0.104 0.107 ± 0.150 0.0115 0.2574
Dorea formicigenerans* 6937 4.8 24.2 0.002 ± 0.010 0.011 ± 0.026 0.0147 0.2917
Ruminococcaceae sp.* 19836 14.3 39.4 0.037 ± 0.144 0.202 ± 0.728 0.0154 0.2917
Dorea formicigenerans* 13285 23.8 45.5 0.094 ± 0.335 0.376 ± 0.715 0.0171 0.3008
Lachnospiraceae sp.* 18150 9.5 30.3 0.005 ± 0.019 0.021 ± 0.057 0.0223 0.3499
Bacteroides ovatus 19772 16.7 36.4 0.009 ± 0.024 0.126 ± 0.364 0.0245 0.3499
Faecalibacterium prausnitzii* 9677 26.2 48.5 0.254 ± 0.890 1.139 ± 3.346 0.0257 0.3499
Streptococcus 2401 21.4 42.4 0.006 ± 0.015 0.037 ± 0.085 0.0257 0.3499
Coprococcus* 22483 4.8 21.2 0.001 ± 0.005 0.017 ± 0.048 0.0269 0.3499
Rothia 20305 28.6 54.5 0.006 ± 0.011 0.015 ± 0.020 0.0284 0.3513
Dialister* 13671 4.8 21.2 0.001 ± 0.005 0.010 ± 0.032 0.0325 0.3682
Lachnospiraceae sp.* 13505 31.0 54.5 0.015 ± 0.036 0.056 ± 0.127 0.0335 0.3682
Coprococcus* 18159 19.0 39.4 0.136 ± 0.651 0.460 ± 1.341 0.0343 0.3682
Streptococcus 24037 61.9 45.5 0.036 ± 0.052 0.014 ± 0.026 0.0392 0.4035
Finegoldia* 16551 9.5 27.3 0.002 ± 0.005 0.029 ± 0.137 0.0419 0.4138
Ruminococcus bromii* 1870 0.0 9.1 0.000 ± 0.000 0.285 ± 1.245 0.0494 0.4697
* OTU belongs to the class Clostridia. Abbreviations: FDR, adjusted by Benjamini–Hochberg false discovery 
rate correction; OTU, 97%-identity operational taxonomic unit; shed+, shedders; shed-, non-shedders.
6.3.5. Microbiota stability
Significant clustering of samples was observed within individuals (adonis, R2 of 0.676 
and 0.651 for unweighted and weighted Unifrac distances, respectively; P  values <0.001), 
and  within-subject  distances  were  significantly  smaller  than  between-subject  distances 
(Wilcoxon’s rank sum, P values <0.001 for both unweighted and weighted Unifrac; Figure 
6.6A).  An  increase  in  community  turnover  between  days  0  and  14  was  observed  in 
azithromycin compared with placebo recipients based on unweighted Unifrac (0.485 ± 0.074 
[mean ± s.d.] vs 0.446 ± 0.076; Wilcoxon’s rank sum, P = 0.005; Figure 6.6B) but not weighted 
Unifrac  (0.230  ±  0.105  vs  0.218  ±  0.101;  P  =  0.694).  Microbiota  stability  did  not  differ 
significantly according to OPV outcome (seroconversion or shedding) based on unweighted 
or weighted distances (Wilcoxon’s rank sum, P values >0.05; Figures 6.6C and 6.6D).
6.3.6. Novel, persistent, and resolved infections
i. Seroconversion
After  adjusting  for  age,  we  observed  a  significant  reduction  in  the  odds  of 
seroconversion among infants harbouring either novel or persistent infections with ≥1 virus 
on day 14 compared with infants who were uninfected on days 0 and 14 (OR 0.43, 95% CI 
0.27–0.67 and OR 0.59, 95% CI 0.40–0.88; P values <0.001 and 0.009, respectively), but not in 
those with recently resolved infections (OR 1.08, 95% CI 0.69–1.69; P = 0.748; Figure 6.7A). 
Findings with respect to individual viral pathogens are summarised in Table 6.10. Notably, a 
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Figure 6.6. Microbiota stability in relation to study arm and oral poliovirus vaccine response. 
(A)  Within-subject unweighted Unifrac distances were significantly smaller than between-subject 
distances.  Mean  values  (±  s.d.)  are  indicated.  (B,  C,  D)  Within-subject  unweighted  Unifrac 
distances, used as an indicator of microbiota stability, are displayed according to (B) study arm, 
(C) seroconversion status, and (D) vaccine take. Mean values in each group are indicated. * P <0.05; 
*** P <0.0005. Abbreviation: PV3, type 3 poliovirus.
A  B                   C                       D   
significant  decrease  in  the  odds of  seroconversion was detected among individuals  with 
novel enteroviruses (adjusted OR 0.33, 95% CI 0.21–0.53; FDR-corrected P <0.001) but not 
persistent  enterovirus  infections  (adjusted OR 0.65,  95% CI  0.42–1.02;  FDR-corrected P = 
0.502; Figure 6.7B). When comparing these infection subclasses directly, we observed a lower 
seroconversion rate among infants with novel as opposed to persistent enteroviruses (44/127 
[35%] vs 63/129 [49%]; χ2, P  = 0.021) – a finding that was not significant for viruses as a 
whole (χ2, P = 0.128). The Ct values of persistent versus novel enterovirus infections did not 
differ significantly at day 14 (27.0 ± 2.2 [mean ± s.d.] vs 27.2 ± 2.1; Wilcoxon’s rank sum, P = 
0.475), suggesting that the discrepancy in seroconversion rate between these groups was not 
driven by pathogen copy number. 
Across  other  viral  enteropathogens,  the  odds  of  seroconversion  did  not  differ 
significantly among infants with novel,  persistent,  or recently resolved infections (logistic 
regression, FDR-corrected P values >0.05; Table 6.10). This was also the case when combining 
all viral pathogens aside from enteroviruses (logistic regression, P values >0.05; Figure 6.7C). 
Contrary to the results observed for enterovirus, in no instance did the seroconversion rate 
differ significantly between individuals with novel as opposed to persistent viral infections 
(χ2, P values >0.05). Immunogenicity was not impacted by the presence of novel, persistent, 
or recently resolved infections for any individual bacterial or eukaryotic pathogens (logistic 
regression,  FDR-corrected  P  values  >0.05 for  all  univariate  and multivariate  analyses)  or 
when combining across the pathogens in these groups (logistic regression, P values >0.05; 
Table 6.11).
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Figure 6.7. Impact of resolved, novel, and persistent viral infections on oral poliovirus vaccine 
immunogenicity. The impact of infection subclasses on the odds of seroconversion are displayed for 
(A) ≥1 virus, (B) enteroviruses, and (C) ≥1 virus (excluding enterovirus). ORs and 95% CIs from 
univariate logistic regression models are shown. * P <0.05; *** P <0.0005. Abbreviation: OR, odds 
ratio.
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ii. Vaccine take
Analyses of infection subclass in relation to vaccine take were constrained by the fact 
that type 3 poliovirus shedding was assessed in only a subset of per-protocol infants with 
available  TAC  data  (291/704).  As  such,  infection  subclasses  often  lacked  sufficient 
individuals for their impact to be assessed. Nonetheless, we observed a reduction in the odds 
of vaccine take among infants who experienced either novel or persistent infections with ≥1 
virus (OR 0.50, 95% CI 0.24–1.04 and OR 0.53, 95% CI 0.28–1.00, respectively; Figure 6.8A); 
however, in contrast to the analyses of seroconversion status, this effect was significant only 
for  the latter  (P values 0.062 and 0.050,  respectively).  Among individual  viral  pathogens 
(including enteroviruses; Figure 6.8B), no infection subclass significantly impacted the odds 
of vaccine take after adjusting for multiple comparisons (logistic regression, FDR-corrected P 
values >0.05 for all univariate and multivariate analyses; data not shown). When combining 
across viruses other than enterovirus, the resolution of infections between days 0 and 14 was 
associated with an increase in the odds of vaccine take (OR 2.46, 95% CI 1.20–5.06; P = 0.014; 
Figure 6.8C). OPV take was not affected by resolved, novel, or persistent bacterial infections 
(logistic regression, FDR-corrected P values >0.05 for univariate and multivariate analyses of 
individual  pathogens  and  P  values  >0.05  when  combining  across  bacteria;  Table  6.12). 
However,  we observed a  significant  decrease  in  the odds of  vaccine take among infants 
persistently infected with ≥1 eukaryote (OR 0.30, 95% CI 0.11–0.74; P = 0.009; Table 6.12) – a 
result consistent with the lower prevalence of Giardia observed in shedders compared with 
non-shedders during the primary outcome analyses (Grassly et al, 2016).
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Figure 6.8. Impact of resolved, novel, and persistent viral infections on oral poliovirus vaccine 
take. The impact of infection subclasses on the odds of vaccine take are displayed for (A) ≥1 virus, 
(B) enteroviruses, and (C) ≥1 virus (excluding enterovirus). ORs and 95% CIs from univariate logistic 
regression models are shown. * P <0.05; †, P <0.05 prior to FDR adjustment. Abbreviation: OR, odds 
ratio.
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6.3.7. Random Forests
The  accuracy  of  Random  Forest  models  for  the  prediction  of  study  arm  and  OPV 
outcome is displayed in Figure 6.9 for different modules of input data. The use of either 
concurrent  pathogen  or  microbiota  data  obtained  from  day-14  samples  enabled  the 
prediction of  study arm with 61.2% and 67.5% accuracy,  respectively  (baseline  accuracy: 
50.9%) – a significant improvement in fit compared with null models (P values <0.05; Figure 
6.9A). Prediction of seroconversion status was poor for all models (Figure 6.9B). Although a 
significant improvement in model fit was observed when 16S rRNA microbiota composition 
was  used  to  distinguish  type  3  poliovirus  shedders  from  non-shedders,  the  increase  in 
accuracy was negligible (61.6% vs 56.0% for fitted and baseline models, respectively; Figure 
6.9C).  In  no instance  did  the  combination of  data  across  different  modules  substantially 
improve the predictive accuracy of the Random Forest models. Variables with the highest 
importance scores for the combined models are displayed in Figure 6.10. Despite the poor 
predictive  capacity  of  the  models,  enterovirus  was  consistently  identified  as  the  most 
important enteropathogen when predicting OPV response.
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Figure 6.9. Predictive accurate of Random Forest models using different modules of data. Mean 
accuracy  (±  s.d.)  across  100  iterations  of  the  Random Forest  algorithm is  displayed for  models 
predicting (A) azithromycin treatment, (B) seroconversion status, and (C) vaccine take. See Table 6.2 
for a list of variables included in each module. Dotted lines indicate baseline accuracy, wherein all 
individuals  are assigned to the majority class.  *  P <0.05;  **  P <0.005.  Abbreviation:  PV3,  type 3 
poliovirus.
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Figure 6.10. Highest ranking variables by Random Forest importance score. Data are displayed for 
models predicting (A) azithromycin treatment, (B) seroconversion status, and (C) vaccine take using 
variables from all modules of data (Table 6.2). Mean importance scores (± s.d.) were calculated over 
100 iterations of the Random Forest algorithm. § Values correspond to TAC Ct for enteropathogens 
and relative abundance (%) for OTUs. Abbreviations: EAEC, enteroaggregative Escherichia coli; HAZ, 
height-for-age Z score.
6.3.8. Multivariate logistic regression
During the analyses of microbiota composition described above, the Shannon index of 
day-14 samples demonstrated the strongest association with OPV outcome (Table 6.5). When 
Shannon index and viral pathogen infection status on day 14 were included as predictors of 
OPV response in multivariate logistic regression models, the associations for the former were 
partially abrogated (Table 6.13), suggesting that the observed link between Shannon index 
and OPV outcome may reflect a degree of confounding between microbiota diversity and 
viral infection status.
6.3.9. Sensitivity analyses
i. Stratification by study arm
When analyses were stratified by study arm, discrepancies in alpha and beta diversity 
according  to  OPV  outcome  were  largely  consistent  among  placebo  and  azithromycin 
recipients, although comparisons were generally not statistically significant (Tables 6.5 and 
6.6).  We  performed similar  stratified  analyses  when  considering  the  impact  of  resolved, 
novel, and persistent infections on OPV outcome (Tables 6.11 and 6.12). This revealed that 
the reduction in the odds of type 3 poliovirus shedding in conjunction with persistent viral 
infections was apparent only in azithromycin recipients (Table 6.12). By contrast, the reduced 
odds of seroconversion among infants with novel viral infections was evident in both study 
arms (Table 6.11). 
Table 6.13. Multivariate logistic regression outputs.
Univariate Multivariate
Variable Day N OR (95% CI) P OR (95% CI) P
Model 1: PV3 seroconversion, full data
≥1 Virus 14 704 0.51 (0.38–0.69) <0.001
Model 2: PV3 seroconversion, microbiota subset
≥1 Virus 14 114 0.44 (0.21–0.96) 0.039 0.48 (0.22–1.06) 0.068
Shannon index 0.46 (0.20–1.03) 0.059 0.50 (0.22–1.15) 0.105
Model 3: PV3 take, full data
≥1 Virus 14 291 0.54 (0.34–0.88) 0.013
Model 4: PV3 take, microbiota subset
≥1 Virus 14 75 0.27 (0.10–0.76) 0.013 0.32 (0.11–0.90) 0.031
Shannon index 0.37 (0.14–0.97) 0.044 0.45 (0.17–1.23) 0.118
Age was included as a covariate in all models (univariate and multivariate).  No other variables 
were adjusted for. ORs signify the change in the relative odds of responding to OPV in conjunction 
with: (i)  the presence versus absence of concurrent infection; or (ii)  a 1-unit change in Shannon 
index.  Abbreviations:  CI,  confidence  interval;  OR,  odds  ratio;  OTU,  97%-identity  operational 
taxonomic unit; PV3, type 3 poliovirus.
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ii. Antibody titre 
Among per-protocol infants included in the microbiota subset, 23/114 (20%) achieved a 
post-vaccination antibody titre of ≥1:256. When these ‘robust responders’ were compared to 
infants who failed to seroconvert, we observed no significant discrepancies in alpha diversity 
(Table 6.5), and no significant clustering of samples based on unweighted or weighed Unifrac 
distances  (Table  6.6).  ORs  associated  with  resolved,  novel,  and  persistent  infections  for 
pathogen groups were generally  consistent  with those observed in the primary analysis, 
though in no instance did infection subclass significantly impact the odds of seroconversion 
within this subset of the study population (data not shown).
iii. Exclusion of infants exposed to non-intervention antibiotics
The observed impact of azithromycin on alpha and beta diversity was consistent when 
infants who received antibiotics other than the study intervention were excluded (Tables 6.5 
and  6.6).  In  a  related  analysis,  we  excluded  infants  who  received  any  antibiotics 
(azithromycin  or  other),  and  examined  the  associated  between  microbiota  diversity  and 
seroconversion status. As with the primary analyses, an increased OTU count and Shannon 
index was apparent  in  non-responders  compared with responders,  albeit  not  statistically 
significant  (Table  6.5).  No  significant  clustering  of  samples  according  to  seroconversion 
status was evident based unweighted or weighted Unifrac distances (Table 6.6).
6.3.10. Negative controls
Across the 12 extraction controls and single no-template control included in the MiSeq 
run, we obtained five sequences in total (0.4 sequences per sample on average), suggesting 
that  any  contamination  of  laboratory  reagents  or  cross-contamination  during  library 
preparation was negligible.
6.4. Discussion
Antibiotic treatment had a marked effect on the composition of the bacterial microbiota 
in this study population. Although tangential to the primary aims of this thesis, these novel 
findings warrant brief  consideration.  Azithromycin has previously been shown to inhibit 
growth of numerous Gram-negative and Gram-positive bacteria, and is widely used to treat 
infections  of  the  respiratory  tract,  urogenital  tract,  and  skin  (Parnham  et  al,  2014). 
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Therapeutic activity also extends to bacterial enteropathogens, as highlighted in previous 
analyses of this study population (Grassly et al, 2016), and the drug has proven effective for 
the  treatment  of  travellers’  diarrhoea  (Adachi  et  al,  2003).  Antibacterial  mechanisms  are 
varied, encompassing the inhibition of protein synthesis via binding of the 50S subunit of the 
prokaryotic ribosome, the disruption of quorum sensing (the mechanism by which bacteria 
regulate gene expression in response to fluctuations in population density), and interference 
with adherence to host cells, among others (Kanoh and Rubin, 2010; Parnham et al, 2014). The 
macrolide  antibiotic  also  appears  to  have  immunomodulatory  effects  independent  of  its 
antibacterial activity, including the suppression of pro-inflammatory cytokines such as TNFα 
(Cigana et al, 2007; Tong et al, 2011).
Although the  antimicrobial  effects  of  azithromycin have been extensively  studied in 
relation  to  pathogenic  bacteria,  less  is  known regarding  the  impact  of  this  drug  on  the 
bacterial microbiota as a whole. We assessed 16S rRNA microbiota composition among 6–11 
month-old infants before and 12 days after the completion of a 3-day course of azithromycin 
or placebo. Antibiotic treatment led to a decline in the number of OTUs by approximately 
10% and a modest but significant shift in community composition based on unweighted or 
weighted  Unifrac  distances.  These  changes  were  driven  primarily  by  the  azithromycin-
induced  depletion  of  Proteobacteria  (including  several  OTUs  classified  as  E.  coli)  and 
Verrucomicrobia  (including  a  single  OTU  classified  as  A.  muciniphila).  Given  the  broad-
spectrum activity of azithromycin, it is likely that absolute decreases in bacterial abundance 
occurred across other phyla in these infants. However, the sequencing pipeline adopted in 
this study only enabled us to capture changes in the relative abundance of bacterial taxa at a 
given sequencing depth. It is important, therefore, to frame any conclusions from this work 
accordingly  –  while  azithromycin  depleted  the  abundance  of  OTUs  in  the  phyla 
Proteobacteria and Verrucomicrobia to a greater extent than other taxa, we cannot preclude a 
broader impact of the antibiotic on the infant microbiota. 
Notably, these results appear to contradict recent findings from Finland regarding the 
impact of macrolide antibiotics on microbiota composition. Among children 2–7 years of age, 
Korpela  et  al  (2016)  observed  a  significant  decrease  in  the  relative  abundance  of 
Actinobacteria  and  a  corresponding  increase  in  Proteobacteria  and  Bacteroidetes  among 
children exposed to  azithromycin or  clarithromycin within  the  preceding 6  months.  The 
discord between these  studies  can likely  be  attributed to  differences  in  setting (India  vs 
Finland), age (6–11 months vs 2–7 years), and time since antibiotic exposure (12 days vs up to 
6 months). A follow-up study exploring the longer-term effects of azithromycin in this study 
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population  is  a  potential  avenue  of  future  investigation,  albeit  beyond the  scope  of  the 
present thesis.
The azithromycin-induced depletion of A. muciniphila (the only OTU observed within 
the  phylum  Verrucomicrobia  in  this  study)  is  also  at  odds  with  previous  findings.  An 
increased abundance of this mucin-degrading species of Gram-negative bacteria has been 
observed  following  the  treatment  of  adults  with  a  range  of  non-macrolide  antibiotic 
regimens  (Dubourg  et  al,  2013).  Similar  findings  have  been  documented  following  the 
treatment of mice with the veterinary macrolide tylosin, suggesting that A. muciniphila may 
be an opportunistic microbe that thrives in response to ecosystem disturbance (Nobel et al, 
2015). However, while the strain was observed in the day-14 stool samples of approximately 
20% of  infants  who received placebo in  the  present  study,  it  was  absent  from the  post-
treatment samples of all azithromycin recipients.
Discrepancies  in  microbiota  composition  with  respect  to  OPV  response  were  more 
modest than those induced by azithromycin. As observed among recipients of tOPV at 6 
weeks  of  age  in  the  previous  chapter,  vaccine  outcome  was  negatively  correlated  with 
diversity  of  the  bacterial  microbiota  at  the  time  of  immunisation  (discrepancies  were 
significant for comparisons of OPV take but not seroconversion status). In line with these 
changes  in  microbiota  diversity  on day 14,  we observed a  significant  shift  in  taxonomic 
composition  with  respect  to  vaccine  outcome  (seroconversion  and  take)  based  on 
unweighted Unifrac distances, albeit accounting for <3% of the variation among samples. By 
contrast, no differences in microbiota diversity or composition were observed 14 days prior 
to immunisation. 
Taken together,  these findings suggest  that  a  transient  shift  in  16S rRNA microbiota 
composition, including an increase in microbial diversity, may represent a significant risk 
factor for OPV non-response.  Whether these shifts  in composition are causally related to 
OPV  outcome,  or  simply  correlate  with  other  risk  factors  for  vaccine  failure,  remains 
uncertain.  Notably,  the  results  of  multivariate  logistic  regression  revealed  a  degree  of 
confounding between microbiota diversity and viral pathogen infection status at day 14. We 
did not identify any OTUs that differed significantly in relative abundance with respect to 
seroconversion  status  or  vaccine  take,  thus  providing  further  evidence  to  refute  the 
hypothesis that ‘keystone taxa’ might inhibit OPV response (see section 1.6). Among OTUs 
with the largest discrepancies in abundance according to seroconversion status or vaccine 
take,  several  taxa  in  the  class  Clostridia  were  observed to  be  negatively  correlated with 
vaccine outcome. However, in contrast to the analyses of alpha and beta diversity described 
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above,  we  did  not  adjust  for  age  during  comparisons  of  taxon  relative  abundance  (a 
constraint of the non-parametric tests adopted for these analyses). Given that older infants 
were less likely to respond to OPV in this study population (Grassly et al, 2016), and that 
OTUs in the class Clostridia were among the highest-ranking age-discriminatory taxa, the 
observed discrepancies in taxon relative abundance may simply reflect the confounding of 
these variables with age. Equally, one cannot preclude the possibility that shifts in microbiota 
composition  are  among  the  factors  responsible  for  age-associated  changes  in  OPV 
immunogenicity.
Our  analyses  of  the  microbiota  also  included  measures  of  stability  and  maturity. 
Whereas  azithromycin  treatment  resulted  in  a  significant  decline  in  microbiota  stability 
(based on within-subject unweighted Unifrac distances), the degree of microbial community 
turnover in the 14 days preceding vaccination did not significantly influence OPV outcome – 
a finding consistent with observations for oral rotavirus vaccine and tOPV in the preceding 
chapters. We assessed microbiota maturity among infant samples by measuring their mean 
Unifrac distance from adult samples. Although not as nuanced, perhaps, as the microbiota-
for-age Z score recently applied among infants in Bangladesh based on the outputs of  a 
Random  Forests  regression  model  (Subramanian  et  al,  2014),  this  approach  nonetheless 
captured the shift towards a more adult-like microbiota with increasing age in this study 
population.  After  adjusting  for  age,  microbiota  maturity  on  the  day  of  vaccination  was 
negatively  correlated  with  OPV outcome (both  seroconversion  and shedding).  However, 
maturity index was closely correlated with OTU count and Shannon index at enrolment. 
Since  the  discrepancies  in  microbiota  maturity  were  absent  on  day  0,  the  differences 
observed in  day-14  samples  are  more  likely  to  be  indicative  of  the  transient  increase  in 
diversity  among vaccine  non-responders  than  an  accelerated  maturation  of  the  bacterial 
microbiota in these individuals.
Turning our attention away from the bacterial microbiota, we observed a reduction in 
OPV immunogenicity in infants with novel as opposed to persistent enterovirus infections. 
This  finding should be interpreted with a  degree of  caution given its  modest  effect  size 
(seroconversion  was  observed  in  35%  and  49%  of  infants  with  novel  and  persistent 
enterovirus  infections,  respectively),  and  the  fact  that  the  discrepancy  was  absent  when 
considering  vaccine  take.  These  caveats  notwithstanding,  the  possibility  that  recently 
acquired  viral  infections  may  have  an  enhanced  inhibitory  impact  on  OPV  response  is 
plausible. Viral infections initiate a cascade of innate immune effectors that typically peak 
within several days of exposure (Van Reeth, 2000; Duan et al, 2014). For example, following 
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the  infection  of  peripheral  blood  leukocytes  with  either  Coxsackie  B4  virus  or  type  1 
poliovirus, the production of pro-inflammatory cytokines, including TNFα  and IL-1β,  has 
been shown to peak within 24 hours (Juhela et al,  1999).  Similarly,  the antiviral cytokine 
IFNα reaches maximum levels in serum within 2 days of the onset of symptomatic rotavirus 
infection (De Boissieu et al, 1993). If the induction of innate antiviral immunity is responsible 
for  the  inhibitory  effect  of  enteroviruses  on  OPV immunogenicity,  the  timescale  of  viral 
exposure may well be pertinent to the outcomes of co-infection.
Our final line of enquiry was to assess the added value of combining different types of 
data when predicting study arm or OPV outcome using Random Forests. The use of either 
TAC or microbiota data alone essentially recapitulated the outcomes of the primary analyses 
described  above  –  models  incorporating  these  variables  had  a  modest  accuracy  when 
predicting azithromycin treatment, but limited predictive capacity for OPV outcome. In no 
instance  did  the  combination  of  data  regarding  baseline  characteristics  (including 
sociodemographic and anthropometric data),  pathogen infection status,  and OTU relative 
abundances  substantially  improve  the  predictive  capacity  of  the  Random  Forest  models 
compared with the most accurate individual module of data. It is possible that alternative 
statistical  or  machine-learning  approaches  may  have  enabled  the  more  productive 
integration of  these data,  or  that  the inclusion of  a  greater  number of  infants  may have 
improved the accuracy of our Random Forest models (of the 705 infants who completed the 
trial per protocol, our models encompassed 75 individuals for the prediction of OPV take 
and 114 for  the prediction of  study arm and seroconversion status).  As high-throughput 
technologies  become more readily available,  how to make best  use of  the resulting data 
represents  a  considerable  bioinformatic  and  statistical  challenge.  The  use  of  machine-
learning approaches such as Random Forests undoubtedly holds significant potential as we 
seek novel insights within these ever-expanding datasets. When used on an exploratory basis 
in the present study, however, such insights were not forthcoming.
6.4.1. Conclusions
The intestinal  microbiota  is  in  a  constant  state  of  flux throughout  infancy.  This  flux 
encompasses a continual expansion in the diversity of the bacterial microbiota, and exposure 
to a diverse array of bacterial, viral, and eukaryotic enteropathogens. The inhibitory effect of 
concurrent  viral  infections  (particularly  NPEVs)  on  OPV  has  become  increasingly  clear 
throughout this thesis, and was confirmed in the EVI study. The influence of the bacterial 
microbiota  is  more  ambiguous,  although  we  have  now  observed  a  modest  increase  in 
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microbial diversity among OPV non-responders in south India at 6 weeks of age (in Chapter 
5) and at 6–11 months of age (above). As expected, azithromycin exposure had a considerable 
impact on composition of the gut’s microbial inhabitants – evident both in the prevalence 
and abundance of bacterial  enteropathogens and in the composition and diversity of the 
bacterial microbiota as a whole.
Perhaps the most interesting finding to emerge from the present chapter, however, is the 
importance of recent changes in microbiota composition to oral vaccine outcome. Failure to 
respond  to  OPV  was  associated  with  a  transient  increase  in  diversity  of  the  bacterial 
microbiota, and novel enteroviruses appeared to have a greater inhibitory impact on vaccine 
immunogenicity than persistent infections. Although these findings do not preclude a role 
for more entrenched risk factors of OPV failure, such as the chronic inflammation associated 
with EE, they suggest that the likelihood of responding to oral vaccination may fluctuate 
from week to  week.  The gut’s  microbial  residents  –  particularly  viral  enteropathogens – 
appear to play a key role in shaping these short-term fluctuations.
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Chapter 7: Conclusions
This  primary  aim  of  this  thesis  was  to  characterise  the  association  between  the 
composition  of  the  intestinal  microbiota  at  the  time  of  immunisation  and  the  ensuing 
response to live-attenuated oral vaccines targeting poliovirus and rotavirus. In doing so, we 
hoped  to  provide  some  insight  into  the  biological  mechanisms  that  undermine  the 
performance of oral vaccines in the low-income countries where they are needed most.
7.1. Summary of findings
There  are  two  distinct  facets  of  the  intestinal  microbiota  that  we  considered  in  the 
research described above: (i) the burden of bacterial, viral, and eukaryotic enteropathogens; 
and (ii) the composition of the bacterial flora as a whole (including the diversity and relative 
abundance of bacterial taxa, irrespective of their pathogenicity). With respect to the former, 
our  findings  have  helped  to  substantiate  the  inhibitory  effect  of  enteropathogens 
(particularly viral infections) on OPV. In Chapter 2, I presented the findings of a systematic 
review and meta-analysis considering the impact of enteric infections on the immunogenicity 
and take of OPV. Within a somewhat conflicted literature, we observed a reduction in the 
odds of responding to a given dose of OPV among individuals with NPEVs or diarrhoea at 
the time of immunisation.
We subsequently extended these findings by exploiting recent advances in molecular 
diagnostics (introduced in Chapter 3) to assess the burden of 31 distinct enteropathogens 
among  infants  living  in  south  India.  In  Chapters  4  and  5,  we  compared  the  burden  of 
pathogens  according  to  the  immunogenicity  and  take  of  Rotarix  and  tOPV  doses 
administered at 6 and 10 weeks of age. Enteropathogens did not have a significant inhibitory 
effect  on Rotarix  outcome (indeed,  a  greater  prevalence of  pathogens was observed at  6 
weeks  of  age  among  infants  who  seroconverted  to  rotavirus).  However,  we  observed  a 
modest but significant increase in the burden of pathogens – and specifically of asymptomatic 
bacterial  infections –  among infants  who failed  to  seroconvert  to  OPV.  The  potential  for 
asymptomatic  bacteria  to  interfere  with  OPV administered  during  routine  immunisation 
constitutes  a  novel  outcome of  this  thesis.  Moreover,  if  we assume the  observed enteric 
infections  to  be  causally  related  to  the  impairment  of  OPV response,  our  findings  were 
consistent  with  approximately  10%  of  failed  seroconversions  per  dose  of  tOPV  being 
attributable to concurrent pathogens in this study population.
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During  a  subsequent  trial  assessing  the  impact  of  azithromycin  treatment  on  the 
immunogenicity of mOPV3 among 6–11 month-old infants, no discrepancy in the prevalence 
of  bacterial  enteropathogens  was  observed  according  to  vaccine  outcome (Grassly  et  al, 
2016). However, viral infections were significantly more common among infants who failed 
to seroconvert to type 3 poliovirus. In Chapter 6, we extended the primary outcome analyses 
of this trial  by discriminating between novel,  persistent,  and recently resolved infections. 
This revealed that novel enteroviruses (present on the day of immunisation but absent 14 
days earlier) had a more dramatic inhibitory effect on OPV immunogenicity than persistent 
infections. Although the same effect was not apparent when considering vaccine take, and 
should thus be interpreted with a degree of caution, the notion that viral interference may 
fade in the window after an infection is acquired is an intriguing possibility.
Our  results  with  respect  to  the  16S  rRNA microbiota  should  –  in  my opinion  –  be 
considered negative findings. Although microbiota diversity at the time of immunisation was 
positively correlated with the take of Rotarix (Chapter 4), and negatively correlated with the 
take and/or immunogenicity of OPV (Chapters 5 and 6), the effect size was modest in each 
instance.  No  significant  associations  were  observed  between  the  relative  abundance  of 
individual taxa and vaccine outcome – or to use the terminology introduced in Chapter 1, we 
did not identify any ‘keystone taxa’ associated with vaccine response. Likewise, machine-
learning  algorithms  were  incapable  of  accurately  discriminating  responders  from  non-
responders for either vaccine based on the OTU abundance data generated in these studies. 
By  contrast,  significant  discrepancies  in  taxon  relative  abundance  were  observed  in 
conjunction with exposure to either L. rhamnosus GG (Chapter 4) or azithromycin (Chapter 
6), confirming that the sequencing pipeline and bioinformatic methods adopted in this thesis 
were capable of distinguishing clinically relevant shifts in the composition of the bacterial 
microbiota.
7.2. Limitations
Specific limitations relating to the methods adopted in this thesis have been discussed in 
detail in the preceding chapters. Here, I will expand briefly on the broader limitations of this 
work. In doing so, I hope to provide better context to the key findings outlined above.
First,  it  is  important  to  acknowledge  constraints  in  the  extent  to  which  we  have 
accurately captured the diversity and functional capacity of the intestinal microbiota in this 
study. Bacteriophages were not considered, nor were many of the diverse array of eukaryotic 
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viruses,  yeasts,  fungi,  and helminths that constitute the intestinal microbiota. Meanwhile, 
despite the use of an amplicon sequencing method that has been widely adopted in recent 
studies of the bacterial microbiota (Caporaso et al, 2012; Subramanian et al, 2014), we cannot 
discount biases introduced by the incomplete coverage of the primers adopted (Nelson et al, 
2014), and by the inability to discriminate between distinct bacterial strains when sequencing 
only the V4 region of the 16S rRNA gene. Indeed, the extraction techniques, primers, and 
sequencing methods should all be seen as caveats to the findings presented in this thesis. It is 
certainly  possible  that  the  use  of  an  alternative  pipeline  –  such  as  profiling  of  the 
metagenome via shotgun sequencing (Smith et al, 2013), assessment of the enteric virome 
(Norman et al,  2015),  or even the selection of a different hypervariable region of the 16S 
rRNA gene  for  amplicon-based  sequencing  –  might  have  highlighted  discrepancies  in 
microbiota composition pertinent to the impaired performance of oral vaccines. Given the 
increased accessibility and cost–effectiveness of  these methods,  it  is  likely that numerous 
studies  will  address  this  possibility  in  the  coming  years.  In  spite  of  the  predominantly 
negative findings reported here, I would not be surprised if the commensal intestinal flora is 
yet found to play an important role in shaping the immune response to oral vaccines.
In  the  latter  chapters  of  this  thesis,  we  explored  potential  associations  between  the 
composition of  the intestinal  microbiota  and oral  vaccine outcome by conducting nested 
case–control studies among infants who had participated in clinical trials of Rotarix and OPV 
in south India. A benefit of this approach is that it enables the risk factors for oral vaccine 
failure to be studied within the very setting in which it manifests itself as a public health 
problem. The poor immunogenicity of Rotarix in the study population described in Chapters 
4 and 5 (at  31% after two doses)  is  a testament to this.  However,  there are limits to the 
mechanistic insights that can be garnered from such an approach. Although the increased 
burden of bacterial enteropathogens observed at 6 and 10 weeks of age among infants who 
failed  to  seroconvert  to  type  3  poliovirus  may  reflect  a  direct  inhibitory  effect  of  these 
infections  on  the  take  of  attenuated  vaccine  polioviruses,  the  infections  might  also  be 
indicative of an alternative underlying risk factor for OPV failure, such as acute malnutrition 
or EE. Exploring oral vaccine failure using animal models may help to delineate the key 
mechanisms responsible for this phenomenon. This is a possibility that I will consider further 
below.
The practical implications of this work are somewhat modest, at least for the foreseeable 
future. While our findings are among the first to implicate bacterial enteropathogens as a risk 
factor for OPV failure, the logical intervention arising from this observation – to treat infants 
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with  antibiotics  prior  to  immunisation  –  did  not  bring  about  any  improvement  in  OPV 
immunogenicity when tested among infants in south India (Grassly et al, 2016). Equivalent 
interventions targeting enteric viruses are presently lacking. However, the findings presented 
in  Chapter  6  raise  the  possibility  that  a  transient  reduction  in  viral  exposure  prior  to 
immunisation  might  be  sufficient  to  boost  the  efficacy  of  oral  vaccination.  The  ongoing 
Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial  in Zimbabwe – examining the 
impact of water, sanitation, and hygiene and/or infant feeding interventions on stunting and 
anaemia  (with  OPV  and  rotavirus  vaccine  immunogenicity  considered  as  secondary 
outcomes) – may provide some insight here (Prendergast et al, 2015). 
Finally,  following  the  rapid  proliferation  of  next-generation  sequencing  and  the 
packaging of bioinformatic tools into open-source pipelines such as Qiime, we are currently 
in a position where our ability to characterise the intestinal microbiota is more advanced 
than our capacity to augment it in a predictable manner. Indeed, it would be reasonable to 
ask the following of the work described above: if shifts in the composition of the bacterial 
microbiota were to be identified as a direct cause of oral vaccine failure, what could we do 
about  it?  Faecal  microbiota  transplantation  has  been  used  as  an  intervention  for  IBD 
(Anderson et al, 2012) and recurrent Clostridium difficile (Gough et al, 2011), though it is hard 
to envision this being applied as a means of boosting the efficacy of oral vaccines during 
infancy.  Meanwhile,  as  described  in  Chapters  3  and  4,  supplementation  with  a  single 
probiotic  strain  did not  substantially  augment  the  immunogenicity  of  Rotarix  and tOPV 
among infants in south India (Lazarus et al,  manuscript in preparation). However, future 
‘microbiota-directed therapeutics’  may enable  us  to  mould the  intestinal  flora  in  a  more 
sophisticated manner – for example, by augmenting the infant diet to foster the growth of 
specific bacterial taxa that are conducive to the development of the mucosal immune system 
(Blanton et al, 2016) or by administering defined mixtures of bacteria (‘probiotic cocktails’) 
that achieve a similar aim (Lemon et al, 2012).
7.3. The road ahead
7.3.1. Viral interference: a day-by-day perspective
In this thesis,  we used snapshots of the intestinal microbiota obtained on the day of 
immunisation as a means of assessing the potential inhibitory effect of enteropathogens on 
Rotarix and OPV. However, this approach may fail to capture the dynamic interplay between 
infections that co-occur in the infant gut. Assessing the abundance of enteropathogens and 
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vaccine viruses in faecal samples at multiple timepoints in the days following immunisation 
may provide a more intimate perspective of these interactions. Notably, such an approach 
was  adopted by  Albert  Sabin  during  the  early  studies  of  viral  interference  among OPV 
recipients, albeit in a small number of individuals (Sabin, 1959). The manifestations of viral 
interference in these cases were varied – while the presence of a concurrent enteric virus 
completely suppressed the replication of vaccine polioviruses in some instances, in others 
interference was characterised only by a delay in poliovirus replication or lower quantities of 
shedding.  I  would  advocate  the  application  of  a  similar  approach  not  only  to  better 
characterise  the  association  between  bacterial,  viral,  and  eukaryotic  enteropathogens  and 
vaccine  virus  replication,  but  to  delineate  the  relationship  between  attenuated  vaccine 
polioviruses  and  rotaviruses  when  these  strains  are  co-administered.  Specifically,  is  the 
replication  efficiency  of  Rotarix  impacted  by  the  quantity  and  duration  of  Sabin  virus 
shedding? And, as posited in Chapter 4, does the suppression of Sabin virus replication by 
existing enteropathogens enhance the replication of vaccine rotaviruses?
7.3.2. Animal models, human microbes
As  noted above,  observing  an  association  between the  composition  of  the  intestinal 
microbiota  and  the  outcome  of  oral  immunisation  does  not  imply  a  causal  relationship 
between the two. Animal models have the capacity to shed light on this issue. Given that 
intestinal poliovirus carriage in mice requires transgenic expression of the human poliovirus 
receptor alongside knockout of the alpha/beta interferon receptor gene (Ohka et al, 2007), 
rotavirus is likely to be a more profitable basis for such enquiries (Little and Shadduck, 1982). 
In particular, one could assess the impact of innate immune stimulation on rotavirus carriage 
in murine models by orally administering poly I:C (a synthetic mimic of double-stranded 
RNA), lipopolysaccharide, or other pathogen-associated molecular patterns (PAMPs) prior to 
viral  inoculation.  In doing so,  we might  gain insight  into the impact  of  PAMP-triggered 
immunity on rotavirus replication efficiency,  as  well  as  the extent  to  which this  effect  is 
conserved across different pattern recognition receptor ligands. Moreover, in line with the 
enhanced inhibitory effect of novel versus persistent infection observed with respect to OPV 
seroconversion in Chapter 6, one could use this approach to assess how the timing of PAMP 
exposure relative to viral inoculation impacts rotavirus take.
In  a  similar  vein,  murine  models  with  a  ‘humanised  microbiota’  (attained  by 
transplanting faecal samples into germ-free mice) have increasingly been used to validate 
causal relationships between the composition of the intestinal microbiota and disease states 
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such as kwashiorkor (Smith et al, 2013) and IBD (Nagao-Kitamoto et al, 2016). It would be 
interesting to apply a similar system to the issue of oral vaccine failure. In particular, does 
transplanting the faecal microbiota of infants who fail to respond to oral vaccination impede 
the take of rotavirus in humanised mouse models? Such an approach might also enable the 
identification of specific taxa that either halt or facilitate rotavirus replication and thereby 
inform the design of future microbiota-directed therapeutics.
7.3.3. Oral vaccine failure on a broader scale
With  the  exception  of  the  systematic  review  described  in  Chapter  2,  the  findings 
presented above relate to a specific geographic setting, thus limiting the extent to which we 
can comment on the mechanisms responsible for broader geographic trends in oral vaccine 
performance. Indeed, as highlighted above (section 4.5), it is possible that all of the infants 
included  in  this  work  harboured  a  bacterial  microbiota  inhibitory  to  the  replication  of 
vaccine viruses. Future work examining the phenomenon of oral vaccine failure on a broader 
geographic and sociodemographic scale is warranted. Although the use of OPV is largely 
restricted  to  low-income  settings,  it  would  be  feasible  to  perform  a  study  considering 
multiple risk factors for rotavirus vaccine failure (microbiota composition, maternal antibody 
titres, HBGA phenotype, etc.) in tandem across infants in high- and low-income countries. 
Given that one would expect to observe marked discrepancies in vaccine immunogenicity 
between these settings, such an approach would provide an effective basis for delineating 
factors that undermine oral vaccine efficacy in low-income countries. 
While conducting a multi-centre study such as this, the inclusion of an arm receiving 
IPV  alone (as opposed to a mixed schedule of OPV and IPV) during routine immunisation in 
low-income trial sites would be beneficial.  As well as enhancing comparability with IPV-
immunised  infants  in  high-income  settings,  this  would  enable  the  influence  of  OPV  on 
rotavirus vaccine outcome to be examined as a secondary objectives. In doing so, the trial 
would  provide  insight  into  the  implications  of  the  impending  withdrawal  of  OPV  for 
rotavirus vaccination efforts.
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Epilogue
We are in the midst of a period of profound change in the use of oral vaccines. As we 
prepare for the synchronised withdrawal of OPV – a vaccine that has formed the foundation 
of  global  efforts  to eradicate poliomyelitis  –  the global  roll-out of  oral  vaccines targeting 
rotavirus continues.  It  is  possible that polio’s eradication will  be achieved in spite of the 
impaired immunogenicity of OPV in endemic settings, though much uncharted terrain lies 
ahead.  On the  other  hand,  the  impaired  performance  of  oral  rotavirus  vaccines  in  low-
income countries is likely to gain ever-greater prominence as immunisation efforts expand. 
Based on the findings presented in this thesis, it appears increasingly certain that enteric 
viruses  present  an  obstacle  to  the  successful  implementation  of  OPV  in  low-income 
countries. Bacterial enteropathogens may also impede the immunogenicity of this vaccine in 
early infancy. However, aside from the potential inhibitory effect of co-administered vaccine 
polioviruses, we failed to identify risk factors associated with the impaired performance of 
oral rotavirus vaccine among infants in south India. There is a pressing mandate to rectify 
this state of affairs as we attempt to combat a disease that is responsible for upwards of 
500,000 deaths among young infants each year.  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